[ߘߩઁ㑐ㅪᣉ⸳╬⎇ⓥᵴേ]㧔1㧕㒝ዻ∛㒮ャⴊㇱ
1㧚⎇ⓥߩ᭎ⷐ
ャⴊ≮ᴺߪ⃻ઍක≮ߦਇนᰳߥᴦ≮ᚻᲑߢ޽ࠆ߇, ߘߩታᘒߪᦨ߽᥉෸ߒߚ‫ޟ‬⒖ᬀක≮‫ੱઁޕࠆ޽ߢޠ‬ߩ⤳ེ㧔ㅧⴊ࡮఺∉♽࡮ᐙ⚦⢩㧕ࠍᦨዋ㒢ߩᬌᩏߢ⒖౉ߔࠆߩߢ㧘⥌ᱫ⊛ߥ೽૞↪࡮ว૬∝߿㔍ᴦᕈ㧔⥌ᱫᕈ㧕ᣂ⥝࡮ౣ⥝ᗵᨴ∝ߩવ៝ߥߤ㧘ߥ߅੹ᓟ߽ᒁ߈⛯޿ߡస᦯ߔࠆߴ߈ᣂߚߥ⺖㗴ߪ಴⃻ߔࠆߣ੍ᗐߐ
ࠇࠆ‫ޕ‬ᣢ⍮ߩ࠙ࠗ࡞ࠬᗵᨴ∝ߩ࠙ࠗࡦ࠼࠙ᦼ₂ⴊ㧘ࠬࠢ࡝࡯࠾ࡦࠣᴺ߇ᧂ㐿⊒㧘޽ࠆ޿ߪ໧⸻ߩήലᕈߩ
᡿ߦ㧘ઁᣇߢߪ㧘ᦨዊ㊂ߩャⴊ≮ᴺ޽ࠆ޿ߪ቟ోߥઍᦧ≮ᴺࠍᮨ⚝ߖߑࠆࠍ߃ߥ޿‫⥄ޕ‬Ꮖⴊャⴊ≮ᴺ߿ࠨ
ࠗ࠻ࠞࠗࡦߩ೑↪㧘ੱᎿⴊᶧߥߤߩ㐿⊒ߢ޽ࠆ‫ޕ‬ᒰ㒮ߢߪ⥄Ꮖⴊャⴊ≮ᴺࠍャⴊㇱਥዉߢ᜛ᄢߒߚ⚿ᨐ㧘ᚻⴚᖚ⠪ߩ߁ߜฃⴊ⠪ߩ߅ࠃߘ 90% ߪ⥄Ꮖⴊ⾂ⴊߒ㧘⾂ⴊߒߚᖚ⠪ߩ 90% એ਄߇ห⒳ⴊࠍ࿁ㆱߢ߈㧘቟ోߥャⴊ≮ᴺߩ৻ߟߣߒߡ⏕┙ߒ㧘20 ᐕߦᷰߞߡᜰዉߒߚ⚿ᨐ㧘ャⴊ≮ᴺߩ৻↹ߣߒߡઍᦧਇ⢻ߦ߹ߢቯ⌕ߒߚ‫ߩߎޕ‬੐ߪㆡᱜߥ㧘ᦨዊ㒢ߩャⴊ≮ᴺࠍផㅴߔࠆ਄ߢၮ␆ߣߥߞߚ‫ޕ‬ᒰャⴊㇱߢߪ․ߦ⥌ᱫ⊛ャⴊ೽૞↪ߢ޽ࠆャⴊᓟ⒖ᬀ ኻኋਥ∛ߩ⊒∝ࡔࠞ࠾࠭ࡓߦߟ޿ߡ⎇ⓥࠍⴕߞߡ߈ߚ⚿ᨐ㧘⃻࿷߽ߥ߅ߎߩ⥌ᱫ⊛ߥว૬∝ߦኻߔࠆ᦭ലߥᴦ≮ᴺߪ⏕┙ߢ߈ߕ㧘ⴊᶧᾖ኿ߣ޿߁੍㒐એᄖߦኻಣᣇᴺߪߥߊ㧘ోߡߩฃⴊ⠪㧘✚ߡߩ⚦⢩⵾೷ߦᾖ኿ߒߡ੍㒐ߒߡ
޿ࠆ‫ޕ‬
2㧚ฬ★
⻠Ꮷ㧦

ᄢႦ▵ሶ

Setsuko Otsuka

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⦁ᚭ㆏ᓼ㧘ᄢႦ▵ሶ㧘ℙየᵏౖ. ╙ 5 ┨ S. ャⴊߩታ㓙㧦MFICU ㅪ⛊ද⼏ળ✬ [MFICU ࡑ࠾ࡘࠕ࡞]
ᄢ㒋㧦ࡔ࠺ࠗࠞ಴ 㧧2008 ᐕ㧦368㧙374㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 㜞ᯅ㜞༑㧘Ⓑ⪲㗉৻㧘ඨ↰⺈㧘ဈᧄਭᶈ㧘Ყ⇐㑆ẖ㧘ᴡේ๺ᄦ㧘᧻ፒ㆏↵㧘┄↰⦟ᰴ㧘⒟ේ᩵ሶ㧘੹ਛ㓶৻㧘ᄢႦ▵ሶ㧘♿㊁ୃ৻㧘㜞᧻⚐᮸㧘૒Ꮉ౏⍶㧚2004 ᐕᐲャⴊ㑐ㅪ✚᜝ࠕࡦࠤ࡯࠻⺞ᩏႎ๔̆ャⴊ▤ℂ૕೙㧘ャⴊ≮ᴺᆔຬળ߅ࠃ߮ⴊᶧߩㆡᱜ૶↪ផㅴߦ㑐ߔࠆ⺞ᩏ̆ ᣣᧄャⴊቇળ⹹ 2006 ᐕ㧧52 Ꮞ㧦414
㧙421㧚
2㧕 㜞ᯅ㜞༑㧘Ⓑ⪲㗉৻㧘ඨ↰⺈㧘ဈᧄਭᶈ㧘Ყ⇐㑆ẖ㧘ᴡේ๺ᄦ㧘᧻ፒ㆏↵㧘┄↰⦟ᰴ㧘⒟ේ᩵ሶ㧘੹ਛ㓶৻㧘ᄢႦ▵ሶ㧘♿㊁ୃ৻㧘㜞᧻⚐᮸㧘૒Ꮉ౏⍶㧚2005 ᐕᐲャⴊ㑐ㅪ✚᜝ࠕࡦࠤ࡯࠻⺞ᩏႎ๔̆ャⴊ▤ℂ૕೙㧘ャⴊ≮ᴺᆔຬળ߅ࠃ߮ⴊᶧߩㆡᱜ૶↪ផㅴߦ㑐ߔࠆ⺞ᩏ̆ ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ⹹ 2007 ᐕ㧧53
Ꮞ㧦365㧙373㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y,
Takemura G, Nishigaki K, Minatoguchi S, Fujiwara H. Granulocyte colony-stimulating factor –anoninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Cir J
2006;70:1093-1098.
IF 2.373

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅቁ༑㧘⎇ⓥಽᜂ⠪㧦ᄢႦ▵ሶ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⎇ⓥ⾌⵬ഥ㊄ ක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࠻࡝࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ੐ᬺ‫ⴊޟ‬ᶧᣂᴺߦ઻߁ャⴊ▤ℂ૕೙ߣ቟ో▤ℂ࡮ㆡᱜ૶↪
ࡑࡀࠫࡔࡦ࠻ࠪࠬ࠹ࡓߩ᭴▽‫ޠ‬㧧ᐔᚑ 17㧙18 ᐕᐲ㧧900 ජ౞(500㧦400 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
ߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᄢႦ▵ሶ㧦
1㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ୶ℂᆔຬળ(㨪⃻࿷)3㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળㆡᱜᆔຬળ I&A ዊᆔຬળ(㨪⃻࿷)4㧕 ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળャⴊ≮ᴺᆔຬળ I&A ዊᆔຬળ(㨪⃻࿷)5㧕 ャⴊ࡮⚦⢩ᴦ≮ቇળෂᯏ▤ℂ࡮ᄢ㊂಴ⴊ࡮↥⑼಴ⴊᆔຬળ(↥⑼ෂᯏ⊛಴ⴊ߳ߩኻᔕࠟࠗ࠼࡜ࠗࡦ૞
ᚑߩߚ߼ߩ 5 ቇળวหᆔຬળ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)6㧕 ャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળᐙ੐(㨪⃻࿷)7㧕 ャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળ I&A ᆔຬળ(㨪⃻࿷)8㧕 ᣣᧄࠕࡈࠚ࡟࡯ࠪࠬቇળਛㇱ࿾ᣇળ਎⹤ੱ(㨪⃻࿷)9㧕 ᣣᧄⴊᶧઍᦧ‛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᄢႦ▵ሶ㧦
1㧕 ╙ 21 ࿁ Transfusion Medicine Conference(ᐔᚑ 18 ᐕ 1 ᦬㧘␹ᄹᎹ㧘ࠪࡦࡐࠫ࠙ࡓ㧦The
Haemovigilance, Section 2. 4) Haemovigilance in Europe㧘5) ☨࿖ߦ߅ߌࠆ⃻⁁㧘6) Serious
Hazard of Transfusion(SHOT㧘⧷࿖)㧘7) 㖧࿖ߦ߅ߌࠆ⃻⁁ ᐳ㐳)2㧕 ╙ 48 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘⻠Ṷળ‫ޟ‬ャⴊࠍߣࠅ߹ߊᦨ
ㄭߩ⁁ᴫ‫⻠ޠ‬Ṷ 1.‫ޟ‬ャⴊ▤ℂᢱߦߟ޿ߡ‫⻠ޠ‬Ṷ 2.‫ޟ‬ャⴊ↪ⴊᶧ࡮ಽ↹⵾೷ߩ৻ర▤ℂߦߟ޿ߡ‫⻠ޠ‬Ṷ 3.‫ޟ‬CD36 ᛫૕㓁ᕈ࠼࠽࡯PC ャⴊߦࠃࠆャⴊ㑐ㅪᕆᕈ⢖㓚ኂ(TRALI)ߩ৻∝଀‫ޠ‬ᐳ㐳)
3㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫․ޟ‬ᱶ⁁ᴫਅߩⴊᶧ⵾೷ߩ૶↪‫ޠ‬1.‫ޟ‬ᢇᕆක≮‫ޠ‬2.‫ޟ‬㓸ਛᴦ≮ㇱ‫ޠ‬3.‫ⴊޟ‬ᶧ∔ᖚ‫ޠ‬4.‫ޟ‬ಽᇂᤨ‫ ޠ‬ᐳ㐳)૒⮮ᒏ჻ᦶ㧦
1㧕 ╙ 46 ࿁ਛㇱකቇᬌᩏቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢ၂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ャⴊ▤ℂᢱขᓧߦะߌߡߩࠪࠬ࠹
ࡓ᭴▽‫ޠ‬1㨪6 ᐳ㐳)2㧕 ╙ 50 ࿁ᣣᧄャⴊ࡮⚦⢩ᴦ≮ቇળ᧲ᶏᡰㇱળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘ᢎ⢒࠮࠶࡚ࠪࡦ‫ޟ‬㔚ሶࠞ࡞࠹ߣャⴊ▤ℂ૕೙ߦߟ޿ߡ‫ޠ‬Ṷ⠪)Ꮭ૒శᵗ㧦
1㧕 ╙ 47 ࿁ਛㇱකቇᬌᩏቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ንጊ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ャⴊ▤ℂㇱ㐷߆ࠄ⥃ᐥ߳ߩࠕࡊ
ࡠ࡯࠴‫ޠ‬1. ✕ᕆャⴊᤨ(ෂᯏ⊛಴ⴊᤨ)ߩኻᔕߦߟ޿ߡ㧘Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേᄢႦ▵ሶ㧦
1㧕 㛽㜑⒖ᬀផㅴ⽷࿅ߩ⺞ᢛකᏧ(㨪⃻࿷)2㧕 ጘ㒂⋵ャⴊᙣ⹤ળ(≮ᴺᆔຬળวหᆔຬળ)ᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⥃ᐥャⴊ⎇ⓥળ੐ോዪ㧒਎⹤ੱ(㨪⃻࿷)4㧕 ⹺ቯャⴊᬌᩏᛛᏧ೙ᐲᜰቯᣉ⸳(㨪⃻࿷)5㧕 ャⴊකቇ⹺ቯක೙ᐲ⹺ቯᣉ⸳(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᄢႦ▵ሶ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ಽᜂႎ๔ᦠ
11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ⻠Ꮷ 1 ฬߩቯຬߦߡ㧘ャⴊᴦ≮ߩ቟ో㧘ㆡᱜ㧘᦭ലᕈߩᜂ଻ߩߚ߼ߦ⸻≮࡮ᢎ⢒࡮⎇ⓥࠍᜂߞߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ኻᔕ╷ャⴊᴦ≮ߩ቟ో㧘ㆡᱜ㧘᦭ലᕈߩᜂ଻ߩߚ߼ߦߪ㧘߹ߕᢎ⢒߇ᦨ㊀ⷐߢ޽ࠆ‫⻠ߪߢ⁁⃻ޕ‬Ꮷ 1 ฬߩቯຬߦߡ㧘ㅢᐕ㧘ㅳ 5 ᣣߩᄖ᧪⸻≮ࠍᜂ޿ߥ߇ࠄ㧘ਛᄩ⸻≮ㇱ㐷ߩ▤ℂߩߺߥࠄߕ㧘ත೨࡮තᓟᢎ⢒ࠍᜂᒰߒߡ޿ࠆ‫ߩߎޕ‬ಽ㊁ߦ߅ߌࠆ⥃ᐥකߩ⍮⼂ߩᰳᅤߣ㧘ャⴊකቇಽ㊁ߦ߅ߌࠆੱ᧚㧔⎇ⓥ⠪㧕ߩዋߥߐߪ⴫ⵣ৻૕ߢ޽ࠆ‫ޕ‬⥌ᱫ⊛ߥ෻ᔕࠍ฽߻ャⴊߦࠃࠆහᤨဳ෻ᔕߩ 90%એ਄߇ᧄ㇌╙৻ߩኾ㐷⎇ⓥᯏ㑐ߩ⹦⚦ߥᬌ⸛ߦ߽߆
߆ࠊࠄߕ㧘੹ᣣߢ߽ේ࿃ਇ᣿ߩ߹߹ߢ޽ࠆ‫ߚ߹ޕ‬㧘ャⴊߦࠃࠆㆃᑧဳ೽૞↪࡮ว૬∝ߩㅊ〔㧘ⵍャⴊᖚ⠪ߩㆡಾߥࠆࡈࠜࡠ࠙ࠕ࠶ࡊߪャⴊක≮ߦ߅޿ߡ଀ᄖ⊛ߦߒ߆ὑߐࠇߡ޿ߥ޿ߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬ᱧผ⊛ߦߪャⴊࠍේ࿃ߣߔࠆ㊀◊߆ߟ⥌ᱫ⊛ߥ೽૞↪ࠍઁߩᣢ⍮∔ᖚߣ⺋⸻ߒ⷗ㅏߒߡ߈ߚน⢻ᕈ߇޽ࠆ‫ߒޕ‬߆ߒ㧘৻ᣇߢ㧘ࡅ࠻ߢߪ⒖ᬀࠍᏀฝߔࠆࡅ࠻⚵❱ㆡว᛫ේ㧔HLA㧕߇ャⴊߩ೽૞↪ߩේ࿃᛫ේߣߒߡ⊒⷗ߐࠇߚ⚻✲߇޽ࠆߎߣ߆ࠄ್ࠆࠃ߁ߦ㧘᦭ኂߥ೽૞↪ࠍ⋴ㆊߖߕ㧘⎇ⓥኻ⽎ߣߔࠆߎߣ߇ଐὼߣߒߡ
㊀ⷐߣ⠨߃ࠄࠇࠆ‫ޕ‬ᓥߞߡ㧘ャⴊක≮ߩㆡᱜ࡮᦭ല࡮቟ోᕈߩㅊ᳞ߦߪャⴊකቇᢎ⢒࡮⸻≮࡮⎇ⓥߩల
ታ߇ਇนᰳߢ޽ࠆ‫ޕ‬
2002 ᐕ 7 ᦬ߦᚑ┙ߒߚㅢ⒓‫ⴊޟ‬ᶧᣂᴺ‫ߡߞࠃߦޠ‬ャⴊߦࠃࠆ೽૞↪ႎ๔߇⟵ോൻߒߚ‫ޕ‬㧔⥌ᱫ⊛㧕㕖
ṁⴊᕈャⴊ೽૞↪ߩ߁ߜ㧘ዋᢙߥ߇ࠄ৻ㇱߢߪ㧘TRALI㧔transfusion related acute lung injury㧕߿㘃ૃ෻ᔕߦ߅޿ߡ㧘᛫ HLA ᛫૕߿᛫㗰☸⃿᛫૕߇ේ࿃ߣߒߡᬌ಴ߐࠇࠆࠃ߁ߦߥߞߡ߈ߚ߇㧘ଐὼߣߒߡ
ߘߩ⹦⚦ߪᧂ⸃᣿ߢ޽ࠆ߇㧘⒳‫ߩ⷗⊒ᧂߩޘ‬᛫૕߇㑐ਈߒߡ޿ࠆ੐߇ផ᷹ߐࠇߡ޿ࠆ‫ޕ‬21 ਎♿ߦ౉ߞߡ߽ዏ㧘᰷☨ߩャⴊኾ㐷⹹ߪ⸒ࠊߕ߽߇ߥ㧘New Engl J Med㧘JAMA ╬ߩ৻ᵹ⥃ᐥකቇ㔀⹹ߦ⥌ᱫ⊛ャⴊ೽૞↪ߩ 1 ଀ႎ๔߇ឝタߐࠇࠆ⃻⁁߇⛯޿ߡ޿ࠆ‫ޕ‬ጘ㒂⋵⿒චሼⴊᶧ࠮ࡦ࠲࡯ߩᬌᩏㇱ㐷ߣ⵾೷ㇱ㐷߇ᗲ⍮⋵ἑᚭᏒߦ⛔วߐࠇߡਭߒ޿‫ޕ‬ฎౖ⊛ャⴊ೽૞↪ߢ޽ࠆṁⴊ෻ᔕࠍᦨㄭ㧘┙⛯ߌߦ⚻㛎ߒߚ㧧ABO ဳ߿ Rho㧔D㧕ဳએᄖߩ᛫ේ᛫૕෻ᔕߦࠃࠆහᤨ
ဳ෸߮ㆃᑧဳṁⴊ෻ᔕߪ㧘౒ߦャⴊ೨ߩਇⷙೣ᛫૕㓁ᕈ⚿ᨐࠍᓧߥ߇ࠄ᛫૕ߩ․⇣ᕈ㧔ߣ⥃ᐥ⊛㊀ⷐᕈ㧕ࠍหቯߢ߈ߕ㧘ਇㆡวャⴊࠍ㒐߉ᓧߕ㧘ᓟ⠪ߢߪ⥌ᱫ⊛ォᏫࠍขߞߚ‫⚻ޕ‬ᷣ⊛ℂ↱ߦࠃࠆᬺോߩ⛔วߦࠃߞߡⴊᶧ࠮ࡦ࠲࡯ߩ Reference Laboratory ᯏ⢻ߪ⪺ߒߊ⴮ㅌߒ㧘ᬌᩏ⚿ᨐߪᬌ૕ឭ಴ᓟ㧘2 ㅳ㑆ᓟ㧔ᖚ⠪ᱫ੢ᓟ 2 ㅳ㑆ᓟ㧕ߦ౉ᚻߐࠇ㧘ታലᕈࠍᰳ޿ߡ޿ࠆ‫ޕ‬Ꮢ⽼ߐࠇߡ޿ࠆ⚦⢩⹜⮎ߪਥߦ USA ⵾㧔⊕ੱ↪㧕ߢ޽ࠅ㧘ㆮવ⊛ߥ⢛᥊ߩ⇣ߥࠆᣣᧄੱ↪ߩ⚦⢩⹜⮎ࠍᏱᤨᔅⷐߣߒߡ޿ࠆߦ߽߆߆ࠊࠄߕ㧘ᴺ⊛ࡃ࡝ࠕ࡯ߩߚ߼౉ᚻਇ⢻߇ᢙචᐕ⛯޿ߡ޿ࠆ⃻⁁߇޽ࠅ㧘߹ߚャⴊㇱࠍᢛ஻ߒߡ⥄ࠄ Reference Laboratory ߣߒߡలታߒߥ޿㒢ࠅ㧘቟ోߥャⴊ≮ᴺࠍឭଏ಴᧪ߥ޿੐߇್ߞߚ‫ޕ‬੹ᓟߩዷᦸㄭᐕ㧘≸ᖚ⠪ߩౣ⊒ߦኻߒߡ DLT㧔donor lymphocyte transfusion㧕ߥߤߩ⚦⢩ᴦ≮߇᦭ലߥᚻᲑߣ
ߥߞߡ߈ߚ‫ޕ‬ャⴊක≮ߩ቟ోᕈߦኻߔࠆ࿖᳃ߩᒝ޿ ᔨߣ㑐ᔃߩ㜞߹ࠅߦട߃㧘੹ᓟߪ DNA ࡟ࡌ࡞ߢHLA㧔human leukocyte antigens㧕ࠍ৻⥌ߐߖߚ࠼࠽࡯ߩ࡝ࡦࡄ⃿ャᵈߦࠃࠆ࿕ᒻ≸ᴦ≮ߥߤ㧘ᦝߥࠆᴦ≮ᴺߩ㐿⊒㧘⎇ⓥߩᔅⷐᕈߪ㜞޿‫ޕ‬ᒰ㒮ߪ㕖ⴊ✼㑆㛽㜑ណข࡮⒖ᬀ∛㒮ߩ⹺ቯࠍฃߌߚ⚿ᨐ㧘ห⒳ㅧⴊᐙ⚦⢩⒖ᬀ߿⥄Ꮖ㛽㜑ᐙ⚦⢩ࠍ⒖㧙㧙ᬀߔࠆⴊ▤ᣂ↢ᴦ≮╬ߩ⚦⢩ᴦ≮߇੹ᓟჇടߔࠆߎߣ߇⷗ㄟ߹ࠇࠆ‫ޕ‬ᦝߦߪ㧘ౣ↢ක⑼ቇኾ᡹࡮⚵❱ེቭᒻᚑಽ㊁߅ࠃ߮ญ⣧ᄖ⑼ߦ⧯ᐕ⠪ߩ⍮ᱤᱤ㜑ࠃࠅ᛽಴ߐࠇߚ㑆⪲♽ᐙ⚦⢩ 200 ઙ߇଻ሽߐࠇ㧘዁᧪ߩ⥃ᐥᔕ↪㧔iPS ⚦⢩ࡃࡦࠢ㧕ࠍ⋡ᜰߒߡ㧘ャⴊㇱߦߪࡃࡦࠢᬺോ߳
ߩ㑐ਈࠍⷐ⺧ߐࠇߡ޿ࠆ‫ޕ‬ታ⃻ߦߪ㧘዁᧪⊛ߦߪ⚦⢩ࡊࡠ࠮࠶ࠪࡦࠣ࠮ࡦ࠲࡯ㆇ༡ߩࠟࠗ࠼࡜ࠗࡦ㧔૞ᚑਛ㧕ߦᓥ޿㧘⚦⢩≮ᴺ჻㧔઒⒓㧕⋧ᒰߩੱ᧚߇ᔅⷐߢ޽ࠅ㧘߆ߟ ଻ሽߦߐ޿ߒߡ㧘ᗵᨴ∝ߩ࠴ࠚ࠶ࠢߩߺߥࠄߕ㧘ⴊᶧဳߩ৻ߟߢ޽ࠆ⚵❱ㆡวᕈᬌᩏ߇ਇนᰳߢ޽ࠆߚ߼㧘ャⴊㇱߦ߅ߌࠆੱ᧚ߩ⏕଻㧘ᬌᩏㆀⴕ⢻ജߩะ਄߇ᔅ㗇ߣߥࠆߣᕁࠊࠇࠆ‫ޕ‬㧙㧙㧔2㧕㒝ዻ∛㒮∛ℂㇱ
1㧚⎇ⓥߩ᭎ⷐ
1㧕ࡕ࠺࡞േ‛ࠍ↪޿ߚ࿕ᒻ≸ߩ⊒↢ࡔࠞ࠾࠭ࡓ⸃ᨆ
ታ㛎⊛ൻቇ⊒≸ࡕ࠺࡞㧔ᄢ⣺࡮⢗ߥߤ㧕ࠍ↪޿ߡ㧘․ߦ⢈ḩ࡮♧ዩ∛࡮㜞⢽ⴊ∝㑐ㅪ࿃ሶߦᵈ⋡ߒߚ⊒߇ࠎࡔࠞ࠾࠭ࡓ⸃ᨆࠍⴕߞߚ‫ޕ‬
2㧕㜞ᐲవㅴක≮ⅣႺߦ߅ߌࠆ∛ℂ⸻ᢿ⥃ᐥฦ⑼ߩ㜞ᐲవㅴක≮㧔࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ߩⴚਛㄦㅦ࡮೨┙⣼≸ዊ✢Ḯ≮ᴺ࡮⒖ᬀක≮࡮FNA ᬌ૕ߥߤ㧕ߦኻᔕߒߡ㧘∛ℂ⸻ᢿᛛⴚߩะ਄෸߮⥃ᐥ⊛࠾࡯࠭ࠍḩߚߔႎ๔᭽ᑼߩᡷༀࠍⴕߞߚ‫ޕ‬
3㧕∛ᄌߩ morphology-based ߥಽሶ∛ℂ⸻ᢿ
Immunohistochemistory࡮in situ hybridization࡮laser capture microdisection ߥߤࠍ㚟૶ߒߚ≸ߩ✚ว⊛ಽሶ∛ᘒ⸻ᢿࠍ⋡ᜰߒ㧘ᚻᆎ߼ߦ੃≸ߦ߅ߌࠆࡎ࡞ࡕࡦฃኈ૕఺∉⚵❱ൻቇ࡮HER2 ఺∉⚵❱ൻቇ࡮HER2 ㆮવሶ ISH ࠍ㒮ౝߢᣉⴕ㐿ᆎߒߚ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦㜞⷗ ೰ᑝἑ ༀା
ಎᢎ᝼㧦⥃ᐥ⻠Ꮷ(૬છ)㧦 ᵻ㊁ ᄹ⟤

Tsuyoshi Takami
Yoshinobu Hirose
Asano Nami

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᑝἑༀା㧚⤟⣲≌ߩᄖ⑼∛ℂ ᦨㄭߩ⹤㗴㧚⥃ᐥ↹௝ 2006 ᐕ㧧22 Ꮞ㧦1306㧙1313.
2㧕 ᓟ⮮⵨ᄦ㧘᧖ፒ࿻ሶ㧘ᤊඳᤘ㧘ᑝἑༀା㧚ẩ≌≚∥㧫㧚ᣣᧄᶖൻེ߇ࠎᬌ⸻ቇળ㔀⹹ 2007 ᐕ㧧45 Ꮞ㧦
445㧙449.
3㧕 ㄭ⮮ᶈผ㧘౗᧻㓷ਯ㧘੖ፉ⡡㧘ᨷᬀ⵨੺㧘㐳↰⌀ੑ㧘ዊ᫪ల༹㧘ᑝἑༀା㧚Misdiagnosis ߦቇ߱ ⴚ೨⸻ᢿ ☼ᶧ↥↢⢙▤⚦⢩≸㧚ᶖൻེ↹௝ 2007 ᐕ㧧9 Ꮞ㧦91㧙94.
4㧕 ጊญ๺਽㧘ዊ᫪ల༹㧘᧻੗⡡㧘૒‫⟵ᧁޘ‬ਯ㧘↰ਛ⑲ౖ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㜞ᯅቁᄦ㧘㐳የᚑᢅ㧘㐳↰⌀ੑ㧘቟㆐ᵗ␭㧘⨹ᧁኡม㧘ᑝἑༀା㧚⢗࡮චੑᜰ⣺ߩ⣲≌ᕈ∔ᖚ ⒘ߥ⚵❱ဳߩ⢗ߩ⣲≌㧘ᄖ⑼ᴦ≮ 2007
ᐕ㧧96 ᏎჇೀ㧦467㧙472.
✚⺑㧔᰷ᢥ㧕
1㧕 Kanematsu M, Kondo H, Goshima S, Kato H, Tsuge U, Hirose Y, Kim MJ, Moriyama N. Imaging liver
metastases: Review and update. Eur J Radiol. 2006;58:217-228.
2㧕 Kato H, Kanematsu M, Ando K, Mizuta K, Ito Y, Hirose Y, Hoshi H. Ossifying pleomorphic adenoma of
the parotid gland: a case report and review. Australas Radiol. 2007;51 Suppl:B173-B175.
3㧕 Mori H, Yamada Y, Hirose Y, Hara A. Precancerous conditions of the colon; multistage carcinogenesis
in animal models. Int J Cancer Prev. 2008;2:363-373.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊፒஜ〝㧘⨹ᧁኡม㧘ᄢፉ㕏ᐢ㧘⊕ᧁ੫㧘⑔ፉ⑲᮸㧘቟↰৻ᦶ㧘᳗ᧁᱜੳ㧘ട⮮ೣᑝ㧘᫪⣁ਭ㓉㧘ᑝἑༀା㧚චੑᜰ⣺㒱ಳဳ⣼⣲ߩ 1 ଀㧚ᣣᧄᶖൻེౝⷞ㏜ቇળ㔀⹹ 2006 ᐕ㧧48 Ꮞ㧦1228㧙1232.
2㧕 ጤਅᜏม㧘቟↰৻ᦶ㧘ਛ੗ታ㧘ᄢፉ㕏ᐢ㧘⊕ᧁ੫㧘᫪⣁ਭ㓉㧘᧻የᶈ㧘㑐㊁⠨ผ㧘ጊ↰ථ਽㧘ᑝἑༀା㧚ਥ⤟▤⁜⓰ࠍ߈ߚߒߚ⤟ౝಽᴲ⣲≌ߩ 1 ଀㧚⢄⢙⤟ᴦ≮⎇ⓥળ⹹ 2006 ᐕ㧧4 Ꮞ㧦63㧙68㧚
3㧕 ㊁ਛਁ␭ሶ㧘ਤ⠀ᙗม㧘᳓㊁ᥓሶ㧘ᣣᳯ੗㚅ઍሶ㧘ᑝἑༀା㧘₹⥢ノᒾ㧚ሶች㗪ㇱ large-cell neuroendocrine
carcinoma ߩ 1 ଀㧚᧲ᶏ↥⑼ᇚੱ⑼ቇળ㔀⹹ 2006 ᐕ㧧43 Ꮞ㧦171㧙174.
4㧕 ↰ਛ㗔㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᧃ▵㛽㛽⣲≌ߩ 1 ଀㧚᧲ᶏ㛽エㇱ⣲≌ 2006 ᐕ㧧18 Ꮞ㧦43㧙44.
5㧕 ട⮮ඳၮ㧘ᤊඳᤘ㧘ጊ↰ධᤊ㧘㕍ᧁ⻞ᄥ㧘᳓↰໪੺㧘દ⮮౎ᰴ㧘᧻᳗⎇๋㧘ᑝἑༀା㧚৻஥⡊ਅ⣼ߦ⊒↢ߒߚᄙ⊒⡊ਅ⣼ౝ␹⚻㕽⣲ߩ 1 ଀㧚⥃ᐥ᡼኿✢ 2007 ᐕ㧧52 Ꮞ㧦312㧙317.
6㧕 ᧻ᧄ⌀੺㧘ጤ↰ዏ㧘⊕ᯅᐘᵗ㧘ᑝἑༀା㧘᳓㊁ศ㓷㧘᧻੗㓷ผ㧘┻᧛ඳᢥ㧚FDG-PET ߢ⇣ߥࠆᚲ⷗ࠍ␜
ߒߚ⢖⎬ൻᕈⴊ▤⣲ߩ 2 ଀㧚ᣣᧄ๭ๆེᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦86㧙91.
7㧕 ᓼጊᵏᴦ㧘㐳↰⌀ੑ㧘૒‫⟵ᧁޘ‬ਯ㧘੹੗ኼ㧘᧻੗⡡㧘ዊ᫪ల༹㧘㜞੗శᴦ㧘ౝᧁ㓉ᢥ㧘੹੗ஜੑ㧘ㄭ⮮ᶈผ㧘੖ፉ⡡㧘౗᧻㓷ਯ㧘ᑝἑༀା㧚ⴚ೨ߦ⢄⚦⢩≸ߣߩ㐓೎߇໧㗴ߣߥߞߚ⢄⚦⢩⣼⣲ߩ 1 ଀㧚⢄⢙⤟ᴦ㧙㧙≮⎇ⓥળ⹹ 2007 ᐕ㧧5 Ꮞ㧦35㧙40.
8㧕 ૒⮮ᕺℂሶ㧘ਤ⠀ᙗม㧘ੑችᦸᵗ㧘᳓㊁ᥓሶ㧘ട⮮ผ㐷㧘ട⮮ඳၮ㧘ᑝἑༀା㧘੹੗◊ᔒ㧚ⴚ೨⸻ᢿน⢻ߢ޽ߞߚሶች⡺⣲ߩ 2 ଀㧚᧲ᶏ↥⑼ᇚੱ⑼ቇળ㔀⹹ 2007 ᐕ㧧44 Ꮞ㧦111㧙116.
9㧕 㜞ᯅቁᄦ㧘ᓼጊᵏᴦ㧘ဈਅᢥᄦ㧘㐳የᚑᢅ㧘ጊญ๺਽㧘㐳↰⌀ੑ㧘⨹ᧁኡม㧘᧖ጊ଻ᐘ㧘ን↰ᒄਯ㧘ᑝἑༀା㧚ਅㇱ⋥⣺ᚳᐔ਄⊹≸߇਄ㇱ⋥⣺ߦหᤨᕈოౝォ⒖ࠍ߈ߚߒߚ 1 ಾ㒰଀㧚ᣣᧄᄢ⣺⢂㐷∛ቇળ㔀⹹
2008 ᐕ㧧61 Ꮞ㧦33㧙38.
10㧕 㝩㗡ാテ㧘ᵄᄙ㊁⵨৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧘ᢪየᓕ⋥㧘᧻ᧄ⌀੺㧘⊕ᯅᐘᵗ㧘ጤ↰ዏ㧘㜞⷗೰㧚
Micronodular thymoma with lymphoid stroma ߩ 1 ଀㧚⸻ᢿ∛ℂ 2008 ᐕ㧧25 Ꮞ㧦267㧙271㧚
11㧕 ⩵ᳰ⟤ᄹ㧘੉੗ା๋㧘቞ጊᵗม㧘࿯ደ᦮ᄢ㧘ਃベᅢ↢㧘ᮮ੗❥᣿㧘ખ㊁ᱜඳ㧘ᳯේ⧷ବ㧘಴ญ㓉㧘ᑝἑༀା㧚FOLFOX4(ࠝࠠࠨ࡝ࡊ࡜࠴ࡦ㧘ࡠࠗࠦࡏ࡝ࡦ㧘5-FU)ࠍⴚ೨᛫≸ൻቇ≮ᴺߦ↪޿ߚዩ⤑▤≸ߩ 1 ଀㧚ᴲዩེ⑼♿ⷐ 2008 ᐕ㧧54 Ꮞ㧦557㧙559.
ේ⪺㧔᰷ᢥ㧕
1㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Kuno T, Hirose Y, Hara A, Mori H. Lack ofenhancing effects of degraded lambda-carrageenan on the development of beta-catenin-accumulated
crypts in male DBA/2J mice initiated with azoxymethane. Cancer Lett. 2006;238:69-75.
IF2㧕 Hata K, Tanaka T, Kohno H, Suzuki R, Qiang SH, Yamada Y, Oyama T, Kuno T, Hirose Y, Hara A,
Mori H. eta-Catenin-accumulated crypts in the colonic mucosa of juvenile Apc(Min/+) mice. Cancer
Lett. 2006;239:123-128.
IF
3㧕 Kuno T, Hirose Y, Yamada Y, Hata K, Qiang SH, Asano N, Oyama T, Zhi H, Iwasaki T, Kobayashi H,
Mori H. Chemoprevention of mouse urinary bladder carcinogenesis by fermented brown rice and ricebran. Oncol Rep. 2006;15:533-538.
IF4㧕 Tanaka O, Kiryu T, Hirose Y, Fujikake R, Sakurai K, Hoshi H. Chest wall Castleman's disease: CT and
MRI findings. Radiat Med. 2006;24:529-533.
5㧕 Suzuki R, Kohno H, Yasui Y, Hata K, Sugie S, Miyamoto S, Sugawara K, Sumida T, Hirose Y, Tanaka T.
Diet sypplemented with citrus unshiu segment membrane suppresses chemically induced colonicpreneoplastic lesions and fatty liver in male db/db mice. Int J Cancer. 2006;120:252-258.
IF
6㧕 Tomita H, Yamaguchi K, Matsuo M, Ohno T, Nishimoto Y, Hirose Y. Metastatic myxoid liposarcoma inthe mesentery: what is debated? Case report and a review of the literature. Am Surg. 2006;72:68-70.
IF
7㧕 Sheng H, Hirose Y, Hata K, Zheng Q, Kuno T, Asano N, Yamada Y, Hara A, Osawa T, Mori H.
Modifying effect of dietary sesaminol glucosides on the formation of azoxymethane-inducedpremalignant lesions of rat colon. Cancer Lett. 2007;246:63-68.
IF8㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynaecol Obstet. 2007;96:49-50.
IF
9㧕 Kato H, Kanematsu M, Kusunoki Y, Shibata T, Murakami H, Mizuta K, Ito Y, Hirose Y. Nasoalveolar
cyst: imaging findings in three cases. Clin Imag. 2007;31:206-209.
IF
10㧕 Manabe T, Hirose Y, Kiryuu T, Koudo H, Hoshi H. Magnetic resonance imaging of endometrial cancer
and clear cell cancer. J Comput Assist Tomo. 2007;31:229-235.
IF
11㧕 Zhi H, Yamada Y, Hirose Y, Kato K, Sheng H, Zheng Q, Oyama T, Asano N, Kuno T, Hara A, Mori H.
Effect of 2-(carboxyphenyl) retinamide and genistein on the formation of early lesions in
1,2-dimethylhydrazine-induced colon carcinogenesis in rats. Asian Pac J Cancer Prev. 2007;8:33-38.
12㧕 Asano N, Kuno T, Hirose Y, Yamada Y, Yoshida K, Tomita H, Nakamura Y, Mori H. Preventive effects
of a flavonoid myricitrin on the formation of azoxymethane-induced premalignant lesions in colons ofrats. Asian Pac J Cancer Prev. 2007;8:73-76.
13㧕 Niwa K, Hirose R, Mizuno T, Hirose Y, Tamaya T. Pseudomyxoma peritonei and mucinous pyometral
fluid arising from an ovarian borderline mucinous tumor: case report. Eur J Gynaecol Oncol.
2007;28:145-146.
IF
14㧕 Phuoc NB, Ehara H, Gotoh T, Nakano M, Yokoi S, Deguchi T, Hirose Y. Immunohistochemical
analysis with multiple antibodies in search of prognostic markers for clear cell renal cell carcinoma.
Urology. 2007;69:843-848.
IF
15㧕 Tomita H, Yamada Y, Oyama T, Hata K, Hirose Y, Hara A, Kunisada T, Sugiyama Y, Adachi Y, Linhart
H, Mori H. Development of gastric tumors in Apc(Min/+) mice by the activation of the beta-catenin/Tcf
signaling pathway. Cancer Res. 2007;67:4079-4087.
IF
16㧕 Mizutani K, Ehara H, Yokoi S, Phunc NB, Deguchi T, Hirose Y. Treatment-related ureteral cancer
following stage II testicular seminoma. Int J Clin Oncol. 2007;12:469-471.
17㧕 Niwa K, Onogi K, Yun W, Hirose Y, Tamaya T. Primary lymphoma of the uterine corpus: an unusual
location for a common disease—case report. Eur J Gynaecol Oncol. 2007;28:522-523.
IF
18㧕 Kato H, Kanematsu M, Mizuta K, Ito Y, Hirose Y. Carcinoma ex pleomorphic adenoma of the parotid
gland: radiologic-pathologic correlation with MR imaging including diffusion-weighted imaging. Am J
Neuroradiol. 2008;29:865-867.
IF
19㧕 Doi S, Yasuda I, Iwashita T, Ibuka T, Fukushima H, Araki H, Hirose Y, Moriwaki H. Needle tract
implantation on the esophageal wall after EUS-guided FNA of metastatic mediastinal
lymphadenopathy. Gastrointest Endosc. 2008;67:988-990.
IF

㧙㧙

3.398

3.398

1.597

4.555
1.241

3.398
1.144
0.742
1.509

0.587

2.134

7.672

0.587

2.338

5.888

20㧕 Iwashita T, Yasuda I, Doi S, Kato T, Sano K, Yasuda S, Nakashima M, Hirose Y, Takami T, Moriwaki H.
The yield of endoscopic ultrasound-guided fine needle aspiration for histological diagnosis on patientssuspected of stage I sarcoidosis. Endoscopy. 2008;40:400-405.
21㧕 Kato H, Kanematsu M, Kiryu T, Iwata H, Shiraishi K, Matsumoto S, Hirose Y, Matsutomo H, Sasaoka
I. Nonfunctional mediastinal parathyroid cyst: imaging findings in two cases. Clin Imag.
2008;32:310-313.
22㧕 Phunc NB, Ehara H, Gotoh T, Nakano M, Kamei S, Deguchi T, Hirose Y. Prognostic value of theco-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear
cell renal cell carcinoma. Oncol Rep. 2008;20:525-530.
23㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo H, Goshima S, Tsuge Y. Carcinosarcoma of
the uterus: radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Reson Imaging. 2008;26:1446-1450.

IF 4.166

IF 0.742

IF 1.597

IF 1.486

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦‐ፉବ๺㧘⎇ⓥಽᜂ⠪㧦ᑝἑༀା㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦୘૕࡟ࡌ࡞ߦ߅ߌࠆ
ᄙᲑ㓏⊒߇ࠎߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18 ᐕᐲ㧧1,700 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅ⌀⟤㧘⎇ⓥಽᜂ⠪㧦ᑝἑༀା㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦⢈ḩ࡮㜞⢽ⴊ∝࡮♧ዩ∛ࡕ࠺࡞േ‛ߩ⊒߇ࠎᗵฃᕈߣ⊒߇ࠎᯏ᭴ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,500 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅ⌀⟤㧘⎇ⓥಽᜂ⠪㧦ᑝἑༀା㧧ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄㧦⢈ḩ࡮㜞⢽ⴊ∝࡮♧ዩ∛ࡕ࠺࡞േ‛ߩ⊒߇ࠎᗵฃᕈߣ⊒߇ࠎᯏ᭴ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,500 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᑝἑ ༀା㧦1㧕 ᣣᧄ∛ℂቇળਛㇱᡰㇱᐙ੐(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥ⚦⢩ቇળ᧲ᶏㅪวળᐙ੐(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᑝἑ ༀା㧦1㧕 ╙ 40 ࿁ᣣᧄᇚੱ⑼⣲≌ቇળቇⴚ⻠Ṷ(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘∛ℂ∝଀ᬌ⸛ળ 2‫ޟ‬ሶች૕ㇱ‫ޠ‬ᐳ㐳)2㧕 ╙৻࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ߅ࠃ߮╙ 38 ࿁ᣣᧄᲧセ⥃ᐥකቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫∛ߩࠎ߇੃ޟ‬ℂቇ⊛᭎ⷐ㧘ࡅ࠻੃⣼⣲≌ߩ∛ℂ‫ޠ‬Ṷ⠪)3㧕 ╙ੑ࿁઻ଛേ‛ߩ⥃ᐥකቇ⎇ⓥળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጟፒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬㛽エ㛽⣲≌ߩ∛ℂቇ⊛᭎ⷐ‫ޠ‬Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ‐ፉବ๺㧘Ⴆᧄᔀ຦㧘⪭ว㓷ሶ㧘ᮘ㊁⥝ᄦ㧘㟱ᷗ⧷ᯏ㧘ᧁධಒ㧘↰ᴧ㗅৻㧘ዊᎹൎᵗ㧘ᑝἑༀା㧘ᧄ↰ᶈ┨㧘⛯ノਭ㧘દ᧲ᢥ↢㧘❱↰ାᒎ㧘੹੗ବᄦ㧦୘૕࡟ࡌ࡞ߦ߅ߌࠆᄙᲑ㓏⊒߇ࠎߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸 ᐔᚑ 17 ᐕᐲ(‐ፉ᢬)㧦12㧙15(2006 ᐕ 9 ᦬)2㧕 ‐ፉବ๺㧘Ⴆᧄᔀ຦㧘⪭ว㓷ሶ㧘ᮘ㊁⥝ᄦ㧘㟱ᷗ⧷ᯏ㧘ᧁධಒ㧘↰ᴧ㗅৻㧘ዊᎹൎᵗ㧘ᑝἑༀା㧘ᧄ↰ᶈ┨㧘⛯ノਭ㧘દ᧲ᢥ↢㧘ᤐ↰㓷ਯ㧘❱↰ାᒎ㧦୘૕࡟ࡌ࡞ߦ߅ߌࠆᄙᲑ㓏⊒߇ࠎߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ ෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸 ᐔᚑ
18 ᐕᐲ(‐ፉ᢬)㧦11㧙14(2007 ᐕ 9 ᦬)
3㧕 㜞ᯅ⌀⟤㧘ᑝἑༀା㧘੹੗ବᄦ㧘ਭ㊁ኼ਽㧘⪭ว㓷ሶ㧘੉੗ᐽ౷㧘ᴛ᧛㆐਽㧦⢈ḩ࡮㜞⢽ⴊ∝࡮♧ዩ∛ࡕ࠺࡞േ‛ߩ⊒߇ࠎᗵฃᕈߣ⊒߇ࠎᯏ᭴ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⋭߇ࠎ⎇ⓥഥᚑ㊄ߦࠃࠆ⎇ⓥႎ๔㓸 ᐔᚑ 19 ᐕᐲ(㜞ᯅ⃰)㧦279㧙283(2008 ᐕ 9 ᦬)
11㧚ႎ㆏
1㧕 ᑝἑༀା㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬ㆮવሶᄌൻࠍട๧ߒߡ⸻ᢿ㧦ጘ㒂ᣂ⡞(2007 ᐕ 8 ᦬ 14 ᣣ)
2㧕 ∛ℂㇱ㧦IT ߢ⸻≮ᖱႎࠍ౒᦭ ⋵࡮⋵කᏧળ࡮ጘ㒂ᄢ∛㒮㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
3㧕 ∛ℂㇱ㧦ጘ㒂⋵㧘19 ᣣ߆ࠄ∛㒮ߣㅪ៤ਃ੐ᬺ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 17 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ࿕ᒻ≸㧔․ߦᄢ⣺≸㧕ߦ߅ߌࠆ⢈ḩ㑐ㅪ࿃ሶߦࠃࠆୃ㘼૞↪ߦߟ޿ߡߪ㧘ࠦࡦࠬ࠲ࡦ࠻ߦ⍮⷗ࠍ⫾Ⓧ
ߒߡ㧘ߘࠇࠍᬺ❣⊒⴫෸߮ᄖㇱ⎇ⓥ⾌₪ᓧߦߟߥߍࠆߎߣ߇ߢ߈ߚ‫ޕ‬
FNA ᬌ૕ߦઍ⴫ߐࠇࠆ㜞ᐲవㅴක≮ߦߟ޿ߡߪ㧘⥃ᐥ⑼ߣߩදജߩਅ㧘ᬺ❣⊒⴫ࠍⴕ߁ߎߣ߇಴᧪ߚ‫ޕ‬ᒻᘒ⸻ᢿߣಽሶ⸻ᢿߩⲢวߦ㑐ߒߡߪ㧘HER2 ㆮવሶߩ in situ hybridization ߹ߢࠍ⁛⥄ߢᣉⴕߒ㧘ታ❣ߦߟߥߍࠆߎߣ߇಴᧪ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐߣߘߩኻᔕ╷⌕ታߥᬺ❣⊒⴫߇ߢ߈ࠆࠃ߁ߦߥߞߚ߇㧘✚ߓߡ∛ℂㇱ߇⊒ାరߦߥࠆᬺ❣߇ዋߥ޿ὐ߇໧㗴ߣߒߡ޽ߍࠄࠇࠆ‫੹ޕ‬ᓟߪ⥄೨ߢߩ⺰ᢥ⊒⴫߅ࠃ߮ቇળ⊒⴫ࠍⓍᭂ⊛ߦⴕߞߡ޿ߊߎߣ߇ᔅⷐߣᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸᄢ⣺⊒߇ࠎߦ߅ߌࠆ⢈ḩ㑐ㅪ࿃ሶߩୃ㘼૞↪ߦߟ޿ߡߪ㧘ᒁ߈⛯߈േ‛ࡕ࠺࡞ࠍ↪޿ߡߘߩේ࿃࿃ሶ
․ቯߦㄼࠆࠃ߁ߥዷ㐿ࠍߒߡ޿ߊ‫ޕ‬੹ᓟ߽ߐࠄߥࠆ㜞ᐲක≮߇⥃ᐥᔕ↪ߐࠇࠆߎߣ߇ᗐቯߐࠇࠆߚ߼㧘ߘߩㇺᐲ㧘⥃ᐥ⊛࠾࡯࠭ߦᔕߓࠄ
ࠇࠆࠃ߁ߥදജ㑐ଥߩ᭴▽ߣਇᢿߩḰ஻ࠍᔃ ߌߡ޿ߊ‫ޕ‬․ߦ⢖࡮ᄢ⣺࡮エㇱ⣲≌ߥߤߦߟ޿ߡ㧘ㆮવሶᖱႎࠍ⋓ࠅㄟࠎߛ∛ℂ⸻ᢿߩ᭴▽ߦᒁ߈⛯޿ߡദജߒ
ߡ޿ߊ‫ޕ‬㧙㧙㧔3㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ౝ⑼♽ಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
ᒰ࠮ࡦ࠲࡯ߪ㧘ᐔᚑ 19 ᐕ 4 ᦬ߦᣂ⸳ߐࠇߚ‫ޕ‬ᄢቇ㒮කቇ♽⎇ⓥ⑼࡮කቇㇱߩ৻ㇱ㐷ߢߪ޽ࠆ߇㧘ߘߩ૶๮ߪઁߩ⥃ᐥ♽⻠ᐳ࡮ಽ㊁ߣห᭽ߦ㧘⸻≮࡮ᢎ⢒࡮⎇ⓥߩ 3 ᧄᩇࠍၮᧄߣߒߡ޿ࠆ‫ౕޕ‬૕⊛ߦߪ㧘Ԙ㧦ᒰ㕙ߩ࿾ၞක≮፣უࠍㆱߌࠆߚ߼ߦ㧘නߦකᏧᢙߩ⏕଻ߦ㗬ࠆߩߢߪߥߊ㧘࿾ၞක≮ᣉ⸳㑆ㅪ៤㧘⥄ᴦ૕߿࿾ၞ૑᳃ߣߩදജ૕೙ߥߤࠍ㚟૶ߒߡ‫ޟ‬ක≮ߩ⏕଻‫ޕ߁ⴕࠍޠ‬ԙ㧦࿾ၞᨒផ⮈౉⹜ߥߤ㧘කቇㇱቯຬჇࠍផㅴߔࠆߣߣ߽ߦ㧘ᣢሽߩࠞ࡝ࠠࡘ࡜ࡓߩਛߢ㧘࿾ၞක≮ߩ⃻႐ࠍᦨᄢ㒢ߦᵴ↪ߒߡත೨㨪තᓟ৻⽾ߒߚ‫ޟ‬࿾ၞක≮ߦ⽸₂ߢ߈ࠆੱ᧚⢒ᚑ‫ࠍޠ‬ᜂᒰߔࠆ‫ߪ᧚ੱ߁޿ߢߎߎޕ‬න৻ߩ⸻≮⑼ߩኾ㐷කࠍ⢒ߡ਄ߍࠆߩߺߢߥߊ㧘޽ࠆ⒟ᐲ᏷ᐢ޿ක≮ᛛⴚࠍりߦઃߌߚ‫ޟ‬ᮮᢿ⊛✚ว⸻≮ක‫ࠍߣߎߩޠ‬ᜰߒ㧘߹ߚකᏧߩߺߢ
ߥߊ⋴⼔Ꮷ㧘ߘߩઁߩࠦࡔ࠺ࠖࠞ࡞ߩ⢒ᚑࠍ߽฽߻‫ޕ‬කቇㇱߩᦨᄢߩ૶๮ߪක≮ੱߩ⢒ᚑߢ޽ࠅ㧘ߎߩߎߣߦᦨᄢ㒢ߩ⾗Ḯࠍᛩ౉ߔࠆ‫ޕ‬Ԛ㧦Ԙԙࠍታⴕߔࠆߦ޽ߚߞߡߩක≮ㅪ៤ࠪࠬ࠹ࡓ߿㧘࿾ၞක≮ੱ⢒ᚑࠞ࡝ࠠࡘ࡜ࡓߩ㐿⊒ߥߤ㧘࿾ၞක≮ࠍ⏕଻ߔࠆߚ߼ߩᣇ╷ࠍ⎇ⓥߔࠆߣߣ߽ߦ㧘࿾ၞߩ․⇣⊛ߥ∔ᖚߦ㑐ߔࠆ⎇ⓥߥߤ߽ᜂᒰߒߡ޿ߊ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

᧛਄໪㓶

Nobuo Murakami

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᧛਄໪㓶㧚ਛ᧛ ⼾✬㧚NST ࡂࡦ࠼ࡉ࠶ࠢ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧚
2㧕 ᧛਄໪㓶㧚᫪⣁ਭ㓉㧚‫ޟ‬⢄ᕈ⣖∝ߩ⸻ᢿၮḰߣ∛ဳಽ㘃‫ޠ‬㧦᫟ᣇᤘඳ㧘ዊᳰ๺ᒾ㧘↰ዥਭ㓶✬㧚⢄ ⥃ᐥߦᓎ┙ߟᶖൻེ∔ᖚߩ⸻ᢿၮḰ࡮∛ဳಽ㘃࡮㊀∝ᐲߩ↪޿ᣇ㧘᧲੩㧦ࡔ࠺ࠖࠞ࡞࠮ࡦ࠲࡯␠㧧2006 ᐕ㧦227
㧙231㧚
3㧕 ᧛਄໪㓶㧚␹⼱ ᤩ㧘የኅ㊀ᴦ✬㧚⮎೷Ꮷߩߚ߼ߩᗵᨴ೙ᓮᮡḰ࠹ࠠࠬ࠻㧘᧲੩㧦ߓ߶߁㧧2008 ᐕ㧚
4㧕 ᧛਄໪㓶㧚Τ┨ ਥⷐ∔ᖚߩᩕ㙃▤ℂ 7. ․ᱶߥ∛ᘒߢߩᩕ㙃▤ℂ D. ᗵᨴ∝㧦ਛደ ⼾✬㧚∛ᘒᩕ㙃ኾ㐷කࠟࠗ࠼ࡉ࠶ࠢ㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦218㧙223㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ᧛਄໪㓶㧚ICD ᵴേႎ๔ᦠ 㨪ICD’s Pearls㨪, ICT ߣ NST ࠍ⛔วߒߚᖚ⠪⸻≮ᡰេ㧘INFECTIONCONTROL 2006 ᐕ㧧15 Ꮞ㧦181㧙184㧚
2㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘㢬⷗ ኼ㧘᧻ᶆసᒾ㧘ᷓየ੝↱⟤㧘ᧁਅᐘሶ㧘᧛ἑ૫ઍሶ㧘㋈ᧁ㤗Ꮧሶ㧘᫪⣁ਭ㓉㧚ቇળ࡟ࡐ࡯࠻㧘╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦174㧙176㧚
3㧕 ᧛਄໪㓶㧚╙ 1 ․㓸 ⍮ߞߡ߅߈ߚ޿ NST ߩၮ␆⍮⼂̆ߐ߹ߑ߹ߥ㗔ၞߢߩขࠅ⚵ߺߩታ㓙̆ⶖ≙࡮ᗵᨴ੍㒐ࠍߺߔ߃ߚ NST㧘⥃ῼ⋴⼔ 2006 ᐕ㧧32 Ꮞ㧦824㧙830㧚
4㧕 ᧛਄໪㓶㧘⑔ፉ⑲᮸㧘⊕ᧁ ੫㧘᫪⣁ਭ㓉㧚․㓸 ᩕ㙃ᛩਈ࡞࡯࠻ߩᎿᄦߣㅴᱠ̆ක≮቟ో▤ℂ߆ࠄߺߚᩕ㙃ᛩਈ ࡞࡯࠻ߩᄌ㕟ߣ᦭↪ᕈ㧘ᩕ㙃⹏ଔߣᴦ≮ 2006 ᐕ㧧23 Ꮞ㧦426㧙431㧚
5㧕 ⺪⸰ື਽㧘ᧁਅᐘሶ㧘ᷓየ੝↱⟤㧘᧛਄໪㓶㧚⍮ߞߡ߅߈ߚ޿ᣂߒ޿ක≮̆කቇ᭎⺰̆ⶖ≙ኻ╷࠴࡯ࡓ㧘
ᣣᧄౝ⑼ቇળ㔀⹹ 2007 ᐕ㧧96 Ꮞ㧦1758㧙1764㧚
6㧕 ᧛਄໪㓶㧘᫪⣁ਭ㓉㧚․㓸㧦⢄ਇో 2㧚ᘟᕈ⢄ਇో 1) ⢄ᕈ⣖∝ߩ⊒∝ᯏᐨߣᴦ≮㧘ᴦ≮ቇ 2007 ᐕ㧧
41 Ꮞ㧦363㧙367㧚
7㧕 ᧛਄໪㓶㧘ᷓየ੝↱⟤㧚․㓸 వㅴ⊛ߥ∛㒮ߦ߅ߌࠆᗵᨴ೙ᓮ ጘ㒂ᄢቇ∛㒮ߦ߅ߌࠆᗵᨴ೙ᓮᵴേ㨪㔚ሶࠞ࡞࠹ߣ㔚ሶൻࠨ࡯ࡌࠗ࡜ࡦࠬ㨪㧘ᗵᨴ೙ᓮ 2007 ᐕ㧧3 Ꮞ㧦231㧙236㧚
8㧕 ᧛਄໪㓶㧘ᷓየ੝↱⟤㧚․㓸 㒮ౝᗵᨴኻ╷࿾ၞࡀ࠶࠻ࡢ࡯ࠢߩ᭴▽̆ጘ㒂⋵࿾ၞࡀ࠶࠻ࡢ࡯ࠢߩᵴേ㧘ᗵᨴ೙ᓮ 2008 ᐕ㧧4 Ꮞ㧦27㧙32㧚
9㧕 ᧛਄໪㓶㧚․㓸 㜞㦂⠪⢖Ἳ ⺋ྚᕈ⢖Ἳࠍਛᔃߦၮ␆ߣ⢛᥊࿃ሶ̆ 2) 㜞㦂⠪⢖Ἳߩኋਥⷐ࿃㧙㗼ᕈ⺋ྚߣਇ㗼ᕈ⺋ྚ㧘ᴦ≮ቇ 2008 ᐕ㧧42 Ꮞ㧦1205㧙1210㧚
10㧕 ᧛਄໪㓶㧚‫ޟ‬ൕോකਇ⿷(3)‫̆ޠ‬ጘ㒂ᄢቇකቇㇱ࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔CRM㧕ߩขࠅ⚵ߺ㧘ጘ㒂⋵කᏧળ
ႎ 2008 ᐕ㧧683 Ꮞ㧦13㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᧻ᯅᑧᄈ㧘౎ᐈ๺ᙗ㧘ᳰ੉↱㚅㧘᪀ේ⑲ᰴ㧘┻᧛ᱜ↵㧘᧛਄໪㓶㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚Ǫ-D-ࠣ࡞ࠞࡦ୯
ࠍᜰᮡߣߒߚᷓ࿷ᕈ⌀⩶∝ߦኻߔࠆࡒࠞࡈࠔࡦࠡࡦߩ᦭ലᕈߩᬌ⸛㧘ᣣᧄ㓸ਛᴦ≮කቇળ⹹ 2007 ᐕ㧧14㧙㧙Ꮞ㧦77㧙80㧚
2㧕 ᾢ↰ᕺ੺㧘ศ↰㓉ᶈ㧘⼾↰ᴰ㧘ዊୖ⌀ᴦ㧘ጊ↰ථ਽㧘᧛਄໪㓶㧘ዊୖ⌀ᴦ㧚࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ ੹㧘૗߇ᔅⷐߢ޽ࠆ߆㧘߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ⹹ 2008 ᐕ㧧9 Ꮞ㧦75㧙78㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Wakahara T, Shiraki M, Murase K, Fukushima H, Matsuura K, Fukao A, Kinoshita S, Kaifuku N,
Arakawa N, Tamura T, Iwasa J, Murakami N, Deguchi T, Moriwaki H. Nutritional screening withsubjective global assessment predicts hospital stay in patients with digestive deseases. Nutrition.
2007:23;634-639.
IF 2.1044㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥ1㧕 ᫪⣁ਭ㓉㧘᧛਄໪㓶㧘㢬⷗ ኼ㧦HIV ᗵᨴ⠪╬଻ஜ⑔␩⋧⺣ផㅴ⎇ⓥ ⎇ⓥᜂᒰ⠪㧔ታോ㧕㧧ᐔᚑ
13㧙18 ᐕᐲ㧧325 ජ౞㧦੍ࠛࠗ࠭㒐⽷࿅ฃ⸤⎇ⓥ
2㧕 ᧛਄໪㓶㧘ᷓየ੝↱⟤㧦㨬㒮ౝᗵᨴኻ╷⎇ⓥ੐ᬺ(ᐔᚑ 17 ᐕᐲ㨪)‫ޠ‬㧧ᐔᚑ 18㧙20 ᐕᐲ㧧150 ජ౞(500㧦
500㧦500 ජ౞)㧦ጘ㒂⋵ක≮ᢛ஻⺖ฃ⸤⎇ⓥ
3㧕౒ห⎇ⓥ1㧕 ᧛਄໪㓶㧦࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮౒ㅢ࠰ࡈ࠻̌ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ̍ࠍ↪޿ߚో⥄േో㕙㔚ሶൻක≮㑐ㅪᗵᨴࠨ࡯ࡌࠗ࡜ࡦࠬߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 12 ᐕ㨪⃻࿷㧧0 ౞㧧⟲㚍ᄢቇ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᧛਄໪㓶㧦
1㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄⅣႺᗵᨴቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 2 ᦬㨪⃻࿷)
3㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 1 ᦬㨪⃻࿷)
4㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ NST ታᣉᆔຬળᆔຬ㧘∛ᘒᩕ㙃ኾ㐷Ꮷ⹺ቯ⾗ᩰᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄౝ⑼ቇ⑼᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄᗵᨴ∝ቇળᐔᚑ 20 ᐕᐲᣉ⸳ౝᗵᨴኻ╷⋧⺣⓹ญ࿁╵⠪(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᧛਄໪㓶㧦
1㧕 ╙ 21 ࿁ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘วหࠪࡦࡐࠫ࠙ࡓ‫ޟ‬NST ߩࠕ࠙࠻ࠞࡓ⹏ଔ‫ޠ‬ᐳ㐳)
2㧕 ╙ 21 ࿁ᣣᧄⅣႺᗵᨴቇળ✚ળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᗵᨴ∝ኻ╷ߩ㔚ሶൻ‫ޠ‬ᐳ㐳)
3㧕 ╙ 3 ࿁࡝ࠬࠢࡑࡀࠫࡔࡦ࠻࠮ࡒ࠽࡯(J&J)(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ 1㧘‫ޟ‬ᚻⴚቶߦ߅ߌࠆ⡯‫ޟ‬ᒰ⑼ߦ߅ߌࠆᚻⴚቶߢߩᗵᨴ㒐ᱛኻ╷‫ޠ‬ᐳ㐳)ᬺᗵᨴߩ⃻⁁ߣኻ╷‫ޠ‬2㧘
4㧕 ╙ 89 ࿁ᣣᧄ⚦⩶ቇળ㑐᧲ᡰㇱ✚ળࡒ࠾ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 11 ᦬㧘⟲㚍㧘․೎⻠Ṷ‫ޟ‬࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮౒ㅢ࠰ࡈ࠻‫ޟ‬ᗵᨴ∝▤ℂࠪࠬ࠹ࡓ‫ߚ޿↪ࠍޠ‬㔚ሶൻ∛㒮ᗵᨴࠨ࡯ࡌࠗ࡜ࡦࠬࠍ㐿ᆎߒߡ‫ޠ‬Ṷ⠪)㧙㧙5㧕 ╙ 22 ࿁ᣣᧄⅣႺᗵᨴቇળ✚ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬NST㧘ഃ்ࠤࠕ㧘ⶖ≙࠴࡯ࡓ㧘ⴚᓟᗵᨴኻ╷ߥߤߩ㒮ౝኾ㐷࠴࡯ࡓߣᗵᨴ೙ᓮ‫ޠ‬ᐳ㐳)
6㧕 ╙ 5 ࿁੩ṑࠨ࡯ࡌࠗ࡜ࡦࠬ⎇ⓥળ(ᐔᚑ 19 ᐕ 4 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬㔚ሶൻࠨ࡯ࡌࠗ࡜ࡦࠬߦࠃࠆ
ක≮㑐ㅪᗵᨴኻ╷‫ޠ‬Ṷ⠪)7㧕 ╙ 6 ࿁ᣣᧄᢇᕆකቇળਛㇱ࿾ᣇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጘ㒂㧘᜗⡜⻠Ṷ‫ޟ‬ᢇᕆ㗔ၞߦ߅ߌࠆක≮㑐ㅪᗵᨴኻ╷ߩၮᧄ‫ޠ‬Ṷ⠪)8㧕 ╙ 4 ࿁ᣣᧄญ⣧ࠤࠕቇળቇⴚᄢળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ᗲ⍮㧘ᢎ⢒⻠Ṷ‫ޟ‬ญ⣧ࠤࠕߣ⺋ྚᕈ⢖Ἳ‫ޠ‬Ṷ⠪)9㧕 ᧲ᶏ 3 ⋵߳߈࿾ක≮⎇ୃળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂⋵ߩ࿾ၞක≮ߩ⺖㗴ߣ࿾ၞක≮කቇ࠮ࡦ࠲࡯ߩᓎഀߦߟ޿ߡ‫ޠ‬Ṷ⠪)10㧕 ╙ 6 ࿁ᢇᕆ㗔ၞᗵᨴኻ╷࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ᗵᨴኻ╷ࠪ࡝࡯࠭⻠Ṷ‫ޟ‬ᢇᕆᄖ᧪ߦ߅ߌ
ࠆᗵᨴኻ╷‫ޠ‬ᐳ㐳)11㧕 APIC ࠻ࡇ࠶ࠢࠬ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩㧘᜗⡜⻠Ṷ‫ޟ‬ᣣᧄ߆ࠄߩṶ㗴ߦࠃࠆෳട࡟ࡐ࡯࠻‫ޠ‬Ṷ⠪)12㧕 ╙ 10 ࿁࿖┙ᄢቇ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળ(ᐔᚑ 20 ᐕ 11 ᦬㧘␹ᚭ㧘․೎⻠Ṷ‫ࠃ߅࠻࠶ࠫࡆ࠻ࠗࠨޟ‬߮Პὼᡰេߩႎ๔‫ޠ‬ᐳ㐳)13㧕 ࠫࠚ࠾࠽࠶ࠢ⊒ᄁ 1 ๟ᐕ⸥ᔨ⻠Ṷળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬๭ๆེᗵᨴ∝ߦኻߔࠆ⚻ญ
᛫⩶⮎≮ᴺ㧙࠾ࡘ࡯ࠠࡁࡠࡦ⮎ࠍਛᔃߦ㧙ᣂᏒਛ⢖Ἳࠟࠗ࠼࡜ࠗࡦࠍ⠨ᘦߒߡ‫ޠ‬ᐳ㐳)
14㧕 ╙ 10 ࿁ᔒ៺ᗵᨴ∝⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ਃ㊀㧘․೎⻠Ṷ‫ޟ‬ᣣᏱ⸻≮ߢᓎ┙ߟᗵᨴኻ╷ߩࡐࠗࡦ࠻‫ޠ‬Ṷ⠪)
15㧕 ᣣක↢ᶦᢎ⢒දജ⻠ᐳ࠮ࡒ࠽࡯㧦࠙ࠗ࡞ࠬᗵᨴ∝ߦ߅ߌࠆ੍㒐ߣኻ╷(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎
⻠Ṷ‫ޟ‬ᣂߒ޿ࡢࠢ࠴ࡦ㧙Hib ࡢࠢ࠴ࡦ㧘⚿วဳ⢖Ἳ⃿⩶ࡢࠢ࠴ࡦ㧘ሶች㗪≸ࡢࠢ࠴ࡦ㧙‫ޠ‬ᐳ㐳)16㧕 ෘ↢ഭ௛⋭ᆔ⸤੐ᬺ㧦ᣣᧄᗵᨴ∝ቇળ㒮ౝᗵᨴኻ╷⻠⠌ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘␹ᚭ㧘᜗⡜⻠Ṷ‫ޟ‬㒮ౝᗵᨴኻ╷ߩࠪࠬ࠹ࡓൻ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᧛਄໪㓶㧦╙ 89 ࿁ᣣᧄ⚦⩶ቇળ㑐᧲ᡰㇱ✚ળ Best Presentation ⾨(ᐔᚑ 18 ᐕᐲ)
9㧚␠ળᵴേ᧛਄໪㓶㧦
1㧕 ࿖┙ᄢቇකቇㇱ㒝ዻ∛㒮ᗵᨴኻ╷ද⼏ળᆔຬ(㨪⃻࿷)2㧕 ห ࠟࠗ࠼࡜ࠗࡦ૞ᬺㇱળᆔຬ㐳(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)3㧕 ጘ㒂࿾ᣇⵙ್ᚲኾ㐷ᆔຬ(㨪⃻࿷)4㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ᆔຬળᖱႎኻ╷ㇱળ⸃ᨆዊᆔຬળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂⋵ᗵᨴ∝੍㒐ᆔຬળ੍㒐ធ⒳ㇱળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)6㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷කᏧ㓸࿅ኾ㐷කᏧ(㨪⃻࿷)7㧕 ጘ㒂⋵ᗵᨴ∝੍㒐⸘↹ᬌ⸛ᆔຬળᆔຬ㐳(ᐔᚑ 19 ᐕᐲ)
8㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷ද⼏ળᆔຬ(㨪⃻࿷)9㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷⋧⺣⓹ญ࿁╵⠪(㨪⃻࿷)10㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾⸻≮ႎ㈽ክᩏᆔຬળᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ᧛਄໪㓶㧦ᗵᨴߣᶖᲥ Vol.13 No.2㧦ᐘᦠᚱ(2006 ᐕ 10 ᦬ 30 ᣣ)
2㧕 ᧛਄໪㓶㧦ਛㇱߩක≮㧦ࠗࡦࡈ࡞ࠛࡦࠩԜ‫ޡ‬ฃ㛎↢ߪ੍㒐ធ⒳ࠍ‫ޢ‬㧦⺒ᄁᣂ⡞(2006 ᐕ 11 ᦬ 27 ᣣ)
3㧕 ᧛਄໪㓶㧦੹ᵹⴕߩ࠙ࠗ࡞ࠬߦߟ޿ߡ㧦ጘ㒂᡼ㅍ㧔ጘ㒂࡜ࠫࠝ㧕(2006 ᐕ 12 ᦬ 7 ᣣ)
4㧕 ᧛਄໪㓶㧦ኅᐸකቇߩᤨ㑆㧧ࠗࡦࡈ࡞ࠛࡦࠩߩ੍㒐㧦ᢥൻ᡼ㅍ(2006 ᐕ 12 ᦬ 10 ᣣ)
5㧕 ᧛਄໪㓶㧦੹౻ߩࠗࡦࡈ࡞ࠛࡦࠩ㧦ጘ㒂᡼ㅍ㧔ጘ㒂࡜ࠫࠝ㧕(2006 ᐕ 12 ᦬ 10 ᣣ)
6㧕 ᧛਄໪㓶㧦⋵ౝ ‫ࠆߥ߁ߤޡ‬㧘ߤ߁ߔࠆ‫ޢ‬㨪ࡁࡠ࠙ࠗ࡞ࠬߦ㑐ߒߡ㧦⺒ᄁᣂ⡞(2006 ᐕ 12 ᦬ 13 ᣣ)
7㧕 ᧛਄໪㓶㧦ᣂဳࠗࡦࡈ࡞ࠛࡦࠩ㧦ጘ㒂᡼ㅍ࠹࡟ࡆ(2007 ᐕ 3 ᦬ 2 ᣣ)
8㧕 ᧛਄໪㓶㧦࿾ၞක≮ࠍᡰ߃ߡ ጘ㒂ᄢቇ࿾ၞක≮කቇ࠮ࡦ࠲࡯㧦ጘ㒂᡼ㅍ࠹࡟ࡆ(2008 ᐕ 2 ᦬ 13 ᣣ)
9㧕 ᧛਄໪㓶㧦ᣂဳࠗࡦࡈ࡞ࠛࡦࠩߦ஻߃ߡ㧦ጘ㒂⋵଻㒾කᣂ⡞(2008 ᐕ 12 ᦬ 10 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔ࡮ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ߩ⸳┙㧔19 ᐕ 4 ᦬㧘ᢎ⢒࡮⸻≮࡮⎇ⓥࠍㅢߒߡ࿾ၞක≮ߩ⏕଻ߦ⽸₂㧘ቇౝភ⟎㧧ᢎ᝼ 5 ฬ㧘ഥᢎ 2 ฬ㧕࡮ ࿾ၞᨒផ⮈౉⹜㧔20 ᐕ 1 ᦬㧘10 ฬ㧕ߩታᣉ࡮ ጘ㒂⋵ߣߩㅪ៤ᒝൻ㧦⋵ነ㒝⻠ᐳ‫ޟ‬࿾ၞක≮ቇ⻠ᐳ‫ߣ⟎⸳ߩޠ‬࿾ၞක≮කቇ࠮ࡦ࠲࡯ౝㇱ㐷ൻ㧔࿾ၞ࡮߳߈࿾ක≮ㇱ㐷㧕
㧔19 ᐕ 11 ᦬㧕ጘ㒂⋵කቇ↢ୃቇ⾗㊄ഃ⸳ߦଥࠆදജᡰេ㧔⟵ോᐕ㒢ൕോࠦ࡯࠺ࠖࡀ࡯࠻㧕ోቇ⊛ߥ⡯ຬ੤ᵹߩ৻⽾ߣߒߡߩጘ㒂⋵⡯ຬߢ޽ࠆ⥄ᴦක⑼ᄢቇතᬺ↢╬ߣߩㅪ៤㧔ቴຬᢎቭߣߒ
ߡ࿾ၞක≮කቇ࠮ࡦ࠲࡯ᬺോᡰេ㧘20 ᐕ 8 ᦬㨪㧕ጘ㒂⋵࿾ၞක≮ኻ╷ද⼏ળ߅ࠃ߮㘧㛗࿾ၞක≮ㅪ៤ળ⼏߳ో㕙⊛ෳട㧔⼏㐳㧘ㇱળ㐳㧕࡮දജ࡮ ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯㧘ጘ㒂Ꮢ᳃∛㒮ߣߩㅪ៤ߦࠃࠆࡕ࠺࡞࿾඙߳߈࿾ක≮᜚ὐ∛㒮ᵴᕈൻ㧦㧔ጘ㒂⋵┙ਅํ᷷ᴰ∛㒮㧘㜞ጊ⿒චሼ∛㒮㧕ೋᦼ⥃ᐥ⎇ୃߦ߅ߌࠆ‫ޟ‬࿾ၞක≮⎇ୃ‫ߩޠ‬ታᣉ㧔1 ࡩ᦬Ფᵷ㆜㧕ጘ㒂ᄢቇ߅ࠃ߮ጘ㒂⋵✚วක≮࠮ࡦ࠲࡯߆ࠄ㧘ᜰዉක࡮ኾ㐷කࠍᵷ㆜ߒ㧘⸻≮࡮⎇ୃකᜰዉࠨ࠹࡜ࠗ࠻⸻≮ᚲ߿ᄢቇߣߩ㑆ߩ⸻≮ㅪ៤ࠪࠬ࠹ࡓߩ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧔ࡋ࡝⒖ㅍ߽฽߻㧕࡮ 㘧㛗࿾ၞฦᏒߩ∛㒮࡮කᏧળߣᧄቇߩㅪ៤ߦࠃࠆዊఽᢇᕆ⸻≮࠮ࡦ࠲࡯㧔㘧㛗࿾ၞߢߩᄛ㑆࡮ભᣣ⸻≮ߦኻᔕ㧕⸳┙ߦଥࠆදജᡰេ࡮ ጘ㒂⋵✚ว๟↥ᦼᲣሶක≮࠮ࡦ࠲࡯෸߮↥⑼ᢇᕆ៝ㅍࠪࠬ࠹ࡓ㧔20 ᐕ 2 ᦬⸳┙㧕߳ߩㆇ༡ᡰេ࡮ ࿷ቇ↢ߦኻߔࠆጘ㒂⋵කቇ↢ୃቇ⾗㊄ฃ⛎ᅑബ㧦㧔╙ 1 ⒳㧧࿾ၞᨒ౉ቇ↢ 10 ฬਛ 10 ฬ 100㧑ฃ⛎㧘╙ 2 ⒳㧧࿾ၞᨒ౉ቇ↢એᄖ㧦1 ᐕ↢ 17 ฬ㧘2 ᐕ↢ 3 ฬ㧘3 ᐕ↢ 3 ฬ㧘4 ᐕ↢ 2 ฬ㧘5 ᐕ↢ 4 ฬ㧘6 ᐕ↢ 3 ฬ㧘ว⸘ 33 ฬฃ⛎㧕࡮ ࿾ၞක≮ߦ㑐ߔࠆࠞ࡝ࠠࡘ࡜ࡓߩలታ㧔࿾ၞᨒ౉ቇ↢ࠍ฽ࠎߛోකቇ⑼ቇ↢߇ኻ⽎㧕㧦
1 ᐕ↢㧦ೋᦼ૕㛎ታ⠌㧔ቇᄖක≮㑐ㅪ⻉ᣉ⸳㧧⡲ቇᩞ㧘⋤ቇᩞ㧘㜞㦂⠪ᣉ⸳㧘ᶖ㒐⟑㧘ⴊᶧ࠮ࡦ࠲
࡯╬㧕߅ࠃ߮࿾ၞ⸻≮ᚲታ⠌ోቇᐕኻ⽎࿾ၞක≮࠯ࡒ㧔⺖ᄖ᝼ᬺ㧕ోቇᐕኻ⽎ᄐቄભᥜਛ࿾ၞ૕㛎ታ⠌㧔ጘ㒂⋵ౝ߳߈࿾ක≮᜚ὐ∛㒮߅ࠃ߮⸻≮ᚲ㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯ᢎቭߦࠃࠆ࿾ၞᨒ౉ቇ↢ߩ‫ޟ‬㉿ⷫ೙ᐲ‫ޠ‬ታᣉ⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷࡮ ࠮ࡦ࠲࡯ࡔࡦࡃ࡯ߪ৻ㇱኾછ⡯ຬߣߥߞߡ޿ࠆ߽ߩߩ㧘ታ㓙ߪฦኾ㐷ಽ㊁ߩ⻠ᐳᬺോߣ౗ോߒߡ޿ࠆ
⁁ᘒߢ޽ࠅ㧘ታ⾰⊛ߥኾછ⡯ຬ߇޿ߥ޿‫ޕ‬ᒰ࠮ࡦ࠲࡯ߩᬺോࠍࠃࠅ৻ጀలታߔࠆߚ߼ߦߪ㧘⌀ߩኾછ⡯ຬߩ㈩⟎߇㊀ⷐߢ޽ࠆ‫ޕ‬࡮ ᒰ࠮ࡦ࠲࡯ߦߪ੍▚㈩ಽ߇ోߊߥ޿‫ޕ‬ነ㒝⻠ᐳߩ੍▚ߪਥߦੱઙ⾌ߦలᒰߐࠇߡ߅ࠅ㧘ㆇ༡࡮⎇ⓥ⾌
ߣߒߡㆇ↪ߢ߈ࠆ⁁ᘒߦߥ޿‫ޕ‬ᤚ㕖ߣ੍߽▚㈩ಽࠍⷐ᳞ߒߚ޿‫ޕ‬࡮ ᒰ࠮ࡦ࠲࡯ߩᬺോߪ㧘ߔߴߡߩ⻠ᐳ㧘⸻≮⑼ߩᬺോߣ౒ㅢߒߚࠅ㧘ዋߥ߆ࠄߕᓇ㗀ࠍ෸߷ߒߚࠅߔࠆ
ߎߣ߇⠨߃ࠄࠇࠆ‫⃻ޕ‬࿷ CRM ㆇ༡ᆔຬળߢ⺞ᢛࠍ࿑ߞߡ޿ࠆߣߎࠈߢ޽ࠆ߇㧘තᓟ⥃ᐥ⎇ୃ࠮ࡦ࠲࡯㧘ක≮ㅪ៤࠮ࡦ࠲࡯ߥߤࠍߪߓ߼ߣߒߚ∛㒮ߩㇱ㐷߿ᢎോෘ↢ᆔຬળ㧘౉⹜ᆔຬળߥߤߩࡔࡦࡃ࡯
߇৻ၴߦળߒߡ⸛⼏ߔࠆᆔຬળߢ޽ࠆߴ߈ߣ⠨߃ࠄࠇࠆ‫ ߪ޿ࠆ޽ޕ‬CRM ߽฽߼ߚ࿾ၞක≮ߩ⸻≮࡮ᢎ⢒࡮⎇ⓥߦ㑐ࠊࠆᆔຬળ࡮ળ⼏߇ᔅⷐߢ޽ࠈ߁‫ޕ‬࡮ ࿾ၞක≮ࠍᜂ߁ක≮ੱࠍ⢒ᚑߔࠆᜰዉ⠪ߩᆫ൓ߩ⛔৻ൻ߇ਇචಽߢ޽ࠆ‫ޕ‬ቇౝᄖߩ⋵ౝฦක≮ᣉ⸳ߩᜰዉ⠪߇৻ਣߣߥߞߡ࿾ၞක≮ੱࠍ⢒ᚑߔࠆࡑࠗࡦ࠼ࠍ৻ߟߦߔߴߊ࿾㆏ߥദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ٤੹ᓟߩข⚵ߺ㧔ᣂߚߦขࠅ⚵߻߽ߩ߿੹ᓟ㧘లታߔࠆ߽ߩ㧕࡮ ‫ߩ⁁⃻ޟ‬ข⚵ߺ‫߮ࠃ߅⛯⛮ߩߡߴߔޠ‬లታ࡮ ࿾ၞක≮ߦ㑐ߔࠆࠞ࡝ࠠࡘ࡜ࡓߩߐࠄߥࠆలታ㧔࿾ၞᨒ౉ቇ↢ࠍ฽ࠎߛోකቇ⑼ቇ↢߇ኻ⽎㧕㧦
3 ᐕ↢㧦3 ࡩ᦬㑆࿾ၞක≮ᣉ⸳߳ߩ㈩ዻ㧔ㆬᛯᕈ㧕
5㧙6 ᐕ↢㧦ቇᄖ⥃ᐥታ⠌ߩ᜛ల㧔᜚ὐ∛㒮ߦട߃㧘߳߈࿾⸻≮ᚲ߽߳ታ⠌දജⷐ⺧㧕࡮ ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ߦ߅ߌࠆೋᦼ⥃ᐥ⎇ୃࡊࡠࠣ࡜ࡓߩ⾰⊛ᡷༀ㧦⥃ᐥ⎇ୃࡊࡠࠣ࡜ࡓߦ㑐ߔࠆࡕ࠺࡞੐ᬺߢ㧘⃻࿷කᏧਇ⿷߇ᷓೞߥዊఽ⑼㧘↥ᇚੱ⑼㧘ᢇᕆ㧘ౝ⑼㧘
ᄖ⑼ߩߘࠇߙࠇߦߟ޿ߡ㧘․೎ࠦ࡯ࠬߩ⎇ୃࡊࡠࠣ࡜ࡓࠍᣂ⸳

㧙㧙⧯ᚻᢎຬࠍਛᔃߣߒߚ‫ ࠻ࠢࠚࠫࡠࡊޟ‬30‫ߜ┙ߩޠ‬਄ߍ㧧ᧄቇߢߩೋᦼ⥃ᐥ⎇ୃߩࡑ࠶࠴ࡦࠣታ❣ࠍ㜞߼ࠆߚ߼ߩᣇ╷㧔ᜰዉ૕೙ߩ⾰⊛ะ਄㧕ߩ⛮⛯ᬌ⸛࡮ ᓟᦼ⎇ୃࡊࡠࠣ࡜ࡓߦ߅ߌࠆ࿾ၞක≮ࡈࠖ࡯࡞࠼ߩᵴ↪
‫ޟ‬ጘ㒂⋵⦟කࡊࡠࠫࠚࠢ࠻‫ޟޠ‬㘧㛗⿒߆߱ක⠪ࡊࡠࠫࠚࠢ࠻‫ޠ‬㧧ᓟᦼ⎇ୃࡊࡠࠣ࡜ࡓߣߒߡ㧘࿾ၞක≮ߦ㑐ࠊࠆฦක≮ᣉ⸳ߢ᏷ᐢ޿⥃ᐥᛛⴚࠍりߦߟߌߚᮮᢿ⊛✚ว⥃ᐥකߩ⢒ᚑࠍⴕ߁࡮ ࡕ࠺࡞࿾඙࿾ၞਛᩭ∛㒮╬ߢߩ⸻≮ᡰេߩ᜛ల㧔ਛỚ࡮᧲Ớ࡮⷏Ớක≮࿤߳㗅ᰴ᜛ల㧕࡮ ቇౝߩߺߥࠄߕ㧘⋵ౝක≮ᣉ⸳ߩක≮ੱ⢒ᚑᜰዉ⠪ࠍኻ⽎ߣߒߚ FD ߩታᣉ࡮ ో࿖ߩ࿾ၞක≮㑐ଥ⻠ᐳߣߩㅪ៤࡮දജ૕೙ߩ⏕┙㧔࿾ၞක≮㑐ㅪ⻠ᐳࡀ࠶࠻ࡢ࡯ࠢ㧕㧙㧙㧔4㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ᄖ⑼ᢇᕆ♽ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
࿾ၞක≮කቇ࠮ࡦ࠲࡯ߢߪ㧘࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ㧘ਛጊ㑆࿾ၞࠍߐߐ߃ࠆࡋ࡝ࠦ
ࡊ࠲࡯៝ㅍߩ㊀ⷐᕈ㧘⣻ㇱᄢേ⣂≜⎕ⵚᢇ๮ߩߚ߼ߩᢇᕆ៝ㅍߩ㊀ⷐᕈ㧘࿾ၞᨒ౉⹜ቇ↢ߩࠠࡖ࡝ࠕࠕ࠶
ࡊߩߚ߼ߩኾ㐷ක⎇ୃࠕࡦࠤ࡯࠻⺞ᩏ╬ࠍ⎇ⓥႎ๔ߒߡ޿ࠆ‫ޕ‬߹ߚ㧘ᶖൻེᄖ⑼ߩ⎇ⓥಽ㊁ߢߪ㓚ኂ⢄ߩᴦ≮߿ⴚᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥࠍਛᔃߦㅴ߼ߡ޿ࠆ‫ޕ‬㓚ኂ⢄ߩᴦ≮ߪ㧘NASH ⢄⎬ᄌߦኻߒ h-HGF ࠍㆮવሶዉ౉ߔࠆߎߣߦࠃࠅ⢄✢⛽ൻߩᛥ೙߇น⢻ߢ޽ࠆߎߣࠍ
⏕⹺ߒߚ‫ⴚޕ‬ᓟ⢄ౣ↢ߦ㑐ߔࠆ⎇ⓥߪ㧘⢄⒖ᬀᤨߩ⢄㕒⣂ౣᑪਇ⦟ߢ໧㗴ߣߥࠆ߁ߞⴊߦࠃࠆ⢄ౣ↢ਇ⦟ㇱಽࠍ G-CSF ߢᡷༀߢ߈ࠆߎߣࠍ␜ߒߚ‫ߚ߹ޕ‬㧘ᄢ㊂⢄ಾ㒰೨ߦⴕ߁㐷⣂ႧᩖⴚࠍੑᲑ㓏ߦಽߌߡⴕ߁
ߎߣߦࠃࠅ㧘ࠃࠅᄢ߈ߥ⢄ౣ↢߇ᓧࠄࠇࠆߎߣࠍ᣿ࠄ߆ߦߒߚ‫⃻ޕ‬࿷ NFNB 㒖ኂ೷ߦࠃࠆ NASH ⢄ߩ⯯ⴊ⠴ኈ⢻ᡷༀ㧘LPS ᗵ૞ߦࠃࠆⴚᓟ⢄ਇో੍㒐㧘ᄢᑪਛḡߦࠃࠆᄢ㊂⢄ಾ㒰ᓟ⢄ౣ↢ᡷༀ㧘PGI2 ߦࠃࠆ㐽Ⴇᕈᄢ⣺Ἳߩᴦ≮㧘᛫⩶ࡍࡊ࠴࠼ߦࠃࠆ૕ౝੱᎿ‛ᗵᨴߩᴦ≮ࠍ⎇ⓥਛߢ޽ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ጊ↰ථ਽
⥃ᐥ⻠Ꮷ㧦 ᾢ↰ᕺ੺

Takuya Yamada
Keisuke Kumada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚3 ᐲߩ㐿⣻ᚻⴚߦࠃࠅᢇ๮ߒߚ഍∝ဳࠕࡔ࡯ࡃᕈᄢ⣺Ἳߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦122㧙126㧚
2㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚⿥㖸ᵄౝⷞ㏜ਅๆᒁ⚦⢩⸻߇᦭ലߢ޽
ߞߚ㕖ᯏ⢻ᕈ⤟ፉ⚦⢩⣲ߩ 1 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦429㧙433㧚
3㧕 ችේ೑ⴕ㧘㘵↰ㄖ⟤㧘ᓟ⮮ోብ㧘᳓⼱ᙗᆭ㧘቟᧛ᐙᄩ㧘᫜ᯅବ੺㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚㥘ᓘࡋ࡞࠾ࠕ߇
㑐ਈߒߚߣ⠨߃ࠄࠇࠆ㊎㊄ߦࠃࠆ࿁⣺⓫ሹߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦455㧙458㧚
4㧕 ᧻የ ᶈ㧘ጊ↰ථ਽㧘㑸㊁⠨ผ㧘ศ↰⋥ఝ㧘ᧁጊ ⨃㧘ጤ↰ ዏ㧘⊕ᯅᐘᵗ㧘┻᧛ඳᢥ㧚Hand-assisted
laparoscopic surgery(HALS)ਅߦ⣛⤳៰಴ⴚࠍⴕߞߚ⣛Ἳ∝ᕈன⣲≌ߩ 1 ଀㧘ᣣᧄౝⷞ㏜ᄖ⑼ቇળ㔀⹹
2006 ᐕ㧧11 Ꮞ㧦185㧙189㧚
5㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘㑸㊁⺈ผ㇢㧘ᧁጊ ⨃㧘ฬ⍮ ␽㧘㑸㊁⠨ผ㧘㒋ᧄ⎇৻㧘┻᧛ඳᢥ㧚ⴚᓟ 4 ᐕ㑆ήౣ⊒↢ሽਛߢ޽ࠆ⍹Ἧൻ⢗≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦841㧙844㧚
6㧕 ችේ೑ⴕ㧘ᧁጊ ⨃㧘᧻የ ᶈ㧘㑸㊁⠨ผ㧘ጊ↰ථ਽㧘┻᧛ඳᢥ㧚D-fetoprotein ↥↢⚿⣺≸ߩ 1 ଀㧘ᣣᧄ
⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦149㧙153㧚
7㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘┻᧛ඳᢥ㧚⤟ౝ೽⣛ߦว૬ߒߚ㘃਄⊹⣲ߩ 2 ଀㧘ᣣᧄ⥃ᐥᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧67 Ꮞ㧦196㧙200㧚
8㧕 ጊ↰ථ਽㧘㑸㊁⠨ผ㧘᧻የ ᶈ㧘੗ේ 㗉㧘ᧁ᧛⌀᮸㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ೋ࿁ᚻⴚᄢ㊂಴ⴊᓟ㧘ੑᦼ⊛ߦಾ㒰ߒߚ㛽⋚⊒↢ Solitary fibrous tumor ߩ 1 ଀㧘ᣣᧄ⣻ㇱᢇᕆකቇળ㔀⹹ 2006 ᐕ㧧26 Ꮞ㧦889
㧙892㧚
9㧕 㑸㊁⠨ผ㧘ጊ↰ථ਽㧘ศ↰⋥ఝ㧘ችේ೑ⴕ㧘ᧁጊ ⨃㧘┻᧛ඳᢥ㧚ᕆᕈ㛽㜑න⃿ᕈ⊕ⴊ∛ᴦ≮ਛߦ⊒↢ߒߚ⢄⤥≌ߦኻߒ㧘⣻⣧㏜ਅ⤥≌㐿⓹ⴚࠍᣉⴕߒߚ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦975㧙978㧚10㧕 ᧁ᧛⌀᮸㧘ጊ↰ථ਽㧘ᧁጊ ⨃㧘㑸㊁⠨ผ㧘┻᧛ඳᢥ㧚ERCP ᓟ⤟Ἳߩᓟߦ⢄Ꮐ⪲ಾ㒰ⴚࠍᣉⴕߒⴚᓟ⤟⤥≌ࠍ⊒↢ߒߚ⢄ౝ⢙▤≸ߩ 1 ଀㧘ᣣᧄᄖ⑼♽ㅪวቇળ⹹ 2006 ᐕ㧧31 Ꮞ㧦979㧙982㧚
11㧕 ᣧᎹ㤗ℂሶ㧘᧛ἑ૫ઍሶ㧘ጊ↰ථ਽㧘ጤ↰ዏ㧘┻᧛ඳᢥ㧚ዊఽ㗔ၞߦ߅ߌࠆ NST(ᩕ㙃ࠨࡐ࡯࠻࠴࡯ࡓ)ߩ
⃻⁁ߣ໧㗴ὐ ዊఽ NST ߦ߅ߌࠆᩕ㙃჻ߩᓎഀ ᩕ㙃㓚ኂᖚఽߦኻߔࠆ๟ⴚᦼᩕ㙃▤ℂ㧘ዊఽᄖ⑼
2007 ᐕ㧧39 Ꮞ㧦823㧙827㧚
12㧕 ᾢ↰ᕺ੺㧘ศ↰㓉ᶈ㧘⼾↰ᴰ㧘ጊ↰ථ਽㧘᧛਄໪㓶㧘ዊୖ⌀ᴦ㧚࿾ᣇߦ߅ߌࠆᢇᕆක≮૕೙ߩ⃻⁁ߣ໧㗴ὐ ੹㧘૗߇ᔅⷐߢ޽ࠆ߆㧘߳߈࿾࡮㔌ፉᢇᕆක≮⎇ⓥળ⹹ 2008 ᐕ㧧9 Ꮞ㧦75㧙78㧚
13㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚㔚ሶࠞ࡞࠹ߪ⚕ࠞ࡞࠹ࠍ⿧߃ࠆߎߣ߇ߢ߈ࠆ߆㧘ᣣᧄක੐ᣂႎ 2007 ᐕ㧧
4360㧦80㧙84㧚
14㧕 ᾢ↰ᕺ੺㧘⑔↰లብ㧘ዊୖ⌀ᴦ㧘ጊፒ㕒ᄦ㧚ᶖ㒐㒐ἴࡋ࡝ࠍ೑↪ߒߚᢇᕆ៝ㅍ㧘ᣣᧄ⥶ⓨක≮ቇળ⹹ 2007
ᐕ㧧8 Ꮞ㧦15㧙19㧚
15㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ⓨ᷼ἴኂߦ߅ߌࠆ✕ᕆක≮૕೙ߩ໧㗴ὐ㧘ᣣᧄ⥃ᐥක≮ቇળ⹹ 2007 ᐕ㧧
10 Ꮞ㧦603㧙608㧚㧙㧙

16㧕 Kumada K, Fukuda F. Successful treatment of penetrating cardiac injury㧘㜞⍮ක≮࠮ࡦ࠲࡯කቇળ⹹
2008 ᐕ㧧2 Ꮞ㧦23㧙26㧚
17㧕 ᾢ↰ᕺ੺㧘⼾↰ ᴰ㧘ዊୖ⌀ᴦ㧚ᖱႎᛛⴚࠍ೑↪ߒߚᢇᕆක≮ᡰេ࡮ᢇᕆᖱႎ౒᦭ࠪࠬ࠹ࡓߩ᭴▽ℂᗐߣߐࠇࠆ⣖තਛᖱႎ౒᦭ࠪࠬ࠹ࡓ㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦222㧙223㧚
18㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᄐߦࠃߊ⷗ࠄࠇࠆ∔ᖚ ᾲਛ∝㧘Emergency care 2008 ᐕ㧧21 Ꮞ㧦36
㧙43㧚
19㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᄐߦࠃߊ⷗ࠄࠇࠆ∔ᖚ ṃ᳓㧘Emergency care 2008 ᐕ㧧21 Ꮞ㧦44㧙
50㧚
20㧕 ᾢ↰ᕺ੺㧘ዊୖ⌀ᴦ㧘⑔↰లብ㧚ᄐߦࠃߊ⷗ࠄࠇࠆ∔ᖚ 㘩ਛᲥ㧘Emergency care 2008 ᐕ㧧21 Ꮞ㧦51
㧙57㧚21㧕 ᾢ↰ᕺ੺㧚๭ๆེ♽ߩ✕ᕆಣ⟎ ᳇▤ᝌ▤㧘੹ᣣߩᴦ≮ᜰ㊎ 2008  2008 ᐕ㧦78㧙80㧚✚⺑㧔᰷ᢥ㧕
1㧕 Kumada K, Toyoda I, Ogura S, Fukuda A. A case of traumatic sinus thrombosis. Neurosurg Emerg㧚
2008;13:94-97.
ේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Yoshida N, Iwata H, Yamada T, Sekino T, Matsuo H, Shirahashi K, Miyahara S, Kiyama S, Takemura
H. Improvement of the survival rate after rat massive hepatectomy due to the reduction of apoptpsis
by caspase inhibitor. J Gastroen Hepatol. 2007;22:2015-2021㧚
IF 1.673
2㧕 Kiyama S, Yamada T, Iwata H, Kimura M, Miyahara T, Umeda Y, Yahida N, Matsuo H, Sekino T,
Miyazaki J, Kosugi K, Matsumoto K, Takemura H. Reduction of fibrosis in fatty cirrhosis liver byhuman HGF gene transfection using electroporation. J Gastroen Hepatol. 2008;23:471-476.
IF 1.673

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ጊ↰ථ਽㧘⎇ⓥಽᜂ⠪㧦ጤ↰ ዏ㧘㑐㊁⠨ผ㧘ᧁ᧛⌀᮸㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ⴚ೨ൻቇ≮ᴺᓟ⢽⢌ᕈ⢄Ἳߦኻߔࠆ᛫ࡅ࠻ TNFDࡕࡁࠢࡠ࠽࡯࡞᛫૕≮ᴺߩ㐿⊒㧧ᐔᚑ 19㧙21 ᐕ
ᐲ㧧4,820 ජ౞(4,420㧦300㧦100 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬጊ↰ථ਽㧦
1㧕 ᣣᧄᄖ⑼ቇળઍ⼏ຬ(㨪ᐔᚑ 20 ᐕ 2 ᦬)
2㧕 ᣣᧄ⢄⢙⤟ᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⢗≸ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᧲ᶏᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)ᾢ↰ᕺ੺㧦1㧕 ᣣᧄᢇᕆකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⥃ᐥᢇᕆකቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ߥߒ㧙㧙

3㧕ቇⴚ㔀⹹ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊ↰ථ਽㧦
1㧕 International College of Surgeons 17th Joint Congress of Asia & Pacific Federations & 53rd
Annual Congress of the Japan Section (2007, Kyoto, Simposist) 2㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘࠺ࠫ࠲࡞ࡐࠬ࠲࡯࠮࠶࡚ࠪࡦ‫(⤟ޟ‬ᕆᕈ⤟Ἳ࡮ߘߩઁ)‫ޠ‬ᐳ㐳)
3㧕 ╙ 108 ࿁ᣣᧄᄖ⑼ቇળ(ᐔᚑ 20 ᐕ 5 ᦬㧘㐳ፒ㧘‫ޟ‬⢗(ㆮવሶ⸻ᢿ)‫ޠ‬ᐳ㐳)
4㧕 ᶖൻེ≸ൻቇ≮ᴺࠪࡦࡐࠫ࠙ࡓ-࠴࡯ࡓක≮(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘╙ 1 ㇱ ⻠Ṷ 1 Ṷ⠪ ੩ㇺᄢቇ ᧻ᧄ❥Ꮘ)ᐳ㐳)
5㧕 ╙ 35 ࿁ CNP ⎇ⓥળ(ᣣᧄ⥃ᐥᩕ㙃≮ᴺ⎇ⓥળ)(ᐔᚑ 20 ᐕ 12 ᦬㧘ᗲ⍮㧘‫ޟ‬ᩕ㙃▤ℂߦᔅⷐߥᶖൻེ
ᄖ⑼ߩ⍮⼂‫ޠ‬Ṷ⠪)ᾢ↰ᕺ੺㧦
1㧕 ╙ 10 ࿁ᣣᧄ⥃ᐥᢇᕆකቇળ✚ળ(ᐔᚑ 19 ᐕ 5 ᦬㧘␹ᚭ㧘‫࡞ࡃࡦࡏޟ‬ᯏ⢵૕⌕㒽ߦ߅ߌࠆኻᔕ‫ޠ‬Ṷ⠪)‫ࠢ࠶࠲ࠕࡦࠗ࡟ࡉޟ‬⣖ࠍᢇ߅߁‫ޠ‬Ṷ⠪)
2㧕 ╙ 10 ࿁⣖තਛࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 19 ᐕ 5 ᦬㧘㜞⍮㧘
3㧕 ╙ 14 ࿁ᣣᧄ⥶ⓨක≮ቇળ✚ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ජ⪲㧘‫ޟ‬ⓨ᷼ἴኂ߳ߩක≮ኻᔕ‫ޠ‬Ṷ⠪)
4㧕 ╙ 35 ࿁ᣣᧄ㓸ਛᴦ≮කቇળ✚ળ(ᐔᚑ 20 ᐕ 2 ᦬㧘᧲੩㧘‫ޟ‬㔚ሶࠞ࡞࠹ࠪࠬ࠹ࡓߩ໧㗴ὐ‫ޠ‬Ṷ⠪)‫ޟ‬ᖱႎᛛⴚࠍ೑↪ߒߚᢇᕆක≮ᡰេ‫ޠ‬Ṷ⠪)
5㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘
6㧕 ╙ 36 ࿁ᣣᧄᢇᕆකቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ർᶏ㆏㧘‫▤ޟ‬ℂ࡮ㆇ༡㧠‫ޠ‬ᐳ㐳)7㧕 ╙ 15 ࿁ᣣᧄ⥶ⓨක≮ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘᧻ᳯ㧘‫ޟ‬ਛጊ㑆࿾ၞࠍߐߐ߃ࠆࡋ࡝ࠦࡊ࠲࡯៝ㅍ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠ
1㧕 ጊ↰ථ਽㧘㑐㊁⠨ผ㧘᧻የ ᶈ㧦ࠗࡦࡇ࡯࠳ࡦࠬ CT ࠍ↪޿ߚ࠮ࡦ࠴ࡀ࡞࡝ࡦࡄ▵ᬌ಴ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ ᐔᚑ 15 ᐕᐲ㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(2007 ᐕ 3 ᦬)
11㧚ႎ㆏1㧕 ጊ↰ථ਽㧦ዊᨋᑪม㧘㜞ᯅቁᄦ㧘ጊ↰ථ਽㧘⨹ᧁኡม㧘ട⮮ᶈ᮸㧘⿷┙ዅੳ㧘᧻੗ᐽม㧦‫ޟ‬ᄢ⣺≸ൻቇ ≮ ᴺ ߩ ⃻ ⁁ ߣ ੹ ᓟ ‫  ޠ‬ጘ 㒂 ࿾ ඙ ߦ ߅ ߌ ࠆ ᄢ ⣺ ≸ ൻ ቇ ≮ ᴺ ߩ ᥉ ෸ ߣ ቯ ⌕  㧦 MEDICAMENT
NEWS(2007 ᐕ 9 ᦬ 15 ᣣ)
2㧕 ጊ↰ථ਽㧦ዊᨋᑪม㧘㜞ᯅቁᄦ㧘ጊ↰ථ਽㧘⨹ᧁኡม㧘ട⮮ᶈ᮸㧘⿷┙ዅੳ㧘᧻੗ᐽม㧦‫ޟ‬ᄢ⣺≸ൻቇ ≮ ᴺ ߩ ⃻ ⁁ ߣ ੹ ᓟ ‫  ޠ‬ጘ 㒂 ࿾ ඙ ߦ ߅ ߌ ࠆ ᄢ ⣺ ≸ ൻ ቇ ≮ ᴺ ߩ ᥉ ෸ ߣ ቯ ⌕  㧦 MEDICAMENT
NEWS(2007 ᐕ 9 ᦬ 15 ᣣ)
3㧕 ጊ↰ථ਽㧦࿾ၞක≮කቇ࠮ࡦ࠲࡯ ᄖ⑼ᢇᕆ♽ಽ㊁ ᢎ᝼ዞછ᜿ᜦ㧦ጘ㒂⋵∛㒮ᤨႎ╙ 45 ภ(2008ᐕ 3 ᦬ 31 ᣣ)
4㧕 ጊ↰ථ਽㧦‫⎇ޟ‬ⓥቶ߆ࠄᄢቇߪ੹‫ޠ‬⢄⤳≸ᚻⴚ㧘ౣ↢ࠍ⠨ᘦ㧦ጘ㒂ᣂ⡞(2008 ᐕ 7 ᦬ 22 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᢎ⢒ᵴേߦߟ޿ߡ࡮ ਅํ᷷ᴰ∛㒮⎇ୃකᄖ⑼♽ࠞ࡝ࠠࡘ࡜ࡓࠍ૞ᚑߒߚ‫ޕ‬࡮ MEDC ߩදജߩ߽ߣߦ㧘ጘ㒂ᄢቇౝߩቇ↢ߣ⎇ୃක߳ะߌߡ㧘ᄖ⑼ቇ↢⧷⺆∝଀⊒⴫㧘Alan Leforవ↢ߣߩࡈ࡝࡯࠺ࠖࠬࠞ࠶࡚ࠪࡦߣ࡟ࠢ࠴ࡖ࡯ࠍⴕߥߞߚ‫ޕ‬࡮ 㒮ᄖᵴേߣߒߡ㧘ጘ㒂⋵┙ਅํ᷷ᴰ∛㒮කዪ࠮ࡒ࠽࡯ߦ߅޿ߡ㧘ਅํ᷷ᴰ∛㒮ߢߩ⎇ୃකᢎ⢒ࠍⴕߞߚ‫ޕ‬ౝኈߪ㨬Surgical Site Infection ߦኻߔࠆ Best Practice‫ޠ‬෸߮㧘ቴຬᢎ᝼ Alan Lefor వ↢ߣߩࡈ㧙㧙࡝࡯࠺ࠖࠬࠞ࠶࡚ࠪࡦࠍⴕߞߚ㧔2007.11.2 ਅํ㧕‫ޕ‬࡮ ╙ 4 ࿁⸻≮ෳടဳ⥃ᐥታ⠌ዉ౉ߩߚ߼ߩࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊᜰዉ⠪㙃ᚑࡢ࡯࡚ࠢࠪ࠶ࡊߦෳ
ട㧘ୃੌߒߚ㧔2007.10.4-6 ⵿㊁㧕‫ޕ‬࡮ ጘ㒂ᄢቇකቇㇱ࿾ၞᨒ౉⹜⺑᣿ળ㧘ጘ㒂ᄢቇ৻ᰴ⹜㛎⋙〈㧘࿾ၞᨒ౉⹜㕙ធࠍⴕߞߚ㧔2007.11.5㧕
‫ޕ‬࡮ ╙ 20 ᐕᐲ౒↪⹜㛎කቇ♽ CBT ໧㗴 ࿾ၞක≮ಽ㊁ࠍ૞ᚑߒߚ‫ޕ‬‫ޕ‬࡮ ጘ㒂ᄢቇ⥃ᐥ⎇ୃᜰዉක⻠⠌ળࠍୃੌߒߚ㧔2008.8.26㧕
⎇ⓥߦߟ޿ߡ
࡮ ╙ 13 ࿁ጘ㒂ᄢቇࠪࡦࡐࠫ࠙ࡓߦෳടߒߚ㧔2007.12.15 ጘ㒂㧕‫ޕ‬࡮ ╙ 44 ࿁ᣣᧄ⣻ㇱᢇᕆකቇળ✚ળ ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ ⣻ㇱᢇᕆ㗔ၞߦ߅ߌࠆ࠴࡯ࡓක≮ߦ߅޿ߡ㧘‫ޟ‬⣻ㇱᄢേ⣂≜⎕ⵚߦኻߔࠆ࠴࡯ࡓක≮ᚢ⇛‫ ޠ‬࿾ၞක≮ߢߩࡋ࡝ࠦࡊ࠲࡯ᢇᕆ៝ㅍߩ㊀ⷐᕈࠍ⊒⴫ߒߚ㧔2008.3.14 ᮮᵿ㧕‫ޕ‬⸻≮ᵴേߦߟ޿ߡ࡮ ਅํ᷷ᴰ∛㒮ߦ 1 ࡩ᦬ߦ 1 ࿁ߩᚻⴚදജࠍቯᦼ⊛ߦⴕߞߚ‫ޕ‬࡮ ቇળ⹺ቯᣉ⸳╬ࠕࡦࠤ࡯࠻⺞ᩏࠍᣉⴕߒߚ‫ޕ‬࡮ M4,M5,M6 ߩቇ↢ߣ⎇ୃකࠍኻ⽎ߣߒߚᄖ⑼ᚻⴚᚻᛛ࠮ࡒ࠽࡯㧔࠼࡜ࠗ࡜ࡏ㧘࠙ࠚ࠶࠻࡜ࡏ㧕ࠍ 2࿁㐿௅ߒߚ‫ޕ‬ቇౝᵴേߦߟ޿ߡ࡮ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ㆇ༡ᆔຬળ㧘CRM ࠬ࠲࠶ࡈળ⼏ߦቯᦼෳടߒߚ‫ޕ‬࡮ M4,M5 ㅴ〝ᜰዉ߅ࠃ߮තᓟ⎇ୃวหᆔຬળ㧔2008.1.9㧕ෳടߒߚ‫ޕ‬࡮ ᐔᚑ 20 ᐕᐲጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮ᓟᦼ⥃ᐥ⎇ୃ⺑᣿ળ ࿾ၞකቇ࠮ࡦ࠲࡯ࠍ⚫੺ߒߚ‫ޕ‬␠ળᵴേߦߟ޿ߡ࡮ ࿾ၞක≮ᝄ⥝දળጘ㒂⋵ᡰㇱળ㧔2007.12.1 ጘ㒂㧕ߢ࿾ၞකቇ࠮ࡦ࠲࡯ࠍ⚫੺ߒߚ‫ޕ‬࡮ 㘧㛗࿾ၞක≮ㅪ៤Ḱ஻ᙣ⺣ળ㧔2007.9.7 㜞ጊ㧕㧘╙ 3 ࿁㘧㛗࿾ၞක≮ㅪ៤ળ⼏࡮㘧㛗ർㇱ࿾ၞක≮ㅪ៤දቯ✦⚿ᑼ㧔2008.4.25 㜞ጊ㧕╙ 4 ࿁㘧㛗࿾ၞක≮ㅪ៤ળ⼏㧔2008.11.13 㜞ጊ㧕ߦෳടߒߚ‫ޕ‬࡮ ࿾ၞක≮කቇ࠮ࡦ࠲࡯ࡎ࡯ࡓࡍ࡯ࠫࠍ㐿⸳ߒߚ‫ޕ‬ో૕ߩ⹏ଔߣߒߡ࡮ ᢎ⢒ᵴേߪ㧘ో૕ߣߒߡ㗅⺞ߦⴕߞߚߣ⠨߃ࠆ‫ޕ‬࡮ ⎇ⓥᵴേߪ㧘Უ૕ಽ㊁ߩ⎇ⓥߩߺߢߥߊ㧘࿾ၞක≮කቇ࠮ࡦ࠲࡯ߣߒߡߩ⎇ⓥᬺ❣ࠍ਄ߍߡ޿ߊᔅⷐ
߇޽ࠆ‫ޕ‬࡮ ⸻≮ᵴേߪ㧘߽߁ዋߒᄖ⑼⸻≮ᡰេߩ㊂ࠍჇ߿ߒ㧘ౝኈߣߒߡ㏜ⷞਅᚻⴚ╬߽ᐢ߼ߡ޿ߊᔅⷐ߇޽ࠆ‫ޕ‬࡮ ቇౝᵴേ㧘␠ળᵴേ߽㧘ߐࠄߦⓍᭂ⊛ߦෳടߔࠆᔅⷐ߇޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷࡮ ࿾ၞᨒቇ↢ࠍਛᔃߣߒߚᄖ⑼ᢇᕆ♽࿾ၞ⎇ୃᢎ⢒ࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆᔅⷐ߇޽ࠆ‫ޕ‬࡮ ⺰ᢥᬺ❣߇ਇ⿷ߢ޽ߞߚ‫ޕ‬ᢇᕆ៝ㅍ╬ߩߺߢߥߊ㧘ጘ㒂⋵ౝߩᄖ⑼ᚻᛛߩဋ╬ൻ㧘ᴦ≮ߩဋ╬ൻߦߟ޿ߡ㧘ቇળ⊒⴫࡮⺰ᢥ૞ᚑࠍㅴ߼ߚ޿‫ޕ‬࡮ ⃻࿷ߩ⢄ౣ↢ߩ⎇ⓥߦߟ޿ߡߪ㧘ᓟㅴߩᜰዉߦ޽ߚࠅ㧘ߔߢߦ㧘⊒⴫ߒߡ޿ࠆ⢄ಾ㒰ᴺ㧘ᚻⴚㇱ૏ᗵᨴ╬ߩ⥃ᐥ⎇ⓥ߽⺰ᢥᬺ❣ߣߒߡᱷߔࠃ߁ߦദ߼ߚ޿‫ࠍ⾌⎇⑼ޕ‬₪ᓧߒߚⴚ೨ൻቇ≮ᴺᓟ⢽⢌ᕈ⢄Ἳߦኻߔࠆ᛫ࡅ࠻ TNFDࡕࡁࠢࡠ࠽࡯࡞᛫૕≮ᴺߩ㐿⊒ߦߟ޿ߡߪ㧘⍴ᦼߢᬺ❣ࠍᱷߔࠃ߁ߦദ߼ߚ޿‫ޕ‬࡮ ਅํ᷷ᴰ∛㒮ߩᚻⴚ⸻≮ᡰេߪ㧘ᄢቇ∛㒮ߣਅํ᷷ᴰ∛㒮ߩᛛⴚ੤ᵹߣ޿߁ᗧ๧ߢ᦭↪ߢ޽ߞߚߣ⠨߃ߡ޿ࠆ‫੹ޕ‬ᓟߪቯᦼᡰេએᄖߦⷐ⺧߇޽ߞߚ႐วߦߪ㧘ోߡኻᔕߒߚ޿‫ޕ‬࡮ ቇળ⹺ቯᣉ⸳╬ࠕࡦࠤ࡯࠻⺞ᩏߪ㧘੹ᓟߩ࿾ၞᨒቇ↢ߩࠠࡖ࡝ࠕࠕ࠶ࡊߩᜰ㊎߇૞ࠇࠆࠃ߁ߦ㧘ߐࠄߦㅴ߼ߡ޿߈ߚ޿‫ޕ‬੹ᓟߩዷᦸ࡮ ᢎ⢒ᵴേߪ㧘ෳടဳ⥃ᐥታ⠌ߩታ〣ࠍㅴ߼ߡ޿ߊߣ౒ߦ㧘࿾ၞᨒផ⮈౉⹜ቇ↢ࠍኻ⽎ߦ㧘࠮ࡒ࠽࡯߿
⋥ធᜰዉࠍㅢߒߡ㧘ታ〣⊛ߥ࿾ၞක≮ࠍᢎ⢒ߔࠆ‫ߚ߹ޕ‬㧘⃻࿷ⴕߞߡ޿ࠆᄖ⑼ᚻⴚᚻᛛ࠮ࡒ࠽࡯ࠍ⊒ዷߐߖ㧘േ‛ታ㛎᫟ࠍ೑↪ߒߡࠕ࠾ࡑ࡞࡜ࡏ߇น⢻ߣߥࠆࠃ߁ߦ⸘↹ߒߡ޿ࠆ‫ޕ‬࡮ 㘧㛗ർㇱ࿾ၞක≮ㅪ៤දቯ✦⚿ߪᄢቇ㑆࡮∛㒮㑆ࠍ⿧߃ߚ࿾ၞක≮ߩᢎ⢒૕೙ߩ⏕┙ߦ᦭↪ߢ޽ࠅ㧘੹ᓟ߽㘧㛗࿾ၞක≮ᡷༀߩߚ߼㘧㛗࿾ၞක≮ㅪ៤ද⼏ળߦ⛮⛯ෳടߒߡ޿ߊ੍ቯߢ޽ࠆ‫ޕ‬㧙㧙㧔5㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔ዊఽ♽ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
ᄙߊߩ∔ᖚߪ㧘ㆮવ⊛ⷐ࿃ߣⅣႺⷐ࿃ߩਔ⠪ߦࠃࠅߘߩ⊒∝߇ⷙቯߐࠇߡ޿߹ߔ‫ޕ‬ㆮવ⊛ⷐ࿃ߣᲧセߔࠆߣⅣႺⷐ࿃ߦߟ޿ߡߪ㧘ᄙߊߩ࿃ሶ߇㑐ਈߔࠆߎߣ߽޽ࠅ㧘ਇ᣿ߥὐ߇ዋߥߊ޽ࠅ߹ߖࠎ‫ޕ‬Ყセ⊛ဋ৻ߥ࿾ၞࠍኻ⽎ߦㆬ߮Ყセߔࠆߎߣߢ㧘∔∛ߩㆮવⷐ࿃㧘ⅣႺⷐ࿃ߩ㑐ਈࠍ᣿ࠄ߆ߦߒ߹ߔ‫ޕ‬ᗵᨴ∝㧘ࠕ࡟࡞ࠡ࡯㧘఺∉㧘↢ᵴ⠌ᘠ∛㧘ᖡᕈ⣲≌ߥߤ߶ߣࠎߤߔߴߡߩ∔ᖚࠍኻ⽎ߣߒ߹ߔ‫ޕ‬ᶏᄖߢߪ࿾ၞක≮ᖱႎߩࡀ࠶࠻ࡢ࡯ࠢൻ߇ߔߢߦㅴⴕߒߡ޿߹ߔ߇㧘ᶏᄖߩᖱႎ߽ෳ⠨ߦ㧘࿾ၞක≮ߦ߅ߌࠆ IT ᛛⴚ╬ߩࠪࠬ࠹ࡓߦ㑐ߒߡߩ⎇ⓥ߽ⴕߥߞߡ޿߹ߔ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

㊄ሶ⧷㓶

Hideo Kaneko

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㊄ሶ⧷㓶㧚Chediak-Higashi ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008
ᐕ㧦865㧙866㧚
2㧕 ㊄ሶ⧷㓶㧚Griscelli㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦866.
3㧕 ㊄⧷⧷㓶㧚X ㅪ㎮࡝ࡦࡄჇᱺᕈ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008
ᐕ㧦866㧙867㧚
4㧕 ㊄ሶ⧷㓶㧚ߘߩઁߩ఺∉⺞▵ਇోߩ∔ᖚ㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧
2008 ᐕ㧦867㧚
5㧕 ㊄ሶ⧷㓶㧚⛯⊒ᕈ఺∉ਇో∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦879
㧙883
6㧕 ㊄ሶ⧷㓶㧚ࡌ࡯࠴ࠚ࠶࠻∛㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦910
㧙912
7㧕 ㊄ሶ⧷㓶㧚ࠪࠚ࡯ࠣ࡟ࡦ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦
912㧙913㧚
8㧕 ㊄ሶ⧷㓶㧚⢷⤑Ἳ࡮⤥⢷㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦865㧙
866㧚
9㧕 ㊄ሶ⧷㓶㧚఺∉ᯏ᭴㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦1018㧙1020㧚
10㧕 ㊄ሶ⧷㓶㧚ⶄว఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦338㧙339㧚
11㧕 ㊄ሶ⧷㓶㧚X ㅪ㎮ήࠟࡦࡑࠣࡠࡉ࡝ࡦⴊ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦343㧙344㧚
12㧕 ㊄ሶ⧷㓶㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦345㧙346㧚
13㧕 ㊄ሶ⧷㓶㧚IgA ᰳਲ∝̆ㆬᛯ⊛ IgG ࠨࡉࠢ࡜ࠬᰳਲ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦347㧙348㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kondo N, Matsui E, Kaneko H, Fukao T, Teramoto T, Kato Z, Ohnishi H, Nishimura A. Genetics ofpediatric asthma. In: Pawankar R, Holgate ST, Rosenwasser LJ, eds. Allergy Frontiers, pt1.
Epigenetics, Allergens and Risk Factors, Heidelberg : Springer; 2009:S189-203.
✚⺑㧔๺ᢥ㧕
1㧕 ㊄ሶ⧷㓶㧚ᶧᕈ఺∉ߩ⇣Ᏹߦࠃࠆ఺∉ਇో∝̆ߎߎ߹ߢಽ߆ߞߡ޿ࠆ఺∉ਇో∝୥⟲㧘ዊఽ⑼⸻≮ 2008
ᐕ㧧61 Ꮞ㧦1775㧙1782㧚
2㧕 ㊄ሶ⧷㓶㧚ಽ㘃ਇ⢻ဳ఺∉ਇో∝̆ේ⊒ᕈ఺∉ਇో∝୥⟲㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦48㧙55㧚
3㧕 ᄢ⷏⑲ౖ㧘ട⮮ༀ৻㇢㧘᧘ᗲ⬒㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘⋧㚍๺૫㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧘ᩔየ⽕ੱ㧘⊕Ꮉ᣽ብ㧚ಽሶ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߩ⥃ᐥ߳ߩࠗࡦࡄࠢ࠻࡯IL-18 ෸߮ࠪࠣ࠽࡞વ㆐♽࠲ࡦࡄࠢ⾰᭴ㅧ⸃ᨆߦၮߠߊഃ⮎߳ߩࠕࡊࡠ࡯࠴. ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦1㧚
4㧕 ㊄ሶ⧷㓶㧚Ataxia-telangiectasia ߣߘߩ㘃✼∔ᖚ̆ዊఽ∔ᖚ⸻≮ߩߚ߼ߩ∛ᘒ↢ℂ㧚╙ 4 ዊఽౝ⑼
2008 ᐕ㧧40 Ꮞ(Ⴧೀภ)㧦1314㧙1317.
✚⺑㧔᰷ᢥ㧕ߥߒ㧙㧙ේ⪺㧔๺ᢥ㧕1㧕 ㄭ⮮⋥ታ㧘ᐔጊ⠹৻㇢㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᛬ዬᑪᴦ㧘Ꮉᧄ⟤ᄹሶ㧘⥵ᚭ㆏ᓼ㧘
ᄢ⷏⑲ౖ㧘Ꮉᧄౖ↢㧘᫪↰⑲ⴕ㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘ၳ෹ඳ㧘ᷰㆻ୶ሶ㧚ዊఽ᳇▤ᡰ༎ᕷᖚఽ
ߣⷫ෶ߪ଻⼔⠪ߩ QOL ⺞ᩏ␿◲ᤃᡷ⸓ 2008(GIFU)㧘ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧57 Ꮞ㧦10221033㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Kondo M, Fukao T, Omoya K, Kawamoto N, Aoki M, Teramoto T, Kaneko H, Kondo N. Protein-losing
enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol.
2008;18:63-66.
2㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Anaphylactoid transfusion reactions
associated with a positively charged white-cell reduction filter a case report. Transfus Apher Sci.
2008;38:199-201.
3㧕 Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N. Age-related changes in BAFF andAPRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody
deficiency.Int J Mol Med. 2008;21:233-238㧚
4㧕 Bai CY, Matsui E, Ohnishi H, Kimata K, Kasahara K, Kaneko H, Kato Z, Fukao T, Kondo N. A novel
polymorphism in the 5-lipoxygenase gene associated with bronchial asthma in Japanese children. Int
J Mol Med. 2008;21:139-144.
5㧕 Kondo M, Kaneko H, Fukao T, Suzuki K, Sakaguchi H, Shinoda S, Kato Z, Matsui E, Teramoto T,
Nakano T, Kondo N. The response of bovine beta-lactoglobulin-specific T-cell clones to single aminoacid substitutions of T-cell core epitope. Pediatric Allergy Immu. 2008;19:592-598.
6㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Pediatric synovial sarcoma of the rightmasseter muscle. A case report and review of the literature. Int J Pediatr Otorhi. 2008;3:105-108.
7㧕 Suzuki H, Kaneko H, Rong J, Kawamoto N, Asano T, Matsui E, Kasahara K, Fukao T, Kondo N.
Induction of 1 and 2 gene expression in selective IgA deficiency. Mol Med. 2008;1:395-399.
8㧕 Kawamoto M, Matsui E, Kaneko H, Fukao T, Teramoto T, Kasahara K, Kondo N. IL-10 plays animportant role as an immune-modulator in the pathogenesis of atopic diseases. Mol Med.
2008;1:837-842.
9㧕 Arai T, Kaneko H, Ohnishi H, Matsui E, Fukao T, Kawamoto N, Kasahara K, Kondo N. Hypothermia
augments NF-kappaB activity and the production of IL-12 and IFN-gamma. Allergol Int. 2008;57:4.
10㧕 Taneichi H, Kanegane H, Sira MM, Futatani T, Agematsu K, Sako M, Kaneko H, Kondo N, Kaisho T,
Miyawaki T. Toll-like receptor signaling is impaired in dendritic cell from patients with X-linked
agammaglobulinemia. Clin Immunol. 2008;126:148-154㧚
11㧕 Matsukuma E, Kato Z, Orii K, Asano T, Orii K, Matsui E, Kaneko H, Kondo N. Acute mumps
cerebellitis .withabnormal findings in MRI diffusion weighted images. EUR J Pediatr.
2008;167:829-830

IF 1.252

IF 0.970

IF 1.847

IF 1.847

IF 2.454
IF 0.851

IF 3.551

IF 1.2274㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧦⁛┙ⴕ᡽ᴺੱㄘᬺ࡮↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᯏ᭴ ↢‛♽․ቯ↥ᬺᛛⴚ⎇ⓥᡰេ࠮ࡦ࠲࡯ ↢‛♽↥ᬺഃ಴ߩߚ߼ߩ⇣ಽ㊁Ⲣว⎇ⓥᡰេ੐ᬺ㧦㘩‛ࠕ࡟࡞ࠡ࡯ᖚ⠪ߩ⥃ᐥ௝ߩ⸃᣿߅ࠃ߮ᣂⷙᴦ≮ᴺߩ㐿⊒㧧ᐔᚑ 17㧙21 ᐕᐲ㧧95,000 ජ౞(19,000㧦19,000㧦19,000㧦19,000㧦19,000ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦㊄ሶ⧷㓶㧦⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦᛫૕↥↢ਇో∝ߦ߅ߌࠆᣂߚߥ∛ᘒߩ⸃᣿ߣ⥃ᐥ௝ߣߩ㑐ㅪ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,110 ජ౞(2,110㧦1,000㧦900 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
ߥߒ

㧙㧙

6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㊄ሶ⧷㓶㧦
1㧕 ᣣᧄࠕ࡟࡞ࠡ࡯ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄࠕ࡟࡞ࠡ࡯දળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
㊄ሶ⧷㓶㧦
1㧕 Pathogenesis of primary antibody deficiency Symposium for PID in Asia Riken RCAI (2008. 12
Yokohama, Ṷ⠪)2㧕 ╙ 18 ࿁ጘ㒂⋵ߎߤ߽ߩஜᐽࠍ⠨߃ࠆߟߤ޿(ᐔᚑ 19 ᐕ 10 ᦬㧘ጘ㒂㧘‫ޟ‬ጘ㒂࿾ၞߩዊఽක≮ߣዊఽ଻ஜ̆ጘ㒂⋵ߦ߅ߌࠆዊఽߩ࿾ၞක≮ߣ࿾ၞ଻ஜߩ⏕┙‫ޠ‬Ṷ⠪)
3㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࡒ࠾ࠪࡦࡐࠫ࠙ࡓ 4‫ߦ࡯ࠡ࡞࡟ࠕ੃‐ޟ‬߅ߌࠆ⚻ญ఺∉ኡኈ⺃ዉ㘩ຠߩ૞ᚑ̆㘩‛ࠕ࡟࡞ࠡ࡯⸻≮ߩᣂߒ޿ዷ㐿‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
1㧕 ㊄ሶ⧷㓶㧦╙ 9 ࿁ዊఽකቇᎹ㊁⾨ዊఽၮ␆කቇಽ㊁(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ
㊄ሶ⧷㓶㧦
1㧕 ጘ㒂࿾ၞዊఽᢇᕆක≮૕೙ㅪ⛊ળ⼏ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘㊄ᩕ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢ഭ௛⋭ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ ╙ 1 ࿁⃰ળ⼏✚ળࡊࡠࠣ࡜ࡓ㧦6(2007 ᐕ 1 ᦬)
2㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢⑼ቇ⎇ⓥ
⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦41㧙43(2007 ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
ዊఽ⑼⎇ୃਛߩೋᦼ⎇ୃක߇ 1㧙2 ㅳ㑆㧘ਅํ᷷ᴰ∛㒮╬ߩ࿾ၞਛᩭ∛㒮ߢ⎇ୃߔࠆߎߣߢ㧘ᄢቇ∛㒮ߢߪ⚻㛎ߢ߈ߥ޿࿾ၞߩዊఽක≮ࠍ⚻㛎ߔࠆߎߣ߇ߢ߈ࠆࠃ߁ߦߥࠅ㧘࿾ၞක≮ߩ㊀ⷐᕈࠍ⹺⼂ߢ߈ࠆࠃ߁ߦߥߞߡ߈ߡ޿߹ߔ‫ߚ߹ޕ‬㧘ᜰዉක߽⎇ୃකࠍᜰዉߔࠆߎߣߢ㧘⍮⼂ߩᢛℂ߿ᗧ⼂ߩะ਄ߥߤ߇⹺
߼ࠄࠇߡ޿߹ߔ‫ޕ‬㘧㛗࿾඙ߩ㜞ጊᣣ⿒㧘ෘ↢ㅪਭ⟤ᗲ∛㒮㧘㘧㛗Ꮢ᳃∛㒮ߣ޿ߞߚᲣ૕ಽ㊁߇⇣ߥࠆ∛㒮㑆ߢ㧘කᏧߩⴕ߈᧪߇ߢ߈ࠆࠃ߁ߦߒ㧘ක≮ߩ⏕଻ߦߟߥߍࠆߎߣ߇ߢ߈߹ߒߚ‫ޕ‬ጘ㒂⋵ਅߩዊఽක
≮ߩౣ✬ࠍ㧘ዊఽ⑼කዪߣㅪ⛊ࠍኒߦߣࠅߥ߇ࠄㅴ߼ߡ޿߹ߔ‫ߚ߹ޕ‬㧘ᣣᧄዊఽ⑼ቇળ߇ឭ໒ߒߡ޿ࠆ㧘
ዊఽ⑼࠮ࡦ࠲࡯∛㒮ߦߟ޿ߡߩ╷ቯ߽ㅴ߼㧘ጘ㒂⋵ో૕ߩዊఽ⸻≮૕೙ߩၮ⋚ߠߊࠅࠍផㅴߒߡ޿߹ߔ‫ޕ‬੹ᓟ㧘ౕ૕⊛ߥὐߦߟ޿ߡߪ㧘ߐࠄߦㅴ߼ࠆᔅⷐ߇޽ࠅ߹ߔ߇㧘એ਄ߩᵴേࠍㅢߓߡ㧘ጘ㒂⋵ߩ࿾ၞක≮ߦචಽ⽸₂ߒߡ޿ࠆߣ⠨߃߹ߔ‫ޕ‬㧙㧙㧔6㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔↥⑼♽ಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
↥ᇚੱ⑼කߩ⃻⁁ߪ㧘↥ᇚੱ⑼ක≮ߩ․ᱶᕈߦട߃㧘ක≮ߩ㜞ᐲൻ߳ߩኻᔕ㧘ᖚ⠪߳ߩ⺑᣿㧘ห௥කᏧߩᷫዋ㧘ߐࠄߦߪ᳃੐࡮ೃ੐⸷⸩ߩჇട╬ᖚ⠪ߣߩ࠻࡜ࡉ࡞ߩჇടߦࠃࠅ㧘ഭ௛ⅣႺߪ߹ߔ߹ߔᖡൻߒߡ
޿ࠆ‫ޕ‬ᐘ޿ߥߎߣߦ㧘ጘ㒂⋵ߢߪ৻ㇱߩ⋵ߢ↢ߓߡ޿ࠆ‫↥߅ޟ‬㔍᳃ߩ⊒↢‫ޠ‬‫ޟ‬SOS ᤨߩฃߌ⋁߇ߥ޿‫ߣޠ‬޿߁⁁ᘒߦߪ⥋ߞߡ޿ߥ޿߇㧘ߘߩෂᯏߦἄߒߡ޿ࠆߎߣ߽੐ታߢ޽ࠆ‫ߩߘޕ‬ኻ╷ߦߪ㧘቟ోߥ↥⑼ක≮ࠍ⛽ᜬߔࠆߚ߼ߦߪಽᇂขࠅᛒ޿ᣉ⸳㓸⚂ൻ߇ਇนᰳ‫ޕ‬࡮౏⊛∛㒮ߛ߆ࠄߎߘ಴᧪ࠆක≮߇಴᧪ߥ޿ߚ߼㧘ࡕ࠴ࡌ࡯࡚ࠪࡦߩૐਅߦ❬߇ߞߡ޿ࠆ‫ޕ‬ᱜᏱᅧᆼ࡮ᱜᏱಽᇂߣ޿߁ߩߪ޽ߊ߹ߢ⚿ᨐ⺰ߢ޽ࠅ㧘ߤࠎߥߦᵈᗧࠍᛄߞߡ߽㧘৻ቯߩ⏕┙ߢᲣ૕ᕆᄌ㧘ᄢ㊂಴ⴊ㧘ᣂ↢ఽ઒ᱫ߇⿠ߎࠅ߁ࠆ‫ޕ‬ᓥߞߡ㧘Ᏹᤨ✕ᕆᏢ₺ಾ㐿߇ⴕ߃ࠆ૕೙㧘ߟ߹ࠅᏱൕක߇ 3 ฬએ਄ᔅⷐߦߥࠆ‫ߒ߆ߒޕ‬㧘⃻ታ໧㗴ߣߒߡ㧘ߎߩ᧦ઙࠍߔߴߡߩᣉ⸳ߢࠢ࡝ࠕߔࠆߎߣߪ࿎㔍ߥߚ߼㧘ㆊᷰᦼ⊛ߦ‫ߊ߆ߦߣޟ‬Ᏹൕක 1 ฬߪ⛘ኻㆱߌࠆ‫⋡ࠍߣߎޠ‬ᜰߒߚ‫ޕ‬‫ޟ‬㒢ࠄࠇߚ 㧔ੱ㧘⢻ജ㧕ߩή㚝㆜޿ࠍ㒐߉㧘᦭ലᵴ↪ߔࠆ‫ߦ߼ߚޠ‬㧘Უ૕៝ㅍߩࠪࠬ࠹ࡓࠍ⏕┙ߔࠆߎߣ߇ᔅⷐ‫ޕ‬ㆡಾߥᣉ⸳ߦ៝ㅍߐࠇߥ޿ߣ
࡮Უ૕࡮⢝ఽߦߣߞߡਇ೑⋉࡮ฃߌ౉ࠇᣉ⸳ߩ∛ᐥ࡮ੱຬߩᶉ⾌࡮ᣉ⸳ߩᓧᗧಽ㊁㧔ജ㊂㧕߇↢߆ߐࠇߥ޿
࡮៝ㅍవߣ៝ㅍరߣߩା㗬㑐ଥߩ፣უߣ޿߁໧㗴߇↢ߓࠆ‫ޕ‬⸻≮ฃ⸻ߩࠃ߁ߦ৻⥸ੱ߇៝ㅍవࠍㆬᛯߔࠆߩߢߪߥߊ㧘ቇળ⹺ቯኾ㐷ක࡮Უ૕଻⼔ᴺᜰቯකᏧ߇៝ㅍ
ߔࠆߩߢ㧘⏕┙ߒߚᲣ૕៝ㅍࡑ࠾ࡘࠕ࡞߇޽ࠇ߫㧘ㆡಾߥᣉ⸳ߦ៝ㅍߐࠇߥ޿ߣ޿߁੐ᘒߪㆱߌࠄࠇࠆ‫ޕ‬Უ૕៝ㅍࠪࠬ࠹ࡓ㧘කᏧߩ㓸⚂ൻ㧘↥ᓟ࡮ሶ⢒ߡਛߩᅚකᡰេߥߤࠍ⎇ⓥ⺖㗴ߣߒߚ޿‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦

੹੗◊ᔒ

Atsushi Imai3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ੹੗◊ᔒ㧚ᣣᧄ↢ᱺකቇળ✬㧘ࠣ࡞ࠦࠦ࡞࠴ࠦࠗ࠼ᛩਈᴺ㧦ᣂߒ޿↢ᱺක≮ᛛⴚߩࠟࠗ࠼࡜ࠗࡦ ╙ 3 ᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦184㧙187㧚
2㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧚↥ᇚੱ⑼ᄖ᧪ࡌࠬ࠻࠽ࡆࠥ࡯࡚ࠪࡦ㧨ή᦬⚻㧪㧦⥃ᐥᇚੱ⑼↥⑼ 61 ᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦403㧙413㧚
3㧕 ੹੗◊ᔒ㧚ක⠪߇ߔߔ߼ࠆኾ㐷∛㒮̆ጘ㒂ᄢቇකቇㇱ㒝ዻ∛㒮↥⑼ᇚੱ⑼㧚᧲੩㧦࡜ࠗࡈડ↹㧧2008 ᐕ㧦
324㧙324㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ฎ੗ㄖ㇢㧘੹੗◊ᔒ㧘₹⥢ノᒾ㧚↢ᱺකቇߦ߅ߌࠆ࡝࠱ࡎࠬࡈࠔ࠴ࠫࡦ㉄ߩᓎഀ㧘᧲ᶏ↥⑼ᇚੱ⑼ቇળ㔀⹹ 2007 ᐕ㧧43 Ꮞ㧦1㧙7㧚
2㧕 ੹੗◊ᔒ㧚ጘ㒂࿾඙ߦ߅ߌࠆ๟↥ᦼක≮ࠍ⠨߃ࠆ㧔Უ૕៝ㅍߣ㓸⚂ൻ㧕㧘޿ߜ޿ 2007 ᐕ㧧49 Ꮞ㧦18㧙21㧚
3㧕 ੹੗◊ᔒ㧚ጘ㒂⋵↥⑼ᇚੱ⑼ක≮ߩ໧㗴ὐ(1)㧘޿ߜ޿ 2007 ᐕ㧦50 Ꮞ㧦23㧙26㧚
4㧕 ੹੗◊ᔒ㧚Უ૕៝ㅍᢇᕆࡑ࠾ࡘࠕ࡞࡯↥⑼ක߆ࠄߩⷞὐ—㧘ጘ㒂⋵කᏧળႎ 2008 ᐕ㧧676 ภ㧦18㧙20㧚✚⺑㧔᰷ᢥ㧕
1㧕 Imai A, Furui T, Yamamoto A. Preservation of female fertility during cancer treatment. Reprod Med
Biol. 2008;7:17-27.
ේ⪺㧔๺ᢥ㧕
1㧕 ጊ↰ᣂዏ㧘ዊဈ੗ᕺሶ㧘ᣣᳯ੗㚅ઍሶ㧘᳓㊁ᥓሶ㧘ዊ㊁ᧁ੩ሶ㧘↰਄ᘮሶ㧘૒⮮ᵏ᣽㧘ᮮጊᐽብ㧘੹੗◊ᔒ㧚ᅧᆼ 27 ㅳߢሶች⎕ⵚߦ⥋ߞߚ೨⟎≹⌕⢝⋚ߩ 1 ଀㧘⥃ᐥᇚੱ⑼↥⑼ 2008 ᐕ㧧62 Ꮞ㧦875㧙878㧚㧙㧙ේ⪺㧔᰷ᢥ㧕1㧕 Imai A, Matsunami K, Takagi H. Preoperative value of CT angiography in the laparoscopic removal of
rudimentary uterine horn. Gynecol Surg. 2007;4:199-200.
2㧕 Imai A, Toyoki H, Furui T. Electronic door interference mimicking distress in fetal monitoring. Int J
Gynecol Obstet. 2007;60-61.
3㧕 Furui T, Ohno T, Imai A. Preterm labor in cases with high testosterone condition. J Obstet Gnecol
2007;27:155-156.
4㧕 Imai A, Itoh N, Matsusi K. Direct extension of a sigmoid colon cancer to a uterine leiomyoma andadherent small intestine. Oncologie. 2007;4:1-2.
5㧕 Furui T, Imai A, Ohno T. Pre-term labour in cases with high maternal testosterone levels. J Obstet
Obstet Gynecol. 2007;27:155-156.
6㧕 Mizuno T, Imai A, Hirose Y. Skeletal muscle metastatic and pelvic leiomyosarcomas following
hysterectomy. Int J Gynecol Obstet. 2007;96:49-50.
7㧕 Kato H, Kanematsu M, Furui T, Imai A, Hirose Y, Kondo, H, Goshima S, Tsuge, Y. Carcinosarcom a of
the uterus: radiologic-pathologic correlations with magnetic resonance imaging including
diffusion-weighted imaging. Magn Resonan Ima. 2008;26:1446-1450.

IF 0.779
IF 1.724
IF 0.779
IF 1.078

IF 1.486

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦੹੗◊ᔒ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧔⎇ⓥ㧕㧦⤑ฃኈ૕࡝ࠟࡦ࠼ߩ⚦⢩Ქᕈࠕ࠽ࡠࠣࠍ↪޿ߚ᛫≸ൻቇ≮ᴺߣࡔࠞ࠾࠭ࡓ㧧ᐔᚑ 19 ᐕᐲ㧧1,130 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ੹੗◊ᔒ㧦㇭਄Ꮢߦ߅ߌࠆ↥⑼ක≮ߩ⃻⁁ߣᡷༀ㧧2000 ජ౞㧦㇭਄Ꮢ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ੹੗◊ᔒ㧦
1㧕 ᣣᧄ↥⑼ᇚੱ⑼ቇળઍ⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↢ᱺකቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ↢ᱺౝಽᴲቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᇚੱ⑼⣲≮ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳੹੗◊ᔒ㧦
1㧕 ╙ 1 ࿁᧲੩੃߇ࠎࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 2 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬ᅚᕈࡎ࡞ࡕࡦߣ੃߇ࠎ Q & A‫ޠ‬Ṷ⠪)
2㧕 ╙ 8 ࿁ RMB (Reproductive Medicine and Biology)(ᐔᚑ 19 ᐕ 7 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬ൻቇ≮ᴺਛߩ⣼଻⼔‫ޠ‬Ṷ⠪)3㧕 ጘ㒂↥⑼ᇚੱ⑼⎇ⓥળ㧙↢ᱺකቇ㧙(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥄ޟ‬ὼ㐽⚻߳ߩㅏߍㄟߺ≮ߣ↢ᱺකቇ Q & A‫ޠ‬Ṷ⠪)4㧕 ጘ㒂⋵↥ᇚੱ⑼කળ࡮ቇળวห✚ળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂ጘ㒂⋵๟↥ᦼක≮ߩ⁁ߣ੹ᓟ‫ޠ‬Ṷ⠪)㧙㧙5㧕 ᐔᚑ 19 ᐕᐲጘ㒂ዊఽᢇᕆ⎇ୃળ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬Უ૕ᢇᕆ៝ㅍࠪࠬ࠹ࡓߩ੹ᓟ‫ޠ‬Ṷ⠪)
6㧕 ᐔᚑ 20 ᐕᐲጘ㒂⋴⼔දળഥ↥Ꮷળ⎇ୃ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ጘ㒂⋵๟↥ᦼක≮ߩ⁁ߣ੹ᓟ‫ޠ‬Ṷ⠪)7㧕 ᐔᚑ 20 ᐕᐲጘ㒂⮎⑼ᄢቇ㒝ዻ⮎ዪ(ᐔᚑ 20 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ሶችౝ⤑∝:∛ᘒ,∝⁁,ᴦ≮‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ੹੗◊ᔒ㧦
1㧕 ጘ㒂࿾ᣇⵙ್ᚲኾ㐷ᆔຬ(ᐔᚑ 16 ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 6 ᦬)
2㧕 ጘ㒂⋵․ቯਇᅧᴦ≮ഥᚑ੐ᬺᜰቯක≮ᯏ㑐ክᩏᆔຬ(ᐔᚑ 19 ᐕ 12 ᦬㨪⃻࿷)3㧕 ጘ㒂⋵๟↥ᦼක≮ද⼏ળᆔຬ(ᐔᚑ 19 ᐕ 7 ᦬㨪⃻࿷)4㧕 ጘ㒂⋵කᏧળᲣ૕଻⼔ᴺᜰቯකክᩏᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ੹੗◊ᔒ㧦ᚻⴚᢙߢࠊ߆ࠆ޿޿∛㒮(ో࿖㧒࿾ᣇ೎࡜ࡦࠠࡦࠣ)㧦ㅳೀᦺᣣ⥃ᤨჇೀภ(2007 ᐕ 3 ᦬ 5ᣣ)2㧕 ੹੗◊ᔒ㧦⋵ౝ 6 ∛㒮 ↥⑼ 3 ∛㒮ߦ㓸⚂㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 4 ᣣ)
3㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮↥⑼㧘ᐕౝߢભᱛ‫ޟ‬ㄭ㓞ߦ∛㒮లታ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
4㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮಴↥ኻᔕ㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
5㧕 ੹੗◊ᔒ㧦⠀ፉᏒ᳃∛㒮޽ࠅᣇᆔຬળ㧦↥⑼ભᱛ㧘㓸⚂:Ფᣣᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
6㧕 ੹੗◊ᔒ㧦3 ∛㒮߇↥⑼ભᱛ㧦⺒ᄁᣂ⡞(2007 ᐕ 10 ᦬ 11 ᣣ)
7㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ කᏧ߇್ᢿ ߚࠄ޿࿁ߒ㒐ᱛ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 19 ᣣ)
8㧕 ੹੗◊ᔒ㧦ක≮ߪ੹‫ޟ‬ᅧᇚฃߌ౉ࠇ࿎㔍 ᰴߩ៝ㅍవ‫ޠ‬㧦ਛᣣᣂ⡞(2007 ᐕ 10 ᦬ 23 ᣣ)
9㧕 ੹੗◊ᔒ㧦߅↥ߩ቟ోߪ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 26 ᣣ)
10㧕 ੹੗◊ᔒ㧦ᅧᇚ៝ㅍవ㧘↥⑼ක߇್ᢿ㧦⋵ౝోၞߦ᜛ᄢ߳㧦ᦺᣣᣂ⡞(2007 ᐕ 11 ᦬ 23 ᣣ)
11㧕 ੹੗◊ᔒ㧦∛㒮ߩታജ㧔ᇚੱ⑼≸㧕㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬ 23 ᣣ)
12㧕 ੹੗◊ᔒ㧦∛㒮ߩታജ㧔ᇚੱ⑼≸㧕㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬ 23 ᣣ)
13㧕 ੹੗◊ᔒ㧦⋵ౝᅧᇚ៝ㅍࠪࠬ࠹ࡓ㧦ጘ㒂ᣂ⡞(2007 ᐕ 12 ᦬ 25 ᣣ)
14㧕 ੹੗◊ᔒ㧦‫ޣ‬07 ߉߰ࠍᝄࠅ㄰ࠆ‫ޤ‬㧨11㧪ᅧᇚߩߚࠄ޿࿁ߒ໧㗴㧦ᦺᣣᣂ⡞(2007 ᐕ 12 ᦬ 28 ᣣ)
15㧕 ੹੗◊ᔒ㧦޿޿∛㒮 2008㧦ㅳೀᦺᣣ MOOK(2007 ᐕ 12 ᦬ 28 ᣣ)
16㧕 ੹੗◊ᔒ㧦ኾ㐷ක߇ផ⮈‫᧲ޟ‬ᶏ࡮↲ା⿧ߩኅᐸක‫ޠ‬25 ੱ㧦AERA(2008 ᐕ 2 ᦬ 18 ᣣ)
17㧕 ੹੗◊ᔒ㧦ೋ⚻(ೋầ)ߩㆃࠇ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯(2008 ᐕ 4 ᦬ 24 ᣣ)
18㧕 ੹੗◊ᔒ㧦ዊఽᦼߩᕈེ಴ⴊ㧦ጘ㒂⋵කᏧળ࡜ࠫࠝࡎ࡯ࡓ࠼ࠢ࠲࡯(2008 ᐕ 4 ᦬ 25 ᣣ)
19㧕 ੹੗◊ᔒ㧦๮ࠍߟߥߋ㧨ਇᅧᴦ≮ߩⓨ⊕࿾Ꮺ㧪㧦ጘ㒂ᣂ⡞(2008 ᐕ 5 ᦬ 9 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᒰೋߩ⋡⊛ߢ޽ࠆ‫⑼↥ޟ‬ⅣႺߩᢛ஻‫ߪޠ‬ᢛ஻ߐࠇߟߟ޽ࠆ‫ߦ․ޕ‬Უ૕ᢇᕆ៝ㅍࡑ࠾ࡘࠕ࡞ߪో࿖⊛߽⹏ଔߐࠇߡ޿ࠆ‫⊛ੱޕ‬㓸⚂ൻ㧔3 ᣉ⸳㧕߽ቢੌߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻ╷৻ᣇ㧘ߘߩ෻േߢ 1㧕㘧㛗࿾඙ߩ↥⑼૕೙ߩᢛ஻߇ㆃࠇߡ޿ࠆߎߣ㧘2㧕⣲≌ක≮߿ਇᅧ∝ߩࠤࠕߦߒ
ࠊነߖ߇෸ࠎߢ޿ࠆߎߣߪุቯߢ߈ߥ޿‫ޕ‬੹ᓟߩዷᦸ⋵ో૕ߩ࿾ၞᩰᏅߩᤚᱜ㧘ᇚੱ⑼⸻≮ߩᐔဋൻ߇੹ᓟߩ⺖㗴ߢ޽ࠆ‫ޕ‬㧙㧙㧔7㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔✚ว⥃ᐥ♽ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
ߎࠇ߹ߢߣห᭽‫ޕ‬࿾ၞක≮ߦ߅ߌࠆᄢቇߩᓎഀ㧔࿾ၞߩ࠾࡯࠭ߣᄢቇߩ㑐ਈᣇᴺߥߤ㧕ߦߟ޿ߡᬌ⸛ߔ
ࠆ‫ޕ‬
2㧚ฬ★
⥃ᐥ⻠Ꮷ㧦 ศ↰㓉ᶈTakahiro Yoshida3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ߥߒ
2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ
ߥߒ

㧙㧙

9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔቇળᵴേߥߤ㧘ᢎຬߣߒߡߩ⹏ଔߢߪᢇᕆἴኂᢎຬߣߒߡߩ㧘ᄖ்ᢎ⢒ࠍⴕ߁ߥߤߒߡ޿ࠆ߇㧘࿾ၞක≮ߣߒߡߪ㧘ቇળᵴേߥߤߪߥ޿߇㧘㜞ጊ㧘ਅํߥߤ㧘ታോߦߟ޿ߡߪ᦬ 6 ࿁⒟ᐲⴕߞߡ߅ࠅ㧘ߎࠇߪᄢቇߢߩᵴേߣᐔⴕߒߡ߅ߎߥ߁ߎߣߪ㧘߆ߥࠅᄢᄌߢ޽ࠅ㧘⹏ଔߐࠇࠆߴ߈߽ߩߣ⠨߃ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ቇળᵴേ࡮⹏⺰ߥߤ߇චಽߦⴕ߃ߡ޿ߥ޿ߩߢ㧘ߘߜࠄߦߟ޿ߡߪ㧘ᢎ⢒ᵴേߩࠕࡦࠤ࡯࠻⚿ᨐ߿࿾ၞක≮ߩ⃻⁁ࠍ࠺࡯࠲ൻߒ㧘޿ߕࠇ߆ߩ႐㕙ߢ⊒⴫ߒߚ޿‫ޕ‬੹ᓟߩዷᦸ✚ว⥃ᐥ♽߇⃻࿷৻ੱߢߩᵴേߢ޽ࠅ㧘ੱ᧚Ⴧടߥࠄ߽߫߁ዋߒ⦡‫ߣࠆ߈ߢ߇ߣߎߥޘ‬⠨߃ࠆ߇㧘⃻⁁ߢߪ㧘ታ⁁ႎ๔⒟ᐲߩᵴേߒ߆ߢ߈ߥ޿ߚ߼㧘࿾㆏ߦขࠅ⚵߻ߒ߆ߥ޿‫ޕ‬㧙㧙㧔8㧕࿾ၞක≮කቇ࠮ࡦ࠲࡯㧔࿾ၞ߳߈࿾✚วක≮ಽ㊁㧕
1㧚⎇ⓥߩ᭎ⷐ
ᧄㇱ㐷ߪጘ㒂⋵߇⸳⟎ߔࠆነઃ⻠ᐳ‫ޟ‬࿾ၞක≮ቇ‫ߣޠ‬ㅪ៤ߒ߳߈࿾╬ߦ߅ߌࠆක≮ߩ⏕଻ߦ㑐ߔࠆਅ⸥ߩ⺞ᩏ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬
1.߳߈࿾ࠍ฽߻࿾ၞߦ߅ߌࠆක≮࠾࡯࠭ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ
2.✚ว⊛ߥ⸻≮⢻ജࠍᜬߞߚකᏧࠍ㙃ᚑߔࠆߚ߼ߩᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
3.߳߈࿾ක≮ࠍᡰេߔࠆߚ߼ߩࠪࠬ࠹ࡓߦ㑐ߔࠆ⎇ⓥ‫⎇ޣ‬ⓥ╬ߩౕ૕⊛ౝኈ‫ޤ‬⃻࿷ᧄ⋵ߩߺߥࠄߕో࿖ฦ࿾ߢක≮፣უ߇ต߫ࠇ㧘࿾ၞߦࠃߞߡᔅⷐߥක≮߇ฃߌࠄࠇߥ޿⁁ᴫ߇↢߹ࠇߡ޿ࠆ‫ߥࠎߘޕ‬ਛߢ࿾ၞߏߣߦ㒢ࠄࠇߚක≮⾗Ḯࠍᵴ↪ߒߡല₸⊛ߦක≮ࠨ࡯ࡆࠬࠍឭଏߔࠆ઀⚵ߺ૞ࠅ߇ᕆ߇ࠇߡ޿ࠆ‫⎇ᧄޕ‬ⓥߢߪ࿾ၞක≮ߣ޿߁ⷞὐ߆ࠄౕ૕⊛ߥᣇ╷ࠍឭ⸒ߔࠆߎߣࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
1.߳߈࿾ࠍ฽߻࿾ၞߦ߅ߌࠆක≮࠾࡯࠭ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ
㧔1㧕⋡⊛߳߈࿾╬ࠍ฽߻࿾ၞߦ߅޿ߡᔅⷐߥක≮ឭଏࠪࠬ࠹ࡓࠍ᭴▽ߔࠆߚ߼ߤߩࠃ߁ߥක≮࠾࡯࠭߇޽ࠆ
߆ࠍ⺞ᩏߔࠆ‫ޕ‬
㧔2㧕ౝኈߣᚻᴺ
Ԙ߳߈࿾╬ߦ߅ߌࠆஜᐽ໧㗴ߩ㗫ᐲ⺞ᩏ߳߈࿾╬ߦ߅޿ߡᣣᏱ⊛ߦ⊒↢ߔࠆஜᐽ໧㗴ߦߟ޿ߡ㧘߳߈࿾╬ߩක≮ᯏ㑐ฃ⸻ߔࠆᖚ⠪ߩฃ⸻ℂ↱㧘∔∛╬ࠍ⺞ᩏߔࠆ‫ޕ‬ԙ߳߈࿾ࠍ฽߻࿾ၞߩੑᰴක≮ᯏ㑐ߩ౉㒮ᖚ⠪ߩ∔∛⺞ᩏ࿾ၞߩੑᰴ∛㒮ߢߩ౉㒮ᖚ⠪ߩ⸻≮㍳╬ࠍ⺞ᩏߔࠆ‫ޕ‬
㧔3㧕ᦼᓙߐࠇࠆലᨐ
࿾ၞߢቢ⚿ߔߴ߈ක≮࠾࡯࠭ࠍ⺞ᩏߔࠆߎߣߦࠃߞߡ㧘࿾ၞߦᔅⷐߥක≮ឭଏߩ࡟ࡌ࡞ߣࠨ࡯ࡆࠬ㊂ࠍ⏕⹺ߔࠆ‫ޕ‬
2.✚ว⊛ߥ⸻≮⢻ജࠍᜬߞߚකᏧࠍ㙃ᚑߔࠆߚ߼ߩᢎ⢒ߦ㑐ߔࠆ⎇ⓥ
㧔1㧕⋡⊛
߳߈࿾╬ߢዋߥ޿කᏧᢙߢᄙ᭽ߥක≮࠾࡯࠭ߦᔕ߃ࠆߚ߼ߦߪ㧘৻ੱߩකᏧ߇✚ว⊛ߦኻᔕߔࠆߎߣ
߇ᔅⷐߢ㧘ߘ߁޿ߞߚකᏧࠍ㙃ᚑߔࠆߚ߼ߩᣇ╷ߦߟ޿ߡ⎇ⓥߔࠆ‫ޕ‬
㧔2㧕ౝኈߣᚻᴺ
Ԙ߳߈࿾⸻≮ᚲකᏧߩታᘒ⺞ᩏ⃻࿷߳߈࿾⸻≮ᚲߦൕോߔࠆකᏧ߆ࠄ㧘߳߈࿾ක≮ࠍᜂ߁ߚ߼ߩᔅⷐߥᛛ⢻㧘⍮⼂ߦߟ޿ߡ⺞ᩏߔࠆ‫ޕ‬ԙ✚ว⊛ߥ⸻≮⢻ജࠍᜬߟකᏧࠍ⢒ᚑߔࠆᢎ⢒⎇ୃߦ㑐ߔࠆ⺞ᩏ⎇ⓥో࿖ߢขࠅ⚵߹ࠇߡ޿ࠆ㧘✚ว⊛ߥ⸻≮⢻ജࠍᜬߟකᏧߩߚ߼ߩත೨ᢎ⢒߿තᓟ⎇ୃߦߟ޿ߡታᘒ
ࠍ⺞ᩏߔࠆ‫ޕ‬Ԛ✚วක⢒ᚑࡊࡠࠣ࡜ࡓߩ╷ቯᧄቇߦ߅޿ߡታⴕߢ߈ࠆත೨ᢎ⢒ߦ߅ߌࠆ࿾ၞක≮ታ⠌㧘තᓟ⎇ୃߦ߅ߌࠆ࿾ ၞක≮⎇ୃ㧘✚วකࠍ⋡ᜰߔᓟᦼ⎇ୃࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆ‫ޕ‬
㧔3㧕ᦼᓙߐࠇࠆലᨐ
዁᧪⋵ౝߩ࿾ၞක≮ࠍⓍᭂ⊛ߦᜂ߅߁ߣߔࠆකᏧࠍ㙃ᚑߔࠆߎߣ߇น⢻ߣߥࠆ‫ޕ‬
2㧚ฬ★
․છᢎ᝼㧦 ጊ↰ 㓉

Takashi Yamada

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ጊ↰㓉ม㧚⃻႐߆ࠄߩឭ⸒㧙ක≮ౣ↢߳ߩࡆ࡚ࠫࡦ㧦කᏧਇ⿷ߣ࿾ၞක≮ߩ፣უ 2㧘 ᧲੩㧦ᣣᧄක≮ડ↹㧧2008 ᐕ㧦250㧙266㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ጊ↰㓉ม㧚࿾ၞක≮ࠍ቞ࠆߚ߼ߦ㧙කᏧߩ┙႐߆ࠄ㧙㧘࿖㓙ᢥൻ⎇ୃ 2008 ᐕ㧧60 ภ㧦56㧙60㧚㧙㧙

2㧕 ጊ↰㓉ม㧚⠧ᐕ✚วකߩዷᦸ㧙ኅᐸක≮࡮߳߈࿾ක≮ߩ┙႐߆ࠄ㧙㧘ᣣᧄ⠧ᐕකቇળ⹹ 2008 ᐕ㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄ߥߒ
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬጊ↰㓉ม㧦
1㧕 ᣣᧄኅᐸක≮ቇળઍ⴫ℂ੐(㨪⃻࿷)2㧕 ᣣᧄࡊ࡜ࠗࡑ࡝࡮ࠤࠕቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ጊ↰㓉ม㧦
1㧕 ╙ 29 ࿁කቇᢎ⢒⎇ୃ࠮ࡒ࠽࡯࡮ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂)2㧕 ╙ 2 ࿁߳߈࿾࡮࿾ၞක≮ቇળ(ᐔᚑ 20 ᐕ 8 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ጊ↰㓉ม㧦
1㧕 කᏧ⥃ᐥ⎇ୃ೙ᐲ࡮⎇ୃ▤ℂᆔຬળ࡮ᆔຬ㐳⎇ୃ(ᐔᚑ 20 ᐕ 1 ᦬㧘ၯ₹㧘․೎⻠Ṷ೎‫ޟ‬࿾ၞ߆ࠄ⷗
ߚᄢቇߩขࠅ⚵ߺ́࿾ၞක≮ቇ⻠ᐳ(ጘ㒂⋵ነ㒝⻠ᐳ)ߩᓎഀ‫ޠ‬Ṷ⠪)
2㧕 ╙ 34 ࿁ජ⪲᧲ᵗකቇࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 3 ᦬㧘ජ⪲㧘․೎⻠Ṷ‫ߗߥ੹ޟ‬ኅᐸක࡮✚วක߇᳞߼
ࠄࠇߡ޿ࠆߩ߆‫ޠ‬Ṷ⠪)
3㧕 ╙ 8 ࿁ᗲᇫࡊ࡜ࠗࡑ࡝ࠤࠕ⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᗲᇫ㧘․೎⻠Ṷ‫ޟ‬࿾ၞක≮ߣ✚วක‫ޠ‬Ṷ⠪)4㧕 COML ක≮ࡈࠜ࡯࡜ࡓ 2008(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋㧘ࠪࡦࡐࠫ࠙ࡓ‫ߩߢ✢৻╙ޟ‬ℂᗐߩᖚ⠪࡮ක≮⠪㑐ଥ‫ޠ‬Ṷ⠪)
5㧕 ╙ 59 ࿁⟲ᤊᴒ✽⥃ᐥᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ᴒ✽㧘᜗⡜⻠Ṷ‫ޟ‬㔌ፉ࡮߳߈࿾ක≮ߣ✚วක‫ޠ‬Ṷ⠪)
6㧕 ක≮ߦ߅ߌࠆ቟ᔃ࡮Ꮧᦸ⏕଻ߩߚ߼ߩኾ㐷ක࡮ኅᐸක㧔කᏧᓟᦼ⎇ୃ೙ᐲ㧕ߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ⃰(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬࿾ၞක≮ߣ✚วක‫ޠ‬Ṷ⠪)7㧕 21 ਎♿ṽᣇකቇࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫✚ޟ‬วකߦ߅ߌࠆṽᣇᢎ⢒ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)㧙㧙8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
ߥߒ
10㧚ႎ๔ᦠߥߒ11㧚ႎ㆏
1㧕 ጊ↰㓉ม㧦කᏧߣᖚ⠪ߩା㗬߇ߟߜ߆ࠊࠇࠆ႐ᚲ㧙࿾ၞක≮ߩⷞὐ߆ࠄ⠨߃ࠆකᏧਇ⿷໧㗴㧦ࠝࡦ࡜ࠗࡦࡑࠟࠫࡦ(2008 ᐕ 1 ᦬ 28 ᣣ)2㧕 ጊ↰㓉ม㧦ᖚ⠪ߦㆡߒߚല₸⊛ߥක≮ߩឭଏࠍ⋡ᜰߒߡ㧙ᖚ⠪࡮ኅᣖ࡮࿾ၞࠍᾫ⍮ߔࠆኅᐸකࠍ⢒ᚑ㧙㧦⮎੐ᣣႎ(2008 ᐕ 2 ᦬)
3㧕 ጊ↰㓉ม㧦⑔␩ࡀ࠶࠻ࡢ࡯ࠢ㧦NHK ᢎ⢒(2008 ᐕ 2 ᦬ 12 ᣣ)
4㧕 ጊ↰㓉ม㧦ੱ㧦ᣣᧄක੐ᣂႎ(2008 ᐕ 10 ᦬ 25 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔᒰㇱ㐷ߪ㐿⸳㑆߽ߥ޿ߎߣ߆ࠄ⎇ⓥߦߟ޿ߡ⺞ᩏ⎇ⓥߩᬺ❣ߪዋߥ޿ߎߣߪุ߼ߥ޿⃻࿷ߪ࿾ၞᨒቇ
↢ߩࠞ࡝ࠠࡘ࡜ࡓᄖߢߩ੺㧘ౕ૕⊛ߦߪ࿾ၞක≮ߦ㑐ߔࠆ࠯ࡒ࠽࡯࡞ߩቯᦼ㐿௅߿㧘ቇᄖߢߩ࿾ၞක≮ߦ㑐ߔࠆળว߳ߩෳടߥߤࠍⓍᭂ⊛ߦⴕ޿㧘዁᧪࿾ၞක≮ߦะ߆߁කቇ↢ߩ⢒ᚑߦߟ޿ߡขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⎇ⓥ㧘ᢎ⢒ߦߟ޿ߡߪ߹ߛቯဳ⊛ߥขࠅ⚵ߺߦߪ⥋ߞߡ޿ߥ޿‫ޕ‬ጘ㒂⋵㧘⥄ᴦක⑼ᄢቇතᬺ↢ߣㅪ៤ߒ㧘ౕ૕⊛ߥ⎇ⓥ㧘ᢎ⢒ߦ⌕ᚻߔࠆ੍ቯߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟකቇㇱ࿾ၞᨒቇ↢߇⏕ታߦჇ߃ߡߊࠆߎߣ߆ࠄ߽ᒰㇱ㐷෸߮࿾ၞක≮ቇ⻠ᐳߩ㊀ⷐᕈߪჇߒߡߊ
ࠆߣᕁࠊࠇࠆ‫ోߚ߹ޕ‬࿖ߩห᭽ߩㇱ㐷ߣࡀ࠶࠻ࡢ࡯ࠢࠍ᭴▽ߒߡ࿾ၞක≮ߦ㑐ߔࠆ⾰ߩ㜞޿⎇ⓥߣᢎ⢒ߦ⽸₂ߒߡ޿߈ߚ޿‫ޕ‬㧙㧙㧔9㧕කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔࠴ࡘ࠻࡯࡝ࠕ࡞ㇱ㐷㧕1㧚⎇ⓥߩ᭎ⷐ
කቇᢎ⢒ߦ߅ߌࠆో࿖౒ห೑↪ᣉ⸳ߣߒߡ㧘
㧔1㧕ᣂߒ޿කቇᢎ⢒ߩ㐿⊒⎇ⓥߣ᥉෸㧘
㧔2㧕කቇᢎ⢒ߦ⽸₂ߢ߈ࠆੱ᧚⢒ᚑ㧘
㧔3㧕࿖ౝᄖߩකቇᢎ⢒ᯏ㑐ߣߩㅪ៤࡮౒ห⎇ⓥ㧘ࠍᄢ߈ߥࡒ࠶࡚ࠪࡦߣߒߡขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
ԘPBL ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒㧦ᄖㇱߦะߌߚ PBL ߦ㑐ߔࠆ࠮ࡒ࠽࡯࡮ࡢ࡯࡚ࠢࠪ࠶ࡊࠍડ↹ߔࠆߣߣ߽
ߦ㧘ጘ㒂ᄢቇߦ߅ߌࠆ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ⢒ 10 ᐕߩ⚻㛎ࠍᬌ⸽ߒ㧘ࠃࠅㅴൻߒߚ PBL ࠹ࡘ࠻࡯࡝ࠕ࡞ᢎ
⢒ࠪࠬ࠹ࡓߩ᭴▽ࠍ߼ߑߒߡ޿ࠆ‫ޕ‬ԙࠗࡦ࠲࡯ࡀ࠶࠻ PBL㧦ᄢቇ߿ቇㇱߩ၂ᩮࠍ⿧߃㧘޿ߟߢ߽㧘ߤߎ߆ࠄߢ߽ෳടߢ߈ࠆ⢻േ⊛෺ᣇะᕈ Web-PBL ࠪࠬ࠹ࡓࠍ㧘ో࿖ߩᢎຬ࡮ቇ↢ߣදജߒߥ߇ࠄ㐿⊒ߒ㧘ታ↪ൻߩᲑ㓏ߦ౉ߞߡ޿ࠆ‫ޕ‬ቇㇱ↢ࠦ࡯ࠬߩઁߦ㧘⧷⺆ࠦ࡯ࠬ㧘ᄢቇ㒮ࠦ࡯ࠬ㧘⥃ᐥࠦ࡯ࠬߥߤ㧘ᄙᓀߥࡊࡠࠣ࡜ࡓࠍ↪ᗧߒߡ޿ࠆ‫ޕ‬Ԛක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡊࡠࡈࠚ࠶࡚ࠪ࠽࡝࠭ࡓᢎ⢒㧦ᮨᡆᖚ⠪ߦࠃࠆක≮㕙ធᢎ⢒ᴺߩ⎇ⓥߣታ〣ࠍㅴ߼ߡ޿ࠆ‫ޕ‬4 ᐕ↢࡮5 ᐕ↢ߦኻߔࠆක≮㕙ធታ⠌㧘ᄖㇱߦะߌߚ࠮ࡒ࠽࡯࡮
㧘21 ᐕᐲ߆ࠄ 2ࡢ࡯࡚ࠢࠪ࠶ࡊࠍታᣉߒߡ޿ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄ 1 ᐕ↢ߦኻߔࠆ࿾ၞ૕㛎ታ⠌㧔8 ㅳ㑆㧕ᐕ↢ߦኻߔࠆකᏧᖚ⠪㑐ଥߩ᝼ᬺߥߤ㧘੹ᓟ㧘♽⛔⊛ߥⴕേ⑼ቇᢎ⢒ߩዉ౉ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬ԛ⥃ᐥࠪࡘࡒ࡟࡯࡚ࠪࡦᢎ⢒ߣࡃ࡯࠴ࡖ࡞ᢎ᧚ߩ㐿⊒㧦⥃ᐥ౉㐷߆ࠄතᓟᢎ⢒ߦ⥋ࠆ᏷ᐢ޿ᤨᦼߦ㧘ലᨐ⊛ߥࠪࡒࡘ࡟࡯࡚ࠪࡦᢎ⢒߇ⴕ߃ࠆࠃ߁ߦ㧘ࡂ࡯࠼࡮࠰ࡈ࠻ਔ㕙߆ࠄࡕ࠺࡞ߣߥࠅ߁ࠆ⥃ᐥࠬࠠ࡞࡮ࠪࡒࡘ࡟࡯࡚ࠪ
ࡦ࠮ࡦ࠲࡯ߩ᭴▽ࠍ߼ߑߒߡ޿ࠆ‫ߚ߹ޕ‬り૕⸻ኤ߿㕙ធ߇น⢻ߥᖚ⠪ࡠࡏ࠶࠻㧘ࡔ࠺ࠖࠞ࡞࡮ࠗ࡜ࠬ࠻㧘Web ⥄Ꮖቇ⠌ᢎ᧚ߥߤߩ㐿⊒ࠍㅴ߼ߡ޿ࠆ‫ޕ‬ᐔᚑ 19 ᐕᐲ߆ࠄ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT‫߇ޠ‬ណᛯߐࠇ㧘⎇ⓥ੐ᬺߩଦㅴ߇࿑ࠄࠇߡ޿ࠆ‫ޕ‬Ԝᣂ⥃ᐥታ⠌ࠪࠬ࠹ࡓߩ⎇ⓥ㐿⊒㧦੹ᐕ߆ࠄᆎ߹ߞߚᣂ᭴ᗐߩጘ㒂ᄢቇဳࠢ࡝࠾ࠞ࡞࡮ࠢ࡜࡯ࠢࠪ࠶ࡊࠍផㅴ࡮ᬌ⸽ߒ㧘ࠪࠬ࠹ࡓߣߒߡ⏕┙ߐߖࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬ԝකቇᢎ⢒࠮ࡒ࠽࡯㧒ࡢ࡯࡚ࠢࠪ࠶ࡊ㧦ᐕ 4 ࿁㧘ㅢ▚ 30 ࿁㐿௅ߒ㧘ߩߴෳട⠪ᢙߪ 3000 ฬࠍ⿧߃ߡ޿ࠆ‫ޕ‬කቇᢎ⢒ಽ㊁ߩో࿖ FD ߣߒߡቯ⹏ࠍᓧ㧘౒ห⎇ⓥߩផㅴߦ߽ᄢ߈ߥᓎഀࠍᨐߚߒߡ޿ࠆ‫ޕ‬Ԟකቇᢎ⢒࡙࠾࠶࠻ߩળ㧦ㄭᐕ㧘ฦᄢቇߢ⸳┙ߐࠇߚකቇᢎ⢒ㇱ㐷㧔࡙࠾࠶࠻㧕ߩㅪ៤⚵❱ࠍᒻᚑߒ㧘ᖱႎ੤឵࡮౒ห⎇ⓥߩଦㅴࠍ࿑ߞߡ޿ࠆ‫ޕ‬කቇᢎ⢒ቇ⎇ⓥߣᄢቇ㒮࡟ࡌ࡞ߩᢎ⢒ߩࠦࡦ࠰࡯ࠪࠕࡓᒻᚑࠍ߼ߑߒߡ޿ࠆ‫ޕ‬ԟᖱႎ⊒ା㧦ࡎ࡯ࡓࡍ࡯ࠫࠍᵴ↪ߒߡ㧘ࠗࡦ࠲࡯ࡀ࠶࠻࡮࠹
ࡘ࠻࡯࡝ࠕ࡞㧘ක≮㕙ធታ⠌㧘࠮ࡒ࠽࡯㧒ࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ቇോ੐ോᖱႎ㧘ࠗࡦ࠲࡯ࡀ࠶࠻࡮ࠫࡖ࡯࠽࡞
ߥߤߩᦨᣂᖱႎࠍ⊒ାߒߡ޿ࠆ‫ޕ‬Ԡᄢቇ㒮‫ޟ‬කቇᢎ⢒ಽ㊁‫ߩޠ‬㐿⸳㧦ᐔᚑ 20 ᐕᐲ㧔2008 ᐕ 4 ᦬㧕ࠃࠅጘ㒂ᄢቇᄢቇ㒮කቇ♽⎇ⓥ⑼ක≮▤ℂቇ⻠ᐳߦ‫ޟ‬කቇᢎ⢒ቇ‫ޠ‬ಽ㊁߇㐿⻠ߒ㧘ᄢቇ㒮↢ 1 ฬߩ౉ቇ߇޽ߞߚ‫ޕ‬ԡ࿖㓙੤ᵹ㧦Ფᐕ 1 ฬߩቴຬᢎ᝼ࠍ᜗⡜ߒ㧘࿖ౝߦ߅ߌࠆකቇᢎ⢒⎇ⓥߩផㅴߣ࿖㓙੤ᵹߦ⽸₂ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
㋈ᧁᐽਯ
ᢎ᝼(૬છ)㧦 ਤ⠀㓷ਯ
ട⮮ᥓ⟤
ഥᢎ㧦
⧯ᨋ⧷᮸
ഥᢎ㧦

Yasuyuki Suzuki
Masayuki Niwa
Tomomi Kato
Hideki Wakabayashi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ౻㧙╙ 15 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙94㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᤐ㧙╙ 16 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙124㧚
3㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᄐ㧙╙ 17 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙211㧚
4㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ⑺㧙╙ 18 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙112㧚
5㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ౻㧙╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙110㧚
6㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᤐ㧙╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙185㧚
7㧕 ㋈ᧁᐽਯ㧚ࡓࠦᄙ♧∝ 1 ဳ㧦㛽♽⛔∔ᖚࡑ࠾ࡘࠕ࡞ᡷ⸓╙ 2 㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦120㧙121㧚
8㧕 ㋈ᧁᐽਯ㧚ࡓࠦᄙ♧∝ 2 ဳ㧦㛽♽⛔∔ᖚࡑ࠾ࡘࠕ࡞ᡷ⸓╙ 2 㧘᧲੩㧦ධᳯၴ㧧2008 ᐕ㧦122㧙123㧚
9㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᄐ㧙╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙237㧚
10㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ⑺㧙╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ

㧙㧙࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙89㧚
11㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ౻㧙╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙120㧚
12㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᤐ㧙╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙152㧚
13㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᄐ㧙╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙121㧚
14㧕 ਤ⠀㓷ਯ㧚ਛᨔ␹⚻૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ
⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦73㧙101㧚
15㧕 ਤ⠀㓷ਯ㧚ᶖൻེ૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦143㧙153㧚
16㧕 ਤ⠀㓷ਯ㧚᛫ᖡᕈ⣲≌⮎㧔᛫≸⮎㧕㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩ
ଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦191㧙203㧚
17㧕 ਤ⠀㓷ਯ㧚᛫Ἳ∝⮎࡮⸃ᾲ㎾∩⮎࡮᛫ࠕ࡟࡞ࠡ࡯⮎࡮఺∉ᛥ೙⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇ
ోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦205㧙224㧚
18㧕 ㋈ᧁᐽਯ㧚⢽⾰⫾Ⓧ∝㧔࡝ࡇ࠼࡯ࠪࠬ㧕㧦⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦230㧙231㧚
19㧕 ㋈ᧁᐽਯ㧚ᩭ㉄ઍ⻢⇣Ᏹ∝㧔Lesch-Nyhan ∝୥⟲㧕㧦⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦
232㧙233㧚
20㧕 ㋈ᧁᐽਯ㧚කቇᢎ⢒㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦309㧙313㧚
21㧕 ㋈ᧁᐽਯ㧚adrenoleukodystrophy (ALD)㧦ዊఽ⑼ቇ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦484㧙486.
22㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ⑺㧙╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙100㧚
23㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ౻㧙╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙130㧚
24㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ᤐ㧙╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙152㧚
25㧕 ਤ⠀㓷ਯ㧚⸃ᾲ㎾∩⮎࡮᛫Ἳ∝⮎㧦㊁᧛㓉⧷㧘⍹Ꮉ⋥ਭ✬㧚ࠪࡦࡊ࡞⮎ℂቇ‫ޣ‬ᡷ⸓╙ 4 ‫ޤ‬㧘᧲੩㧦ධᳯၴ㧧
2008 ᐕ㧦229㧙245㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Suzuki Y, Niwa M, Shibata T, Chirasak K, Ariyawardana A, Ramesh JC, Evans P, Takahashi Y.
Internet PBL: International Collaborative Learning Experiences In: Oon-Seng Tan, ed. Problem-based
Learning in E-learning Breakthroughs. Singapore: Thomson Learning; 2007:131-146.
2㧕 Hara A, Niwa M, Aoki H, Taguchi A, Yamada Y, Mori H. New research on neuronal networks. In:
Neuronal Network Research Horizons, ed. Weiss ML: Nova Science Publish; 2007:99-118.
3㧕 Hara A, Oka N, Aoki H, Taguchi A, Yamada Y, Niwa M, Mori H. OCT-3/4 Expressing Cells as Cancer
Stem Cells in Human Immature Teratoma: Cancer Differentiation Potential. In: Saitama H ed. New
Cell Differentiation Research Topics. New York: Nova Science Publisher; 2008:1-6.
✚⺑㧔๺ᢥ㧕
1㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛-ࠊ߇࿖ߢ∛㒮߇⸃᣿ߐࠇߚవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006
ᐕ㧧69 Ꮞ㧦1646㧙1652㧚
2㧕 ㋈ᧁᐽਯ㧚㛽∝⁁ߢ⷗ߟ߆ࠆవᄤઍ⻢⇣Ᏹ∝-ᣣᏱ⸻≮ߢߩవᄤઍ⻢⇣Ᏹ∝㧘ዊఽ⑼⸻≮ 2006 ᐕ㧧69 Ꮞ㧦
1590㧙1594㧚
3㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᒻᚑ⇣Ᏹ∝ –Zellweger ∝୥⟲ࠍਛᔃߦ㧘ዊఽౝ⑼ 2007 ᐕ㧦39
ภ㧦536㧙538㧚
4㧕 ㋈ᧁᐽਯ㧚ࡓࠦᄙ♧∝㧘ዊఽౝ⑼ 2007 ᐕ㧦39 ภ㧦503㧙504㧚
✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧚ጘ㒂ᄢቇකቇㇱකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔ో࿖౒ห೑↪ᣉ⸳㧕࡮කቇᢎ⢒ડ↹㐿⊒ቶ㧘කቇᢎ⢒ 2006 ᐕ㧧37 Ꮞ㧦54㧙55㧚
2㧕 ㋈ᧁᐽਯ㧘㜞ᯅቁ㓶㧘ਛ⇌㦖ବ㧘ᅏጊ⋿♿ሶ㧘᧻የ㓷ᢥ㧘ႇ ⵨ᐘ㧘੖ච፲㓉㧘ᴡ㊁㓁৻㧘ฎᎹ ẋ㧘ේኼ㇢㧚ᣣᧄዊఽ⑼ቇળᢎ⢒ᆔຬળႎ๔ ዊఽ⑼ත೨⥃ᐥታ⠌ߦ㑐ߔࠆࠕࡦࠤ࡯࠻⺞ᩏ⚿ᨐ㧘ᣣᧄዊఽ⑼ቇ
ળ㔀⹹ 2008 ᐕ㧧112 Ꮞ㧦793㧙801㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kato T, Isogai K, Orii K, Kuratsubo I, Kondo N, Orii T, Suzuki Y. Portal hypertension in a patient withHunter disease. J Inherit Metab Dis. 2006;29:686.
IF 1.668
2㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal㧙㧙beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
3㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
4㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
5㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-alpha decreases hsp 27 in humanblood mononuclear cells: involvement of protein kinase C. Life Sci. 2006;80:181-186.
6㧕 Kato T, Kato Z, Kuratsubo I, Ota T, Orii T, Kondo N, Suzuki Y. Evaluation of ADL in patients withHunter disease using FIM score. Brain Dev. 2007;29:298-305.
7㧕 Ochiai T, Suzuki Y, Kato T, Shichino H, Chin M, Mugishima H, Orii T. Natural history of extensive
Mongolian spots in mucopolysaccharidosis type II (Hunter syndrome): a survey amond 52 Japanesepatients. J Eur Acad Dermatol Venereol. 2007;21:1082-1085.
8㧕 Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R,
Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation ofadrenoleukodystrophy protein (ALDP/ABCD1) with naturally occurring missense mutations. J
Neurochem. 2007;101:1632-1643.
9㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
10㧕 Hara A, Taguchi A, Niwa M, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model ofphotoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.
11㧕 Evans P, Suzuki Y. “Beyond Competence”. Why Should Outcomes be Adopted in Favour ofCompetences? Medical Education (Japan). 2008;39:87-91.
12㧕 Evans P, Suzuki Y. “Beyond Competence”, Assessment for Capability. Medical Education (Japan).
2008;39:93-96.
13㧕 Evans P, Suzuki Y, Begg M, Lam W. Can medical students from two cultures learn effectively from ashared web-based learning environment? Medical Education. 2008;42:27-33.
14㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of Childhood X-linked Adrenoleukodystrophy:
High Risk for Depression and Neurosis. Brain Dev. 2008;30:477-482.
15㧕 Morita M, Kanai M, Mizuno S, Iwashima M, Hayashi T, Shimozawa N, Suzuki Y, Imanaka T.
Baicalein 5,6,7-trimethyl ether activates peroxisomal but not mitochondrial fatty acid beta-oxidation.
J Inherit Metab Dis. 2008;31:442-449.
16㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
17㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like differentiation andselective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4
promoter. Stem Cells Dev. 2008;17:619-627.
18㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.

IF 1.464

IF 2.218

IF 2.218
IF 2.257
IF 1.464

IF 1.437

IF 4.451

IF 2.651

IF 2.085

IF 2.562
IF 1.464

IF 1.668

IF 1.590

IF 3.224
IF 2.2184㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧧ᢥㇱ⑼ቇ⋭․⦡޽ࠆᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ㧔․⦡ GP㧕㧦⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧧ᐔᚑ 15㧙18 ᐕᐲ㧧60,000 ජ౞(15,000㧦15,000㧦15,000㧦15,000ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)(2)㧦ࠦࠕ࡮ࠞ࡝
ࠠࡘ࡜ࡓኻᔕဳߩකቇታ⠌ᢎ᧚ߩ㐿⊒ߣ᥉෸㧧ᐔᚑ 16㧙17 ᐕᐲ㧧12,400 ජ౞(6,200㧦6,200 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)(2)㧦ో࿖೑↪น⢻ߥ⢻േ⊛ዊఽකቇᢎ⢒ࠪࠬ࠹ࡓߩ᭴▽㧧ᐔᚑ 16㧙17 ᐕᐲ㧧12,800 ජ౞(8,200㧦4,600 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ⴡ⮮⟵ൎ㧘ಽᜂ⎇ⓥ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕㧦࡜ࠗ࠰࠱࡯ࡓ∛㧔ࡈࠔࡉ࡝࡯∛฽߻㧕ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰㧧ᐔᚑ 16㧙18 ᐕᐲ㧧3,550 ජ
౞(1,350㧦1,000㧦1,200 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦⷏Ỉᱜ⼾㧘ಽᜂ⎇ⓥ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕㧦ㆇേᄬ⺞ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰㧧ᐔᚑ 17㧙19 ᐕᐲ㧧3,700 ජ౞(1,300㧦1,300㧦1,100 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦ጊญᷡᰴ㧘ಽᜂ⎇ⓥ⠪㧦᛬ዬᔘᄦ㧘⎇ⓥදജ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕㧦ᚒ߇࿖ߩ 21 ਎♿ߦ߅ߌࠆᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣߩ޽ࠅᣇߦ㑐ߔࠆ⎇㧙㧙ⓥ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧600 ජ౞(200㧦200㧦200 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦CoCl2 ߩㆬᛯ⊛ⷞ␹⚻㓚ኂࡕ࠺࡞ߩ⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧900 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦᧻ේᵗ৻㧘ಽᜂ⎇ⓥ⠪㧦ᅏጊ⯥ਯ㧘⎇ⓥදജ⠪㧦㋈ᧁᐽਯ㧧ᚑ⢒ක≮ᆔ⸤⎇ⓥ⾌㧦వᄤઍ⻢⇣Ᏹ∝ߩ⸻ᢿࡀ࠶࠻ࡢ࡯ࠢࠍ੺ߒߚ㐳ᦼ੍ᓟㅊ〔ࠪࠬ࠹ࡓߩ᭴▽㧧ᐔᚑ 18㧙19 ᐕᐲ㧧400 ජ౞(200㧦200 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ጊญᷡᰴ㧘⎇ⓥಽᜂ⠪㧦᛬ዬᔘᄦ㧘⎇ⓥදജ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕㧦ࠊ߇࿖ߩ 21 ਎♿ߦ߅ߌࠆᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣߩ޽ࠅᣇߦ㑐ߔࠆ⎇ⓥ⃰㧧ᐔᚑ 19㧙21 ᐕᐲ(200㧦150 ජ౞㧦ᧂቯ)㧦10㧕 ⎇ⓥઍ⴫⠪㧦ⴡ⮮⟵ൎ㧘⎇ⓥಽᜂ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕࡜ࠗ࠰࠱࡯ࡓ∛ߩ∛ᘒߩ⸃᣿෸߮ᴦ≮ᴺߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ⃰㧧ᐔᚑ 19㧙21 ᐕᐲ㧧4,050 ජ౞(1,350㧦1,350㧦1,350 ජ౞)
11㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦ࠦࡃ࡞࠻ࠢࡠ࡜ࠗ࠼⺃⊒ⷞ⚦⢩ㆬᛯ⊛㓚ኂࡕ࠺࡞ߩ⊒⃻ᯏᐨ⸃᣿ߥࠄ߮ߦߘߩ㒐ᓮ࡮ᴦ≮㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,500 ජ౞(2,700㧦800ජ౞)12㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦‫ࡑ࡯࠹ޟ‬Σ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧦ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧46,432 ජ౞(23,200㧦23,232 ජ౞)
13㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧧ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ㧔⃻ઍ GP㧕㧦‫⥃ޟ‬ᐥකቇ
ᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦
21,980㧦24,000 ජ౞)
14㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᥓ⟤㧘㒙ㇱᕺሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(৻⥸)㧦ዊఽ㗔ၞߦ߅ߌࠆቴⷰ⊛⥃ᐥ⢻ജ⹏ଔࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,800 ජ౞(2,300㧦
1,100㧦700 ජ౞)
15㧕 ⎇ⓥઍ⴫⠪㧦ᅏጊ⯥ਯ㧘ಽᜂ⎇ⓥ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔ක≮ᛛⴚታ↪ൻ✚ว⎇ⓥ੐ᬺ㧕㧦ᣂⷙᴦ≮ᴺ߇㐿⊒ߐࠇߚዊఽᏗዋ㔍∛ߩ∉ቇ⺞ᩏߣ㐳ᦼࡈࠜࡠ࡯ࠕ࠶ࡊ૕೙ߩ⏕┙㧧ᐔᚑ 20ᐕᐲ㧧2,000 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦⷏Ỉᱜ⼾㧘⎇ⓥಽᜂ⠪㧦㋈ᧁᐽਯ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕㧦ㆇേᄬ⺞ߦ㑐ߔࠆ⺞ᩏ෸߮∛ᘒᯏᐨߦ㑐ߔࠆ⎇ⓥ⃰㧧ᐔᚑ 20㧙22 ᐕᐲ㧧3,000 ජ౞(1,000㧦1,000㧦
1,000 ජ౞)2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㋈ᧁᐽਯ㧦1㧕 ᣣᧄකቇᢎ⢒ቇળℂ੐(㨪⃻࿷)2㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)
3㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᧲ᶏ⥃ᐥㆮવ࡮ઍ⻢ᙣ⹤ળ਎⹤ੱ(㨪⃻࿷)ਤ⠀㓷ਯ㧦1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄἻ∝࡮ౣ↢කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙4㧕 ᣣᧄ⥃ᐥ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
㋈ᧁᐽਯ㧦1㧕 ╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 4 ᦬㧘ߟߊ߫)3㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᮮᵿ)
5㧕 ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂)
6㧕 ╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩)7㧕 ╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧛╙ 7 ࿁ᣣᧄዊఽකቇᢎ⢒⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)8㧕 ╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᓼፉ)9㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)10㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)11㧕 ጘ㒂ᄢቇᮨᡆᖚ⠪ߩળ 10 ๟ᐕ⸥ᔨࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂)12㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)13㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹
㋈ᧁᐽਯ㧦1㧕 Medical Education: Editor(2008 ᐕ㨪⃻࿷)7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
㋈ᧁᐽਯ㧦
1㧕 ᐔᚑ 17 ᐕᐲᄢቇ∛㒮ᖱႎࡑࡀ࡯ࠫࡔࡦ࠻ㇱ㐷ㅪ⛊ળ⼏ಽ⑼ળ 3‫∛ޟ‬㒮ᖱႎࠪࠬ࠹ࡓߩ‫ޔ‬ᢎ⢒ߣ EBM
ߦ߅ߌࠆଔ୯‫(ޠ‬ᐔᚑ 18 ᐕ 1 ᦬㧘ᵿ᧻,‫≮⸻ޟ‬ෳടဳ⥃ᐥታ⠌ߣ㔚ሶࠞ࡞࠹ㆇ↪ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗ
ࡦ㧔᩺㧕‫ޠ‬ᐳ㐳㧘Ṷ⠪)2㧕 ⚻ᷣ↥ᬺ⋭ഥᚑ࡮ක≮⚻༡ੱ⢒ᚑࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻วห FD ⻠Ṷળ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᄢ㒋㧘‫ޟ‬ක≮ᢎ⢒ߦ߅ߌࠆࡐ࡯࠻ࡈࠜ࡝ࠝ⹏ଔ‫ޠ‬Ṷ⠪)3㧕 6th Asian-Pacific Conference on PBL, Symposium 2 “E-PBL”(2006.05, Tokyo, Introductory
remarks for e-PBL; Chairman, Symposist)4㧕 ╙ 6 ࿁ዊఽකቇᢎ⢒⎇ⓥળࠪࡦࡐࠫ࠙ࡓ 2‫ߥ࠼࡯࠳ࡦ࠲ࠬ࡞ࡃ࡯ࡠࠣޟ‬ዊఽ⑼ኾ㐷ක㙃ᚑߦะߌߡ
૗ࠍߥߔߴ߈߆‫(ޠ‬ᐔᚑ 18 ᐕ 7 ᦬㧘᧲੩㧘‫ޟ‬ᄢቇ∛㒮߅ࠃ߮කቇᢎ⢒ኾ㐷ኅߣߒߡߩ⚻㛎߆ࠄ‫ޠ‬Ṷ⠪)
5㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘‫ޟ‬PBL revisited: ၮᧄߦ┙ߜ㄰ࠈ߁‫ޠ‬Ṷ⠪)6㧕 ╙ 30 ࿁ㆮવࠞ࠙ࡦ࠮࡝ࡦࠣ࡝ࡈ࡟࠶ࠪࡘ࠮ࡒ࠽࡯‫ࠦࡓޟ‬ᄙ♧∝(MPS)ߩㆮવࠞ࠙ࡦ࠮࡝ࡦࠣ‫(ޠ‬ᐔ
ᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘‫ࠦࡓޟ‬ᄙ♧∝ߩ∛ᘒ࡮⸻ᢿ࡮ᴦ≮‫ޠ‬Ṷ⠪)7㧕 ╙ 39 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 19 ᐕ 7 ᦬㧘⋓ጟ㧘ࠪࡦࡐࠫ࠙ࡓ II‫ޟ‬࿾ၞක≮ߣත೨කቇᢎ⢒ߩ࿷ࠅᣇ‫ޠ‬ᐳ㐳)8㧕 ╙ 39 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 19 ᐕ 7 ᦬㧘⋓ጟ㧘ࠪࡦࡐࠫ࠙ࡓ߹ߣ߼‫ޟ‬࿾ၞක≮ߣකቇ࡮ක≮ᢎ⢒ߩ໧㗴ὐ‫ޠ‬Ṷ⠪)9㧕 ╙ 111 ࿁ᣣᧄዊఽ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘᧲੩㧘ᄢቇ∛㒮ߩ┙႐߆ࠄ⷗ߚᢎ⢒࡮⎇ⓥߦ߅ߌࠆ∛⸻ㅪ៤㧚✚วࠪࡦࡐࠫ࠙ࡓ 5‫࡮≮⸻ޟ‬ᢎ⢒࡮⎇ⓥࠍ߰߹߃ߚ∛⸻ㅪ៤ߩ⃻⁁ߣᧂ᧪‫ޠ‬Ṷ⠪)10㧕 23rd Annual Meeting of Korean Society of Medical Education. (2008.05, Seoul, Plenary Lecture:
Medical Education in Japan: past, present and future; Performer)
11㧕 ᧲ᶏർ㒽࿾඙⥃ᐥ⎇ୃ∛㒮⺑᣿ળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ฬฎደ㧘‫ߩ᧪ᧂޟ‬ᣣᧄࠍഃࠆዊఽ⑼ක‫ޠ‬Ṷ⠪)12㧕 ᐔᚑ 20 ᐕᐲጘ㒂⋵⋴⼔ᢎ⢒ㅪ⛊ද⼏ળ✚ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⼔⋴ޟ‬ᢎ⢒ߦ߅ߌࠆᮨ
ᡆᖚ⠪ዉ౉ߩᗧ⟵‫ޠ‬Ṷ⠪)
13㧕 ᐔᚑ 20 ᐕᐲవᄤᕈઍ⻢⇣Ᏹ∝╬ᬌᩏᛛⴚ⠪⎇ୃળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘࡜ࠗ࠰࠱࡯ࡓ∛ I㧔ࡓࠦᄙ♧∝㧕—ၮ␆ߣ⥃ᐥ‫ޔ‬ᣂ↢ఽࠬࠢ࡝࡯࠾ࡦࠣ࡯ Ṷ⠪)
14㧕 ╙ 40 ࿁ᣣᧄකቇᢎ⢒ቇળᄢળ(ᐔᚑ 20 ᐕ 7 ᦬㧘᧲੩㧘Medical Education in Korea: The Historicalbackground and the influence of U.S. by Myung-Hyun Chung. ᐳ㐳)15㧕 ╙ 122 ࿁ᣣᧄዊఽ⑼ቇળጤᚻ࿾ᣇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘⋓ጟ㧘‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆዊఽ⑼කߩᓎഀ‫ޠ‬

㧙㧙

Ṷ⠪)
ਤ⠀ 㓷ਯ㧦1㧕 6th Asia-Pacific Conference on Problem-Based Learning,࡮Symposium 2 “E-PBL”(2006.01, Tokyo,
Web-based Internet PBL-tutorial 'Rakuichi The Tutorial; Symposist)2㧕 ╙ 45 ࿁ᣣᧄ⮎ቇળਛ࿖྾࿖ᡰㇱ଀ળ(ᐔᚑ 18 ᐕ 6 ᦬㧘⑔ጊ㧘ቇળ᜗ᓙ⻠Ṷ‫ޟ‬ᣂߒ޿ක≮♽ᢎ⢒ߩᵹࠇߣ PBL/࠹ࡘ࠻࡯࡝ࠕ࡞‫ޠ‬Ṷ⠪)3㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫⚦ޟ‬⢩ᱫߣ∛᳇‫ߩߘޔ‬ౣ↢‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേ
㋈ᧁ ᐽਯ㧦
1㧕 ෘ↢ഭ௛⋭╙ 102 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄࡓࠦᄙ♧∝ⷫߩળ㘈໧(㨪⃻࿷)
3㧕 ALD ⷫߩળ㘈໧(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㋈ᧁᐽਯ㧘ട⮮ᥓ⟤㧘ୖဝ๺ᴰ㧘᛬ዬᔘᄦ㧦ࡓࠦᄙ♧∝ߩ㊀∝ᐲߣㆇേ࡮⹺⍮㕙ߩ ADL ⹏ଔ㧦ᐔᚑ
17 ᐕᐲෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕࡜ࠗ࠰࠱࡯ࡓ∛㧔ࡈࠔࡉ࡝࡯∛฽߻㧕ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ✚᜝⎇ⓥႎ๔ᦠ㧦12㧙14(2006 ᐕ 3 ᦬)
2㧕 ㋈ᧁᐽਯ㧘ਅỈિⴕ㧦೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯߅ࠃ߮ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩᣧᦼ⸻ᢿࠪࠬ࠹ࡓ᭴▽ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌㧔․ቯ∔ᖚኻ╷⎇ⓥ੐ᬺ㧕ㆇേᄬ⺞∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰⎇ⓥႎ๔ᦠ㧦21㧙24(2006 ᐕ 3 ᦬)
3㧕 ᄢ⷏ᒄ㜞㧘㋈ᧁᐽਯ㧦╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧦කቇᢎ⢒ 38㧦282(2007 ᐕ 1 ᦬)
4㧕 ਤ⠀㓷ਯ㧦╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦121(2007ᐕ 1 ᦬)
5㧕 ਤ⠀㓷ਯ㧦╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38㧦334(2007 ᐕ 10
᦬)6㧕 ਤ⠀㓷ਯ㧦╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦354(2007ᐕ 10 ᦬)7㧕 ਤ⠀㓷ਯ㧦╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦410(2007ᐕ 12 ᦬)8㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ㧘㋈ᧁᐽਯ㧘Phillip Evans㧦⁛⥄ᕈ⼾߆ߥ SP 㙃ᚑࡊࡠࠣ࡜ࡓ-ࠬࠦ࠶࠻࡜ࡦ࠼ 5 ᄢቇⷞኤႎ๔-㧦කቇᢎ⢒ 39㧦199㧙204(2008 ᐕ)
9㧕 ㋈ᧁᐽਯ㧘ୖဝ๺ᴰ㧘᛬ዬᔘᄦ㧘ട⮮ᥓ⟤㧦ࡓࠦᄙ♧∝ II ဳ㊀∝ဳߩ⥄ὼᱧߣ BMT ߩലᨐߦ㑐ߔࠆᬌ⸛㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕࡜ࠗ࠰࠱࡯ࡓ∛㧔ࡈࠔࡉ࡝࡯∛฽߻㧕ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦35㧙36(2008 ᐕ 3 ᦬)
10㧕 ㋈ᧁᐽਯ㧘ਅỈિⴕ㧘ୖဝ๺ᴰ㧦ዊఽᄢ⣖ဳ೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩᣧᦼ⸻ᢿᴦ≮ߣኅᣖߩࡔࡦ
࠲࡞ࡋ࡞ࠬ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕ㆇേᄬ⺞∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔ
ᚑ 19 ᐕᐲ⎇ⓥႎ๔ᦠ㧦27㧙29(2008 ᐕ 3 ᦬)
11㧕 ㋈ᧁᐽਯ㧘ਅỈિⴕ㧘ୖဝ๺ᴰ㧦೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩਔⷫߩࡔࡦ࠲࡞ࡋ࡞ࠬ㧦ෘ↢ഭ௛⑼ቇ
⎇ⓥ⾌㧔㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧕ㆇേᄬ⺞∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰ ᐔᚑ 17 ᐕᐲ㧙19 ᐕᐲ✚ว ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦79㧙81(2008 ᐕ 3 ᦬)
12㧕 ㋈ᧁᐽਯ㧘᛬ዬᔘᄦ㧘↰ਛ޽ߌߺ㧘ᅏጊ⯥ਯ㧘ⴡ⮮⟵ൎ㧘੗↰ඳᐘ㧦ࡓࠦᄙ♧∝ I ဳ࡮II ဳߩో࿖ታᘒ⺞ᩏ̆ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣߦะߌߡ̆㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦53㧙54(2008 ᐕ 3 ᦬)
13㧕 ᛬ዬᔘᄦ㧘ᣧဈ๺ሶ㧘↰ㇱ⟤Ⓞ㧘᛬ዬᕡᴦ㧘㋈ᧁᐽਯ㧦ࡓࠦᄙ♧∝ߩዩߦࠃࠆࠬࠢ࡝࡯࠾ࡦࠣᚑ❣
‫ޟ‬ㆊ෰ 20 ᢙᐕ㑆ߩ⚻㛎‫ޠ‬㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ
๔ᦠ㧦49㧙52(2008 ᐕ 3 ᦬)㧙㧙14㧕 ᚭ᧻ବᴦ㧘ࠕ࠼࡝ࠕ࡯࠽࡮ࡕࡦ࠲࡯࠾࡚㧘ዊᾢᢅᐢ㧘㋈ᧁᐽਯ㧘᛬ዬᔘᄦ㧘૒ୖિᄦ㧘⑔჻ ൎ㧘ጊญᷡᰴ㧦ࡓࠦᄙ♧∝ߩᣂ↢ఽࠬࠢ࡝࡯࠾ࡦࠣ㐿⊒㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌㧔ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧕࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ⃰ ᐔ
ᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦55㧙57(2008 ᐕ 3 ᦬)
15㧕 ਤ⠀㓷ਯ㧦╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38㧦86(2008ᐕ 3 ᦬)
16㧕 ਤ⠀㓷ਯ㧦╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38㧦359(2008 ᐕ 10
᦬)17㧕 ਤ⠀㓷ਯ㧦╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39㧦346(2008ᐕ 10 ᦬)18㧕 ਤ⠀㓷ਯ㧦╙ 31 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39㧦469(2008ᐕ 12 ᦬)11㧚ႎ㆏
1㧕 ㋈ᧁᐽਯ㧦ࠬ࡯ࡄ࡯․ႎ‫ޟ‬ALD ೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯‫ޠ‬㧦ࡈࠫ࠹࡟ࡆ㧔࠭࡯ࡄ࡯࠾ࡘ࡯ࠬౝ㧕(2007ᐕ 4 ᦬ 25 ᣣ)2㧕 ㋈ᧁᐽਯ㧦․ᝡ‫ޟ‬ALD ೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯‫ޠ‬㧦࠹࡟ࡆᦺᣣ(2007 ᐕ 10 ᦬ 20 ᣣ)
3㧕 ㋈ᧁᐽਯ㧦․㓸ࠦ࡯࠽࡯‫ࠦࡓޟ‬ᄙ♧∝‫ޠ‬㧦ਛ੩࠹࡟ࡆ㧔࠾ࡘ࡯ࠬ࡝ࠕ࡞࠲ࠗࡓౝ㧕(2007 ᐕ 10 ᦬ 31
ᣣ)4㧕 ਤ⠀㓷ਯ㧦‫ޟ‬ᄢቇߪ޿߹-⎇ⓥቶ߆ࠄ‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 11 ᦬ 13 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
2001 ᐕߦකቇㇱߣߒߡೋߩో࿖౒ห೑↪ᣉ⸳ߣߒߡ⸳⟎ߐࠇߡએ᧪㧘
㧔1㧕ᣂߒ޿කቇᢎ⢒ߩ㐿⊒⎇ⓥ
ߣ᥉෸㧘㧔2㧕කቇᢎ⢒ߦ⽸₂ߢ߈ࠆੱ᧚⢒ᚑ㧘㧔3㧕࿖ౝᄖߩකቇᢎ⢒ᯏ㑐ߣߩㅪ៤࡮౒ห⎇ⓥ㧘ࠍਥߥࡒ࠶࡚ࠪࡦߣߒߡ㧘࿾૏ߩ⏕┙ߦദ߼ߡ߈ߚ‫ޕ‬ᐘ޿ߥߎߣߦකቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩਥ௅
╬ࠍㅢߓߡ㧘ో࿖ߩකቇㇱ࡮ක≮♽ᢎ⢒ᯏ㑐ߦ⹺⍮ߐࠇ㧘ᡰᜬࠍᓧࠄࠇࠆࠃ߁ߦߥߞߚ‫ߚ߹ޕ‬ᶏᄖߩ⪺ฬߥකቇᢎ⢒⠪ࠍᲤᐕ᜗⡜ߔࠆߎߣߦࠃߞߡ㧘࿖㓙⊛ߦ߽ᒰ࠮ࡦ࠲࡯ߩሽ࿷߇⍮ࠄࠇࠆࠃ߁ߦߥߞߚ‫ޕ‬ㄭᐕ㧘ฦᄢቇߦකቇᢎ⢒ㇱ㐷⸳⟎ߩേ߈߇ᐢ߹ߞߡ޿ࠆ߇㧘ߎࠇࠄߩ⚵❱ߣߩㅪ៤߽ᒝ߹ࠅߟߟ޽ࠆ‫ޕ‬
ᐔᚑ 20 ᐕᐲ߆ࠄᄢቇ㒮߽⸳⟎ߐࠇ㧘ੱ᧚⢒ᚑ㧘⎇ⓥ૕೙߇ᢛ޿ߟߟ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷කቇᢎ⢒ᣇᴺߩ㐿⊒⎇ⓥߦ㑐ߒߡߪ㧘౨㗡ߢ୘‫ߩޘ‬ขࠅ⚵ߺߦߟ޿ߡㅀߴߚ‫᦭ࠍࠄࠇߎޕ‬ᯏ⊛ߦ⛔วߒ㧘ᣂߚߥකቇᢎ⢒ࠞ࡝ࠠࡘ࡜ࡓࠍឭ᩺ߔࠆߎߣ߇੹ᓟߩ⺖㗴ߢ޽ࠆ‫ޕ‬ᐔᚑ 20 ᐕᐲ߆ࠄዉ౉ߐࠇߚᣂࠞ
࡝ࠠࡘ࡜ࡓߩਛߢ㧘ߘߩታ⃻ߦദജߔࠆߣߣ߽ߦ㧘࿖ౝᄖ߳⊒ାߒߡⴕߊ੍ቯߢ޽ࠆ‫ోޕ‬࿖⊛ߥකᏧਇ⿷߆ࠄකቇㇱቇ↢ቯຬჇ໧㗴߇ᕆᶋ਄ߒߡ޿ࠆ߇㧘ᢎ⢒ߩੱ⊛࡮⚻ᷣ⊛ߥⵣߠߌߪᭂ߼ߡ㊀ⷐߥ⺖㗴ߣߥߞߡ߅ࠅ㧘ᢎ⢒ࠍᜂᒰߔࠆ┙႐߆ࠄឭ⸒ߒߡⴕ߈ߚ޿‫᧚ੱޕ‬⢒ᚑߦ㑐ߒߡߪ㧘⃻࿷ߩᢎ⢒ࠬ࠲࠶ࡈో
⥸ߩ FD ផㅴߣ዁᧪ߩකቇᢎ⢒ቇࠍᡰ߃ࠆੱ᧚⢒ᚑࠍᐔⴕߒߡㅴ߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬ᓟ⠪ߦߟ޿ߡߪ㧘ᄢቇ㒮߇⸳⟎ߐࠇ૕೙߇ߢ߈ߚ߇㧘࿖ౝᄖߩකቇᢎ⢒ㇱ㐷ߣߩㅪ៤ࠍ৻ጀᒝൻߐߖࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸකቇᢎ⢒ߩಽ㊁ߢ⸃᳿ߔߴ߈⺖㗴ߪጊⓍߒߡ޿ࠆ‫ޕ‬ᢎ⢒ߩ㊀ⷐᕈߪ⺕ߒ߽߇⹺⼂ߒߡ޿ࠆ߇㧘ታ㓙ߦߪ⒳‫ߩޘ‬೙⚂ߦࠃߞߡ㧘ߘࠇ߇ታ⃻ߢ߈ߥ޿⃻⁁߇޽ࠆ‫ޕ‬කቇ࡮ක≮⇇ో૕߇⥄Ꮖ㕟ᣂࠍ⛯ߌߥ߇ࠄ㧘ᢎ⢒ߩ㊀ⷐᕈࠍ␠ળߦኻߒߡ⊒ାߒ㧘ᦸ߹ߒ޿ᢎ⢒ߩታ⃻߇น⢻ߣߥࠆࠃ߁ദജߒߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔10㧕කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧔ࡃ࡯࠴ࡖ࡞ࠬࠠ࡞ㇱ㐷㧕1㧚⎇ⓥߩ᭎ⷐ
ᒰㇱ㐷ߢߪ㧘ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒㧘ᮨᡆᖚ⠪࠻࡟࡯࠾ࡦࠣ㧘り૕⸻ኤࠍ฽߼ߚᮨᡆ⸻ኤߩ㐿⊒࡮
⎇ⓥࠍⴕߞߡ޿ࠆ‫ߚ߹ޕ‬㧘ࠪࡒࡘ࡟࡯࠲࡯ࠍ↪޿ߚり૕⸻ኤߪ⹜ⴕᲑ㓏ߦ౉ߞߡ޿ࠆ‫ޕ‬කቇ⧷⺆ߪၮᧄ߆ࠄࠃࠅታ〣⊛ߥ࡟ࡌ࡞ߩᢎ⢒߇ߢ߈ࠆࠃ߁Ḱ஻ࠍㅴ߼ߡ޿ࠆ‫ߚ߹ޕ‬㧘ᰴᐕᐲએ㒠ߦ߻ߌ㧘ⴕേ⑼ቇᢎ⢒ߣߒߡ‫ޟ‬ᖚ⠪කᏧ‫߮ࠃ߅ࠬ࡯ࠦޠ‬㧘‫ߩࠬ࡯ࠦޠ࡞ࠢࠗࠨࡈࠗ࡜ޟ‬Ḱ஻࡮૞ᚑࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦

⮮ፒ๺ᒾ
㒙ㇱᕺሶ

Kazuhiko Fujisaki
Keiko Abe3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ౻㧙╙ 15 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙94㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᤐ㧙╙ 16 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙124㧚
3㧕 ⮮ፒ๺ᒾ㧘↰ች⩿ᄹሶ㧘ጊᧄ⑲᮸✬㧚␠ળߣஜᐽ࡮∔∛ߣߩ㑐ଥ㧦ࠦࠕ࡮ࠞ࡝ࠠࡘ࡜ࡓኻᔕ කቇ࡮ක≮ߣ␠ળ㧘੩ㇺ㧦㊄⧐ၴ㧧2006 ᐕ㧦1㧙4㧚
4㧕 ⮮ፒ๺ᒾ㧚ో࿖ᖚ⠪ળ㓚ኂ⠪࿅૕ⷐⷩ✬㓸ቶ✬㧚ක≮ߦ߅ߌࠆᖚ⠪ળ㧦ో࿖ᖚ⠪ળ㓚ኂ⠪࿅૕ⷐⷩ ╙ 3㧘ᄢ㒋㧦ࡊ࡝ࡔ࠼␠㧧2006 ᐕ㧦10㧙13㧚
5㧕 ⮮ፒ๺ᒾ㧚කቇᢎ⢒ቇળ✬㧚ක≮ߩᄌൻߣකቇᢎ⢒㧦කቇᢎ⢒⊕ᦠ 2006 ᐕ 㧦◉ේ಴ ᣂ␠㧧2006 ᐕ㧦
118㧙121㧚
6㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ᄐ㧙╙ 17 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙211㧚
7㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’05 ⑺㧙╙ 18 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙112㧚
8㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ౻㧙╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙110㧚
9㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᤐ㧙╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦1㧙185㧚
10㧕 ⮮ፒ๺ᒾ㧚කቇᢎ⢒ߣ⺆ࠅ㧦ᳯญ㊀ᐘ㧘ᢪ⮮ᷡੑ㧘㊁᧛⋥᮸✬㧚࠽࡜࠹ࠖࡧߣක≮㧦㊄೰಴ 㧧2006 ᐕ㧦
107㧙112㧚
11㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ᄐ㧙╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙237㧚
12㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’06 ⑺㧙╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙89㧚
13㧕 ㊁ํᐞਭሶ㧘㒙ㇱᕺሶ㧘⍹Ꮉ߭ࠈߩ㧚ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦಽᨆߩᣇᴺ—The Roter Method ofInteraction Process Analysis System (RIAS)—㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙71㧚
14㧕 㒙ㇱᕺሶ㧚╙ 4 ┨㧦ᖚ⠪ߣකᏧߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ㧦⍹Ꮉ߭ࠈߩ㧘ᱞ↰⵨ሶ⋙⸶㧚in Debra L. Roter,
Judith A Hall㧚කᏧߣᖚ⠪ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߦᓇ㗀ࠍਈ߃ࠆᖚ⠪ߩ․ᕈ㧘◉ේ಴ ᣂ␠㧧2007 ᐕ㧦
59㧙74㧚
15㧕 ⮮ፒ๺ᒾ㧚shared decision making(ᗧᕁ᳿ቯߩ޽ࠅᣇ)ࠍᡰ߃ࠆකᏧߩ⢻ജ㙃ᚑߩ⃻⁁ߣ⺖㗴㧦᧻↰੫ਃ㧘᧻ፉ੩㧘᫟ዬᓼሶ✬㧚ක≮࡮⑔␩ߦ߅ߌࠆ࿾ၞ࡮૑᳃ࠛࡦࡄࡢࡔࡦ࠻́ታ〣✬́㧦┙๮㙚ᄢቇੱ㑆⑼ቇ⎇ⓥᚲ㧧2007 ᐕ㧦43㧙79㧚
16㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ౻㧙╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙120㧚
17㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᤐ㧙╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙152㧚
18㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ᄐ㧙╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦1㧙121㧚
19㧕 ⮮ፒ๺ᒾ㧚කᏧߩ࠹ࠢ࠾࠶ࠢ㧔ᛛ⢻㧕⹏ଔ㧦ฬㇹ⋥᮸⋙ୃ㧚ዊ⼱๺ᒾ㧘ᦺ੗㕏ᒾ㧘ධㇹᩕ⑲㧘የ⮮⺈ม✬㧚⸻ኤ࡮ᬌᩏ㧦⟠࿯␠㧧2007 ᐕ㧦16㧙23㧚
20㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’07 ⑺㧙╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙100㧚
21㧕 ⮮ፒ๺ᒾ㧚ⴕേᄌኈࠍ߁ߥ߇ߔߚ߼ߩ㕙ធࠬࠠ࡞଻ஜᜰዉኻੱេഥࠬࠠ࡞ߩቇ⠌㧦ᣣᧄ↢ᵴදห⚵วㅪวળක≮ㇱળ㧧2008 ᐕ㧦1㧙45㧚
22㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ౻㧙╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙130㧚㧙㧙

23㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ’08 ᤐ㧙╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊߩ⸥㍳㧙㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦1㧙152㧚
24㧕 ⮮ፒ๺ᒾ㧚ᖚ⠪㧙ක≮⠪㑐ଥ㧙㧦ᣣᧄ↥ᬺࠞ࠙ࡦ࠮࡝ࡦࠣቇળ✬㧚↥ᬺࠞ࠙ࡦ࠮࡝ࡦࠣㄉౖ㧦㊄ሶᦠᚱ㧧2008 ᐕ㧦74㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Yoshida T, Fujisaki K. Interpersonal Communication Training in Dental Education. In: David I.
Mostofsky and Albert G. Forgione eds. Behavioral Dentistry. Iowa: Blackwell Pub Professional;
2006:255-263.
✚⺑㧔๺ᢥ㧕
1㧕 ⮮ፒ๺ᒾ㧚NBM ߩၮ␆࡮ℂ⺰—ක≮ੱ㘃ቇ㧘⸻ᢿߣᴦ≮ 2006 ᐕ㧧94 Ꮞ㧦232㧙236㧚
2㧕 ⮮ፒ๺ᒾ㧚ߎࠇ߆ࠄߩ⮎೷Ꮷߦ᳞߼ࠄࠇࠆක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦߣߪ㧘᦬ೀ⮎੐ 2006 ᐕ㧧48 Ꮞ㧦501
㧙506㧚
3㧕 ⮮ፒ๺ᒾ㧚ක≮‫ޡ‬ᡷ㕟‫ߣޢ‬ක≮ᓥ੐⠪ߩᓎഀ㧘᦬ೀ࿖᳃ක≮ 2007 ᐕ㧧234 Ꮞ㧦2㧙24㧚
4㧕 ⮮ፒ๺ᒾ㧚⹣߼ㄟߺဳකቇᢎ⢒߆ࠄ⺖㗴⸃᳿ဳᢎ⢒߳ߩォ឵㧘ੱ㑆ߣᢎ⢒ 2007 ᐕ㧧54 Ꮞ㧦112㧙123㧚
5㧕 ⮮ፒ๺ᒾ㧚කቇㇱߢㅴ߻ታ〣⊛ᢎ⢒߳ߩᡷ㕟㧘BERD 2007 ᐕ㧧9 Ꮞ㧦22㧙27㧚
6㧕 ⮮ፒ๺ᒾ㧚ක≮␠ળቇߦߟ޿ߡ㧘᦬ೀ࠽࡯ࠪࡦࠣ 2007 ᐕ㧧27 Ꮞ㧦63㧙67㧚
7㧕 ⮮ፒ๺ᒾ㧚ⴕേᄌኈࠍ↢߻ᖚ⠪ࠕࡊࡠ࡯࠴㧘᦬ೀ଻࿅ㅪ 2007 ᐕ㧧952 Ꮞ㧦70㧙82㧚
8㧕 Ꮉ਄ߜ߭ࠈ㧘⮮ፒ๺ᒾ㧚ᮨᡆᖚ⠪ߩߚ߼ߩ‫ߩޠ࠻࡯ࠪࠢ࡯ࡢࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ឭ᩺㧘කቇᢎ⢒ 2008 ᐕ㧧
39 Ꮞ㧦417㧙420㧚
9㧕 ᮯ↰⟤㓶㧘ጟ↰శᒄ㧘੖ච፲⚛ሶ㧘ችፒᓀሶ㧘⌀㍿㒽ᄥ㇢㧘⮮ፒ๺ᒾ㧘ർ᧛㓉ᙗ㧘㜞ጊᥓሶ㧘ᄥ↰⢻㧘₹⟎ବᤩ㧘ኹ᎑ศ଻㧘㒙ㇱᥓᕺሶ㧘ፉ↰ᤘੳ㧘ዊᴰ⑲᮸㧚㜞╬ᢎ⢒ᡷ㕟ߩ⋧੕ⴕὑಽᨆ㧙ࡆ࠺ࠝ࡮ࠛࠬࡁࠣ
࡜ࡈࠖ࡯⎇ⓥߩ⁓޿ߣᎿቇㇱㇺᏒᎿቇṶ⠌ߩታ㓙㧙㧘ᄢቇᢎ⢒⎇ⓥࠫࡖ࡯࠽࡞ 2008 ᐕ㧧5 ภ㧦93㧙104㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 㒙ㇱᕺሶ㧘㋈ᧁን㓶㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧚ᮨᡆᖚ⠪ߩ⃻ᴫ෸߮ḩ⿷ᗵߣ⽶ᜂᗵ̆ో࿖ᗧ⼂⺞ᩏ╙৻ႎ̆㧘කቇᢎ⢒ 2007 ᐕ㧧38 Ꮞ㧦301㧙307㧚
2㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧚ᮨᡆᖚ⠪ߩදജࠍᓧߚり૕⸻ኤታ⠌ߩ੹ᓟߩᣇะᕈ㧘ᣣᧄ଻㒾ක≮ⴕേ⑼ቇቇળᐕႎ 2008 ᐕ㧧23 Ꮞ㧦59㧙73㧚ේ⪺㧔᰷ᢥ㧕
ߥߒ

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧧ᢥㇱ⑼ቇ⋭․⦡޽ࠆᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ(․⦡ GP)㧦⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧧ᐔᚑ 15㧙18 ᐕᐲ㧧60,000 ජ౞(15,000㧦15,000㧦15,000㧦15,000 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦ᮯ↰⟤㓶(ᓼፉᄢቇ✚ว⑼ቇㇱ)㧘⎇ⓥಽᜂ⠪㧦⮮ፒ๺ᒾ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(B)(৻⥸)㧦㜞╬ᢎ⢒ᡷ㕟ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦಽᨆ㧙⃻႐ߦ߅ߌࠆᢥൻᄌኈߩ⾰⊛ᬌ⸛㧙㧧
ᐔᚑ 18㧙20 ᐕᐲ㧧14,500 ජ౞(5,100㧦4,800㧦4,800 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁን㓶(ฬฎደᄢቇකቇㇱ㒝ዻ∛㒮✚ว⸻≮ㇱ)㧘⎇ⓥಽᜂ⠪㧦㒙ㇱᕺሶ㧘઻ାᄥ㇢㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ᣣᧄߩකቇᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕേ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,400 ජ౞(1,300㧦900㧦1,200 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᬀ᧛๺ᱜ(ฬฎደᄢቇකቇㇱකቇᢎ⢒࠮ࡦ࠲࡯)㧘⎇ⓥಽᜂ⠪㧦㒙ㇱᕺሶ㧘⨃ᧁ৾㚅㧧ᢥ
ㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦කቇ↢ߩ‫ޟ‬ᱫߩᢎ⢒‫ߩ߳ޠ‬ᮨᡆᖚ⠪ዉ౉ߩᢎ⢒⊛ലᨐߩ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,870 ජ౞(1,417㧦1,453 ජ౞)
5㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧧ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ(⃻ઍ GP)㧦‫⥃ޟ‬ᐥකቇ
ᢎ⢒ࠍᒝൻะ਄ߐߖࠆ ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦21,980㧦24,000 ජ౞)
6㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁᐽਯ㧘⎇ⓥಽᜂ⠪㧦ട⮮ᥓ⟤㧘㒙ㇱᕺሶ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦
ዊఽ㗔ၞߦ߅ߌࠆቴⷰ⊛⥃ᐥ⢻ജ⹏ଔࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,800 ජ౞(2,300㧦1,100㧦
700 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
ߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ⮮ፒ๺ᒾ㧦
1㧕 ᣣᧄ଻ஜක≮ⴕേ⑼ቇળળ㐳(㨪ᐔᚑ 19 ᐕ 10 ᦬)
2㧕 ․ቯ㕖༡೑ᵴേᴺੱᣣᧄኅᐸක≮ቇળℂ੐(㨪ᐔᚑ 20 ᐕ 6 ᦬)
3㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ࡮ℂ੐(㨪⃻࿷)4㧕 ᣣᧄකቇᢎ⢒ቇળᢎ᧚㐿⊒࡮SP ዊᆔຬળᆔຬ㐳(㨪⃻࿷)5㧕 ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળળ㐳(㨪⃻࿷)6㧕 ᣣᧄ␠ળකቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄක≮⚻ᷣቇળᐙ੐(㨪⃻࿷)
8㧕 RIAS ⎇ⓥળળ㐳(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)㒙ㇱᕺሶ㧦
1㧕 ᣣᧄකቇᢎ⢒ቇળ࡮ⴕേ⑼ቇੱ㑆㑐ଥᆔຬળ(㨪ᐔᚑ 18 ᐕ 3 ᦬)
2㧕 Association of Standardized Patient Educators, International committee member (ᐔᚑ 19 ᐕ 11᦬㨪⃻࿷)3㧕 RIAS ⎇ⓥળᆔຬ(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)2㧕ቇળ㐿௅
කቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯㧦1㧕 ╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 4 ᦬㧘ߟߊ߫)3㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᮮᵿ)
5㧕 ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂)
6㧕 ╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩)7㧕 ╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧛╙ 7 ࿁ᣣᧄዊఽකቇᢎ⢒⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)8㧕 ╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᓼፉ)9㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)10㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)11㧕 ጘ㒂ᄢቇᮨᡆᖚ⠪ߩળ 10 ๟ᐕ⸥ᔨࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂)12㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)13㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)⮮ፒ๺ᒾ㧦
1㧕 ╙ 10 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ฬฎደ)2㧕 ╙ 11 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ)3㧕 ╙ 12 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ฬฎደ)
4㧕 ╙ 13 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ)⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦
1㧕 ╙ 1 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ)2㧕 ╙ 2 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ)3㧕 ╙ 3 ࿁ RIAS ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘ฬฎደ)㧙㧙3㧕ቇⴚ㔀⹹ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳⮮ፒ๺ᒾ㧦
1㧕 ᐔᚑ 17 ᐕᐲ࿾ၞ଻ஜ✚วផㅴ੐ᬺ⊒⴫ળ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬࿾ၞߦ߅ߌࠆᣂ⥃ᐥකᏧ⎇ୃߦߟ޿ߡ‫ޠ‬Ṷ⠪ ‫ޟ‬කቇᢎ⢒ߩⷞὐ߆ࠄ⷗ߚ࿾ၞߦ߅ߌࠆᣂ⥃ᐥකᏧ⎇ୃ‫ޠ‬Ṷ⠪)2㧕 2006 ᐕᐲᣣᧄᴺ␠ળቇળቇⴚᄢળ(ᐔᚑ 18 ᐕ 5 ᦬㧘⷏ች㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬Ꮢ᳃ߣᴺኾ㐷ᢎ⢒㧙ࡠ࡯ࠬࠢ࡯࡞ߦ߅ߌࠆታᛛᢎ⢒ߩ⺖㗴‫ޠ‬Ṷ⠪ ‫ޟ‬කቇㇱߦ߅ߌࠆᮨᡆᖚ⠪ߩᢎ⢒ෳടߩ⃻⁁ߣߘߩᚑᨐ‫ޠ‬Ṷ⠪)3㧕 ᐔᚑ 18 ᐕጘ㒂ᄢቇකቇㇱห⓹ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘ᢎ⢒⸥ᔨ⻠Ṷ‫ޟ‬਎⇇⊛ߥකቇᢎ⢒ᡷ㕟ߩേะߣጘ㒂ᄢቇකቇㇱකቇᢎ⢒㐿⊒⎇ⓥ࠮ࡦ࠲࡯ߩᓎഀ‫ޠ‬Ṷ⠪)
4㧕 ╙ 30 ࿁ᣣᧄක≮⚻ᷣቇળᄢળ(ᐔᚑ 18 ᐕ 9 ᦬㧘᧲੩㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬කᏧߩਇ⿷࡮஍࿷‫ࠖ࠺ࡔࠦޔ‬ࠞ࡞㙃ᚑߩ⃻⁁ߣ໧㗴ὐ‫ޠ‬ᐳ㐳㧘Ṷ⠪)
5㧕 ╙ 39 ࿁ᣣᧄ⮎೷Ꮷળቇⴚᄢળ(ᐔᚑ 18 ᐕ 10 ᦬㧘⑔੗㧘․೎ࡊࡠࠣ࡜ࡓ⻠Ṷ‫⮎ޟ‬೷Ꮷߣߒߡ᳞߼ࠄ
ࠇࠆ⥃ᐥࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ࡞ߣߘߩᢎ⢒‫ޠ‬Ṷ⠪)
6㧕 ╙ 13 ࿁਄✚࿖㓙㜞ᐲኾ㐷⡯ᢎ⢒⎇ⓥቇળᢎ⢒࡮⎇ⓥ㓸ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ንጊ㧘ၮ⺞⻠Ṷ‫ޟ‬ᣂකᏧ⎇ୃ೙ᐲߩశߣᓇ‫ޠ‬Ṷ⠪)7㧕 ╙ 5 ࿁ࡈࠔ࡯ࡑࠪࡘ࡯࠹ࠖࠞ࡞ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᧅᏻ㧘ၮ⺞⻠Ṷ‫ޟ‬ක≮ੱ⢒ᚑߦ߅ߌࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߩ⃻࿷ߣᧂ᧪‫ޠ‬Ṷ⠪)8㧕 ᣣᧄᱤ⑼කቇᢎ⢒ቇળᱤቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 12 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ޟ‬ක≮ࠦࡒࡘ࠾ࠤ࡯
࡚ࠪࡦᢎ⢒ߣᮨᡆᖚ⠪ߩ㙃ᚑߦߟ޿ߡ‫ޠ‬Ṷ⠪)9㧕 ╙ 27 ࿁ᣣᧄකቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬කቇᢎ⢒ࠍ⠨߃ࠆ㧙᣿ᣣߩฬකࠍߤ߁⢒ߡࠆ߆㧙‫ޠ‬ᐳ㐳)10㧕 ╙ 107 ࿁ᣣᧄᄖ⑼ቇળቯᦼቇⴚ㓸ળතᓟᢎ⢒࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢ㒋㧘⻠Ṷ‫ޟ‬ක≮㕙ធߣࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒‫ޠ‬Ṷ⠪)11㧕 ╙ 20 ࿁ᣣᧄญ⣧⸻ᢿቇળ✚ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᮮ㗇⾐㧘․೎⻠Ṷ‫ޟ‬කቇᢎ⢒ߦ߅ߌࠆ⸻≮㍳⸥タ‫ޠ‬Ṷ⠪)12㧕 ᐔᚑ 19 ᐕᐲో࿖ℂቇ≮ᴺ჻࡮૞ᬺ≮ᴺ჻ቇᩞㅪ⛊ද⼏ળ✚ળ(ᐔᚑ 19 ᐕ 6 ᦬㧘␹ᚭ㧘⻠Ṷ‫⥃ޟ‬ᐥታ⠌ߩ⹏ଔߩା㗬ᕈߣᅷᒰᕈ㧔OSCE ࠍ฽߼ߡ㧕‫ޠ‬Ṷ⠪)
13㧕 ╙ 17 ࿁ᣣᧄක≮⮎ቇળᐕળࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 9 ᦬㧘೨ᯅᏒ㧘⻠Ṷ‫ޟ‬ᮨᡆᖚ⠪දജဳ⎇ୃߦ߅ߌࠆࡈࠖ࡯࠼ࡃ࠶ࠢ⢻ജࠍ⏴ߊ㧍‫ޠ‬Ṷ⠪)⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦
1㧕 5th Asia Pacific Regional Meeting “Mental Health” Agenda of Impaired Healers Workshop (2007㧚
03, Osaka ; Performer)㒙ㇱᕺሶ㧦
1㧕 ฬฎደᄢቇ╙৻࿁ SP ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘ฬฎደ㧘‫ޟ‬ᣣᧄߣ☨࿖ߦ߅ߌࠆᮨᡆᖚ⠪ᵴേ㧦⃻⁁࡮໧㗴ὐ࡮੹ᓟߩ⺖㗴‫ޠ‬Ṷ⠪)
2㧕 ᧲੩ᄢቇ RIAS ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 18 ᐕ 3 ᦬㧘᧲੩㧘‫ޟ‬ᣣᧄߦ߅ߌࠆ RIAS ዉ౉‫ޠ‬Ṷ⠪)
3㧕 ╙ 10 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ฬฎደ㧘‫ޟ‬ᣣ☨ߩᮨᡆᖚ⠪ߩ⃻⁁ߣ੹ᓟߩᣇะᕈ‫ޠ‬Ṷ⠪)
4㧕 ฬฎደᏒ┙ᄢቇ∛㒮⋴⼔Ꮷ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 10 ᦬㧘ฬฎደ㧘‫ߪߌߛࠇߎޟ‬⍮ߞߡ᰼ߒ޿ࠦࡒࡘ࠾
ࠤ࡯࡚ࠪࡦߩၮᧄ‫ޠ‬Ṷ⠪)
5㧕 ╙ 11 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ㧘‫ ࠆߌ߅ߦࠬ࡝ࠡࠗޟ‬SP ੐ᖱ‫ޠ‬Ṷ⠪)‫♧ޟ‬ዩ∛ᖚ⠪ߩ࠽࡜࠹ࠖࡉߩ⸥ㅀ߇ᣣ
6㧕 ฬฎደᏒ┙ᄢቇ࠽࡜࠹ࠖࡉ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ฬฎደ㧘Ᏹ⸻≮ߦ෸߷ߔᓇ㗀‫ޠ‬Ṷ⠪)7㧕 ਭ⇐☨ᄢቇ SP ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘ਭ⇐☨㧘‫ޟ‬SP ߩ⃻⁁㧦ᣣ☨ߩᗧ⼂⺞ᩏࠃࠅ‫ޠ‬Ṷ⠪)8㧕 ╙ਃ࿁ฬၔᄢቇ⥃ᐥ⮎ቇᢎ⢒⥃ᐥᛛ⢻࠻࡟࡯࠾ࡦࠣࡊࡠࠣ࡜ࡓࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࡢ࡯࡚ࠢࠪ࠶ࡊ
‫⮎ޟ‬ቇಽ㊁ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߦ߅ߌࠆലᨐ⊛ߥࡈࠖ࡯࠼ࡃ࠶ࠢߩᣇᴺ㧦ࡈࠔࠪ࡝࠹࡯࠲

㧙㧙࡯࡮SP ߆ࠄቇ↢߳૗ࠍ㄰ߔ߆‫߁ߤޔ‬㄰ߔ߆‫(ޠ‬ᐔᚑ 19 ᐕ 1 ᦬㧘ฬฎደ㧘‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)
9㧕 ᣣᧄࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥ⠪ળ⼏(ᐔᚑ 19 ᐕ 5 ᦬㧘ฬฎደ㧘‫ޟ‬ක≮ߦ߅ߌࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ
⢒㧦ၮᧄ߆ࠄኾ㐷߳‫ޔ‬ᛛ⢻⠌ᓧ߆ࠄᘒᐲᢎ⢒߳ߩំࠅᚯߒ‫ޠ‬Ṷ⠪)‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)10㧕 ╙ 1 ࿁ၯᮨᡆᖚ⠪㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 11 ᦬㧘ၯ₹㧘11㧕 ╙ 21 ࿁⮮↰଻ஜⴡ↢ᄢቇකቇㇱකቇᢎ⢒ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘‫⥃ޟ‬ᐥታ⠌߿තᬺ⹺ቯߩߚ߼ߩᛛ⢻࡮ᘒᐲ⹏ଔ Advanced OSCE ߩዉ౉ߩ⠨߃ᣇ‫ޠ‬Ṷ⠪)12㧕 ╙ 1 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡈࠔࠪ࡝࠹࡯࠲࡯㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 12 ᦬㧘ฬฎደ㧘‫ޟ‬਎⇇
ߩ SP ੐ᖱ‫ޠ‬Ṷ⠪)
13㧕 ᗲ⍮ක⑼ᄢቇ SP 㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᣣᧄߣ਎⇇ߩ SP ੐ᖱ‫ޠ‬Ṷ⠪)
14㧕 Association for Medical Education in Europe, Pre-conference :“High stakes, low stakes, the proof
is in the pudding: preparation for quality SP programs” (by ASPE International committee
member)(2008.08, in Prague, Czech Republic)
15㧕 International Conference on Communication in Healthcare 2008 by European Association forCommunication in Healthcare (2008.09, Oslo, Norway, Symposium: Developing a global networkof national RIAS centres; Title “RIAS Japan” Symposiast)16㧕 ᐔᚑ 18㧙20 ᐕᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⵬ഥ㊄੤ઃ⎇ⓥ‫ޟ‬ᣣᧄߩකቇㇱᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕ
േ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ‫ࡓ࠙ࠫࡐࡦࠪޠ‬㧦ත೨කቇᢎ⢒ߦ߅ߌࠆⴕേ⑼ቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ in NAGOYA(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬࿾ၞߢߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒߇ᖱേߦਈ߃ࠆᓇ㗀ߣኅᣖ࡜ࠗࡈࠨࠗࠢ࡞ߣ޿߁ⷞὐߩᔅⷐᕈ㧦࿦ఽ࡮ᅧᇚߣߩ⛮⛯⊛੤ᵹ߆ࠄ‫ޠ‬Ṷ⠪)17㧕 ╙ 2 ࿁ၯᮨᡆᖚ⠪㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ၯ₹㧘‫ߩࠢ࠶ࡃ࠼࡯ࠖࡈޟ‬ၮᧄ‫ޠ‬Ṷ⠪)18㧕 ╙ 11 ࿁ᣣᧄࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦቇળਛㇱ྾࿖ᡰㇱᄢળ࡮ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒⎇ⓥ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 11 ᦬㧘ᐢፉ㧘‫ޟ‬਎⇇ߩ SP ᵴേ㧦SP ߩṶᛛ࡮ࡈࠖ࡯࠼ࡃ࠶ࠢ‫ޠ‬Ṷ⠪)
19㧕 ╙ 15 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘‫ޟ‬AMEE࡮EACH ቇળႎ๔‫ޠ‬Ṷ
⠪)20㧕 ╙ 2 ࿁ක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ࡮ࡈࠔࠪ࡝࠹࡯࠲࡯㙃ᚑ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘‫ޟ‬਎⇇
ߩ SP ᵴേ‫ޠ‬Ṷ⠪)⧯ᨋ⧷᮸㧦
1㧕 ᐔᚑ 18㧙20 ᐕᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⵬ഥ㊄੤ઃ⎇ⓥ‫ޟ‬ᣣᧄߩකቇㇱᢎ⢒ߦ߅ߌࠆ 6 ᐕ㑆⛔วဳⴕ
േ⑼ቇᢎ⢒ࡊࡠࠣ࡜ࡓߩ㐿⊒ߦ㑐ߔࠆ⎇ⓥ‫ࡓ࠙ࠫࡐࡦࠪޠ‬㧦ත೨කቇᢎ⢒ߦ߅ߌࠆⴕേ⑼ቇᢎ⢒ࠪࡦࡐࠫ࠙ࡓ in NAGOYA(ᐔᚑ 20 ᐕ 11 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬ᣣᧄߦ߅ߌࠆ੹ᓟߩ⛔วဳⴕേ⑼ቇᢎ⢒ࠍ⠨߃ࠆ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 㒙ㇱᕺሶ㧦ࡉ࡞࡯࡝ࡏࡦ⾨㧛౒ห⎇ⓥㇱ㐷ᦨఝ⑲⾨(The 5th Association of Standardized Patient
Educators conference㧦╙ 5 ࿁ᮨᡆᖚ⠪ᢎ⢒⠪ቇળ㧘ᐔᚑ 18 ᐕᐲ)
9㧚␠ળᵴേ⮮ፒ๺ᒾ㧦
1㧕 ක≮♽ᄢቇ㑆౒↪⹜㛎ታᣉ⹏ଔᯏ᭴කቇ♽ OSCE ੐ᓟ⹏ଔ⸃ᨆዊᆔຬળᆔຬ㧘ቇ⠌࡮⹏ଔ㗄⋡╬ᡷ⸓ኾ㐷ㇱળᆔຬ㧘⺖㗴ᡷ⸓ኾ㐷ㇱળᆔຬ(㨪⃻࿷)2㧕 ᄢቇၮḰදળ‫ࠆ޽⦡․ޟ‬ᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ‫(࡯࡝ࠚࡈ࡟࡯ࡄ࡯ࡍޠ‬㨪⃻࿷)3㧕 ෘ↢ഭ௛⋭╙ 101 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)4㧕 ෘ↢ഭ௛⋭╙ 102 ࿁කᏧ࿖ኅ⹜㛎 ⹜㛎ᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ⮮ፒ๺ᒾ㧦ஜᐽߠߊࠅࠍ૑᳃ߩᚻߢ㧙૑᳃ਥ૕ߩᵴേࠍᡰ߃ࠆ଻ஜᏧߩᓎഀ㧦╙ 27 ࿁ో࿖࿾ၞ଻ஜ
Ꮷቇⴚ⎇ⓥળ⻠Ṷ෼㍳㓸㧦28㧙60(2006 ᐕ 1 ᦬)
2㧕 ઻ାᄥ㇢㧘㒙ㇱᕺሶ㧦ක≮㕙ធ෸߮り૕⸻ኤߦ⽸₂ߔࠆᮨᡆᖚ⠪㙃ᚑߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15࡮16࡮
17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥ ✚᜝࡮ಽᜂႎ๔ᦠ㧦1㧙214 (2006 ᐕ 2 ᦬)
3㧕 ⮮ፒ๺ᒾ㧘㒙ㇱᕺሶ㧦IMPROVING MEDICAL EDUCATION㧙Enhancing the Behavioral andSocial Science Content of Medical School Curricula Institute of Medicine 2005㧘ࠦࡒࡘ࠾ࠤ࡯ࠪ

㧙㧙࡚ࡦࠥ࡯ࡓ㧦ᣣᧄකቇᢎ⢒ቇળⴕേ⑼ቇ࡮ੱ㑆㑐ଥᢎ⢒ᆔຬળႎ๔ᦠ‫ⴕޟ‬േ⑼ቇᢎ⢒ࠍ⠨߃ࠆ㧙ࡊࡠࡈࠚ࠶࡚ࠪ࠽࡞ߩᢎ⢒ࠍ߼ߑߒߡ‫ޠ‬㧦18㧙20㧘80㧙81(2006 ᐕ 3 ᦬)
4㧕 ⮮ፒ๺ᒾ㧦࿖ኅ⹜㛎 OSCE ߦ߅ߌࠆᮨᡆᖚ⠪㧘Advanced OSCE ߢߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ⺖㗴㧦2005
ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ‫ޟ‬OSCE ࠻࡜ࠗࠕ࡞ߩታᣉ╬කᏧ࿖ኅ⹜㛎ߩᡷༀߦ߆߆ࠆ⎇ⓥ‫ޠ‬ಽᜂ⎇ⓥ‫ޟ‬࿖ኅ⹜㛎 OSCE ࠻࡜ࠗࠕ࡞ߩታᣉߦଥࠆ⎇ⓥ‫ޠ‬2005 Advanced OSCE ႎ๔ᦠ㧦289㧙293㧘313㧙
317(2006 ᐕ 3 ᦬)
5㧕 㒙ㇱᕺሶ㧦”Student Perception of Feedback from Simulated Patient during Communication
Training Sessions” ࠍ᜙⺒ߒߡ‫ߺ߇ߡޔ‬㧦කቇᢎ⢒ 38㧦299(2007 ᐕ 1 ᦬)
6㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ㧘㋈ᧁᐽਯ㧘Phillip Evans㧦⁛⥄ᕈ⼾߆ߥ SP 㙃ᚑࡊࡠࠣ࡜ࡓ-ࠬࠦ࠶࠻࡜ࡦ࠼ 5 ᄢቇⷞኤႎ๔-㧦කቇᢎ⢒ 39㧦199㧙204(2008 ᐕ)
7㧕 㒙ㇱᕺሶ㧘㋈ᧁን㓶㧘⮮ፒ๺ᒾ㧘઻ାᄥ㇢㧦ᮡḰᮨᡆᖚ⠪ߩ✵⠌⁁ᴫߣ OSCE ߦኻߔࠆᗧ⼂ ో࿖⺞ᩏ╙ 2 ႎ㧦කቇᢎ⢒ 39㧦259㧙266(2008 ᐕ)
8㧕 ⮮ፒ๺ᒾ㧦⥃ᐥ୶ℂታ〣ߩߚ߼ߩࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦ㧦ᣣᧄකቇᢎ⢒ቇળ୶ℂ࡮ⴕേ⑼ቇዊᆔຬળ
╙ 3 ࿁⥃ᐥ⎇ୃᜰዉ⠪ߩߚ߼ߩ୶ℂᢎ⢒ࡢ࡯࡚ࠢࠪ࠶ࡊႎ๔ᦠ㧦55㧙58(2008 ᐕ 1 ᦬)
9㧕 ⮮ፒ๺ᒾ㧘਄↸੝Ꮧሶ㧦⮎ቇㇱ 6 ᐕ೙߳㧙ߎࠇ߆ࠄߩ⮎೷Ꮷߦ᳞߼ࠄࠇࠆࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ
࡞㧦㒋␹࡮᷆〝ᄢ㔡ἴᓟߩ࿾ၞ␠ળߣߩ౒↢ࠍ߼ߑߒߚᄢቇߩᣂߒ޿ᓎഀߦ㑐ߔࠆታ〣⊛⎇ⓥႎ๔
ᦠ╙ 27 ภ㧦1㧙50(2008 ᐕ 1 ᦬)
11㧚ႎ㆏
1㧕 ⮮ፒ๺ᒾ㧦৻✜ߦᱠ߻කᏧ ᢎ⢒ࠍ㧦ାỚᲤᣣᣂ⡞(2006 ᐕ 2 ᦬ 1 ᣣ)
2㧕 ⮮ፒ๺ᒾ㧦૑᳃ෳടߩஜᐽߠߊࠅᡰេ㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 8 ᣣ)
3㧕 ⮮ፒ๺ᒾ㧦⺕߽߇ฃߌࠄࠇࠆක≮ࠍ㧦Ფᣣᣂ⡞(2006 ᐕ 8 ᦬ 23 ᣣ)
4㧕 ⮮ፒ๺ᒾ㧦⮎೷Ꮷߣߒߡ᳞߼ࠄࠇࠆ⥃ᐥࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦࠬࠠ࡞ߣߘߩᢎ⢒㧦⮎ዪᣂ⡞(2006 ᐕ
10 ᦬ 18 ᣣ)
5㧕 ⮮ፒ๺ᒾ㧦↢߆ߐࠇߡ↢߈ࠆ༑߮ߩ↢ᵴߣ⮎೷Ꮷ㧦⺞೷ߣᖱႎ.Vol.12.No.12.(2006 ᐕ 11 ᦬)
6㧕 ⮮ፒ๺ᒾ㧦⥃ᐥࠍ⺆ࠇࠆ⮎೷Ꮷߦߥߞߡ߶ߒ޿㧦Pharma Next(2007 ᐕ 5 ᦬)
7㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ᧄ૏߳‫ޟ‬කߪ໧⸻ജ‫ޠ‬㧦ᦺᣣᣂ⡞(2007 ᐕ 5 ᦬ 10 ᣣ)
8㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ߩᗐ޿ߩࠨࠗࡦࠍ⷗ㅏߒߡ޿߹ߖࠎ߆㧫㧦S.M.C No.9(2007 ᐕ 9 ᦬)
9㧕 ⮮ፒ๺ᒾ㧦ᢎ⢒࡞ࡀ࠶ࠨࡦࠬ‫ޟ‬ක≮ੱࠍ⢒ߡࠆ(5) ᖚ⠪ᓎ‫ߩޠࡠࡊޟ‬ᔃᓧ‫ޠ‬㧦⺒ᄁᣂ⡞(2007 ᐕ 12 ᦬
22 ᣣ)
10㧕 ⮮ፒ๺ᒾ㧦Ꮢ᳃߇ᮨᡆᖚ⠪ߣߒߡෳടߔࠆකቇᢎ⢒㧦Medical Tribune(2008 ᐕ 2 ᦬ 21 ᣣ)
11㧕 ⮮ፒ๺ᒾ㧦ᧂ᧪ߩකᏧ߇᧪ߥ޿㨪⎇ୃක࠯ࡠߩⴣ᠄㨪㧦NHK ࠽ࡆࠥ࡯࡚ࠪࡦ ࠬ࠲ࠫࠝ⸃⺑(2008ᐕ 6 ᦬ 6 ᣣ)
12㧕 㒙ㇱᕺሶ㧘⮮ፒ๺ᒾ㧦ᖚ⠪ࠍ↢߈ࠆ ᮨᡆᖚ⠪ ᖱႎ✬㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 5 ᣣ)
13㧕 ⮮ፒ๺ᒾ㧦ᖚ⠪ࠍ↢߈ࠆ ᮨᡆᖚ⠪ ᖱႎ✬㧦ᦺᣣᣂ⡞(2008 ᐕ 10 ᦬ 10 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔක≮ࠦࡒࡘ࠾ࠤ࡯࡚ࠪࡦᢎ⢒ߩታ⠌ᣇᴺߪ⏕┙ߐࠇߡ߈ߚ߇㧘ࠃࠅቇ⠌⠪ਛᔃߢ㧘ࠃࠅലᨐ⊛ߥታ⠌ߣߥࠆࠃ߁ᡷ⦟ࠍⴕߞߡ߈ߚ‫ޕ‬කቇ⧷⺆ߪ㧘1 ᐕ↢ኻ⽎ߩၮᧄක≮ળ⹤ߩ⻠ᐳ߅ࠃ߮㧘4㨪6 ᐕ↢ኻ⽎ߩ⥃ᐥታ〣⊛ߥ࡟ࡌ࡞ߩᢎ⢒࠮࠶࡚ࠪࡦࠍᢙ࿁ᜬߟߎߣ߇ߢ߈ߚ‫ߚ޿↪ࠍ࠲࡯࡟ࡘࡒࠪޕ‬り૕⸻ኤታ⠌ߩࡊࡠࠣ࡜ࡓߪ㧘ߎࠇ߹ߢᢙ࿁ߩ࠻࡜ࠗࠕ࡞࠮࠶࡚ࠪࡦࠍⴕ޿㧘ᢎຬߩ㑆ߢᝄ㄰ࠅ⼏⺰ߒߡ߈ߚ‫ࠄࠇߎޕ‬޿ߕࠇ߽㧘ࡑ࡯ࠬ࠻࡝ࡅ࠻ᄢቇ㧔ࠝ࡜ࡦ࠳㧕㧘ࠣ࡜ࠬࠧ࡯ᄢቇ㧔⧷࿖㧕㧘⥄ᴦක⑼ᄢቇ㧘ᣣᧄᄢቇߥߤ࿖
ౝᄖߩቴຬᢎຬߣߩ੤ᵹ࡮⼏⺰ࠍ㊀ߨߥ߇ࠄⴕߞߡ߈ߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ㄭᐕ㧘࿖㓙⊛ߥකቇᢎ⢒ಽ㊁ߢߪ㧘ᢎ⢒ߩࠕ࠙࠻ࠞࡓࠍቴⷰ⊛ߦ⹏ଔߔࠆߎߣ㧘ࠛࡆ࠺ࡦࠬߦၮߠ޿
ߚᢎ⢒߇ߥߐࠇࠆߎߣ߇㊀ⷞߐࠇߡ޿ࠆ‫ޕ‬ᒰ࠮ࡦ࠲࡯ߢ㐿⊒ߒߡ߈ߚᣂߒ޿ᵹࠇߩකቇᢎ⢒ߪ゠㆏ߦਸ਼
ߞߡ߈ߚߣߎࠈߢ޽ࠆ߇㧘࿖㓙⊛ߥ࡟ࡌ࡞ߩ⹏ଔ߇߹ߛචಽߦ౏⴫ߢ߈ߡ޿ߥ޿‫ߦࠇߎޕ‬ኻߒߡߪ࡝ࠨ
࡯࠴ߩᣇᴺ⺰ߦജὐࠍ⟎ߊߥߤߩኻᔕ߇น⢻ߢ޽ࠆ‫ޕ‬߹ߚ㧘⥃ᐥታ〣ߦ⋥⚿ߔࠆㇱಽߩ౒ㅢᢎ⢒㧘ߔߥࠊߜ㧘ක≮㕙ធ߆ࠄり૕⸻ኤ㧘⥃ᐥផ⺰㧘⸻ᢿᴦ≮ᴺߩ┙᩺ߦ޿ߚࠆၮᧄ⊛⥃ᐥ⢻ജߪ㧘߹ߛචಽߥὶὐ߇⟎߆ࠇࠆߦߪ⥋ߞߡ޿ߥ޿‫ߪߡ޿ߟߦࠇߎޕ‬㧘ቇౝᄖߩ⥃ᐥᢎ⢒⠪ߣߩㅪ៤ࠍ࿑ࠅ㧘ࠦ࡯࠺ࠖࡀࠗ࠲࡯ࠍോ߼ࠆߎߣ߇᦭⋉ߢ޽ࠈ߁‫ޕ‬㧙㧙੹ᓟߩዷᦸ
੹ᓟ߽⃻ઍ␠ળߩ࠾࡯࠭ߦᔕ߃ࠄࠇࠆࠃ߁ߥකᏧ࡮කቇ⎇ⓥ⠪ࠍ㙃ᚑߔࠆߚ߼ߦ㧘1㧕ࠃࠅലᨐ⊛ߥකቇᢎ⢒ࠍ㐿⊒ߒߘߩലᨐࠍቴⷰ⊛ߦ⹏ଔߒߡ޿ߊ㧘2㧕ᜰዉജߣੱ㑆๧ߩ޽ࠆකቇᢎ⢒ߩᓟ⛮⠪ࠍ⢒ᚑߔࠆ㧘3㧕࿖ౝᄖߩකቇᢎ⢒ߦ㑐ࠊࠆᢎຬ㧘ᜰዉකߣߩ੤ᵹࠍߐࠄߦᷓ߼ࠆ㧘ߣ޿߁ߎߣ߇੹ᓟߩዷᦸߢ޽
ࠆ‫ޕ‬

㧙㧙

㧔11㧕ነ㒝⻠ᐳ‫ޟ‬ஜᐽ㓚ኂඨᷫ⻠ᐳ㧔ጘ㒂⋵㧕‫ޠ‬1㧚⎇ⓥߩ᭎ⷐ
ጘ㒂⋵ߣᄢቇ߇ㅪ៤ߒ㧘⋵ౝߩ↢ᵴ⠌ᘠ∛ߩ⺞ᩏ⎇ⓥࠍⴕ߁ߣߣ߽ߦ㧘․ߦ᦭∛₸߇ᄙ޿ߣߐࠇࠆ♧ዩ∛ߦߟ޿ߡߪ㧘∉ቇ⊛ߥ⎇ⓥߣ଻ஜᜰዉ╬ߦࠃࠆ੍㒐ߦࠃࠅ∛⟕ᖚ⠪ߩᷫዋࠍ࿑ࠆ‫ޕ‬2㧚ฬ★
ಎᢎ᝼⋧ᒰ㧦 ㋈ᧁ⧷ม
ഥᢎ⋧ᒰ㧦
ᄢᐸᔒ㊁

Eiji Suzuki
Shino Oba3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ㋈ᧁ⧷ม㧚ၮ␆✬㧦PWV ࠍ⍮ࠆ ⤳ེ࡮ᯏ⢻㓚ኂߣ PWV㧚ਅ⢇ᓴⅣߣ PWV㧦ࡂࡦ࠭ࠝࡦࡉ࠶ࠢ PWVࠍ⍮ࠆ PWV ߢ⸻ࠆ ᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦132㧙138㧚⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ࡑࠢࡠࠕࡦࠡࠝࡄࠪ࡯ߩᬌᩏ࡮⸻ᢿᴺߩㅴᱠ ⏛᳇౒㡆ᴺߦࠃࠆᣂߒ޿⸻ᢿᴺ㧘ᣣᧄ⥃ᐥ 2006 ᐕ㧧64 Ꮞ㧦2062㧙2068㧚
2㧕 ㋈ᧁ⧷ม㧚Technics Guide ⏛᳇౒㡆ࠍ↪޿ߚࡈ࠶࠻ࡊࡠ࠻ࠦ࡞ߦࠃࠆ♧ዩ∛⿷∛ᄌߩᣧᦼ⊒⷗㧘Diabetes
Journal 2006 ᐕ㧧35 Ꮞ㧦31㧙35㧚
3㧕 ㋈ᧁ⧷ม㧚ᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘Diabetes In The News (DITN) 2007 ᐕ㧧353 Ꮞ㧦
8㧚4㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ᖚ⠪ߦ߅ߌࠆᧃ᪳ᓴⅣ㓚ኂߦኻߔࠆᣂߒ޿ࠕࡊࡠ࡯࠴㧘Angiology Frontier 2007 ᐕ㧧
6 Ꮞ㧦96㧙103㧚
5㧕 ㋈ᧁ⧷ม㧚♧ዩ∛ߣᧃ᪳ᓴⅣ㓚ኂ㧘৻ችකႎ 2008 ᐕ㧧172 Ꮞ㧦12㧙17㧚
6㧕 ㋈ᧁ⧷ม㧚C㧚♧ዩ∛ߩ∉ቇ࡮∛ᘒ࡮⸻ᢿቇߩㅴᱠ V㧚♧ዩ∛ᬌᩏቇߩㅴᱠ ♧ዩ∛㑐ㅪ⻉ᬌᩏ㧙᷹ቯᴺ㧘⥃ᐥ⊛ᗧ⟵㧘⹏ଔᴺ㧙↹௝ᬌᩏ MRA㧘ᣂᤨઍߩ♧ዩ∛ቇ 2 Ꮞ㧘ᣣᧄ⥃ᐥ 2008 ᐕ㧧66 Ꮞ(Ⴧೀภ 4)㧦
546㧙550㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Oba S, Shimizu N, Nagata C, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. The
relationship between the consumption of meat, fat, and coffee and the risk of colon cancer: aprospective study in Japan. Cancer Lett. 2006;244:260-267.
2㧕 Nagata C, Oba S, Shimizu H. Associations of menstrual cycle length with intake of soy, fat, and dietaryfiber in Japanese women. Nutr Cancer. 2006;54:166-170.
3㧕 Yoshimura T, Suzuki E, Egawa K, Nishio Y, Maegawa H, Morikawa S, Inubushi T, Hisatomi A,
Fujimoto K, Kashiwagi A. Low blood flow estimates in lower-leg arteries predict cardiovascular eventsin Japanese patients with type 2 diabetes with normal ankle-brachial indexes. Diabetes Care.
2006;29:1884-1890.
4㧕 Oba S, Nagata C, Shimizu N, Shimizu H, Kametani M, Takeyama N, Ohnuma T, Matsushita S. Soy
product consumption and the risk of colon cancer: a prospective study in Takayama, Japan. Nutr
Cancer. 2007;57:151-157.
5㧕 Tanaka T, Nagata C, Oba S, Takatsuka N, Shimizu H. Prospective cohort study of body mass index inadolescence and death from stomach cancer in Japan. Cancer Sci. 2007;98:1785-1789.
6㧕 Oba S, Nakamura K, Sahashi Y, Hattori A, Nagata C. Consumption of vegetables alters morning
urinary 6-sulfatoxymelatonin concentration. J Pineal Res. 2008;45:17-23.
7㧕 Nakamura K, Nagata C, Oba S, Takatsuka N, Shimizu H. Fruit and vegetable intake and mortality
from cardiovascular disease are inversely associated in Japanese women but not in men. J Nutr.
2008;138:1129-1134.
8㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Smoking and risk ofcedar pollinosis in Japanese men and women. Int Arch Allergy Immunol. 2008;147:117-124.
9㧕 Nagata C, Nakamura K, Fujii K, Kawachi T, Takatsuka N, Oba S, Shimizu H. Soy isoflavone intake is㧙㧙

IF 3.398
IF 2.361

IF 7.851

IF 2.361
IF 3.165
IF 4.098

IF 3.771
IF 2.160

not associated with the development of cedar pollinosis in adults. J Nutr. 2008;138:1372-1376.
10㧕 Oba S, Nagata C, Nakamura K, Takatsuka N, Shimizu H. Self-reported diabetes mellitus and risk ofmortality from all causes, cardiovascular disease, and cancer in Takayama: a population-based
prospective cohort study in Japan. J Epidemiol. 2008;18:197-203.
11㧕 Yoshimura T, Suzuki E, Ito I, Sakaguchi M, Uzu T, Nishio Y, Maegawa H, Morikawa S, Inubushi T,
Hisatomi A, Fujimoto K, Takeda J, Kashiwagi A. Impaired peripheral circulation in lower-leg arteriescaused by higher arterial stiffness and greater vascular resistance associates with nephropathy in type2 diabetic patients with normal ankle-brachial indices. Diabetes Res Clin Pract. 2008;80:416-423.
12㧕 Hirota T, Suzuki E, Ito I, Ishiyama M, Goto S, Horikawa Y, Asano T, Kanematsu M, Hoshi H, Takeda J.
Coronary artery calcification, arterial stiffness and renal insufficiency associate with serum levels oftumor necrosis factor-alpha in Japanese type 2 diabetic patients. Diabetes Res Clin Pract.
2008;82:58-65.

IF 3.771

IF 1.906

IF 1.823

IF 1.8234㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(C)㧦੃≸ᖚ⠪ߩ≸ߩ࿃ᨐ㑐ଥⷰߣ≸߳ߩㆡᔕᐲ
ߦߟ޿ߡ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧3,400 ජ౞(1,600㧦1,800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧧⎇ⓥᵴᕈൻ(ක)ߩߚ߼ߩᡰេ੐ᬺ⚻⾌㧦৻⥸૑᳃ߦ߅ߌࠆฃേ༛ᾍߣ♧ዩ∛Ⴚ⇇ဳߩ㑐ㅪ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞3㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧘⎇ⓥಽᜂ⠪㧦᳗↰⍮㉿㧘ጊᧄ⋿↱⟤㧘㋈ᧁ⧷ม㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦⢻േ෸߮ฃേ༛ᾍߣ♧ઍ⻢⢻ߩᜰᮡߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20㧙22 ᐕᐲ㧧4,050 ජ౞(1,950㧦
1,400㧦700 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ᄢᐸᔒ㊁㧧⎇ⓥ⑼㐳࡮කቇㇱ㐳ⵙ㊂⚻⾌ߦࠃࠆ⎇ⓥ⾌ߩ㊀ὐ⊛㈩ಽ㧦৻⥸૑᳃ߦ߅ߌ
ࠆ៨㘩෸߮ዞኢᤨೞߦଥࠆ↢ᵴ⠌ᘠߣⴊ♧୯෸߮♧ઍ⻢⢻ߩ㑐ㅪ㧧ᐔᚑ 20 ᐕᐲ㧧250 ජ౞
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
㋈ᧁ⧷ม㧦1㧕 ᣣᧄ♧ዩ∛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ߥߒ
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേߥߒ㧙㧙

10㧚ႎ๔ᦠ
1㧕 ᄢᐸᔒ㊁㧦੃≸ᖚ⠪ߩ≸ߩ࿃ᨐ㑐ଥⷰߣ≸߳ߩㆡᔕᐲߦߟ޿ߡ㧦ᐔᚑ 17 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ႎ๔ᦠ㧦1㧙2(2006 ᐕ 1 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ޿ࠊࠁࠆ♧ዩ∛੍஻ァߦኻߔࠆ଻ஜᜰዉᣇᴺߩត⚝ߣ㧘♧ዩ∛᦭∛⠪ࠍᷫዋߐߖࠆߎߣߦߟ޿ߡߩ⎇ⓥ㧘♧ዩ∛ࠍ฽߻↢ᵴ⠌ᘠ∛ߩലᨐ⊛ߥ੍㒐ᣇᴺ╬ߩᖱႎ෼㓸ߣ⎇ⓥ㧘ਥⷐߥ↢ᵴ⠌ᘠ∛ߦ㑐ߔࠆవ┵ක≮߿⵬ቢ࡮ઍᦧක≮ߦߟ޿ߡߩᢥ₂⊛⎇ⓥᚑᨐߩᖱႎឭଏ㧘ߥߤߩ⎇ⓥࠍⴕߞߚ‫ޕ‬2006 ᐕ 1 ᦬㨪2008
ᐕ 12 ᦬߹ߢߩᧄ⻠ᐳߩ⎇ⓥᚑᨐߣߒߡ㧘ቇⴚ⺰ᢥߪ๺ᢥ 6 ႎߣ⧷ᢥ 12 ႎ㧘✚⺑ߣ⪺ᦠߪ๺ᢥ 1 ႎߩႎ๔߇ⴕࠊࠇߚ‫⻠ᧄޕ‬ᐳߩ⎇ⓥᚑᨐߪ㧘࿖ౝᄖߦะߌߡ㕖Ᏹߦᵴ⊒ߦႎ๔ߐࠇߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᐔᚑ 21 ᐕ 3 ᦬ᧃߢ㧘ᒰೋ੍ቯߩ⻠ᐳ㐿⸳ᦼ㑆߇⚳ੌߔࠆ‫ޕ‬ᐔᚑ 21 ᐕ 4 ᦬એ㒠ߪ㧘ࡃ࠶ࠢࠕ࠶ࡊ⻠ᐳߢ޽ࠆ∉ቇ࡮੍㒐කቇಽ㊁ߦߡ⎇ⓥࠍ⛮⛯ߔࠆ੍ቯߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸߎࠇ߹ߢߣห᭽㧘↢ᵴ⠌ᘠ∛ߩ੍㒐ᣇᴺ╬ࠍ⺞ᩏ⎇ⓥߒߡ⌕ታߦᚑᨐࠍ޽ߍࠆߣߣ߽ߦ㧘⎇ⓥᚑᨐࠍ
ಽ߆ࠅ߿ߔߊ৻⥸ะߌߦ౏㐿ߒߡ㧘⋵᳃ߩஜᐽჇㅴߦነਈߔࠆ‫ޕ‬㧙㧙㧔12㧕ነ㒝⻠ᐳ‫ޟ‬㛽㑐▵ౣᑪᄖ⑼ቇ⻠ᐳ㧔ࠫࡦࡑ࡯㧕‫ޠ‬1㧚⎇ⓥߩ᭎ⷐ
⎇ⓥߪ⣄ᬁ⣄㜑ౣᑪᄖ⑼ߦ㑐ߔࠆ߽ߩ(ችᧄಎᢎ᝼ᜂᒰ)㧘ᘟᕈ㑐▵࡝࠙ࡑ࠴ߦ㑐ߔࠆ߽ߩ㧔૒⮮ᱜᄦഥᢎᜂᒰ㧕ߩ 2 ߟࠍࡔࠗࡦ࠹࡯ࡑߣߒߡⴕߞߡ߅ࠅ㧘એਅ߇⃻࿷ㅴⴕਛߩࡊࡠࠫࠚࠢ࠻ߢ޽ࠆ‫ޕ‬1㧕ᬁ㑆᧼⚵❱ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚵❱ߦ߅޿ߡ㧘ࠞ࡞ࡄࠗࡦߩዪ࿷ߩᬌ⸽ࠍⴕߞߚ‫ޕ‬ᬁ㑆᧼ᄌᕈߣࠞ࡞ࡄࠗࡦߩ
⊒⃻߇㑐ㅪߒߡ޿ࠆߎߣ߇᣿ࠄ߆ߣߥߞߚ‫ޕ‬
2㧕ᘟᕈ㑐▵࡝࠙ࡑ࠴ᖚ⠪ߦኻߔࠆ↢‛⵾೷ࠍ↪޿ߚᴦ≮ߦ߅ߌࠆ૕ౝࠨࠗ࠻ࠞࠗࡦߩᄌേߦߟ޿ߡߩ⎇ⓥ
3㧕ᬁ㑆᧼⚦⢩ᄖၮ⾰ઍ⻢ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩᓎഀߣ⸃᣿
࠙ࠪ෸߮ࡅ࠻ߩᬁ㑆᧼⚦⢩ࠍ↪޿㧘Ἳ∝࡮ᬁ㑆᧼ᄌᕈߣ޿߁ዪ㕙ߦ߅޿ߡࠞ࡞ࡄࠗࡦ߇ᬁ㑆᧼ၮ⾰ಽ⸃ߦ޿߆ߦ㑐ਈߔࠆ߆ߦߟ޿ߡ⎇ⓥࠍߔߔ߼ߡ޿ࠆ‫ޕ‬
4㧕ᘟᕈ㑐▵࡝࠙ࡑ࠴ᖚ⠪ߦኻߔࠆ↢‛⵾೷ࠍ↪޿ߚᴦ≮ߦ߅ߌࠆ೽૞↪ߩ⊒⃻㧘ߘߩ੍㒐ߦ㑐ߔࠆ⎇ⓥ
5㧕ࡅ࠻⣶ᬁ⩄㊀⽶⩄ߦ߅ߌࠆᬁ㑆᧼࡮ᬁ㑆㑐▵ߩᒻᘒᄌൻߦ㑐ߔࠆ⎇ⓥ
ࡅ࠻⣶ᬁߩ┙૏⩄㊀⁁ᘒࠍࠪࡒࡘ࡟࡯࠻ߔࠆⵝ⟎ࠍ૶↪ߒ㧘CT ᠟ᓇߦࠃߞߡᓧࠄࠇߚ⣶ᬁ↹௝ࠍ 3ᰴర⸃ᨆߒ㧘ᬁ㑆᧼࡮ᬁ㑆㑐▵ߩ 3 ᰴర⊛ᒻᘒᄌൻࠍ⸃ᨆߒߡ޿ࠆ‫ޕ‬
6㧕⣶ᬁⵝౕߩ૕ᐙ૏⟎ⷡ㧘ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬߦਈ߃ࠆᓇ㗀ߩᬌ⸛⣶ᬁⵝౕ߇߽ߟ૕ᐙ૏⟎ⷡะ਄ലᨐ߇ࠬࡐ࡯࠷ࡄࡈࠜ࡯ࡑࡦࠬ(ࠧ࡞ࡈ㧘࠙ࠜ࡯ࠠࡦࠣ╬)ߦ޿߆ߥࠆ
ᓇ㗀ࠍਈ߃ࠆ߆ࠍ 3 ᰴరേ૞⸃ᨆߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬7㧕⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬8㧕ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑ߩ 3 ᰴర⊛േᘒ⸃ᨆ⣄㜑ㅧᓇᬌᩏᓟߩࡈࠔࡦ࡚ࠢࠪ࠽࡞ CT ࠍ↪޿㧘ࡅ࠻㗪ᬁߩዮᦛિዷേᘒߦ߅ߌࠆ⎬⤑▤࡮㗪ㇱ⣄㜑
ߩ 3 ᰴర⊛േᘒ⸃ᨆࠍฦ⒳∛ᘒߣߩ㑐ㅪߦߡᬌ⸽ߒߡ޿ࠆ‫ޕ‬
9㧕⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜߩ 3 ᰴర⸃ᨆ⣶ᬁᄌᕈ஥ᒭ∝ߦኻߔࠆࡉ࡯ࡔ࡜ࡦဳࠬࡍ࡯ࠨ࡯ࠍ↪޿ߚᓟᣇᬁ૕㑆࿕ቯⴚߦࠃࠆᄌᒻ⍶ᱜ߇ᬁ㑆᧼ⷺ㧘ᬁ㑆㑐▵ᒻᘒߦਈ߃ࠆലᨐࠍ 3 ᰴర↹௝⸃ᨆߦࠃࠅᬌ⸽ߒߡ޿ࠆ‫ޕ‬10㧕㗪ᬁ㒰࿶ᚻⴚ(೨ᣇ㒰࿶㧘ᓟᣇ㒰࿶)߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩᬌ⸛
㗪ᬁ೨ᣇ㒰࿶ⴚ㧘㗖ᬁᓟᣇ㒰࿶ⴚߩ 2 ⴚᑼ߇⎬⤑▤࡮㗪ㇱ⣄㜑ߦਈ߃ࠆᒻᘒᄌൻߩ⋧㆑ߦߟ޿ߡ
ultrasonography ࠍ↪޿ߡ㧘⥃ᐥᚑ❣ߣ㑐ㅪߐߖߡᬌ⸛ߒߡ޿ࠆ‫ޕ‬
11㧕MRI ߣ⣄㜑ㅧᓇᓟ CT ߩ⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⋧㆑ߦ㑐ߔࠆ⎇ⓥ⣄ᬁ⣄㜑∔ᖚߦኻߔࠆ↹௝⸻ᢿߦ߅ߌࠆ 2 ߟߩઍ⴫⊛ᚻᴺߢ޽ࠆ MRI ߣ⣄㜑ㅧᓇᓟ CT ߦߟ޿ߡ㧘⎬⤑▤࡮⣄㜑࡮㚍የ␹⚻ᒻᘒ⹏ଔߩ⾰⊛࡮㊂⊛⋧㆑ࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬12㧕ࡅ࠻⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩേᘒߩ⎇ⓥ
ࡅ࠻⣖⣄㜑ᶧߦ߅ߌࠆㆶరဳ࡮㉄ൻဳࠕ࡞ࡉࡒࡦߩሽ࿷Ყ₸ߦߟ޿ߡ㧘ᐕ㦂㧘∔ᖚ╬ߩ࿃ሶࠍ฽߼ߡ
ᬌ⸽ࠍⴕߞߡ޿ࠆ(ಽሶ↢ℂቇ⻠ᐳߣ౒ห⎇ⓥ)‫ޕ‬
2㧚ฬ★
ಎᢎ᝼⋧ᒰ㧦 ችᧄ ᢘ
ഥᢎ⋧ᒰ㧦
૒⮮ᱜᄦ

Kei Miyamoto
Masao Sato3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu K, Miyamoto K. Inflammatory Diseases of the Spine: Juvenile Rheumatoid Arthritis. In:
Surgery of the Pediatric Spine. New York: Thieme;2007:375-380.
✚⺑㧔๺ᢥ㧕ߥߒ㧙㧙✚⺑㧔᰷ᢥ㧕ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㛽☻㝃∝ᕈ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚߩⴚᓟ⚻ㆊ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧49 Ꮞ㧦967㧙968㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆⴚᑼㆬᛯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2006 ᐕ㧧17 Ꮞ㧦525㧚3㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ችᧄ ᢘ㧘ዊේ ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever-TLIF)㧙PLIF ߣߩᲧセ㧙㧘ᣣᧄᢛᒻᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧80 Ꮞ㧦S285㧚
4㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦353㧙354㧚
5㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ㇱ⣄㜑∝ᚻⴚߩว૬∝㧙೨ᣇᴺ‫ޔ‬
ᓟᣇᴺߩᲧセ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦579㧙580㧚
6㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
7㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2007 ᐕ㧧18 Ꮞ㧦223㧚
8㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
9㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚ࡉࠪ࡜ࡒࡦ߇ᄼഞߒߚ㜞㦂⊒∝㑐▵࡝࠙ࡑ࠴߆ߩ 1 ଀߆ࠄ੹ᓟߩ࡝࠙ࡑ࠴ᴦ≮ࠍ⠨߃ࠆ㧘Pharma Medica 2008 ᐕ㧧26 Ꮞ㧦156㧙157㧚
10㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧘ጟ᧛⑲ੱ㧘㋈ᧁ ᷡ㧚LCS ੱᎿ⤒㑐▵⟎឵ⴚᓟߦ⣊㛽ࡌࠕ࡝ࡦࠣߩ⣕ォࠍ᧪ߚߒߚ 1 ଀㧘ጘ㒂ੱᎿ㑐▵ࡈࠜ࡯࡜ࡓ⹹ 2008 ᐕ㧧11 Ꮞ㧦9㧙12㧚
11㧕 ጟ᧛⑲ੱ㧘⮮ზ␭⟤㧘↰၂ᢕᦶ㧘྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧚↢‛ቇ⊛⵾೷ߣ࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦߢ⪺᣿ߥ ADL
ߩᡷༀ߇ᓧࠄࠇߚ㑐▵࡝࠙ࡑ࠴(class 4)ߩ৻଀㧘ᣣᧄ RA ߩ࡝ࡂࡆ࡝⎇ⓥળ⹹ 2008 ᐕ㧧22 Ꮞ㧦89㧙92㧚
12㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧘ጟ᧛⑲ੱ㧘ᷡ᳓సᤨ㧚ක≮ᓥ੐⠪ߦ߅ߌࠆ⣶∩᦭⸷₸㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦207㧙208㧚
13㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚㜞㦂⠪ᄢ⣽㛽ㄭ૏ㇱ㛽᛬ᖚ⠪ߩട≮⁁ᴫ‫ޔ‬ㄭᐕߩᄌൻ㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦419㧙420㧚
14㧕 ૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧚᛫ CCP ᛫૕ߪ↢‛ቇ⊛⵾೷ߩലᨐ್ቯߦ᦭↪ߢ޽ࠆ߆㧫㧘ਛㇱ࡝࠙ࡑ࠴ 2008 ᐕ㧧39 Ꮞ㧦24㧙25㧚
15㧕 ↰ਛ 㗔㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡፉ ḩ㧘ᷡ᳓సᤨ㧚㑐▵࡝࠙ࡑ࠴ߦ߅ߌࠆ Infliximabᴦ≮ലᨐߣⴊᷡࠠ࠿࡟࠾ࡦỚᐲߩᄌൻ㧘ਛㇱ࡝࠙ࡑ࠴ 2008 ᐕ㧧39 Ꮞ㧦26㧙27㧚
16㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚㜞㦂⠪ᄢ⣽㛽ㄭ૏ㇱ㛽᛬ߩ࿷㒮ᣣᢙߦ㑐ߔࠆ࿾ၞᩰᏅ㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦623㧙624㧚
17㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘┻᧛ᱜ↵㧘ᷡፉ ḩ㧘ᢧ⮮㇌᣿㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆࠨ࡜࠱ࠬ࡞ࡈࠔࡇ࡝ࠫࡦૐ
↪㊂ᛩਈߩᬌ⸛㧘⥃ᐥ࡝࠙ࡑ࠴ 2008 ᐕ㧧20 Ꮞ㧦188㧙193㧚
18㧕 ૒⮮ᱜᄦ㧘྾ᚭ㓉ၮ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧘ᷡ᳓సᤨ㧚↢‛ቇ⊛⵾೷ᴦ≮ߦ߅ߌࠆ∛⸻ㅪ៤㧘ਛㇱᣣᧄᢛ
ᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2008 ᐕ㧧51 Ꮞ㧦943㧙944㧚
19㧕 ྾ᚭ㓉ၮ㧘૒⮮ᱜᄦ㧘㚍႐ጪ჻㧘ⷺ↰ ᕡ㧚㜞㦂⠪ᄢ⣽㛽ㄭ૏ㇱ㛽᛬ᖚ⠪ߩᐕ㦂඙ಽߦࠃࠆᴦ≮ᚑ❣㧘᧲ᶏᢛᒻᄖ⑼ᄖ்⎇ⓥળ⹹ 2008 ᐕ㧧21 Ꮞ㧦96㧙98㧚
20㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘ችᧄᢘ㧘↰ਛஜ৻㇢㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚㛽☻㝃∝ᕈᬁ૕࿶ẩߦኻߔࠆᬁᑿࠍ
ߣࠄ߃ࠆ⣄ᬁ⍴❗ⴚ㧙ⴚᓟ㛽᛬ߣᓟᒗ㧙㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹹ 2008 ᐕ㧧51 Ꮞ㧦643㧙644㧚
21㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻ㧙X ✢⹏ଔ㧙㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ ࡌࠬ࠻ࡍ࡯ࡄ࡯⾨ 2008 ᐕ㧧10 Ꮞ㧦117㧙119㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Masuda T, Miyamoto K, Hosoe H, Sakaeda H, Tanaka M, Shimizu K. Surgical treatment with spinal
instrumentation for pyogenic spondylodiscitis due to methicillin-resistant Staphylococcus aureus(MRSA): a report of five cases. Arch Orthop Trauma Surg. 2006;126:339-345.
2㧕 Masuda T, Miyamoto K, Shimizu K. Intramuscular hemodynamics in bilateral erector spinae muscles
in symmetrical and asymmetrical postures with and without loading. Clin Biomecha. 2006;21:245-253.
3㧕 Ohara A, Miyamoto K, Naganawa T, Matsumoto K, Shimizu K. Sagittal alignment of the cervicalspine: comparison of five standard methods of measurement. Spine. 2006;31:2585-2591.
4㧕 Fushimi K, Miyamoto K, Nishimoto H, Hosoe H, Kodama H, Shimizu K. Clinical outcomes ofmultilevel anterior corpectomy and fusion as a revision surgery of the cervical spine. Report of sevencases. Spinal Cord. 2006;44:449-456.
5㧕 Miyamoto K, Masuda K, Inoue N, Okuma M, Meuhlmem C, An HS. Anti-adhesion properties ofthrombin-based hemostatic gelatin in a canine laminectomy model. –a biomechanical, biochemical,
and histological study. Spine. 2006;31:E91-E97.

㧙㧙

IF 0.913
IF 1.642
IF 2.499

IF 1.578

IF 2.499

6㧕 Hosoe H, Miyamoto K, Wada E, Shimizu K. A surgical treatment of scoliosis in Larsen’s syndrome withbilateral hip dislocation: A case report. Spine. 2006;31:E302-E306.
7㧕 Ohnishi K, Miyamoto K, Hashimoto K, Hosoe H, Shimizu K. Mixed connective tissue disease (MCTD)
associated with atlantoaxial subluxation. A case report. Orthopaedics. 2006;29:369-370.
8㧕 Sasaki T, Miyamoto K, Hosoe H, Shimizu K. Transoral Anterior Approach Used for Extensive Anterior
Decompression of C3 Vertebrae Level in a Patient with Severe Atlantoaxial Vertical Subluxation andRheumatoid Arthritis - A Case Report -. Spinal Cord. 2006;44:52-55.
9㧕 Shimizu T, Miyamoto K, Masuda K, Miyata T, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
10㧕 Hosoe H, Shimizu K, Miyamoto K, Fukuta S, Iwai C. Cantilever-TLIF for patients with degenerative
scoliosis. Eur Spine J. 2007;16:S51.
11㧕 Aoki T, Terashima H, Itokazu M, Miyamoto K, Shimizu K. Stimulation of Music Prolonged
Disturbance of Consciousness Patients in Early Rehabilitation. J Saitama Kenou Rehabilitation.
2007;7:50-53.
12㧕 Nagano A, Miyamoto K, Fushimi K, Hosoe H, Shimizu K. Failure of reconstruction surgery using
anterior fibular strut grafting for postlaminectomy kyphosis A case report. J Clin Neurosci.
2007;14:376-379.
13㧕 Inoue T, Miyamoto K, Kodama H, Hosoe H, Shimizu K. Total spondylectomy for treatment of asymptomatic hemangioma of the lumbar spine - A case report. J Clin Neurosci. 2007;14:806-809.
14㧕 Yamada K, Miyamoto K, Hosoe H, Mizutani M, Shimizu K. Scoliosis associated with Prader-Willi
syndrome A case report. Spine J. 2007;7:345-348.
15㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H, Hosoe H. Surgical treatment of scoliosis
associated with central core disease: Minimizing the effects of malignant hyperthermia withprovocation tests - Report of a case -. J Pediatric Orthop B. 2007;16:239-242.
16㧕 Shimizu T, Miyamoto K, Masuda K, Miyata Y, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
17㧕 Shinohe R, Sato M, Takemura M, Shimizu K, Koishi K, Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type II collagen monoclonal antibody plus
lipopolysaccharide. Jap J Clin Chem. 2008;37:53-62.
18㧕 Oguri K, Fujimoto H, Sugimori H, Miyamoto K, Tachi T, Nagasaki S, Kato Y, Matsuoka T. Pronounced
muscle deoxygenation during supramaximal exercise under simulated hypoxia in sprint athletes. J
Sport Sci Med. 2008;7:512-519.
19㧕 Kikuike K, Miyamoto K, Hosoe H, Kushima Y, Shimizu K. Double-level posterior spinal shortening forparalytic osteoporotic vertebral collapse of two vertebral bodies with a normal vertebra in between: acase report. Arch Orthop Trauma Surg. 2008;128:E221-224.
20㧕 Miyamoto K, Iinuma N, Ueki S, Shimizu K. Effects of Abdominal Belts on the Cross-Sectional Shape of
the Trunk during Intense Contraction of the Trunk Muscles Observed by Computer Tomography. Clin
Biomecha. 2008;23:1220-1226.
21㧕 Terabayashi N, Miyamoto K, Sakai H, Hosoe H, Shimizu K. Multiple steroid-induced vertebral
fracture with paraparesis associated with Wegener’s granulomatosis treated with posterior spinal
instrumentation. J Neurological Sciences (Turkish). 2008;25:67-71.
22㧕 Hioki A, Miyamoto K, Hosoe H, Fukuta S, Shimizu K. Two-stage decompression for combined epiconus
and cauda equina syndrome due to multilevel spinal canal stenosis of the thoracolumbar spine: a casereport. Arch Orthop Trauma Surg. 2008;128:955-958.
23㧕 Yamamoto T, Miyamoto K, Iinuma N, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental Wire
Fixation for Lumbar Spondylolysis Associated with Spina Bifida Occulta. Arch Orthop Trauma Surg.
2008;128:1177-1182.
24㧕 Chi D, Miyamoto K, Hosoe H, Kawai G, Ohnishi K, Suzuki N, Sumi H, Shimizu K. Symptomatic
Lumbar Mobile Segment with Spinal Canal Stenosis in a Fused Spine Associated with Diffused
Idiopathic Skeletal Hyperostosis: A Case Report. Spine J. 2008;8:1019-1023.
25㧕 Hirakawa A, Miyamoto K, Ohno Y, Hioki A, Ogawa H, Nishimoto H, Yokoi T, Hosoe H, Shimizu K.
Two-Stage (posterior and anterior) surgical treatment of spinal osteomyelitis due to atypicalmycobacteria and associated thoracolumbar kyphoscoliosis in a non-immunocompromised patient.
Spine. 2008;32:E221-224.
26㧕 Hioki A, Ohnishi K, Miyamoto K, Hosoe H, Shimizu K. Spondylolysis of the Second Lumbar Vertebra
Treated with Segmental Wiring and Bone Grafting: A case report. Orthopaedics. 2008;31:287.
27㧕 Hioki A, Miyamoto K, Hosoe H, Shimizu K. Two-staged decompression for thoracic paraparesis due tothe combined ossification of the posterior longitudinal ligament and the ligamentum flavum: A casereport. Arch Orthop Trauma Surg. 2008;127:175-177.
28㧕 Hashimoto K, Miyamoto K, Hosoe H, Kawai G, Kikuike K, Shimokawa K, Suzuki N, Matsuo M,
Kodama H, Shimizu K. Solitary fibrous tumor in the cervical spine with destructive vertebral㧙㧙

IF 2.499
IF 0.581

IF 1.578

IF 0.913
IF 2.021

IF 0.801
IF 0.801

IF 0.619

IF 0.793

IF 0.290

IF 0.913

IF 1.642

IF 0.913

IF 0.913

IF 2.499
IF 0.581

IF 0.913

involvement: a case report and review of the literature. Arch Orthop Trauma Surg. 2008;128:1111-1116. IF 0.913
29㧕 Yamamoto T, Iinuma N, Miyamoto K, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental wire
fixation for lumbar spondylolysis associated with spina bifida occulta. Arch Orthop Trauma Surge.
2008;128:1177-1182.
IF 0.793

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᄢ㊁⾆ᢅ㧘⎇ⓥಽᜂ⠪㧦ᧁ᧛ᱜᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦㛽エㇱ⣲≌ߩࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩ⸃ᨆ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧3,600 ජ౞(2,600㧦500㧦500 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦⚦ᳯ⧷ᄦ㧘⎇ⓥಽᜂ⠪㧦ᄢ㊁⾆ᢅ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦࡙࡯ࠗࡦࠣ⡺⣲ࡑ࠙ࠬࡕ࠺࡞ߩ᮸┙ߣ⸃ᨆ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,300 ජ౞(2,600㧦700 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦Ⴧ↰೰ብ㧦ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⎇ⓥ⾌㧦㛽エㇱ⣲≌ߦ߅ߌࠆ Aurora Kinaseߩ⸃ᨆ㧧ᐔᚑ 18 ᐕᐲ㧧200 ජ౞4㧕 ⎇ⓥઍ⴫⠪㧦Ⴧ↰೰ብ㧦ᢛᒻἴኂᄖ⑼ቇ⎇ⓥഥᚑ⽷࿅ ᐔᚑ 18 ᐕᐲ⎇ⓥഥᚑ㊄⑼⎇⵾⮎ᅑബ⾨㧦㛽エㇱ⣲≌ߦ߅ߌࠆࠝ࡯ࡠ࡜ࠠ࠽࡯࠯ߩᓎഀ㧧ᐔᚑ 18 ᐕᐲ㧧1,000 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ጤ੗ᥓ቞↵㧧ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦࡙࡯ࠗࡦࠣ⡺⣲ߦኻߔࠆⴊ▤ౝ⊹Ⴧᱺ࿃ሶࠍᮡ⊛ߣߒߚಽሶᮡ⊛ᴦ≮ߩ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,120 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ችᧄᢘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ᐔᚑ 19 ᐕᐲᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)㧦ౝ࿃ᕈἻ∝ᕈࠨࠗ࠻ࠞࠗࡦߩ೙ᓮࠍ࿑ߞߚᣂߒ޿ᬁ㑆᧼ౣ↢ࠕࡊࡠ࡯࠴㧧ᐔᚑ 18㧙20 ᐕᐲ㧧2,900 ජ
౞(1,100㧦1,100㧦700 ජ౞)
7㧕 ⎇ⓥઍ⴫⠪㧦᧻ጟᢅ↵㧘⎇ⓥಽᜂ⠪㧦ችᧄᢘ㧧ᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)㧦ਛ㜞㦂⠪ߩૐ㉄⚛ⅣႺਅ(ૐ㉄⚛ቶ)ߩㆇേ߇ࠛࡀ࡞ࠡ࡯ᶖ⾌㊂෸߮╭ߦ෸߷ߔᓇ㗀㧧ᐔᚑ 19㧙20 ᐕᐲ㧧2,860
ජ౞(1,560㧦1,300 ජ౞)
2㧕ฃ⸤⎇ⓥ
1㧕 ⎇ⓥઍ⴫⠪㧦ችᧄᢘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧⚻ญ࡝ࡑࡊࡠࠬ࠻ߩ⣶ㇱ⣄ᩇ▤⁜⓰∝㐳ᦼᛩਈߩᣣ
Ᏹ↢ᵴᵴേᕈ‫ޔ‬QOL ߦኻߔࠆലᨐߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦ዊ㊁⮎ຠᎿᬺ(ᩣ)
2㧕 ⎇ⓥઍ⴫⠪㧦ችᧄᢘ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧⚻ญ࡝࠮࠼ࡠࡀ࡯࠻⵾೷ߩㅳ৻᦯↪⵾೷෸߮Ფᣣ᦯
↪⵾೷ߩ㛽☻㝃ᖚ⠪ߦ߅ߌࠆ᦯⮎ࠦࡦࡊ࡜ࠗࠕࡦࠬߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦ᱞ↰⮎ຠᎿᬺ(ᩣ)3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬችᧄᢘ㧦
1㧕 ጘ㒂⣄ᬁ⣄㜑ᙣ⹤ળ਎⹤ੱ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)2㧕 ጘ㒂⣄ᬁ࠮ࡒ࠽࡯਎⹤ੱ(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)
3㧕 ᧲ᶏ⣄ᬁᄖ⑼⎇ⓥળᐙ੐(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)૒⮮ᱜᄦ㧦
1㧕 ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ↹௝කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ࡝࠙ࡑ࠴ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ਛㇱᣣᧄ࡝࠙ࡑ࠴ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ߥߒ㧙㧙3㧕ቇⴚ㔀⹹ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ችᧄ ᢘ㧦
1㧕 ╙ 9 ࿁ጘ㒂⣄ᬁ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᕈᬁ㑆᧼߳ߩౣ↢ක≮ࠕࡊࡠ࡯࠴‫ޠ‬Ṷ⠪)
2㧕 ╙ 21 ࿁ᣣᧄᢛᒻᄖ⑼ቇળၮ␆ቇⴚ㓸ળ ࠪࡦࡐࠫ࠙ࡓ ࡔࠞ࠾ࠞ࡞ࠬ࠻࡟ࠬߣ㛽エ㛽ઍ⻢(ᐔᚑ 18
ᐕ 10 ᦬㧘㐳ፒ㧘Ṷ㗴‫ޟ‬EXPOSURE TO PULSED LOW INTENSITY ULTRASOUND STIMULATESMETABOLISM OF BOVINE INTERVERTEBRAL DISC CELLS CULTURED IN ALGINATEBEADS‫ޠ‬Ṷ⠪)
3㧕 ᐔᚑ 18 ᐕᐲ ጘ㒂ᄢቇᢛᒻᄖ⑼ቇᢎቶห㐷ળ✚ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᬁ㑆᧼߳ߩౣ↢ᴦ≮ࠕࡊࡠ࡯࠴- 3 ᐕ㑆ߩ Chicago ⇐ቇࠍ⚳߃ߡ -‫ޠ‬Ṷ⠪)4㧕 ∩ߺߣἻ∝ 2007(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਎⇇ࠍ߼ߑߖ㧍ጘ㒂ߩ⣄ᬁ⥃ᐥ‫ޠ‬Ṷ⠪)
5㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∔ᖚߩ∛⸻ㅪ៤㧙ߚ߆߇⢋ߎࠅ‫ߤࠇߐޔ‬⢋ߎࠅ㧙‫ޠ‬Ṷ⠪)
6㧕 ࡌࡀ࠶࠻ Weeklyjy ㍤ᣂ⊒ᄁ⸥ᔨ⻠Ṷળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߦ઻߁⣶∩ߩ
QOL ⹏ଔ‫ޠ‬ᐳ㐳)7㧕 ੩ㇺᄢቇ⧯ᚻ⣄ᬁᄖ⑼කߩળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢ㒋Ꮢ㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃ᕈ⣄ᬁ㛽᛬࿶ẩߦኻߔࠆ
ᄖ⑼⊛ᴦ≮‫ޠ‬Ṷ⠪)8㧕 ᐔᚑ 20 ᐕᐲᣣᧄ᧚ᢱቇળ↢૕࡮ක≮᧚ᢱㇱ㐷⻠Ṷળ(ᐔᚑ 20 ᐕ 12 ᦬㧘੩ㇺᏒ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁߦ
ኻߔࠆ㊄ዻࠗࡦࡊ࡜ࡦ࠻ࠍ↪޿ߚᚻⴚᴦ≮ ́ㆊ෰࡮⃻࿷࡮ᧂ᧪́‫ޠ‬Ṷ⠪)૒⮮ᱜᄦ㧦
1㧕 ╙ 10 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ᦨޟ‬ㄭߩ㑐▵࡝࠙ࡑ࠴⮎‛≮ᴺ‫ޠ‬ᐳ㐳)2㧕 ╙ 83 ࿁ጘ㒂⋵ᢛᒻᄖ⑼㓸⺣ળ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬㑐▵࡝࠙ࡑ࠴ᚻ∛ᄌߦኻߔࠆ
ᴦ≮‫ޠ‬ᐳ㐳)3㧕 ╙ 18 ࿁ਅํᏒ⮎೷Ꮷળቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ਅํ㧘․೎⻠Ṷ‫ޟ‬㑐▵࡝࠙ࡑ࠴ߦ߅ߌࠆ⮎‛≮ᴺ‫ޠ‬Ṷ⠪)
8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ችᧄᢘ㧦New Investigator Recognition Award/ 52nd Ortopaedic Research Society (2006)2㧕 ችᧄᢘ㧦Russell Hibbs Award for the Best Basic Science Paper / The 41st Annual Meeting of
Scoliosis Research Society (2006)3㧕 ችᧄᢘ㧦CSRS Basic Science Research Award 3rd Prize / The 34th Annual Meeting of Cervical
Spine Research Society (2006)4㧕 ችᧄᢘ㧦ጘ㒂⣄ᬁ⣄㜑ᙣ⹤ળ ╙ 5 ࿁ᄢᱜࠕࡢ࡯࠼(ᐔᚑ 18 ᐕᐲ)‫ޟ‬ᬁ㑆᧼ࡃࠠࡘ࡯ࡓ⃻⽎ߩ⥃ᐥ⊛ᗧ⟵‫ ╙ޠ‬109 ࿁ਛㇱᣣᧄ
5㧕 ༑ਭ↢ஜᄥ㧘ችᧄᢘ㧘ㆃᄢ᣿㧘ᷡ᳓సᤨ㧦
ᢛᒻᄖ⑼࡮ἴኂᄖ⑼ቇળ ળ㐳ᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
6㧕 ችᧄᢘ㧦╙ 15 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ best paper ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേችᧄᢘ㧦
1㧕 ጘ㒂⋵࡜ࠣࡆ࡯ࡈ࠶࠻ࡏ࡯࡞දળකോᆔຬળ೽ᆔຬ㐳(㨪⃻࿷)2㧕 ጘ㒂⋵ቇ↢ᨵ㆏ㅪ⋖ᐙ੐(ᐔᚑ 18 ᐕᐲ㨪⃻࿷)3㧕 ጘ㒂⋵ᨵ㆏ㅪ⋖කോᆔຬળᆔຬ(ᐔᚑ 20 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
ߥߒ
11㧚ႎ㆏
ߥߒ

㧙㧙

12㧚⥄Ꮖ⹏ଔ
⹏ଔၮ␆⎇ⓥ㧘⥃ᐥ⎇ⓥߩᚑᨐࠍ⧷ᢥ⺰ᢥߣߒߡႎ๔ߒߡ߈ߚ‫ߪߡ޿ߟߦࠇߎޕ‬㧘ࡑࡦࡄࡢ࡯߇ਇ⿷ߒߡ
޿ࠆߥ߆㧘චಽߦஜ㑵ߒߡ޿ࠆߣᕁࠊࠇࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ࠬ࠲࠶ࡈ߇⥃ᐥᵴേߣ⎇ⓥᵴേࠍਗⴕߒߡⴕߞߡ޿ࠆߩߢ㧘ᤨ㑆㧘ࡑࡦࡄࡢ࡯߇⿷ࠅߥ޿ᗵ߇޽ࠆ‫ޕ‬ߎࠇߦߟ޿ߡߪฦ⒳㑐ㅪᯏ㑐ߣߩኒߥ࠴࡯ࡓࡢ࡯ࠢ㧘౒ห૞ᬺ╬ߦߡ⵬޿ߚ޿‫ޕ‬੹ᓟߩዷᦸㄭᐕߩ㜞㦂⠪ߩභ߼ࠆഀว߇㜞޿ੱญᲧࠍ⠨߃ࠆߣ࿖᳃ߦ㗫ᐲߩ㜞޿⣄ᬁ∔ᖚ㧘ߘߒߡ㜞ᐲߩኾ㐷⊛ක≮ᛛⴚࠍⷐߔࠆᘟᕈ㑐▵࡝࠙ࡑ࠴ߦኻߔࠆᴦ≮ࠍࡔࠗࡦ࠹࡯ࡑߣߒߡ㧘⎇ⓥ࡮ᢎ⢒࡮⸻≮ࠍⴕߥߞߡ
޿ߊ૕೙ߢ޽ࠆ‫ߪߦࡈ࠶࠲ࠬޕ‬⣄ᬁ∔ᖚ㧘࡝࠙ࡑ࠴ᕈ∔ᖚࠍኾ㐷ߣߔࠆ 2 ฬࠍᠩߒ㧘ၮ␆⎇ⓥ࡮ᢎ⢒ߦ߅޿ߡጘ㒂⋵ߩ࠮ࡦ࠲࡯⊛ᓎഀࠍ᦭ߔࠆᯏ㑐ߣߒߡᯏ⢻ߒ㧘߆ߟጘ㒂ᄢቇ߳ߩ⽸₂ࠍⴕߞߡ޿߈ߚ޿‫ޕ‬ᄙ᭽ߥࡊࡠࠫࠚࠢ࠻ࠍ᦭ߒߡ߅ࠅ㧘ᄙߊߩ⥃ᐥක㧘⎇ⓥ⠪㧘කቇ↢㧘ડᬺߥߤ߇ෳടߒߡ޿ࠆ‫ࡓ࡯࠴ޕ‬ࡢ࡯ࠢ㧘⋧੕⽸₂ߩ♖␹ࠍ㊀ⷞߒ㧘⎇ⓥߩᵴേᕈ߇ߐࠄߦ޽߇ࠆࠃ߁ߦዧജࠍⴕ޿ߚ޿‫ޕ‬ၮ␆⎇ⓥ㧘⥃ᐥ⎇ⓥ㧘෸߮࠻࡜ࡦࠬ࡟࡯࡚ࠪ࠽࡞ߥ૏⟎ߠߌߩ⎇ⓥࠍ⛮⛯ߒߡⴕ޿㧘ᒰ⹥ಽ㊁ߦ߅ߌࠆ࠻࠶ࡊࠫࡖ࡯
࠽࡞߳ߩᛩⓂࠍ⋡ᜰߒߡദജࠍ㊀ߨߚ޿‫ߚ߹ޕ‬㧘ߎࠇ߹ߢߦߪᲧセ⊛ᚻ⭯ߢ޽ߞߚฦ⒳࿖ౝ࿖ᄖቇળᵴ
േ߽ᵴ⊒ߦⴕ޿㧘ᓧࠄࠇߚ⍮⷗ࠍᐢ߼ࠆദജࠍⴕ޿ߚ޿‫ߪߡ޿ߒޕ‬㧘ጘ㒂߆ࠄᣣᧄ㧘਎⇇ߦ߻ߌߡ⣄ᬁ㛽㑐▵ౣᑪᴦ≮ߩࠬ࠲ࡦ࠳࡯࠼ࠍ⊒ାߔࠆߎߣࠍ⋡⊛ߣߒߚ޿‫ޕ‬㧙㧙㧔13㧕ነ㒝⻠ᐳ‫ޟ‬࿾ၞක≮ቇ⻠ᐳ㧔ጘ㒂⋵㧕‫ޠ‬1㧚⎇ⓥߩ᭎ⷐ
ᧄ⻠ᐳߪ㧘એਅߩ⢛᥊ߩ߽ߣ㧘ጘ㒂⋵߇✚ോ⋭ߩหᗧࠍᓧߡᡰ಴ߔࠆነ㒝㊄ߦࠃࠅ⸳⟎ߐࠇ㧘ਅ⸥ౝኈߦߟ޿ߡ⺞ᩏ࡮⎇ⓥ࡮ታ〣ࠍⴕߞߡ޿ࠆ‫ޕ‬‫ޣ‬⢛᥊‫ޤ‬ᐔᚑ 16 ᐕᐲ߆ࠄ⟵ോൻߐࠇߚකᏧ⥃ᐥ⎇ୃ೙ᐲዉ౉એ㒠㧘ㇺᏒㇱߩ∛㒮ߢ⎇ୃࠍฃߌࠆකᏧ߇Ⴧടߒ㧘ᄢቇ∛㒮ߢ⎇ୃࠍฃߌࠆ߽ߩ߇ᷫዋߒߚ‫߼ߚߩߎޕ‬㧘ᧄ⋵ߦ߅޿ߡ߽ᄢቇකቇㇱ߆ࠄ࿾ᣇߩ∛㒮߳ߩකᏧᵷ㆜ᯏ⢻߇ૐਅߒ㧘࿾ၞක≮ߦᓥ੐ߔࠆකᏧߩਇ⿷߇ㅴߺ㧘࿾ၞߩක≮ឭଏ૕೙ߦᷓೞߥᓇ㗀߇಴ߡ߈ߚ‫ޕ‬ߎߩߚ߼㧘㒢ࠄࠇߚක≮⾗Ḯࠍ᦭ലߦᵴ↪ߒ㧘ක≮ᯏ㑐⋧੕ߩᯏ⢻ಽᜂߣㅪ៤ߦࠃࠅකᏧߩലᨐ⊛ߥ㈩⟎ࠍⴕ߁ߣߣ߽ߦ㧘৻ᣇߢ࿾ၞක≮ߦᾲᗧࠍᜬߞߚකᏧࠍ㙃ᚑߔࠆߎߣ߇ᕆോߣߥߞߡ޿ࠆ‫ޕ‬1㧕ੑᰴක≮࿤ߦ߅ߌࠆක≮ឭଏ૕೙ߩ⺖㗴ߣ⸃᳿╷ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ
1㧕⋡⊛࿾ၞߩၮᐙ⊛∛㒮ࠍਛᔃߣߒߚක≮ᯏ㑐⋧੕ߩᯏ⢻ಽᜂߣㅪ៤ߦࠃࠆല₸⊛ߥක≮ឭଏ૕೙ߣකᏧ
ߩലᨐ⊛ߥ㈩⟎ࠪࠬ࠹ࡓࠍ᭴▽ߔࠆߎߣࠍ⋡⊛ߣߔࠆ‫ޕ‬
2㧕ౝኈߣᚻᴺ
ੑᰴක≮࿤ߏߣߦᰴߩᚻᴺߦࠃࠅ㧘⺖㗴ߣ⸃᳿╷ࠍ⎇ⓥߔࠆ‫ޕ‬Ԙ ∔∛േะ⺞ᩏߣ૑᳃࠾࡯࠭ߩᛠីԙ ၮᐙ⊛∛㒮ࠍਛᔃߣߒߚ࿾ၞක≮ㅪ៤૕೙ߩ᭴▽Ԛ ㆡᱜߥක≮ኾ㐷⡯⒳㈩⟎ࠪࠬ࠹ࡓߩ㐿⊒
3㧕ᦼᓙߐࠇࠆലᨐ
ല₸⊛ߥක≮ឭଏ૕೙ߣലᨐ⊛ߥකᏧ㈩⟎ࠪࠬ࠹ࡓߥߤߦࠃࠅ㧘㒢ࠅ޽ࠆක≮⾗Ḯࠍᦨᄢ㒢ߦ᦭ലᵴ↪ߐࠇࠆߎߣߦࠃࠅ㧘࿾ၞක≮ߩలታߦߟߥߍࠆ‫ޕ‬
2㧕࿾ၞߩၮᐙ⊛∛㒮ࠍࡈࠖ࡯࡞࠼ߣߒߚ࿾ၞක≮ቇߩ⎇ⓥߣ࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑ1㧕⋡⊛
Ԙ ࿾ၞ․᦭ߩ∔∛ኻ╷ߩଦㅴߣ൮᜝ක≮ߩឭଏࠍ⋡⊛ߣߒߚ࿾ၞක≮ቇߩ⎇ⓥࠍታᣉߔࠆ‫ޕ‬ԙ ࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑࠍ⋡⊛ߣߒߡ㧘࿾ၞකኅቇߩ⎇ⓥࠍ฽߼ߚ㝯ജ⊛ߥ✚ว⥃ᐥක⢒ᚑࡊࡠࠣ࡜ࡓࠍ╷ቯߔࠆ‫ޕ‬
2㧕ౝኈߣᚻᴺ
Ԙ࿾ၞකኅቇߩ⎇ⓥ
٤࿾ၞ․᦭ߩ∔∛⊒↢ⷐ࿃ߦ㑐ߔࠆ࿾ၞ∉ቇ⎇ⓥԙ࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑ٤✚ว⥃ᐥක⢒ᚑࠞ࡝ࠠࡘ࡜ࡓߩ╷ቯ٤೨⸥ࠞ࡝ࠠࡘ࡜ࡓࠍ⛔วߒ㧘ㇺᏒㇱߩᄢⷙᮨ∛㒮ߢߩ㜞ᐲኾ㐷ක≮ߣ࿾ၞ࡮߳߈࿾ߩක≮ᯏ㑐ߢߩ෺ᣇ߇⎇ୃน⢻ߥጘ㒂⋵ᣇᑼߩ✚วක⢒ᚑࠞ࡝ࠠࡘ࡜ࡓࠍ╷ቯߔࠆ‫ޕ‬٤਄⸥ߦࠃࠅ㧘⥃ᐥ⎇ୃක╬ߦ࿾ၞක≮㨯කቇߩ㊀ⷐᕈࠍ⹺⼂ߐߖ⥝๧ࠍᜬߚߖࠆ‫ޕ‬
3㧕ᦼᓙߐࠇࠆലᨐ
࿾ၞ․᦭ߩ∔∛੍㒐ኻ╷ߣ൮᜝ක≮ߩឭଏ߇ଦㅴߐࠇࠆߣߣ߽ߦ㧘లታߒߚ✚ว⥃ᐥක⢒ᚑࠞ࡝ࠠࡘ
࡜ࡓߩ╷ቯߦࠃࠅ㧘࿾ၞක≮ࠍᜂ߁කᏧߩ㙃ᚑߩଦㅴߦߟߥ߇ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼⋧ᒰ㧦
ቝ㊁ཅᒄ
ಎᢎ᝼⋧ᒰ㧦 Ꮉญ㗅ᢘ

Yoshihiro Uno
Yoshihiro Kawaguchi

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
ߥߒ⪺ᦠ㧔᰷ᢥ㧕ߥߒ㧙㧙✚⺑㧔๺ᢥ㧕ߥߒ✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ᨋ⟤૫㧘ጤᧁඳ⟤㧘᫪↰ᶈਯ㧘ḡ਄⧷⤿㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓߦࠃࠆ㒠࿶ലᨐ㧙ஜᐽ⸻ᢿߢߩ㕖೑↪⠪ߣߩᲧセ⎇ⓥ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2006 ᐕ㧧2 Ꮞ㧦222㧙223㧚
2㧕 ጤᧁඳ⟤㧘ᨋ⟤૫㧘᫪↰ᶈਯ㧘ḡ਄⧷⤿㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓߩ᦭↪ᕈ㧙ᔃ㔚࿑ߦࠃࠆਇᢛ⣂ߩ᦬೎࡮ᐕઍ೎ᄌേ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2006 ᐕ㧧2 Ꮞ㧦224㧙225㧚
3㧕 ᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘⍹Ⴆ㆐ᄦ㧘଻૑ഞ㧘›Ⴆ⾆㧚කቇ↢ߦࠃࠆ⸰໧⋴⼔૕㛎ታ⠌ߩ⹏ଔ㧘කቇᢎ⢒ 2006ᐕ㧧37 Ꮞ㧦311㧙315㧚
4㧕 ᫪↰ᶈਯ㧘᳓㊁ᥓሶ㧘᫃↰๺↵㧘ቝ㊁ཅᒄ㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘᧻ේஜᴦ㧘᧻ᧄ㓷⟤㧘㐳੗ቁᄥ㇢㧘⍹Ⴆ㆐ᄦ㧚ਔ஥ߦ೽⣢⊹⾰⣼⣲߇⷗ࠄࠇߚේ⊒ᕈࠕ࡞࠼ࠬ࠹ࡠࡦ∝ߩ 1 ଀㧙ฝࠕ࡞࠼ࠬ࠹ࡠࡦ↥↢⣼⣲ߣᏀ㕖ᯏ⢻ᕈ⣼⣲㧙㧘ᣣᧄౝಽᴲቇળ㔀⹹ ╙ 16 ࿁⥃ᐥౝಽᴲઍ⻢ Update Proceeding 2006 ᐕ㧧82 Ꮞ(Ⴧೀ)㧦
61㧙63㧚
5㧕 ㊁ᣇᢥ㓶㧘ቝ㊁ཅᒄ㧘᫪↰ᶈਯ㧘⍹Ⴆ㆐ᄦ㧘ᴡ᧛ᵗሶ㧘ᮮ↰ᐽᚑ㧘ਅਛᥓ㧘↰ਛ㕏ື㧚ஜᐽ㜞㦂⠪ᬌᩏࠪࠬ࠹ࡓߩ㐿⊒㧘ᣣᧄࠦࡦࡇࡘ࡯࠲ᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧8 Ꮞ㧦134㧙135㧚
6㧕 ᧻ේஜᴦ㧘᫪৻㇢㧘ᳰ↰⾆⧷㧘᧻ᧄ㓷⟤㧘᧖ጊජ਎㧘᫃↰๺↵㧘ቝ㊁ཅᒄ㧘᫪↰ᶈਯ㧘⍹Ⴆ㆐ᄦ㧚㐳ኼߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛ ࿖ᐭ࡮⟤ጊ࿾඙Ყセ⎇ⓥ㧘ጘ㒂⋵ౝ⑼කળ㔀⹹ 2007 ᐕ㧧21 Ꮞ㧦19㧙21㧚
7㧕 ⍹Ⴆ㆐ᄦ㧘Ḋญା਽㧘⑔ᴛཅቁ㧘ൎᧁ㗼㧘ቝ㊁ཅᒄ㧚ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ㧙ኾ㐷㗔ၞ߆ࠄߩࡔ࠶࠮
࡯ࠫߣ⸛⺰㧙ᣣᧄౝ⑼ቇળኾ㐷කㇱળᡰㇱ࠮ࡒ࠽࡯߆ࠄ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2007 ᐕ㧧96 Ꮞ㧦174㧙180㧚
8㧕 ᫪↰ᶈਯ㧘ᨋ⟤૫㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘⮮ጟ࿻㧘᫪৻㇢㧘ᳰ↰⾆⧷㧘᧻ේஜᴦ㧘๺↰␭Ὼ㧘ጤᧁඳ⟤㧘ḡ਄⧷⤿㧘⍹Ⴆ㆐ᄦ㧚࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓ೑↪ߦࠃࠆ↢ᵴ⠌ᘠ∛㑐ㅪᜰᮡ߳ߩലᨐ㧙ஜᐽ⸻ᢿߢߩ㕖೑↪⠪ߣߩᲧセ⎇ⓥ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦229㧙230㧚
9㧕 ᳰ↰⾆⧷㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘ችౝ࡞ࡒሶ㧘᫪৻㇢㧘⮮ጟ࿻㧘ጟ↰⧷ਯ㧘⮮ដ⾆ᢅ㧘๺↰␭Ὼ㧘⍹Ⴆ㆐ᄦ㧘ᄢႦዅ㧚㆙㓒ක≮ߩ࠾࡯࠭ߣ࠲࡯ࠥ࠶࠻㧙ጊ㑆࿾ၞߢߩ࿷ቛஜᐽ▤ℂࠪࠬ࠹ࡓᄾ⚂⠪߳ߩࠕࡦࠤ࡯࠻⺞ᩏ㧙㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦306㧙307㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Takahashi M, Minatoguchi S, Nishigaki K, Kawasaki M, Arai M, Uno Y, Fujiwara H. Long-term andstrict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients withessential hypertension: an evaluation using a novel indicator of burden on the left ventricle.
Hypertens Res. 2006;29:89-94.
2㧕 Lu C, Arai M, Misao Y, Chen X, Wang N, Onogi H, Kobayashi H, Uno Y, Takemura G, Minatoguchi S,
Fujiwara T, Fujiwara H. Autologous bone marrow cell transplantation improves left ventricularfunction in rabbit hearts with cardiomyopathy via myocardial regeneration-unrelated mechanisms.
Heart Vessels. 2006;21:180-187.
3㧕 Suzuki K, Nagashima K, Arai M, Uno Y, Misao Y, Takemura G, Nishigaki K, Minatoguchi S, Watanabe
S, Tei C, Fujiwara H. Effect of granulocyte colony-stimulating factor treatment at a low dose but for along duration in patients with coronary heart disease. Circ J. 2006;70:430-437.
4㧕 Arai M, Misao Y, Nagai H, Kawasaki M, Nagashima K, Suzuki K, Tsuchiya K, Otsuka S, Uno Y,
Takemura G, Nishigaki K, Minatoguchi S, Fujiwara H. Granulocyte colony-stimulating factor: anoninvasive regeneration therapy for treating atherosclerotic peripheral artery disease. Circ J.
2006;70:1093-1098.
5㧕 Onogi H, Minatoguchi S, Chen XH, Bao N, Kobayashi H, Misao Y, Yasuda S, Yamaki T, Maruyama R,
Uno Y, Arai M, Takemura G, Fujiwara H. Edaravone reduces myocardial infarct size and improves
cardiac function and remodelling in rabbits. Clin Exp Pharmacol Physiol. 2006;33:1035-1041.
6㧕 Sugiyama C, Ishizawa M, Kajita K, Morita H, Uno Y, Matsubara K, Matsumoto M, Ikeda T, Ishizuka T.
Platelet aggregation in obese and diabetic subjects: association with leptin level. Platelets.
2007;18:128-134.
7㧕 Chen X, Minatoguchi S, Arai M, Wang N, Lu C, Narentuoya B, Uno Y, Misao Y, Takemura G, Fujiwara
T, Fujiwara H. Celiprolol, a selective beta1-blocker, reduces the infarct size through production of
nitric oxide in a rabbit model of myocardial infarction. Circ J. 2007;71:574-579.
8㧕 Ishizuka T, Miura A, Kajita K, Matsumoto M, Sugiyama C, Matsubara K, Ikeda T, Mori I, Morita H,
Uno Y, Mune T, Kanoh Y, Ishizawa M. Effect of dehydroepiandrosterone on insulin sensitivity in
Otsuka Long-Evans Tokushima fatty rats. Acta Diabetol. 2007;44:219-226.
9㧕 Kajita K, Mune T, Ikeda T, Matsumoto M, Uno Y, Sugiyama C, Matsubara k, Morita H, Takemura M,
Seishima M, Takeda J, Ishizuka T. Effect of fasting on PPARǫand AMPK activity in adipocytes.
Diabetes Res Clin Pract. 2008;81:144-149.

㧙㧙

IF 2.951

IF 1.043

IF 2.373

IF 2.373

IF 2.038

IF 1.915

IF 2.373

IF 1.619

IF 1.823

10㧕 Mori I, Ishizuka T, Morita H, Matsumoto M, Uno Y, Kajita K, Ikeda T, Fujioka K, Matsubara K.
Comparison of biochemical data, blood pressure and physical activity between longevity andnon-longevity districts in Japan. Circ J. 2008;72:1680-1684.
IF 2.373

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᫪↰ᶈਯ㧘⎇ⓥಽᜂ⠪㧦⍹Ⴆ㆐ᄦ㧘ቝ㊁ཅᒄ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(B)(2)㧦㐳ኼߣ↢ᵴ⠌ᘠ㧙ጘ㒂↢ᵴ⠌ᘠ⺞ᩏ࡮੺౉ࡊࡠࠫࠚࠢ࠻㧙㧧ᐔᚑ 16㧙19 ᐕᐲ㧧14,900 ජ౞(7,600㧦4,000㧦1,900㧦1,400 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦㊁ᣇᢥ㓶㧘⎇ⓥಽᜂ⠪㧦᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘㘵↰ብ᮸㧘㘵↰⌀⟤㧘ᮮ↰ᐽᚑ㧘⍹Ⴆ㆐ᄦ㧘ᷡፉḩ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃ↢੐ᬺ㧙ࡠࡏ࠹࠶ࠢవ┵ක≮ࠢ࡜ࠬ࠲࡯㧙㧦ක≮⸻ᢿᡰេࠪࠬ࠹
ࡓߩ㐿⊒㧙േ⣂⎬ൻ⸃ᨆ࡮⸻ᢿࠪࠬ࠹ࡓ㧙㧧ᐔᚑ 17㧙20 ᐕᐲ 50,409 ජ౞(9,500㧦20,000㧦7,500㧦
13,409 ජ౞)
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥ1㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘᧻ේஜᴦ㧘᧻ᧄ㓷⟤㧘ᳰ↰⾆⧷㧘᫪৻㇢㧦ጘ㒂⋵ౝߩ㐳ኼ࿾ၞߣ㕖㐳ኼ࿾ၞߢߩ㧘り૕߅ࠃ߮↢ᵴ⠌ᘠ(㘩੐㧘ㆇേ╬)ߩ∉ቇ⊛⺞ᩏߦࠃࠆේ࿃ߩ⸃᣿㧧ᐔ
ᚑ 18 ᐕᐲ㧧2,000 ජ౞㧦ࠗ࠮࠶࠻(ᩣ)
2㧕 ⍹Ⴆ㆐ᄦ㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧘᫃↰๺↵㧘ᳰ↰⾆⧷㧘᫪৻㇢㧘⮮ጟ࿻㧘ችౝ࡞ࡒሶ㧦ᵹേ㘩㐳ᦼ៨ขߦࠃࠆࡔ࠲ࡏ࡝࠶ࠢ∝୥⟲ߩ੍㒐࡮ᡷༀലᨐ㧧ᐔᚑ 19 ᐕᐲ㧧2,970 ජ౞㧦᫪᳗੃ᬺ(ᩣ)
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ㊁ᣇᢥ㓶㧘᫪↰ᶈਯ㧘ቝ㊁ཅᒄ㧦⵬ᱜⵝ⟎(⊒᣿)㧧ᐔᚑ 19 ᐕ(․㗿 2006-003862)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ
ቝ㊁ཅᒄ㧦
1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏᡰㇱ⹏⼏ຬ(㨪⃻࿷)Ꮉญ㗅ᢘ㧦1㧕 ᣣᧄ੃≸ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳
ቝ㊁ཅᒄ㧦
1㧕 ᐔᚑ 20 ᐕᐲᣣᧄ㆙㓒ක≮ቇળᄢળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬࿾ၞක≮‫ޠ‬ᐳ㐳)Ꮉญ㗅ᢘ㧦
1㧕 ੃≸ቇળ᧲ᶏ࿾ᣇળ(ᐔᚑ 20 ᐕ 8 ᦬㧘㊄ᴛ㧘৻⥸Ṷ㗴‫ޟ‬ൻቇ≮ᴺ‫ޠ‬ᐳ㐳)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേߥߒ㧙㧙

10㧚ႎ๔ᦠ
ߥߒ
11㧚ႎ㆏
1㧕 ቝ㊁ཅᒄ㧘㊁ᣇᢥ㓶㧦5 ಽߢಽ߆ࠆⴊ▤ᐕ㦂 ጘ㒂ᄢ߇ᬌᩏࠪࠬ࠹ࡓ㐿⊒㧦ਛᣣࠬࡐ࡯࠷(2006 ᐕ 5
᦬ 31 ᣣ)2㧕 ቝ㊁ཅᒄ㧘㊁ᣇᢥ㓶㧦േ⣂⎬ൻᬌᩏ 5 ಽߦ⍴❗ ጘ㒂ᄢࠣ࡞࡯ࡊ㐿⊒㧦⺒ᄁᣂ⡞(2007 ᐕ 1 ᦬ 15 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ
ᐔᚑ 19 ᐕ 11 ᦬ߦ⊒⿷ߒߚᒰ⻠ᐳߪ㧘߹ߛ㐿⸳㑆߽ߥ޿ߎߣ߆ࠄᒰ⻠ᐳࠝ࡝ࠫ࠽࡞ߩᬺ❣ߪዋߥ޿߇㧘੹ᓟߪ࿾ၞ߳߈࿾✚วක≮ಽ㊁ߣߒߡ␠ળ⊛ߥ⹺⍮߿⁛┙ᕈࠍ⠨߃㧘․⦡޽ࠆ⺰ᢥᬺ❣㧘⎇ⓥࠍㅴ߼ߡ޿߈ߚ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷߹ߛ⊒⿷㑆߽ߥߊ㧘⎇ⓥ┙᩺㧘࠺࡯࠲෼㓸࡮⸃ᨆ㧘⺰ᢥ⸥タߥߤ⎇ⓥߦ⾌߿ߔᤨ㑆߇߆ߥࠅਇ⿷ߒߡ
޿ࠆߩ߇⃻⁁ߢ޽ࠆ‫ޕ‬ᒰᢎቶ‫ޟ‬࿾ၞ߳߈࿾✚วක≮ಽ㊁‫ߩޠ‬ᓎഀ߿㝯ജࠍలಽߦ⹺⼂ߒߡ߽ࠄ߃ࠆࠃ߁
ߦദജߒߡࠁߊ‫␠ޕ‬ળ⊛ߥ⹺⍮ᐲਇ⿷ߦኻߒߡߪ㧘੹ᓟቇળߢߩ⊒⴫߿⺰ᢥൻߣߣ߽ߦ㧘ነ㒝⻠ᐳߣߒߡጘ㒂⋵ߣදജߒߡ࿾ၞක≮ᵴേߦⓍᭂ⊛ߦᵴേߒߡࠁߊ‫ޕ‬
੹ᓟߩዷᦸ
2008 ᐕ 4 ᦬߆ࠄ㧘කቇㇱ࿾ၞᨒ౉ቇ↢ 10 ੱ߇౉ቇ㧘2009 ᐕ 4 ᦬߆ࠄߪหᣂ౉↢߇ 15 ੱߦჇຬߐࠇ
౉ቇߒߡߊࠆߎߣࠃࠅ㧘߹ߔ߹ߔᒰ⻠ᐳߩᢎ⢒ߦ߅ߌࠆ㊀ⷐᕈ߇᳞߼ࠄࠇߡߊࠆߣ⠨߃㧘ቇ↢ᢎ⢒ࠍਛᔃߦ࿾ၞᡰេ࡮⥃ᐥ⎇ⓥࠍផㅴߒߡࠁ߈ߚ޿‫ޕ‬߹ߚ㧘ో࿖⊛ߦᣂ⸳ߐࠇߡ߈ߡ޿ࠆฦ⋵ߩነ㒝⻠ᐳߢ޽ࠆ࿾ၞක≮ቇ⻠ᐳߣ࠲ࠗࠕ࠶ࡊߒߡᄙᣉ⸳ߢ
ߩ౒ห⎇ⓥࠍⴕ޿㧘ో࿖⊛ߦ࿾ၞක≮ߩᡷༀ࡮⊒ዷߦ㑐ਈߒߡࠁ߈ߚ޿‫ޕ‬㧙㧙㧔14㧕଻ஜ▤ℂ࠮ࡦ࠲࡯㧔ቇౝᣉ⸳㧕1㧚⎇ⓥߩ᭎ⷐ
⢈ḩߣ↢ᵴ⠌ᘠ∛㧘ญ⣧ౝᚲ⷗ߣ↢ᵴ⠌ᘠ㧘ቇ↢ߩ♖␹り૕⺞ᩏ㧘ᄢቇ↢ߩஜᐽታᘒ⺞ᩏߥߤࠍਛᔃߦ
⎇ⓥߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬ቇ↢ᡰេ GP㧔ᣂߚߥ␠ળ⊛࠾࡯࠭ߦኻᔕߒߚቇ↢ᡰេࡊࡠࠣ࡜ࡓ㧕ߦࠃࠅ㧘‫↢ޟ‬ᶦஜᐽᢎ⢒ߩផㅴߣஜᐽᡰេߩలታ‫⑼ߩ߼ߚߩޠ‬ቇ⊛ᩮ᜚ࠍㅊ᳞ߒ㧘ౝᄖ߳ᖱႎ⊒ାߒߡ޿ࠆ‫ࠍࠇߎޕ‬ㅢ
ߓߡ࿾ၞ⽸₂ߦ߽ജࠍ౉ࠇߡ޿ࠆ‫ޕ‬2㧚ฬ★
ᢎ᝼(૬છ)㧦 ᷡ᳓సᤨ
ጊᧄ⋿↱⟤
ᢎ᝼㧦
↰ਛ↢㓷
ಎᢎ᝼㧦
ᵻ↰ୃᏒ
ഥᢎ㧦
૒ᷰᔘᵗ
ഥᢎ㧦

Katuji Shimizu
Mayumi Yamamoto
Mika Tanaka
Syuichi Asada
Tadahiro Sado

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ߩℂ⸃ߩߚ߼ߦ㧙㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞㧧2006 ᐕ㧦22㧙37㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣄ᩇ஥ᒗ∝㧦⩵࿾⤿৻㧘ਛ᧛೑ቁ㧘⿧ᥓశᄦ✬㧚ᢛᒻᄖ⑼ኾ㐷කࠍ߼ߑߔߚ߼ߩ ⚻㛎ߔߴ߈ᄖ்࡮∔ᖚ 97㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2006 ᐕ㧦127㧙133㧚
3㧕 ጊᧄ⋿↱⟤㧚╙Σ▵ ஜᐽ⸻ᢿ㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧚ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂ᣂ⡞␠㧧2006 ᐕ㧦8㧙11㧚
4㧕 ጊᧄ⋿↱⟤㧚╙Χ▵ ᗵᨴ∝㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧚ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂ᣂ⡞␠㧧2006 ᐕ㧦89㧙92㧚
5㧕 ጊᧄ⋿↱⟤㧚ઃ㍳ 1 ක≮࡮⑔␩೙ᐲ㧦ጘ㒂⋵ᄢቇ଻ஜ▤ℂ⎇ⓥળ✬㧚ࠠࡖࡦࡄࠬ࡜ࠗࡈߩஜᐽ▤ℂ㧘ጘ㒂㧦ጘ㒂ᣂ⡞␠㧧2006 ᐕ㧦111㧙113㧚
6㧕 ⚦ᳯ⧷ᄦ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮㧦ᷡ᳓సᤨ✬㧚ࡐࠤ࠶࠻  ߎࠇߛߌߪ⍮ߞߡ߅߈ߚ޿ ⿷⣶ߩ∩ߺߩ⥄Ꮖ▤ℂ㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ߩℂ⸃ߩߚ߼ߦ㧙㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞㧧2007 ᐕ㧦38㧙66㧚
7㧕 ᷡ᳓సᤨ✬⪺㧚⣶ᬁᄌᕈߔߴࠅ∝㧙⑳ߩࠗࡦࡈࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧦࠻࡜ࡉ࡞ߦߥࠄߥ޿ᢛᒻᄖ⑼ࠗࡦࡈ
ࠜ࡯ࡓ࠼ࠦࡦ࠮ࡦ࠻㧘᧲੩㧦㊄ේ಴ 㧧2007 ᐕ㧦212㧙213㧚
8㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ✬⪺㧚⣶ㇱ⣄ᬁ⣄ᩇ▤⁜⓰∝㧙⸻ᢿߣᴦ≮㧙㧦⠧ᐕකቇ update 2007-08㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2007 ᐕ㧦14㧙24㧚
9㧕 㕍ᧁ㓉᣿㧘ᷡ᳓సᤨ✬⪺㧚⣶∩ߩㆇേ≮ᴺ㧦⣶∩⍮ࠆ⸻ࠆᴦߔ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦130
㧙155㧚
10㧕 ጊᧄ⋿↱⟤㧚╙ 7 ┨⚵❱ߩᵴᕈൻ‫غ‬
1 ੱ᧚▤ℂ㧦ක≮⚻༡ᢎ⢒ද⼏ળ✬㧚ක≮ࡑࡀࠫࡔࡦ࠻́ක≮ߩ⾰ะ਄ߩߚ߼ߩක≮⚻༡ቇ́㧘᧲੩㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2008 ᐕ㧦148㧙169㧚
11㧕 ጊᧄ⋿↱⟤㧚╙ 7 ┨⚵❱ߩᵴᕈൻ‫غ‬
3 ࠻࡯࠲࡞ࠢࠝ࡝࠹ࠖࡑࡀࠫࡔࡦ࠻(TQM)㧦ක≮⚻༡ᢎ⢒ද⼏ળ✬㧚ක≮ࡑࡀࠫࡔࡦ࠻́ක≮ߩ⾰ะ਄ߩߚ߼ߩක≮⚻༡ቇ́㧘᧲੩㧦ᣣ⚻ࡔ࠺ࠖࠞ࡞㐿⊒㧧2008 ᐕ㧦191㧙205㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Shimizu K, Miyamoto K. Inflammatory diseases of the spine-juvenile rheumatoid arthritis. In:
Surgery of the Pediatric Spine. New York: Thieme;2007:375-380.
✚⺑㧔๺ᢥ㧕
1㧕 ᷡ᳓సᤨ㧚․㓸 ᚻߩ∩ߺߩ⸻ᢿߣᴦ≮ ᐨ㧘∩ߺߣ⥃ᐥ 2006 ᐕ㧧6 Ꮞ㧦1㧚
2㧕 ㊄᫪ᐽᄦ㧘ᷡ᳓సᤨ㧚⣶∩ ᕆᕈ⣶∩ߣᘟᕈ⣶∩㧘⥃ᐥߣ⎇ⓥ 2006 ᐕ㧧83 Ꮞ㧦12㧙15㧚
3㧕 ᷡ᳓సᤨ㧚ࠪࡦࡐࠫ࠙ࡓ ⣶ㇱ⣄ᩇ▤⁜⓰∝㧙ᦨㄭߩㅴᱠ㧙 ✜⸒㧘⥃ᐥᢛᒻᄖ⑼ 2006 ᐕ㧧41 Ꮞ㧦852㧚
4㧕 ᷡ᳓సᤨ㧚ᣣᧄ⣄ᬁ⣄㜑∛ቇળߣർ☨⣄ᬁ㑐ㅪቇળߣߩ੤ᵹ 㧙Spine Across the Sea ႎ๔㧙㧘⣄ᬁ⣄㜑ࠫࡖ࡯࠽࡞ 2006 ᐕ㧧19 Ꮞ㧦1174㧙1175㧚
5㧕 ᷡ᳓సᤨ㧚ጘ㒂⟤Ớ⥄ォゞ↢ᵴ㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1798㧚
6㧕 ጊᧄ⋿↱⟤㧚ൕഭ⠪ߩ♧ዩ∛ߩ∛ᘒߣ੍㒐㧘ᕺ㇊කᏧળߛࠃࠅ 2006 ᐕ㧧50 Ꮞ㧦35㧙41㧚
7㧕 ጊᧄ⋿↱⟤㧚੍㒐ធ⒳ߦߟ޿ߡ㧘ጘᄢ߭ࠈ߫ 2006 ᐕ㧧47 Ꮞ㧦8㧙10㧚
8㧕 ᷡ᳓సᤨ㧚৻⥸ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮㧘ጘ㒂ᏒකᏧળߛࠃࠅ 2007 ᐕ㧧39 Ꮞ㧦25㧙27㧚
9㧕 ⑔↰┨ੑ㧘ᷡ᳓సᤨ㧚⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮㧘㛽࡮㑐▵࡮㕤Ꮺ 2007 ᐕ㧧20 Ꮞ㧦455㧙461㧚
10㧕 ᷡ᳓సᤨ㧚⣄ᬁౝⷞ㏜ਅᚻⴚ㧙ၮᧄᚻᛛ߆ࠄᛛⴚ⹺ቯ߹ߢ㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1656㧚
11㧕 ᷡ᳓సᤨ㧚⣶ߩ∩ߺ(⣶ㇱ⣄ᩇ▤⁜⓰∝)ࠍ㒐ߋ㧘ࠢ࠶ࠢ㧒࡜ࠗࡈ 2007 ᐕ㧧433 Ꮞ㧦8㧙9㧚
12㧕 ጊᧄ⋿↱⟤㧚ᮡḰ⊛ߥஜ⸻࡮଻ஜᜰዉࡊࡠࠣ࡜ࡓߩታᣉߣ♧ዩ∛੍㒐ኻ╷㧘ᕺ㇊කᏧળߛࠃࠅ 2007 ᐕ㧧
55 Ꮞ㧦17㧙20㧚
13㧕 ೨ේ⑲੫㧘ᷡ᳓సᤨ㧚ࠞ࡞ࡄࠗࡦߣᄌᕈᕈ㑐▵∝㧘೎ౠᢛᒻᄖ⑼‫ޛ‬ᄌᕈᕈ㑐▵∝㧙ᦨㄭߩ⍮⼂‫ ޜ‬2008 ᐕ㧧㧙㧙53 Ꮞ㧦38㧙41㧚
14㧕 ᧻ᧄ቞㓶㧘ජ⪲৻⵨㧘ᚭጊ⧐ᤘ㧘┻ਅసᔒ㧘ᤊ࿾੝ㇺม㧘ਛ᧛⠹ਃ㧘᦭᳓ ᷕ㧘⮮ᨋବ੺㧘ᐔᨋ ⨃㧘ᐔ㊁ ᔀ㧘ጤፒᐙቄ㧘㊄ጟᕡᴦ㧘Ꮉญༀᴦ㧘੗ዥᐘᚑ㧘೨↰ ᑪ㧘᧻ጊᐘᒄ㧘ਃ਄㕏ᄦ㧘᧛਄⧷᮸㧘᳗ፉ⧷᮸㧘᳗↰⷗↢㧘ਛේㅴਯ੺㧘㊁ේ ⵨㧘ጟ ผᦶ㧘㒋ᧄ᩵ㅧ㧘₎ᯅᐽ㓶㧘╣↢ ⼾㧘ᷡ᳓సᤨ㧘↰ญᢅᒾ㧘㜞ᯅ ⺈㧘↰ਛ㕏ਭ㧘⼱ ବ৻㧘ᓼᯅᵏ᣿㧘ౝ↰⎇ㅧ㧘ጊᧄ⻞๋㧘ጊፒᱜᔒ㧘ᮮጊ ᔀ㧘ศ↰ቬੱ㧘⷏⣁␭ม㧚⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᚻⴚᚑ❣ߦᓇ㗀ࠍਈ߃ࠆ࿃ሶߩᬌ⸛㧙ઁᣉ⸳ᓟࠈะ߈⎇ⓥ㧙 ⹹਄ࠪࡦࡐࠫ࠙ࡓ ⢷ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߩᴦ≮㧙ᦨㄭߩㅴᱠ㧘⥃ᐥᢛᒻᄖ⑼ (೎೚) 2008 ᐕ㧧43 Ꮞ㧦531㧙538㧚
15㧕 ᷡ᳓సᤨ㧚㗖ᬁ∝㧘OPLL ߩᚻⴚᴦ≮㧘ฬฎደ㧦ਛㇱធ㛽ቇળ⹹ 2008 ᐕ㧧89 Ꮞ㧦19㧚✚⺑㧔᰷ᢥ㧕
ߥߒේ⪺㧔๺ᢥ㧕
1㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆᣂߒ޿ゲᬁㇱᓟᣇ㒰࿶ᴺ㧘⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛ 2006 ᐕ㧧8 Ꮞ㧦79㧙82㧚
2㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘ዊේ᣿㧚⣶ᬁᄌᕈߔߴࠅ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ(cantilever㧙TLIF)ߩ⚻㛎㧘ਛㇱᢛἴ⹹ 2006 ᐕ㧧49 Ꮞ㧦31㧙32㧚
3㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㛽☻㝃∝ᕈ㛽᛬ߦኻߔࠆ⣄ᬁ⍴❗ⴚߩⴚᓟ⚻ㆊ㧘ਛㇱᢛἴ⹹ 2006 ᐕ㧧49 Ꮞ㧦967㧙968㧚
4㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⷏ᧄඳᢥ㧚㗖ᬁᓟ❑㕤Ꮺ㛽ൻ∝ߦኻߔࠆⴚᑼㆬᛯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2006 ᐕ㧧17 Ꮞ㧦525㧚
5㧕 ↰ਛ㗔㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᧃ▵㛽㛽⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2006 ᐕ㧧18 Ꮞ㧦43㧙44㧚
6㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚਄૏⣶ᬁᬁ㑆᧼ࡋ࡞࠾ࠕᓟᣇ៰಴ⴚᓟߦ೨ᣇ࿕ቯ
ࠍⷐߒߚ 1 ଀㧘᧲ᶏ⣄ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦5㧙9㧚
7㧕 ㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘᧖ጊ⺈৻㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚⣶ᬁᄌᕈ஥ᒗߦ೨ᣇ࿕ቯࠍⴕߞߚ 2 ∝଀㧘᧲ᶏ⣄
ᬁᄖ⑼ 2006 ᐕ㧧20 Ꮞ㧦102㧙108㧚
8㧕 ᷡ᳓సᤨ㧘⚦ᳯ⧷ᄦ㧘᧖ጊ⺈৻㧘⧯ᨋ ⧷㧘㊁‫⻀᧛ޘ‬㚅㧚Informed Consent ߩታ㓙㧘ᣣᢛળ⹹ 2006 ᐕ㧧
80 Ꮞ㧦33㧙34㧚
9㧕 Ⴧ↰೰ብ㧘ᷡ᳓సᤨ㧚ᗵᨴᕈ⣄ᬁἻߦኻߔࠆ⣄ᬁࠗࡦࠬ࠷࡞ࡔࡦ࠹㧙࡚ࠪࡦᚻⴚ㧘Orthopaedics 2006ᐕ㧧19 Ꮞ㧦25㧙32㧚
10㧕 ㊁Ỉ ⡡㧘ᷡ᳓సᤨ㧚ࠬࡐ࡯࠷ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߦኻߔࠆᚻⴚ≮ᴺ㧙segmental wire fixation ᴺ㧙㧘
Orthopaedics 2006 ᐕ㧧19 Ꮞ㧦15㧙21㧚
11㧕 ફ⷗৻ᚑ㧘ᷡ᳓సᤨ㧚ᄌᒻᕈ㑐▵∝エ㛽ߦ߅ߌࠆࠞ࡞ࡄࠗࡦߩ⊒⃻㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19
Ꮞ㧦81㧙84㧚
12㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘♻ᢙਁᱜ㧘ᱞౝ┨ੑ㧘ᷡ᳓సᤨ㧚㒸ᣥᕈ೸㔌㛽 ߦࠃࠅ↢ߓߚ⤒⬄㛽੝⣕⥓ߩ 1 ଀㧘ᢛᒻᄖ⑼ 2006 ᐕ㧧57 Ꮞ㧦1623㧙1625㧚
13㧕 ᧻ᧄ ๺㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧚Smith-Petersen ㅴ౉ᴺ߇᦭↪ߢ޽ߞߚੱᎿ⢆㑐▵ౣ⟎឵ⴚߩ 2 ଀㧘Hip Joint ೎೚ 2006 ᐕ㧧32 Ꮞ㧦411㧙414㧚
14㧕 㕍ᧁ㓉᣿㧘ኹፉብ᣿㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ਤ⠀᡽⟤㧘ዊ㊁Ⴆኪ㧚⣶ㇱ⣄ᩇ▤⁜⓰∝ᖚ⠪ߩ⚻ญ PGE1 ⺃ዉ૕⵾೷ᛩਈߦ߅ߌࠆ࠻࡟࠶࠼ࡒ࡞⹏ଔ㧘ᣂ⮎ߣ⥃ᐥ 2006 ᐕ㧧55 Ꮞ㧦74㧙76㧚
15㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᚻ㑐▵⚿ᩭߩᚻⴚᴦ≮ߩ⚻㛎㧘ᣣᧄ㛽࡮㑐▵ᗵᨴ∝ቇળ㔀⹹ 2006 ᐕ㧧
20 Ꮞ㧦29㧙31㧚
16㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᧃ▵㛽߇㔺಴ߒߚᜰውㇱ⊹⤏ᰳ៊ߦኻߔࠆㆆ㔌⊹ᑯ⒖ᬀߩ⚻㛎㧘ᣣᧄᚻ
ߩᄖ⑼ቇળ㔀⹹ 2006 ᐕ㧧23 Ꮞ㧦209㧙212㧚
17㧕 ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᧄᄙᕶሶ㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ጘ㒂ᄢቇߦ߅ߌࠆ⑌ᾍኻ
╷ߩ᦭ലᕈߩᬌ⸛㧙࠾ࠦ࠴ࡦࡄ࠶࠴ߩቇ↢ήఘឭଏࠍ⹜ߺߡ㧙㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦160㧚
18㧕 ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩญ⣧ஜ⸻⚿ᨐߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦211㧚
19㧕 㐳ἑᳯ೑㧘ᓮ↰᧛⋧ᮨ㧘ᧄᄙᕶሶ㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩ㗡∩ߩታᘒ⺞ᩏ
㧙▤ℂᜰዉ૕೙ߦ㑐ߔࠆᬌ⸛㧙㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦238㧚
20㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᬀᧁ໪ᢥ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚UPI ߣ GHQ60
ߩหᤨ⺞ᩏ⚿ᨐࠃࠅ㧘ቇ↢ஜᐽ⺞ᩏߦ߅ߌࠆ UPI ᦭↪ᕈߩᬌ⸛㧘Campus Health 2006 ᐕ㧧43 Ꮞ㧦269㧚
21㧕 ጊᧄ⋿↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚♧ዩ∛⸻≮ߩᣂᤨઍߣ IT㧙ోᯏ⒳ߩ⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲ࠍጘ㒂ᄢቇ∛㒮ߩ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߐߖࠆ⹜ߺ㧘⢈ḩߣ♧ዩ∛ 2006 ᐕ㧧5 Ꮞ㧦47㧙51㧚
22㧕 ↰ਛ↢㓷㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ᵴߣࡔࡦ࠲࡞ࡋ࡞ࠬࠨࡐ࡯࠻㧙2005 ᐕጘ㒂ᄢቇቯᦼஜᐽ⸻ᢿᤨ UPI ⺞ᩏࠃࠅ⠨ኤ㧘߉߰♖␹଻ஜ⑔␩ 2006 ᐕ㧧42 Ꮞ㧦47㧙52㧚
23㧕 ጊᧄ⋿↱⟤㧚ጘ㒂⋵ߦ߅ߌࠆ♧ዩ∛ኻ╷ߩขࠅ⚵ߺߦߟ޿ߡ㧙♧ዩ∛ߩࡑࡀ࡯ࠫࡔࡦ࠻ࠍਛᔃߦ㧘ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦63㧙68㧚
24㧕 ጟ቟િੑ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂ૕೙ᡷༀࠍ⋡⊛ߣߒߚ㒮ౝᮡḰᦠߩ૞ᚑߣߘߩ⹏
ଔ㧘ࡊ࡜ࠢ࠹ࠖࠬ 2006 ᐕ㧧23 Ꮞ㧦464㧙468㧚
25㧕 ↰ਛ↢㓷㧚ᔃ᳇㓚ኂߦኻߒߡ㧘ࡃࠗࠝࡈࠖ࡯࠼ࡃ࠶ࠢᴺࠍ૬↪ߒߚฃേ⊛㖸ᭉ≮ᴺ߇᦭ലߢ޽ߞߚ৻∝଀,ጘ㒂⋵කᏧળකቇ㔀⹹ 2006 ᐕ㧧19 Ꮞ㧦95㧙99㧚㧙㧙26㧕 ᄢፉᐽม㧘ਃቛᥓ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧚㛽ේ⊒ⴊ▤⡺⣲ߩ৻೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦463㧙464㧚
27㧕 ⑔↰┨ੑ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚⿷⢛ߦ⊒↢ߒߚ⍹Ἧൻࠍ઻ߞߚᏂᄢߥⴊ▤ᐔṖ╭⣲ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦515㧙516㧚
28㧕 ᳗㊁ᤘੳ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘ጊ↰৻ᚑ㧘ᷡ᳓సᤨ㧚㛽ᄖᕈ㛽⡺⣲ߩ 1 ೬ᬌ଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ
⑼ቇળ㔀⹹ 2007 ᐕ㧧3 Ꮞ㧦525㧙526㧚
29㧕 ᄢ㊁⾆ᢅ㧘ᄢፉᐽม㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧚ੱᎿ㛽ࠍ↪޿ߚ⦟ᕈ㛽⣲≌ߩⴚᓟᚑ❣㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂ
ᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧4 Ꮞ㧦627㧙628㧚
30㧕 ᮮ↰ᴦ㧘ᄢ㊁⾆ᢅ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘⷏ᧄ⵨㧘ᑝἑༀା㧘᧻᳗⎇๋㧚ᄢ⣽エㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦1㧙2㧚
31㧕 ᄢፉᐽม㧘ᢧ⮮ḩ㧘ᄢ㊁⟵ᐘ㧘ᷡ᳓సᤨ㧘ᄢ㊁⾆ᢅ㧘⷏ᧄ⵨㧘㜞⷗⑲৻㇢㧘᧻᳗⎇๋㧘ᑝἑༀା㧚ᏀᲚㇱ⣲≌ߩ 1 ଀㧘᧲ᶏ㛽エㇱ⣲≌ 2007 ᐕ㧧19 Ꮞ㧦37㧙38㧚
32㧕 ᄢ㊁⟵ᐘ㧘ᐔᎹ᣿ᒄ㧘ᷡ᳓సᤨ㧚ᛥ೙Ꮺߦࠃࠅ⊒↢ߒߚᚻߦ㒢ዪߒߚ㒖ⴊᕈ᜔❗ߩ 1 ଀㧘ਛㇱᣣᧄᢛᒻᄖ
⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦861㧙862㧚
33㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯⴚ㧘ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦353㧙354㧚
34㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㗖ㇱ⣄㜑∝ᚻⴚߩว૬∝㧙೨ᣇᴺ㧘
ᓟᣇᴺߩᲧセ㧙 ਛㇱᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦579㧙580㧚
35㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
36㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘ጤ੗ᥓ቞↵㧘⑔↰┨ੑ㧚⣶ᬁᄌᕈ஥ᒗ∝ߦኻߔࠆ⚻ᬁ㑆ሹ⣶ᬁᬁ૕㑆࿕ቯ㧘ᣣᧄ⣄ᬁ⣄㜑∛ቇળ㔀⹹ 2007 ᐕ㧧18 Ꮞ㧦223㧚
37㧕 㕍ᧁ㓉᣿㧘ᷰㄝ๺ሶ㧘ਤ⠀᡽⟤㧘⮮↰㓷ᢥ㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ዊ㊁Ⴆኪ㧚functionalMRI ߇᦭↪ߢ޽ߞߚᘟᕈᦼ⣖᪪Ⴇ 㤗∽ߩ 1 ∝଀㧘J Clin Rehabil 2007 ᐕ㧧6 Ꮞ㧦558㧙561㧚
38㧕 ⍹ਣᄢ࿾㧘ᄢ㊁⾆ᢅ㧘ዊᎹኡᕶ㧘⷏ᧄ⵨㧘ᷡ᳓సᤨ㧚ᓟ㗖ㇱߦ⊒↢ߒߚ infantile fibromatosis ߩ৻଀㧘ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ㔀⹹ 2007 ᐕ㧧50 Ꮞ㧦90㧙91㧚
39㧕 ᧻ᧄ ๺㧘♻ᢙਁᱜ㧘દ⮮⧐Პ㧘⑔↰ 㓷㧘Ꮉ੗ ⽕㧘ᷡ᳓సᤨ㧚ㅘᨆᖚ⠪ߦኻߔࠆੱᎿ⢆㑐▵ᚻⴚߩ๟ⴚᦼว૬∝㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦511㧙515㧚
40㧕 㕍ᧁ㓉᣿㧘ᷰㄝ๺ሶ㧘ਤ⠀᡽⟤㧘⮮↰㓷ᢥ㧘♻ᢙਁᱜ㧘ᷡ᳓సᤨ㧘ዊ㊁Ⴆ ታ㧚Functional MRI ߇᦭↪
ߢ޽ߞߚᘟᕈᦼ⣖᪪Ⴇ 㤗∽ߩ 1 ∝଀㧘J Clin Rehabil ೎೚ 2007 ᐕ㧧16 Ꮞ㧦558㧙561㧚
41㧕 ↰ਛ 㗔㧘૒⮮ᱜᄦ㧘┻᧛ᱜ↵㧘྾ᚭ㓉ၮ㧘ᢧ⮮㇌᣿㧘ᷡ᳓ సᤨ㧘ᷡፉ ḩ㧚㑐▵࡝࠙ࡑ࠴ߦኻߔࠆ↢‛ቇ⊛⵾೷ᴦ≮ߣ࠻࡝ࡊ࠻ࡈࠔࡦઍ⻢ߦߟ޿ߡ㧘ਛㇱ࡝࠙ࡑ࠴ ೎೚ 2007 ᐕ㧧38 Ꮞ㧦12㧙13㧚
42㧕 ਭፉᵏੳ㧘⍹੗శ৻㧘ᷡ᳓సᤨ㧘૒‫ᤩᧁޘ‬㧘ጊᧄᙗม㧘ᱞౝ┨ੑ㧘ᣣᲧ㊁శ↵㧘ᬢ ਛੳ㧘ᷡ᳓ᢅੱ㧘ᄢᯅീ㧘⥓੗ᱜ᣿㧘⪉↰ ⼾㧘੹੗⑲ᴦ㧘Ᏹ↰᣽ᒄ㧘㋈ᧁ⹷㧘ᐔ᧻ື㧘⋉↰๺᣿㧘የਅ૫ผ㧘⑔↰㓷㧘਄᧛ୃ৻㧘ᷰㄝᢙੱ㧘᫪ஜᄥ㇢㧘⠀႐ℂᒾ㧘⷏ၳᒄ⸥㧚ේ⊒ᕈ㛽☻㝃∝ߦኻߔࠆ࡝࠮࠼ࡠࡀ࡯࠻ߣࡆ࠲ࡒࡦ K2
ߩ૬↪ലᨐߦ㑐ߔࠆᄙᣉ⸳౒ห⎇ⓥ㧙1 ᐕ⚻ㆊ∝଀ߩਛ㑆⸃ᨆ㧙㧘Osteoporosis Japan 2007 ᐕ㧧15 Ꮞ㧦
104㧙107㧚
43㧕 ᳗㊁ᤘੳ㧘㋈ᧁ⋥᮸㧘㊄᫪ᐽᄦ㧘⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧚ᕆᕈ㛽㜑ᕈ⊕ⴊ∛ൻቇ≮ᴺਛߦ⊒∝ߒߚ⣄ᬁ㛽㜑
Ἳߩ 1 ଀㧘ᢛᒻᄖ⑼ 2007 ᐕ㧧58 Ꮞ㧦1699㧙1702㧚
44㧕 ⚦ᳯ⧷ᄦ㧘ᷡ᳓సᤨ㧘㋈ᧁ⋥᮸㧘ችᧄ ᢘ㧘⑔↰┨ੑ㧘ጤ੗ᥓ቞↵㧚㛽☻㝃∝ᕈᬁ૕㛽᛬ߦኻߔࠆࡀࠬࡊ
ࡠࡦࠤ࡯ࡉ࡞ࠍ૶↪ߒߚ⣄ᬁ⍴❗ⴚ㧘ᣣᧄ⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪࡦቇળ⹹ 2007 ᐕ㧧6 Ꮞ㧦25㧙
28㧚
45㧕 ጊᧄ⌀↱⟤㧚࿾ၞක≮ㅪ៤ߣ↢ᵴᜰዉߩ੺౉㧘ౝಽᴲ࡮♧ዩ∛⑼ 2007 ᐕ㧧24 Ꮞ㧦32㧙37㧚
46㧕 ጊᧄ⌀↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚SMBG ࠺࡯࠲ߩ㔚ሶࠞ࡞࠹਄ߢߩㆇ↪ߪ㧫㧙⥄Ꮖⴊ♧᷹ቯེߩ࠺࡯࠲
ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߐߖࠆ⹜ߺߦߟ޿ߡᢎ߃ߡߊߛߐ޿㧙㧘⢈ḩߣ♧ዩ∛‫ޟ‬IT ߢߤߎ߹ߢࠊ߆ࠆ߆㧫‫ޠ‬
2007 ᐕ㧧6 Ꮞ㧦475㧙477㧚
47㧕 ጊᧄ⋿↱⟤㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘↰ਛ↢㓷㧘ᵻ↰ୃᏒ㧘૒ᯅᢥੳ㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰⚐㧚ጘ㒂ᄢቇ↢ߦᱤ⑼ஜᐽ⸻ᢿࠍታᣉߒߡ㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦109㧙114㧚
48㧕 ᧄᄙᕶሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘’↰ᶈ᮸㧘࿯੗↰⺈㧘ᩊ↰ᢅਯ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߦ߅ߌࠆญ⣧ߩஜᐽ⁁ᘒߣ↢ᵴ⠌ᘠߣߩ㑐ㅪߦߟ޿ߡ㧘ቇᩞ଻ஜ⎇ⓥ 2007
ᐕ㧧49 Ꮞ㧦112㧙116㧚
49㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇߩቇ↢࡮⡯ຬోຬߦᣉⴕߒߚᢝ࿾ౝో㕙⑌ᾍߦ㑐ߔࠆή⸥ฬ⥄⸥ᑼ⺞ᩏ㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦10㧙15㧚
50㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘ᱞ↰⚐㧘㤥ᧁ⊓ᔒᄦ㧚ᄢቇ⡯ຬߩ༛ᾍ⠪ࠍኻ⽎ߦታᣉߒߚ༛ᾍߩታᘒ⺞ᩏ㧙ᢝ࿾ౝో㕙⑌ᾍᣉⴕ 2 ᐕࠍ⚻ㆊߒߡ㧙㧘⑌ᾍ⑼ቇ 2007 ᐕ㧧1 Ꮞ㧦18㧙24㧚
51㧕 ⥓੗ࠆࠅሶ㧘↰ਛ↢㓷㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ஜᐽ⸻ᢿߩ⾰ߩะ਄ࠍ⋡ᜰߒߡ㧙ቇ↢ߩฃ⸻ḩ⿷ᐲߩⷰὐ߆ࠄ㧙㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦125㧚
52㧕 ૒ᯅᢥੳ㧘↰ਛ↢㓷㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ቇ↢㧘⡯ຬోຬߦᣉⴕ
ߒߚቇౝ⑌ᾍߩࠕࡦࠤ࡯࠻⺞ᩏ㧙ᢝ࿾ౝ⑌ᾍታᣉ 2 ᐕࠍ⚻ㆊߒߡ㧙㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦
149㧚
53㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᧄᄙᕶሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘⥓੗ࠆࠅሶ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ቇ↢↢ᵴߢ᳞߼ࠄࠇࠆ଻ஜ▤ℂ࠮ࡦ࠲࡯㧙ࡔࡦ࠲࡞ࡋ࡞ࠬࠨࡐ࡯࠻ߩᓎഀߦ㑐ߔࠆᬌ⸛㧙㧘Campus Health 2007㧙㧙ᐕ㧧44 Ꮞ㧦196㧚
54㧕 ᫃Ꮉᐘ਎㧘↰ਛ↢㓷㧘Ꮉፉᕺሶ㧘Ꮉㄝᢘሶ㧘૒ᯅᢥੳ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚UPIᓧὐߣ↢ᵴ⠌ᘠ⺞ᩏߩ㑐ㅪߦߟ޿ߡ㧘Campus Health 2007 ᐕ㧧44 Ꮞ㧦198㧚
55㧕 ਛ᧛ᱜ↢㧘ᷡ᳓సᤨ㧚⣶ਅ⢇∩ࠍ઻߁㛽☻㝃∝∝଀ߦኻߔࠆᣣᧄ⺆
Roland㧙Morris Disability
Questionnaire ࠍ↪޿ߚ QOL ⹏ଔ㧙ࠛ࡞ࠞ࠻࠾ࡦ⵾೷ᛩਈਅߢߩ−∩ߦ㑐ㅪߔࠆ QOL ᡷༀߦߟ޿ߡߩᬌ
⸛㧙㧘Osteoporosis Japan (೎೚) 2008 ᐕ㧧16 Ꮞ㧦207㧙215㧚
56㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻㧚ක≮ኾ㐷⡯ߩࡑࡀࠫࡔࡦ࠻ᢎ⢒ߦ߅ߌࠆ IT ᵴ↪ߩน⢻ᕈ㧘ᣂක≮
2008 ᐕ㧧35 Ꮞ㧦54㧙57㧚
57㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ዊ಴ᶈਯ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ጘ㒂ᄢቇᄢቇ↢ࡔࡦ࠲࡞ࡋ࡞ࠬ⋧⺣ߩᄌㆫߣᦨㄭߩേะ㧙ጘ㒂ᄢቇ଻ஜ▤ℂ࠮ࡦ࠲࡯ࠕࡦࠤ࡯࠻⺞ᩏ߅ࠃ߮ቇ↢ߩஜᐽ⊕ᦠ
2005(ᧄቇ⚿ᨐ)ࠃࠅ㧙㧘ጘ㒂ᄢቇකቇㇱ♿ⷐ 2008 ᐕ㧧55 Ꮞ㧦43㧙50㧚
58㧕 ጟ቟િੑ㧘ਅ↰ᶈᰵ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ࠗࡦࠬ࡝ࡦߩ቟ో▤ℂߦ㑐ߔࠆ㔚ሶࠞ࡞࠹ᯏ⢻ߩ᦭↪ᕈߣ໧㗴ὐ㧘⢈ḩߣ♧ዩ∛‫ޟ‬Chronic illness ߣߒߡߩ♧ዩ∛ߩ⥄Ꮖ▤ℂ‫ޠ‬2008 ᐕ㧧7 Ꮞ㧦28㧙35㧚
59㧕 ጊᧄ⋿↱⟤㧘Ꮉ಴㕏ᒾ㧘ᚭ⼱ℂ⧷ሶ㧘ᱞ↰⚐㧘᪢ᧄᢘᄦ㧘♿ࡁቯ଻⤿㧚ጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓߦ
߅ߌࠆ㧘♧ዩ∛∛⸻ㅪ៤ࠨࡐ࡯࠻ࠪࠬ࠹ࡓߩ⹜૞㧘⢈ḩߣ♧ዩ∛‫ޟ‬Chronic illness ߣߒߡߩ♧ዩ∛ߩ⥄Ꮖ▤ℂ‫ ޠ‬2008 ᐕ㧧7 Ꮞ㧦56㧙61㧚
60㧕 ਅ↰ᶈᰵ㧘ጟ቟િੑ㧘♿ࡁቯ଻⤿㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚㔚ሶࠞ࡞࠹ᖱႎ߆ࠄಽᨆߔࠆᄢቇ∛㒮ߩ♧ዩ∛∛᫟ᖚ⠪ߩ․ᓽಽᨆߩ⹜ⴕ㨪ᬺോࠍนⷞൻߔࠆ᦭↪ᕈߦߟ޿ߡ㨪㧘⢈ḩߣ♧ዩ∛‫ޟ‬Chronic illness ߣߒߡߩ♧ዩ∛ߩ⥄Ꮖ▤ℂ‫ ޠ‬2008 ᐕ㧧7 Ꮞ㧦89㧙93㧚
61㧕 ጊᧄ⋿↱⟤㧘ᱞ↰⚐㧘♿ࡁቯ଻⤿㧚♧ዩ∛ߩ㆙㓒∛⸻ㅪ៤ࠍᡰេߔࠆጘ㒂⋵කᏧળ∛⸻ㅪ៤ࠪࠬ࠹ࡓ᭴▽ߩႎ๔㧘ᣣᧄ㆙㓒ක≮ቇળ㔀⹹ 2008 ᐕ㧧4 Ꮞ㧦325㧙327㧚
62㧕 㐳ἑᳯ೑㧘ᓮ↰᧛⋧ᮨ㧘↰ਛ↢㓷㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ࠍኻ⽎ߦታᣉߒߚ㗡∩ታᘒ⺞ᩏ㧘ቇᩞ଻ஜ⎇ⓥ 2008 ᐕ㧧50 Ꮞ㧦264㧙269㧚
63㧕 ૒ᷰᔘᵗ㧚ࠗࡔ࡯ࠫ⼾߆ߥᅚሶ㜞ᩞ 2 ᐕ↢ߣߩ㑐ࠊࠅ́࠮࡜ࡇࠬ࠻ߣߒߡߩࠗ࠾ࠪࠛ࡯࡚ࠪࡦ́㧘ጘ㒂ᄢቇᔃℂᢎ⢒⋧⺣⎇ⓥ 2008 ᐕ㧧7 Ꮞ㧦31㧙40㧚
64㧕 ૒ᷰᔘᵗ㧘㋈ᧁჾ㧚┹ᛛ⠪ߩ⥄ᚒߩᒝߐߣ⥄ᚒႺ⇇ߩᬌ⸛́ࡠ࡯࡞ࠪࡖ࠶ࡂᴺߦࠃࠆ৻⥸ቇ↢ߣߩᲧセ߆ࠄ́㧘⥃ᐥᔃℂり૕ㆇേቇ⎇ⓥ 2008 ᐕ㧧10 Ꮞ㧦1㧙10㧚
65㧕 ↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ᵻ↰ୃᏒ㧘ጊᧄ⾆ሶ㧘ᱞ↰⚐㧘ጊᧄ⋿↱⟤㧚ᄢቇ↢ߩ߁ߟ∛ߦ㑐ߔࠆቇ⠌ᯏળߣ଻ஜ▤ℂ࠮ࡦ࠲࡯೑↪ߦ㑐ߔࠆᬌ⸛㧘Campus Health 2008 ᐕ㧧45 Ꮞ㧦295㧙297㧚
66㧕 ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧘᫃Ꮉᐘ਎㧘Ꮉፉᕺሶ㧘Ꮉㄝᢘሶ㧘ᓮ↰᧛⋧ᮨ㧘㐳ἑᳯ೑㧘ጊᧄ⾆ሶ㧘ᱞ↰⚐㧚ᱤ
⑼⋧⺣࡮⢈ḩᜰዉ࡮ቇ↢⋧⺣╬ߩᬺോ࠾࡯࠭ߩ޽ࠆቇ↢ߦ߅ߌࠆ UPI ᓧὐߩ․ᓽߦߟ޿ߡ㧘Campus Health
2008 ᐕ㧧45 Ꮞ㧦268㧙270㧚
ේ⪺㧔᰷ᢥ㧕
1㧕 Hosoe H, Miyamoto K, Wada E, Shimizu K. A surgical treatment of scoliosis in Larsen's syndrome withbilateral hip dislocation- A case report. Spine. 2006;31:E302-306.
2㧕 Morita M, Banno Y, Dohjima T, Nozawa S, Fushimi K, Fan D, Ohno T, Miyazawa K, Liu N, Shimizu K.
Ǵ-Calpain is involved in the regulation of TNF--induced matrix metalloproteinase-3 release in arheumatoid synovial cell line. Biochem Biophys Res Commun. 2006;343:937-942.
3㧕 Ohnishi K, Miyamoto K, Hashimoto K, Hosoe H, Shimizu K. Surgical Treatment for Atlantoaxial
Subluxation Associated With Mixed Connective Tissue Disease. Orthopedics. 2006;29:369-370.
4㧕 Masuda T, Miyamoto K, Shimizu K. Intramuscular hemodynamics in bilateral erector spinase muscles
in symmetrical and asymmetrical postures with and without loading. Clin Biomecha. 2006;21:245-253.
5㧕 Matsumoto K, Kamiya N, Suwan K, Atsumi F, Shimizu K, Shinomura T, Yamada Y, Kimata K,
Watanabe H. Identification and Characterization of Versican/PG-M Aggregates in Cartilage. J Biol
Chem. 2006;281:18257-18263.
6㧕 Yoshida M, Kida K, Kodama H, Itokazu M, Shimizu K. Calcitonin treatment for calcifying tendinitis of
the shoulder. J Orthopaed Traumatol. 2006;7:6-11.
7㧕 Masuda T, Miyamoto K, Hosoe H, Sakaeda H, Tanaka M, Shimizu K. Surgical treatment with spinal
instrumentation for pyogenic spondylodiscitis due to menthicillin-resistant Staphylococcus
aureus(MRSA): a report of five cases. Arch Orthop Trauma Surg. 2006;126:339-349.
8㧕 Kamiya N, Watanabe H, Habuchi H, Takagi H, Shinomura T, Shimizu K, Kimata K. Versican/PG-M
Regulates Chondrogenesis as an Extracellular Matrix Molecule Crucial for Mesenchymal
Condensation. J Biol Chem. 2006;281:2390-2400.
9㧕 Matsumoto K, Wakahara K, Sumi H, Shimizu K. Central Cord Syndrome in Patients With Klippel-Feil
Syndrome Resulting From Winter Sports. Am J Sports Med. 2006;34:1685-1689.
10㧕 Wakahara K, Matsumoto K, Sumi H, Sumi Y, Shimizu K. Traumatic Spinal Cord Injuries From
Snowboarding. Am J Sports Med. 2006;34:1670-1674.
11㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Shimizu K. The therapeutic outcome of minimally invasive
synovectomy assisted witharthroscopy in the rheumatoid knee. Mod Rheumatol. 2006;16:360-363.
12㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks: a case report. Arch Orthop Trauma Surg. 2006;127:47-50.

㧙㧙

IF 2.499

IF 2.749
IF 0.581
IF 1.642

IF 5.581

IF 0.913

IF 5.581
IF 3.397
IF 3.397

IF 0.913

13㧕 Ogawa H, Itokazu M, Ito Y, Fukuta M, Simizu K. An unusual meniscal ganglion cyst that triggered
recurrent hemarthrosis of the knee. Arthroscopy. 2006;22:455.e1-4.
14㧕 Ohara A, Miyamoto K, Naganawa T, Matsumoto K, Shimizu K. Sagittal alignment of the cervicalspine: comparison of five standard methods of measurement. Spine. 2006;31:2585-2591.
15㧕 Fushimi K, Miyamoto K, Nishimoto H, Hosoe H, Kodama H, Shimizu K. Clinical outcomes ofmultilevel anterior corpectomy and fusion as a revision surgery of the cervical spine. Report of sevencases. Spinal Cord. 2006;44:449-456.
16㧕 Sasaki T, Miyamoto K, Hosoe H, Shimizu K. Transoral Anterior Approach Used for Extensive Anterior
Decompression of C3 Vertebrae Level in a Patient with Severe Atlantoaxial Vertical Subluxation andRheumatoid Arthritis - A Case Report. Spinal Cord. 2006;44:52-55.
17㧕 Shimizu T, Miyamoto K, Masuda K, Miyata T, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-21.
18㧕 Aoki T, Terashima H, Itokazu M, Miyamoto K, Shimizu K. Stimulation of Music Prolonged
Disturbance of Consciousness Patients in Early Rehabilitation. J Saitama Kenou Rehabilitation.
2007;7:50-53.
19㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome after segmental
wire fixation and bone grafting for repair of the defects in multiple level lumbar spondylolysis. J
Spinal Disord Tech. 2007;20:521-525.
20㧕 Nagano A, Miyamoto K, Fushimi K, Hosoe H and Shimizu K. Failure of reconstruction surgery using
anterior fibular strut grafting for postlaminectomy kyphosis A case report. J Clin Neurosci .
2007;14:376-379.
21㧕 Inoue T, Miyamoto K, Kodama H, Hosoe H and Shimizu K. Total spondylectomy for treatment of asymptomatic hemangioma of the lumbar spine - A case report. J Clin Neurosci. 2007;14:806-809.
22㧕 Yamada K, Miyamoto K, Hosoe H, Mizutani M and Shimizu K. Scoliosis associated with Prader-Willi
syndrome A case report. Spine J. 2007;7:345-348.
23㧕 Miyamoto K, Shimizu K, Matsumoto S, Sumida H, Iida H and Hosoe H. Surgical treatment of scoliosis
associated with central core disease: Minimizing the effects of malignant hyperthermia withprovocation tests - Report of a case -. J Pediatric Orthop B. 2007;16:239-242.
24㧕 Shimizu T, Miyamoto K, Masuda K, Miyata Y, Hori H, Shimizu K, Maeda M. The clinical significanceof impaction at the femoral neck fracture site in the elderly. Arch Orthop Trauma Surg.
2007;127:515-521.
25㧕 Fushimi K, Nakashima S, You F, Takigawa M, Shimizu K. Prostaglandin E2 Downregulates TNF-DInduced Production of Matrix Metalloproteinase-1 in HCS-2/8 Chondrocytes by Inhibiting
Raf-1/MEK/ERK Cascade Through EP4 Prostanoid Receptor Activation. J Cell Biochem.
2007;100:783-793.
26㧕 Maehara H, Suzuki K, Sasaki T, Oshita H, Wada E, Inoue T , Shimizu K. G1-G2 Aggrecan Productthat can be Generated by M-calpain on Truncationat 709-Ala710 is Present Abundantly in Human
Articular Cartilage. J Biochem. 2007;141:469-477.
27㧕 Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, Shimizu K, Tomita K,
Yamomoto H, Tsuchiya H. Endogenous secretory receptor for advanced glycation endproducts as anovel prognostic marker in chondrosarcoma. Cancer. 2007;9:2532-2540.
28㧕 Ogawa H, Nishimoto H, Hosoe H, Suzuki N, Kanamori Y, Shimizu K. Clinical outcome aftersegmental wire fixation and bone grafting for repair of the defects in multiple level lumbar
spondylolysis. J Spinal Disord Tech. 2007;20:521-525.
29㧕 Matsumoto K, Itokazu M, Uemura S, Takigami I, Naganawa T, Shimizu K. Successful joint
arthroplasty after treatment of destructive MRSA arthritis of the knee using antibiotic-loadedhydroxyapatite blocks -a case report-. Arch Orthop Trauma Surg. 2007;127:47-50.
30㧕 S Kuriyama, Y Miwa, H Fukushima, H Nakamura, K Toda, M Shiraki, M Nagaki, M Yamamoto, E
Tomita, H Moriwaki. Prevalence of diabetes and incidence of angiopaathy in patients with chronicviral liver disease. J Clin Biochem Nutr. 2007;40:116-122.
31㧕 Hioki A, Miyamoto K, Hosoe H, Shimizu K. Two-staged decompression for thoracic paraparesis due tothe combined ossification of the posterior longitudinal ligament and the ligamentum flavum a casereport. Arch Orthop Trauma Surg. 2008;128:175-177.
32㧕 Yamamoto T,Inoue N, Miyamoto K, Sugiyama S, Nozawa S, Hosoe H, Shimizu K. Segmental wire
fixation for lumbar spondylolysis associated with spina bifida occulta. Arch Orthop Trauma Surg.
2008;128:1177-1182.
33㧕 Hashimoto K, Miyamoto K, Hosoe H, Kawai G, Kikuike K, Shimokawa K, Suzuki N, Matsuo M,
Kodama H, Shimizu K. Solitary fibrous tumor in the cervical spine with destructive vertebral
involvement:A case report and review of the literature. Arch Orthop Trauma Surg. 2008;128:1111-1116.
34㧕 Takigami I, Itoh Y, Itokazu M, Shimizu K. Radio-opaque marker of a surgical sponge appearing as an
intra-articular foreign body after total hip arthroplasty. Arch Orthop Trauma Surg.
2008;128:1167-1168.

㧙㧙

IF 2.296
IF 2.499

IF 1.578

IF 1.578

IF 0.913

IF 1.303

IF 0.801
IF 0.801

IF 0.619

IF 0.913

IF 3.381

IF 2.020

IF 4.632

IF 1.303

IF 0.913

IF 0.630

IF 0.913

IF 0.913

IF 0.913

IF 0.913

35㧕 Chi D, Miyamoto K, Hosoe H, Kawai G, Ohnishi K, Suzuki N, Sumi H, Shimizu K. Symptomatic
lumbar mobile segment with spinal canal stenosis in fused spine associated with diffused idiopathic
skeletal hyperostosis A case report. Spine J. 2008;8:1019-1023.
36㧕 Hioki A, Ohnishi K, Miyamoto K, Hosoe H and Shimizu K. Spondylolysis of the second lumbar
vertebra treated with segmental wiring and bone grafting:a case report. Orthopaedics. 2008;31:287.
37㧕 Terabayashi N, Miyamoto K, Sasaki H, Hosoe H, Shimizu K. Multiple steroid-induced vertebral
fracture with paraparesis associated with Wegener’s granulomatosis treated with posterior spinal
instrumentation. Journal of Neurological Sciences(Turkish). 2008;25:67-71.
38㧕 Hioki A, Miyamoto K, Hosoe H, Fukuta S, Shimizu K. Two-stage decompression for combined epiconus
and cauda equina syndrome due to multilevel spinal canal stenosis of the thoracolumbar spine-a casereport. Arch Orthop Trauma Surg. 2008;128:955-958.
39㧕 Kawaguchi A, Chiba K, Tanimura Y, Motohashi T, Aoki H, Takeda T, Hayashi S, Shimizu K and
Kunisada T. Isolation and characterization of Kit-independent melanocyte precursors induced in theskin of Steel factor transgenic mice. Dev Growth Differ. 2008;50:63-69.
40㧕 Shinohe R. Sato M, Takemura M, Shimizu K, Koishi H, Tanaka R, Saito K, Seishima M. Cytokine
profiles in mice with arthritis induced by anti-type Τ collagen monoclonal antibody plus
lipopolysaccharide. Japanese Journal of Clinical Chemistry. 2008;37:53-62.
41㧕 Hirakawa A, Miyamoto K, Ohno Y, Hioki A, Ogawa H, Nishimoto H, Yokoi H, Shimizu K. Two-stage(posterior and anterior) surgical treatment of spinal osteomyelitis due to antypical mycobacteria andassociated thoracolumbar kyphoscoliosis in a nonimmunocompromised patient. Spine.
2008;33:E221-224.
42㧕 Takigami I, Itokazu M, Itoh Y, Matsumoto K, Yamamoto T, Shimizu K. Limb-length measurement in
total hip arthroplasty using a calipers dual pin retractor. Bulletin of the NYU Hospital for Joint
Diseases. 2008;66:107-110.
43㧕 Matsumoto M, Chiba K, Toyama Y, Takeshita K, Seichi A, Nkamura K, Arimizu J, Fujibayashi S,
Hirabayashi S, Hirano T, Iwasaki M, Kaneoka K, Kawaguchi Y, Ijiri K, Maeda T, Matsuyama
Y,Mikami Y, Murakami H, Nagashima H, Nagata K, Nakahara S, Nohara Y, Oka S, Sakamoto K,
Saruhashi Y, Sasao Y, Shimizu K, Taguchi T, Takahashi M, Tanaka Y, Tani T, Tokuhashi Y, Uchida K,
Yamamoto K, Yamazaki M, Yokoyama T, Yoshida M,and Nishiwaki Y. Surgical results and related
factors for ossification of prosterior longitudinal ligament of the thoracic spinea multi-institutional
retrospective study. Spine. 2008;33:1034-1041. 
44㧕 Miyamoto K, Iinuma N, Ueki S, Shimizu K. Effects of abdominal belts on the cross-sectional shape ofthe trunk during intense contraction of the trunk muscles observed by computer tomography. Clin
Biomech (Bristol, Avon). 2008;23:1220-1226.

IF 0.581

IF 0.913

IF 1.908

IF 2.499

IF 2.499

IF 1.6424㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᬁᩇ㕢Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧1,300 ජ౞(500㧦800 ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧 (⽷)ጘ㒂⋵ஜᐽ㐳ኼ⽷࿅⎇ⓥ੐ᬺഥᚑ㊄㧦㕍ᐕᦼߦ߅ߌࠆ⢈ḩ⠪ኻ╷ߩߚ߼ߩ⺞ᩏ⎇ⓥ㧧ᐔᚑ 17㧙18 ᐕᐲ㧧700 ජ౞(350㧦350 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦ᱞ↰⚐㧘↰ਛ↢㓷㧘ᄢᐸᔒ㊁㧧⑼ቇ⎇ⓥ⵬ഥ㊄ၮ⋚⎇ⓥ(C)㧦
ᄢቇ↢ߩ⢈ḩߣ૕⾰ߩ㑐ଥ⺞ᩏ㧦዁᧪ߩ↢ᵴ⠌ᘠ∛ߩ⊒∝ࠍ੍㒐ߔࠆߚ߼ߦ㧧ᐔᚑ 17㧙19 ᐕᐲ㧧
3,640 ජ౞(1,200㧦1,400㧦1,040 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦Ꮉጯ⥜ᔒ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ஜᐽ⑼ቇ࡮଻ஜ૕
⢒(ోቇ౒ㅢᢎ⢒)㧧ᐔᚑ 18 ᐕᐲ㧧500 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂ᄢቇᛛⴚ੤ᵹ⎇ⓥળᵴേᡰេ⾌㧦⥄Ꮖⴊ♧᷹ቯ୯ࠍ㔚ሶࠞ࡞࠹਄ߢ
ㆇ༡ߔࠆࠪࠬ࠹ࡓ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧150 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂⋵කᏧળൕോකㇱળ⎇ⓥഥᚑ㊄㧦ጘ㒂⋵ߩᄢቇ↢ߩ⢈ḩߦ㑐ߔࠆታᘒ⺞ᩏ㧙዁᧪ߩஜᐽ㓚ኂࠍ㒐ߋߚ߼ߩ㕍ᐕᦼߩஜᐽࠨࡐ࡯࠻ߪߤ߁޽ࠆߴ߈߆㧙㧧ᐔᚑ 18 ᐕᐲ㧧300ජ౞
7㧕 ✚᜝੐ᬺઍ⴫⠪㧦ጊᧄኈᱜ(ᄢ㒋ᄢቇ)㧘✚᜝೽ઍ⴫⠪㧦ጊᧄ⋿↱⟤(ጘ㒂ᄢቇ)㧧⎇ⓥᜂᒰ⠪㧦♿ࡁቯ଻⤿㧘㜞Ⴆ⋥⢻㧘᪢᧛዁ᄦ㧦⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑࡊࡠࠫࠚࠢ࠻‫ޠ‬ක≮⚻༡ੱ᧚⢒ᚑࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 18 ᐕᐲ㧧5,000 ජ౞8㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦♿ࡁቯ଻⤿㧘ᱞ↰⚐㧧ጘ㒂ᄢቇ↥ቭቇⲢว࠮ࡦ࠲࡯㊀ὐ⎇ⓥഥᚑ㧦⥄Ꮖ᷹ቯஜᐽ▤ℂ࠺࡯࠲ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߔࠆࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18㧙20 ᐕᐲ㧧
2,150 ජ౞(1,000㧦650㧦500 ජ౞)
9㧕 ⎇ⓥઍ⴫⠪㧦ਛ᧛⠹ਃ(᧲੩ᄢቇ)㧘⎇ⓥಽᜂ⠪㧦ᷡ᳓సᤨ㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄㧦⣄ᩇ㕢Ꮺ㛽㧙㧙ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧1,000 ජ౞
10㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧(⽷)ጘ㒂⋵ஜᐽ㐳ኼ⽷࿅⎇ⓥ੐ᬺഥᚑ㊄㧦㕍ᐕᦼߦ߅ߌࠆ⢈ḩ⠪ᷫዋߩ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19 ᐕᐲ㧧350 ජ౞
11㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺߦ߅ߌࠆࠤ࡯ࠬࠬ࠲࠺ࠖᢎ᧚㐿⊒ࡊࡠࠫࠚࠢ࠻‫ޠ‬㧦㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ ක≮⚻༡ᢎ⢒ታ⸽ࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 19 ᐕᐲ㧧2,380ජ౞
12㧕 ⎇ⓥઍ⴫⠪㧦ㅦ᳓ᖗ㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ᐔᚑ 19 ᐕᐲ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒́ࡑ࡞࠴ࡕ࡯࠳࡞ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒́㧧ᐔᚑ 19 ᐕᐲ㧧2,820 ਁ౞
13㧕 ⎇ⓥઍ⴫⠪㧦↰ਛ↢㓷㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(⎇ⓥ)㧦ᄢቇ↢ߩࡔࡦ࠲࡞ࡋ
࡞ࠬߦ㑐ߔࠆㅊ〔⺞ᩏг♖␹ක≮ᯏ㑐೑↪ߣୃቇ⁁ᴫߦߟ޿ߡг(ⅣႺ㧘ᢎ⢒)㧧ᐔᚑ 19 ᐕᐲ㧧1,000ජ౞
14㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧘⎇ⓥಽᜂ⠪㧦Ꮉጯ⥜ᔒ↵㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(ᢎ⢒)㧦ஜᐽ⑼ቇ࡮ోࠬࡐ
࡯࠷Ṷ⠌(ోቇ౒ㅢᢎ⢒)㧧ᐔᚑ 19㧙20 ᐕᐲ㧧1,000 ජ౞(500㧦500 ජ౞)
15㧕 ੐ᬺផㅴઍ⴫⠪㧦᫪⑲᮸㧘੐ᬺផㅴ⽿છ⠪㧦ฎ↰ༀષ㧘ታⴕᆔຬ㧦ጊᧄ⋿↱⟤㧘↰ਛ↢㓷㧧ᣂߚߥ␠ળ⊛࠾࡯࠭ߦኻᔕߒߚቇ↢ᡰេࡊࡠࠣ࡜ࡓ㧦↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧧ᐔᚑ
19㧙20 ᐕᐲ㧧48,972 ජ౞
16㧕 ⎇ⓥઍ⴫⠪㧦೨↰೑ਯ(㒋ධᄢቇ⚻༡ᖱႎቇㇱ)㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(A)㧦ක≮⚵❱ߢ៤Ꮺ┵ᧃߩᵴ↪ߦࠃࠆක≮࡝ࠬࠢ㒐ᱛߩߚ߼ߩ⎇ⓥ㧧ᐔᚑ 19㧙21 ᐕᐲ㧧15,860
ජ౞
17㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄ⋿↱⟤㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌(࿾ၞㅪ៤㧦৻⥸)㧦ጘ㒂⋵ߦ߅ߌࠆᄢቇ଻ஜ▤ℂᬺോ
ߥࠄ߮ߦ⎇ⓥߩ⊒ዷࡊࡠࠫࠚࠢ࠻㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞
18㧕 ਥ⎇ⓥᜂᒰ⠪㧦ㅦ᳓ᖗ㧘ಽᜂ⎇ⓥ⠪㧦ጊᧄ⋿↱⟤㧧⽷࿅ᴺੱጘ㒂⋵⎇ⓥ㐿⊒⽷࿅ᐔᚑ 20 ᐕᐲ⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ㧦ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧙ࡑ࡞࠴ࡕ࡯࠳࡞ක≮⸻ᢿᡰេࠪࠬ࠹ࡓߩ㐿⊒㧙㧧ᐔᚑ 20 ᐕᐲ㧧29,819 ජ౞
19㧕 ⎇ⓥઍ⴫⠪㧦ᱞ↰⚐㧘⎇ⓥಽᜂ⠪㧦ጊᧄ⋿↱⟤㧧ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(ᓴⅣེ∔ᖚ╬↢ᵴ⠌ᘠ∛ኻ╷✚ว⎇ⓥ੐ᬺ)㧦ᓴⅣེ࡝ࠬࠢߣ⠴♧⢻㓚ኂߩല₸⊛ߥஜ⸻ࡑ࡯ࠞ࡯ߩត⚝㧧ᐔᚑ 20㧙23 ᐕᐲ㧧18,945 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ጊᧄ⋿↱⟤㧦⥄Ꮖ᷹ቯஜᐽ▤ℂ࠺࡯࠲ࠍ㔚ሶࠞ࡞࠹਄ߢㆇ↪ߔࠆࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧
1,000 ජ౞㧦PBJ ᩣᑼળ␠3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷡ᳓సᤨ㧦
1㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)2㧕 ᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ 5 ᦬㨪⃻࿷)3㧕 member scientific committee of inspiration 6th INSPIRATION MEETING(2006.10.13~10.14)
4㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 19 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 18 ᐕ 10 ᦬ 18 ᣣ)
5㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓઍ⴫਎⹤ੱ(ᐔᚑ 19 ᐕ 1 ᦬ 20 ᣣ)
6㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⹏⼏ຬ(ᐔᚑ 19 ᐕ 4 ᦬㨪⃻࿷)7㧕 ᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬)
8㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળᜰዉක೙ᐲᬌ⸛ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬)
9㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)10㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)11㧕 ᣣᧄ⣄ᬁ⣄㜑∛ቇળ⽷ോᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 6 ᦬㨪⃻࿷)㧙㧙

12㧕 Fighting Vascular Events in Gifu ᐔᚑ 19 ਎⹤ੱ(ᐔᚑ 19 ᐕ 6 ᦬ 9 ᣣ)
13㧕 ╙ 37 ࿁ᣣᧄ⣄ᬁ⣄㜑∛ቇળࡊࡠࠣ࡜ࡓᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬㨪ᐔᚑ 20 ᐕ 4 ᦬)
14㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 20 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 19 ᐕ 10 ᦬ 24 ᣣ)
15㧕 ╙ 1 ࿁᧲ᶏ㕒⣂ⴊᩖႧᩖ∝(VTE)੍㒐ࡀ࠶࠻ࡢ࡯ࠢࠪࡦࡐࠫ࠙ࡓ਎⹤ੱ(ᐔᚑ 19 ᐕ 12 ᦬ 8 ᣣ)
16㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)17㧕 ᐔᚑ 20 ᐕᐲᣣᧄᚻߩᄖ⑼ቇળ୶ℂᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 5 ᦬㨪⃻࿷)18㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╭㛽ᩰ♽ TAG ⚵❱ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 11 ᦬㨪⃻࿷)19㧕 ᣣᧄᢛᒻᄖ⑼ቇળ╙ 21 ࿁ኾ㐷ක⹜㛎ญ㗡⹜㛎ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬㨪⃻࿷)ጊᧄ⋿↱⟤㧦
1㧕 ᣣᧄౝ⑼ቇળ᧲ᶏ࿾ᣇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄౝಽᴲቇળઍ⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ∛ᘒᩕ㙃ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄᴤൻቇળ᧲ᶏᡰㇱᏱછᐙ੐(㨪⃻࿷)6㧕 ᣣᧄ♧ዩ∛ቇળቇⴚ⹏⼏ຬ(㨪⃻࿷)7㧕 ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ)
8㧕 ᴤൻቇળ⻠Ṷળ‫ޟ‬ᯏ⢻ᕈ㘩ຠߩ⑼ቇߣዷᦸ‫ޠ‬ᣣᧄᴤൻቇળᜂᒰᐙ੐(ᐔᚑ 18 ᐕᐲ)
9㧕 ᣣᧄ㕒⣂⚻⣺ᩕ㙃ቇળ TNT ጘ㒂⎇ୃળታⴕᆔຬ(ᐔᚑ 19 ᐕᐲ)
10㧕 ᐔᚑ 20 ᐕᐲో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏർ㒽࿾ᣇㇱળታⴕᆔຬ(ᐔᚑ 20 ᐕᐲ)
11㧕 ో࿖ᄢቇ଻ஜ▤ℂ⎇ⓥળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)↰ਛ↢㓷㧦
1㧕 ᐔᚑ 18 ᐕᐲ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬ㐳(ᐔᚑ 18 ᐕᐲ)
2㧕 ᐔᚑ 19 ᐕᐲ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬ(ᐔᚑ 19 ᐕᐲ)
3㧕 ᐔᚑ 20 ᐕᐲో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏർ㒽࿾ᣇㇱળታⴕᆔຬ(ᐔᚑ 20 ᐕᐲ)
4㧕 ᐔᚑ 20 ᐕᐲࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળㆇ༡ᆔຬ(ᐔᚑ 20 ᐕᐲ)૒ᷰᔘᵗ㧦
1㧕 ᣣᧄ⥃ᐥᔃℂり૕ㆇേቇળ╙ 11 ࿁ᄢળታⴕᆔຬ(ᵿ᧻ᄢቇ)(ᐔᚑ 19 ᐕ 1 ᦬㨪ᐔᚑ 20 ᐕ 1 ᦬)
2㧕ቇળ㐿௅ᷡ᳓సᤨ㧦
1㧕 ╙ 8 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 7 ᦬㧘ጘ㒂)2㧕 ╙ 9 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)
3㧕 ╙ 10 ࿁ጘ㒂ᢛᒻᄖ⑼තᓟᄐᦼ࠮ࡒ࠽࡯2008(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷡ᳓సᤨ㧦1㧕 ጘ㒂⋵කᏧળஜᐽࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)2㧕 ጘ㒂⋵ᄖ்ᢇ๮ᢇᕆ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⃻ޟ‬ઍߩ㜞ᐲᄖ்ක≮‫ޠ‬ᐳ㐳)3㧕 ᴒ✽⣶∩࡮ਅ⢇∩ࡈࠜ࡯࡜ࡓ 2006(ᐔᚑ 18 ᐕ 1 ᦬㧘ᴒ✽㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)
4㧕 ችፒ⋵⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 2 ᦬㧘ችፒ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)
5㧕 ╙ 16 ࿁⑔ፉ⋵ᢛᒻᄖ⑼කߩ㓸޿(ᐔᚑ 18 ᐕ 2 ᦬㧘⑔ፉ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁࠗࡦࠬ࠻࠘࡞ࡔࡦ࠹࡯࡚ࠪ
ࡦߦࠃࠆᄌᒻ⍶ᱜ‫ޠ‬Ṷ⠪)
6㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓ in ᾢᧄ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)7㧕 ጘ㒂⋵⥃ᐥᢛᒻᄖ⑼කળ⻠Ṷળ(ᐔᚑ 18 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ዊఽߩ⣄ᩇᄌᒻ‫ޠ‬Ṷ⠪)㧙㧙8㧕 ╙ 392 ࿁ጤᚻᢛᒻἴኂᄖ⑼ᙣ⺣ળ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጤᚻ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߦ߅ߌࠆ⣶ᬁಽ㔌∝ߩᚻⴚ‫ޠ‬Ṷ⠪)9㧕 ╙ 35 ࿁㐿᡼ဳ∛ᐥࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 18 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)10㧕 ╙ 79 ࿁ᣣᧄᢛᒻᄖ⑼ቇળቇⴚ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘␹ᄹᎹ㧘ᢎ⢒⎇ୃ⻠Ṷ‫ޟ‬⢋ߎࠅߩකቇ‫ޠ‬ᐳ㐳)11㧕 ╙ 8 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᒻᕈ㑐▵∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)12㧕 ⣶∩࠮ࡒ࠽࡯in ၔධ(ᐔᚑ 18 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
13㧕 ⟲㚍⋵⣶࡮⿷ߩߒ߮ࠇ∩ߺ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 6 ᦬㧘⟲㚍㧘․೎⻠Ṷ‫ޟ‬⣶ㇱᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)
14㧕 ╳ᓟ⥃ᐥᢛᒻᄖ⑼කળቇⴚ⻠Ṷળ(ᐔᚑ 18 ᐕ 7 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)15㧕 ╙ 33 ࿁ࠬࡐ࡯࠷කቇ⎇ୃળ(ᐔᚑ 18 ᐕ 8 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣄ᩇ㧘⢷࡮⣶ᬁߩᄖ்ߣ㓚ኂ‫ޠ‬Ṷ⠪)
16㧕 ⣶∩࡮ਅ⢇∩∔ᖚࡈࠜ࡯࡜ࡓᾢᧄ(ᐔᚑ 18 ᐕ 9 ᦬㧘ᾢᧄ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)17㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈ⣄ᬁ㛽᛬ߩᴦ≹ㆊ⒟߆
ࠄߺߚᚢ⇛⊛଻ሽ࡮ᚻⴚᴦ≮ߩታ㓙ߣዷᦸ‫ޠ‬ᐳ㐳)18㧕 㛽☻㝃∝ᦨᣂ⻠Ṷળ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߩࠣࡠ࡯ࡃ࡞ࠬ࠲ࡦ࠳࡯࠼ߣᚒ࿖
ߩ⃻⁁‫ޠ‬ᐳ㐳)
19㧕 ጘ㒂⋵⣶∩ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)20㧕 ╙ 107 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘‫ޟ‬㛽☻㝃∝ᕈ࿶ㄼ㛽᛬ߦኻߔࠆᴦ
≮‫ޠ‬ᐳ㐳)21㧕 㒋␹ LCS ࡈࠜ࡯࡜ࡓ(ᐔᚑ 18 ᐕ 10 ᦬㧘౓ᐶ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)22㧕 ╙ 5 ࿁ጘ㒂࡝ࡂࡆ࡝࠹࡯࡚ࠪࡦ⎇ⓥળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫╭ޟ‬ജჇᒝലᨐߩࠛࡆ࠺ࡦ
ࠬ‫ޠ‬ᐳ㐳)23㧕 ╙ 87 ࿁๺᱌ጊ⥃ᐥᢛᒻᄖ⑼කળ⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ
⠪)24㧕 ╙ 34 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᗲ⍮㧘․೎⻠Ṷ‫ޟ‬⢆㑐▵ߣ⣄ᬁߦ߅ߌࠆᚻ
ⴚᚻᛛߩᎿᄦߣታ㓙‫ޠ‬ᐳ㐳)25㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 12 ᦬㧘੩ㇺ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)26㧕 ⣶∩∔ᖚ࠮ࡒ࠽࡯2006(ᐔᚑ 18 ᐕ 12 ᦬㧘ṑ⾐㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)27㧕 ╙ 8 ࿁ Latest Orthopedics ⎇ⓥળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ጟጊ㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)28㧕 ╙ 166 ࿁⑔ጊᄖ⑼ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)29㧕 ╙ 5 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ߦ࡞࡯ࡎ࠻࠶ࡇޟ‬፰ࠄߥ޿⿷∔ᖚ࡮ᄖ்ߩ⷗ᣇ‫ޠ‬ᐳ㐳)30㧕 ╙ 6 ࿁ጘ㒂㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪ߦ߅ߌࠆ᦯⮎ᜰዉߩታ〣㨪㛽☻㝃∝ᴦ≮⮎ࠍਛᔃߦ㨪‫ޠ‬ᐳ㐳)31㧕 㖧ᣣ⣄ᬁᄖ⑼ᙣ⹤ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㖧࿖ߦ߅ߌࠆ⣄ᬁᄖ⑼࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)32㧕 2 ᦬ౝ⑼ળ(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)33㧕 ╙ 5 ࿁৾㓊 LCS ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)34㧕 ╙ 3 ࿁ጘ㒂ㆇേེ㩖ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 2 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣣᏱㆣㆄߔࠆエㇱ⣲≌㧙⸻≮ߩⷐὐߣ⋤ὐ㧙‫ޠ‬ᐳ㐳)35㧕 ವ㙚ᢛᒻᄖ⑼ળቇⴚ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ವ㙚㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)36㧕 ╙ 10 ࿁ጘ㒂⣄ᬁ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣄ᬁ㛽㜑Ἳߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)37㧕 Medical Tribune ࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)38㧕 ࡊ࡜ࠗࡑ࡝࡮ࠤࠕ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒ㧘⸻ᢿߣᴦ≮㧙⸻ᢿࠨࡐ࡯࠻࠷࡯࡞ࠍ฽߼ߡ㧙‫ޠ‬Ṷ⠪)39㧕 ⥄ォゞߦࠃࠆஜᐽߠߊࠅ⻠Ṷળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥄ޟ‬ォゞߣஜᐽ‫ޠ‬Ṷ⠪)40㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∔ᖚߩ∛⸻ㅪ៤㧙ߚ߆߇⢋ߎࠅ㧘ߐࠇߤ⢋ߎࠅ㧙‫ޠ‬ᐳ㐳)41㧕 ╙ 4 ࿁ጘ㒂ㆇേེࡊ࡜ࠗࡑ࡝࡯ࠤࠕ࡮࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 3 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩⸻ᢿߩ⪭ߣߒⓣ‫ޠ‬ᐳ㐳)42㧕 ╙ 108 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ޟ‬਄૏㗖ᬁㇱ்㧙㧙∛ߩ⸻≮ߩⷐὐ‫ޠ‬ᐳ㐳)43㧕 ⠀ፉ㇭ࡔ࠺ࠖࠞ࡞࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫⥸৻ޟ‬ౝ⑼ක߇⍮ߞߡ߅߈ߚ޿⣶∩ߩ⸻ᢿᴦ≮‫ޠ‬Ṷ⠪)44㧕 ╙ 6 ࿁߮ࠊߎࠬࡐ࡯࠷㓚ኂࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 4 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ‫ޟ‬⣶ߩ∩ߺߣࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)45㧕 ࠪࠞࠧ㨯ጘ㒂 ⣄ᬁ⣄㜑∛࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 4 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᄌᕈᬁ㑆᧼ߩᴦ≮ ☨࿖ߢߩᦨㄭߩ⹤㗴߆ࠄ‫ޠ‬ᐳ㐳)46㧕 ╙ 9 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫࠷࡯ࡐࠬ⤒ޟ‬㓚ኂᴦ≮ߩ࠻ࡇ࠶ࠢࠬ‫ޠ‬ᐳ㐳)47㧕 Inspiration Asia(2007.06㧘Bali㧘Long term complications after cervical fusion; chairperson)48㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝⸻ᢿߩⷞὐ߆ࠄߺߚ㧘ABI ߩᝒ߃ᣇ‫ޠ‬ᐳ㐳)49㧕 Fighting Vascular Events in Gifu 2007(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬PAD ߦኻߔࠆᄖ⑼ᴦ≮ᚢ⇛㧙ઁ⑼ߣߩㅪ៤ߦࠃࠆ integrated therapy㧙‫ޠ‬ᐳ㐳)50㧕 ╙ 63 ࿁⷏ᣣᧄ⣄ᬁ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘⑔ጟ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ஥ᒭ∝ߩᚻⴚ‫ޠ‬Ṷ⠪)51㧕 ጘ㒂 Biological ⎇ⓥળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ᣂߒ޿ RA ᴦ≮ߩน⢻ᕈ㧙↢‛ቇ⊛⵾೷ߣエ㛽⎕უ㧙‫ޠ‬ᐳ㐳)52㧕 ╙ 7 ࿁ ATST ࡒ࡯࠹ࠖࡦࠣ(ᐔᚑ 19 ᐕ 6 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᄌᕈ∔ᖚ߳ߩࡠ࡯ࡊࡠࡈࠔࠗ࡞
ࠪࠬ࠹ࡓߦߟ޿ߡ‫ޠ‬ᐳ㐳)53㧕 The 17th Korean-Japanese Combined Orthpaedic Symposium(2007.07, Soul, Free paper
12:Spine 1; chairperson)
54㧕 ᄢಽ⣶ㇱ⣄ᩇ▤⁜⓰∝ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 7 ᦬㧘ᄢಽ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)55㧕 ጘ㒂㛽☻㝃∝ᴦ≮⎇ⓥળ․೎⻠Ṷળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ਛਅ૏㗖ᬁߩ೨ᣇᚻⴚ‫ޠ‬Ṷ
⠪)56㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08, Morocco, Surgical treatment for spondylolysis in young
athletes; Lecturer)
57㧕 SICOT ࿖㓙ᢛᒻᄖ⑼ቇળ(2007.08, Morocco, Session 05: Spine degenerative; chairperson)
58㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬㜞㦂⠪㗖㜑∝ߩ∛ᘒ߅ࠃ߮೨ᣇ㒰࿶࿕ቯⴚߩᚑ❣-dynamic plate ߩ᦭↪ᕈߦߟ޿ߡ-‫ޠ‬ᐳ㐳)59㧕 ╙ 14 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬ABC 㗖ᬁ࠳ࠗ࠽ࡒ
࠶ࠢࡊ࡟࡯࠻ߩᚻⴚᚻᛛߩ⚫੺ߣᵈᗧὐ(ࡂࡦ࠭ࠝࡦ࠮࠶࡚ࠪࡦ B)‫ޠ‬ᐳ㐳)60㧕 ࠝࠬ࠹ࠝࡐࡠ࡯ࠪࠬ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 9 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ߦ઻߁㛽᛬ߩ੍㒐‫ޠ‬ᐳ㐳)61㧕 ╙ 109 ࿁ᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄹ⦟㧘․೎⻠Ṷ‫ޟ‬ᄢ੽࠮ࡒ࠽࡯9 ⣶∩ᴦ≮ Up to Date 㧙⣶ㇱ⣄ᩇ▤⁜⓰∝ࠍਛᔃߦ㧙‫ޠ‬ᐳ㐳)62㧕 ၯ₹⣶∩ࡈࠜ࡯࡜ࡓ 2007(ᐔᚑ 19 ᐕ 10 ᦬㧘ᎹญᏒ㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)63㧕 6th Combined Meeting of Orthopaedic Reseach Societies(2007.10, Hawaii, Session 22:
Intervertebral Disc; chairperson)64㧕 ╙ 36 ࿁᧲ᶏ࿾඙ᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫ޟ‬⣶ᬁᬁ㑆᧼㓚ኂߩၮ␆ߣ⥃ᐥ‫ޠ‬ᐳ㐳)65㧕 㛽☻㝃∝ࡈࠜ࡯࡜ࡓ(ᐔᚑ 19 ᐕ 11 ᦬㧘⑔੗㧘․೎⻠Ṷ‫ޟ‬㛽☻㝃∝ᕈᬁ૕㛽᛬ߩᚻⴚ‫ޠ‬ᐳ㐳)66㧕 ᐔᚑ 19 ᐕᐲ╙ 4 ࿁᧲੩ㇺ⥃ᐥᢛᒻᄖ⑼කળ⛔ว⎇ୃળ(ᐔᚑ 19 ᐕ 11 ᦬㧘᧲੩㧘․೎⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)67㧕 ASEAN OA27 VOA06 SSHV12(2007.12, Vietnam, Two staged(posterior and anterior) surgicaltreatment for pyogenic abd tuberculotic spondylitis; Lecturer)
68㧕 ╙ 110 ࿁ਛㇱᣣᧄᢛᒻᄖ⑼ἴኂᄖ⑼ቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 4 ᦬㧘ᄢᵤ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩ∛ᘒߣᴦ≮‫ޠ‬ᐳ㐳)69㧕 ⼾↰ട⨃ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 4 ᦬㧘⼾↰㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)70㧕 ␹ᄹᎹ LCS ࡈࠜ࡯࡜ࡓ 2008(ᐔᚑ 20 ᐕ 4 ᦬㧘ᮮᵿ㧘⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ⁜⓰∝ߩᴦ≮‫ޠ‬Ṷ⠪)71㧕 ╙ 14 ࿁ጊญ⋵⣶∩⎇ⓥળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጊญ㧘․೎⻠Ṷ‫ޟ‬⣶ㇱ⣄ᩇ▤⁜⓰∝ߩᚻⴚ⊛ᴦ≮‫ޠ‬Ṷ⠪)72㧕 ╙ 10 ࿁ጘ㒂ᄢቇᢛᒻᄖ⑼ᢎ⢒⎇ୃળ(ᐔᚑ 20 ᐕ 5 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬਄⢇ߩ⛉ᛗᕈᧃ᪳␹⚻㓚ኂߦߟ޿ߡ‫ޠ‬ᐳ㐳)73㧕 ጘ㒂㛽☻㝃∝࡝ࡃ࡯ࠨࠗ࠼ࠞࡦࡈࠔ࡟ࡦࠬ(ᐔᚑ 20 ᐕ 6 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬㜞㦂⠪ߩ㛽᛬੍㒐ߣォୟ㧙㧙੍‫ޠ‬ᐳ㐳)74㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Symposium 2㧦Cervicalspondylotic myelopethy; chairperson)
75㧕 APOA,the Spine and Pediatric Sections 2008(2008.06, Jeju Island, Surgical treatment forspondylolysis in young Athletes. Lecture)76㧕 The 18th Japanese-Korean Combined Orthopaedic Symposium(2008.07, Nagasaki, Symposium
1:spondyloarthropathy following hemodialysis. chairperson)77㧕 ጘ㒂⋵ VTE ੍㒐࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫ޟ‬ᒰ㒮ߦ߅ߌࠆࡈࠜࡦ࠳ࡄ࡝࠿ࠢࠬߩ૶↪⚻㛎‫ޠ‬‫ޟ‬ਅ⢇ᢛᒻᄖ⑼๟ⴚᦼ੍㒐ߩᦨᣂࠬ࠻࡜࠹ࠫ࡯‫ޠ‬ᐳ㐳)78㧕 ᄖ⑼කㇱળ࡮ഭἴᜰቯකㇱળวห⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣄ᬁߩࠬࡐ࡯࠷㓚ኂ‫ޠ‬Ṷ⠪)ᢎ⢒⎇ୃ⻠Ṷ
‫ޟ‬Current status79㧕 ╙ 41 ࿁ᣣᧄᢛᒻᄖ⑼ቇળ㛽࡮エㇱ⣲≌ቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ᵿ᧻㧘
of spinal tumors in the USA‫ޠ‬ᐳ㐳)80㧕 ᢛᒻᄖ⑼ቇⴚ⻠Ṷળ(ᐔᚑ 20 ᐕ 7 ᦬㧘㇊ⷓ㧘⻠Ṷ‫ޟ‬⣄ᬁᗵᨴ∝ߩ⸻ᢿߣᴦ≮‫ޠ‬Ṷ⠪)81㧕 ጘ㒂⋵࿖᳃ஜᐽ଻㒾ㆇ༡ද⼏ળળ㐳ㅪ⛊ද⼏ળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬⣶∩㧙ㆇേེߩ↢ᵴ⠌ᘠ∛‫ޠ‬Ṷ⠪)82㧕 ╙ 7 ࿁የᒛ↢ᵴ⠌ᘠ∛⎇ⓥળ(ᐔᚑ 20 ᐕ 8 ᦬㧘ฬฎደ㧘⻠Ṷ‫ޟ‬⣶∩ᴦ≮ߩ∛⸻ㅪ៤‫ޠ‬Ṷ⠪)83㧕 ᄢ↰⣶ㇱ⣄ᩇ▤⁜⓰∝࠮ࡒ࠽࡯2008(ᐔᚑ 20 ᐕ 8 ᦬, ᄢ↰(Korea), Hospital-clinic partership in low
back pain practice. Lecture)84㧕 SICOT/SIROT2008 XX Φ
Triennial World Congress (2008.08, Hong Kong, Free
Papers-Spine:Cervical Spine Τ. chairperson)85㧕 ∩ߺߩᴦ≮ࡈࠜ࡜ࡓ in ጘ㒂(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⣶∩ߩ∛ᘒߣᴦ≮㧙ᣂߒ޿᭎ᔨߣᚢ⇛㧙‫ޠ‬Ṷ⠪)86㧕 ߉߰㊄⪇ጊᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ᢛᒻᄖ⑼කߩ⍮ߞߡ߅ߊߴ߈ක≮⸷⸩ߣ࡝ࠬࠢࡑࡀࠫࡔࡦ࠻ߩ⍮⼂㧙ᢛᒻᄖ⑼කߣᖚ⠪ߩ቟ోߣ቟ᔃߩߚ߼ߦ㧙‫ޠ‬ᐳ㐳)87㧕 ╙ 6 ࿁ᢛᒻᄖ⑼㐳⦟࡝ࡃ࡯ࠨࠗ࠼ࡈࠜ࡯࡜ࡓ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬⢋↲Ꮺ⣲≌ߩౣᑪߣᯏ
⢻‫ޠ‬ᐳ㐳)88㧕 ╙ 15 ࿁ᣣᧄ⣄ᬁ࡮⣄㜑␹⚻ᚻⴚᚻᛛቇળቇⴚ㓸ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ᄢᵤ㧘․೎⻠Ṷ‫ޟ‬Percutaneousvertebroplasty‫ޠ‬ᐳ㐳)89㧕 ╙ 42 ࿁ᣣᧄ஥ᒭ∝ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ᄹ⦟㧘⻠Ṷ‫ޟ‬஥ᒗ∝ᴦ≮ߩࠦ࠷ ᚻⴚ(೨ᣇᴺ)‫ޠ‬Ṷ⠪)90㧕 8th Inspiration Meeting(2008.10~11, Rome, Round-table discussionn of clinical cases : Anteriorstabilization of degenerative cervical spinal lesions. chairperson )91㧕 ╙ 43 ࿁᧲ᶏធ㛽ቇળ࡮╙ 90 ࿁ਛㇱធ㛽ቇળ(ᐔᚑ 20 ᐕ 11 ᦬㧘⠀ፉ㧘․೎⻠Ṷ‫ޟ‬㗖ᬁ∝㧘OPLL ߩᚻⴚᴦ≮‫ޠ‬Ṷ⠪)92㧕 ฬᏒᄢᢛᒻᄖ⑼࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 12 ᦬㧘ฬฎደ㧘․೎⻠Ṷ‫࠷࡯ࡐࠬޟ‬ㆬᚻߩ⣶ᬁಽ㔌∝‫ޠ‬Ṷ⠪)93㧕 ଻㒾⸻≮ߦ㑐ߔࠆ⻠⠌ળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ጘ㒂㧘⻠Ṷ‫଻ޟ‬㒾කߣ⸻≮ႎ㈽ߩክᩏ‫ޠ‬ᐳ㐳)ጊᧄ⋿↱⟤㧦
‫♧ޟ‬ዩ∛੍㒐ߩ㊀ⷐᕈߦߟ޿ߡ‫ޠ‬Ṷ⠪)1㧕 ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂㧘
2㧕 㜞ᐲක≮ࠦࡦ࠰࡯ࠪࠕࡓ(ᐔᚑ 18 ᐕ 2 ᦬㧘ᄢ㒋㧘‫ࡓ࡯࠴ޟ‬ක≮ߣක≮ࡕ࠺࡞㧙♧ዩ∛⸻≮ࡕ࠺࡞‫ޠ‬Ṷ⠪)‫♧ޟ‬ዩ∛ߩᩕ㙃ᜰዉࠍߤ߁⚵ߺ┙ߡࠆ߆‫ޠ‬Ṷ⠪)3㧕 ጘ㒂⋵ᩕ㙃჻ળ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛੍㒐ߦะߌߚขࠅ⚵ߺߦߟ޿ߡ‫ޠ‬Ṷ⠪)
4㧕 ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂㧘
5㧕 ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘㊄ᴛ㧘‫ࠬࡄࡦࡖࠠޟ‬ౝ⑌ᾍ 2ᐕࠍ⚻ㆊߒߡ㧙⃻⁁ߣ⺖㗴㧙‫ޠ‬Ṷ⠪)‫♧ޟ‬ዩ∛ߩว૬∝ߣߘߩ੍㒐࡮ᴦ≮‫ޠ‬Ṷ⠪)6㧕 ጘ㒂⋵ᩕ㙃჻ળ(ᐔᚑ 19 ᐕ 8 ᦬㧘ጘ㒂㧘
7㧕 ᐔᚑ 19 ᐕᐲ࿖଻੐ᬺផㅴ࠻࠶ࡊ࠮ࡒ࠽࡯(ᐔᚑ 20 ᐕ 1 ᦬㧘ጘ㒂㧘‫ߟߦࡓ࡯ࡠ࠼ࡦࠪࠢ࠶࡝ࡏ࠲ࡔޟ‬޿ߡ‫ޠ‬Ṷ⠪)8㧕 ᣣᧄஜᐽ࡮ᩕ㙃ࠪࠬ࠹ࡓቇળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛‫ޠ‬Ṷ⠪)9㧕 ጘ㒂⋵ᩕ㙃჻ળ(ᐔᚑ 20 ᐕ 9 ᦬㧘ጘ㒂㧘‫♧ޟ‬ዩ∛ߥࠄ߮ߦ♧ዩ∛੍஻ァߩᜰዉ㧙♧ዩ∛ኻ╷੐ᬺ㧘․ቯஜᐽ⸻ᢿᬺോߩℂ⸃ࠍᢛℂߔࠆ㧙‫ޠ‬Ṷ⠪)‫ޟ‬㆙㓒ක≮ߦ߅ߌࠆ‫ޡ‬ᩕ㙃≮ᴺ‫ߩޢ‬น⢻ᕈߣ⺖㗴‫ޠ‬ᐳ㐳)10㧕 ᣣᧄ㆙㓒ක≮ቇળ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘
11㧕 ᐔᚑ 20 ᐕᐲ(╙ 46 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘‫଻࡮ࡦ࡚ࠪ࠶ࠞࠬࠖ࠺࡞ࡀࡄޟ‬ஜ▤ℂᜂᒰ⡯⎇ⓥળႎ๔‫ޠ‬ᐳ㐳)㧙㧙

12㧕 ᐔᚑ 20 ᐕᐲ(╙ 46 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ቇ↢ᡰេߦ߅ߌࠆ IT ൻߩ዁᧪ߦߟ޿ߡ‫ޠ‬ᐳ㐳)13㧕 ᐔᚑ 20 ᐕᐲ(╙ 35 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળ଻ஜ▤ℂᜂᒰ⡯⎇ⓥળ(ᐔᚑ 20 ᐕ
7 ᦬㧘ጘ㒂㧘᜗ᓙṶ⠪‫․ޟ‬ቯஜ⸻ߣ․ቯ଻ஜᜰዉߦ߆߆ࠊࠆ⹤㗴ߣቇ↢ߩࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ
੍㒐‫ޠ‬Ṷ⠪)↰ਛ↢㓷㧦
1㧕 ᐔᚑ 18 ᐕᐲ(╙ 44 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ㨯ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 18 ᐕ 7 ᦬㧘ᵿ᧻㧘ࠪࡦࡐࠫ࠙ࡓ‫଻ޟ‬ஜ▤ℂ࠮ࡦ࠲࡯(଻ஜቶ)ߦ᳞߼ࠄࠇࠆ଻ஜࠨ࡯ࡆࠬ߳ߩኻᔕ‫ޠ‬Ṷ⠪)
2㧕 ᐔᚑ 20 ᐕᐲ(╙ 46 ࿁)ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ㨯ർ㒽࿾ᣇㇱળ⎇ⓥ㓸ળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘ࡄࡀ࡞࠺ࠖࠬࠞ࠶࡚ࠪࡦ‫ޟ‬ቇ↢ߩࡔࡦ࠲࡞ࡋ࡞ࠬߦ㑐ߔࠆᦨㄭߩ⹤㗴‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേᷡ᳓సᤨ㧦
1㧕 ⁛┙ⴕ᡽ᴺੱᣣᧄቇⴚᝄ⥝ળ⑼ቇ⎇ⓥ⾌ᆔຬળኾ㐷ᆔຬ(ᐔᚑ 18 ᐕᐲ)
2㧕 ᣣᧄࠬ࠻࡜ࠗࠞ࡯ᩣᑼળ␠⥃ᐥ㐿⊒ㇱ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(ᐔᚑ 18 ᐕᐲ)
3㧕 ㆇേེߩ 10 ᐕᣣᧄᆔຬળ࿖㓙ᆔຬળᆔຬ(ᐔᚑ 18 ᐕᐲ)
4㧕 ⥃ᐥᴦ㛎ߦ㑐ߔࠆකቇኾ㐷ኅ(㨪⃻࿷)5㧕 ᢛᒻἴኂᄖ⑼ቇ⎇ⓥഥᚑ⽷࿅ㆬ⠨ᆔຬ(㨪⃻࿷)6㧕 ᢛᒻἴኂᄖ⑼⑼ቇ⎇ⓥഥᚑ⽷࿅ડ↹㨯൐㊄ᆔຬળᆔຬ(ᐔᚑ 19 ᐕ 5 ᦬)
7㧕 ⽷࿅ᴺੱᢛᒻἴኂ⑼ቇ⎇ⓥഥᚑ⽷࿅ℂ੐(ᐔᚑ 19 ᐕ 5 ᦬㨪⃻࿷)8㧕 ጘ㒂㔍∛ㅪ㔍∛ක≮⑔␩⋧⺣ળ⋧⺣ຬ(ᐔᚑ 20 ᐕ 10 ᦬)
9㧕 ╙ 10 ࿁࿖㓙࠹࠾ࠬ࡮ࠬࡐ࡯࠷කቇળ⼏⚵❱ᆔຬ(ᐔᚑ 20 ᐕ 10 ᦬)ጊᧄ⋿↱⟤㧦
1㧕 ጘ㒂↢ᵴ⠌ᘠ∛ㆇേ≮ᴺ⎇ⓥળ਎⹤ੱ(㨪⃻࿷)2㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળᆔຬ(㨪⃻࿷)3㧕 ᕺ㇊࿾ၞ♧ዩ∛ද⼏ળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂Ꮢஜᐽ↥ᬺᝄ⥝ಽ⑼ળᆔຬ(ᐔᚑ 19 ᐕᐲ)
5㧕 ጘ㒂⋵଻ஜක≮ផㅴද⼏ળ࿾ၞ଻ஜ⸘↹ㇱળᆔຬ(㨪⃻࿷)6㧕 ጘ㒂⋵ᚑੱ∛ஜ⸻▤ℂᜰዉද⼏ળᓴⅣེ∔ᖚ╬ᆔຬ(㨪ᐔᚑ 19 ᐕ 3 ᦬)
7㧕 ␠࿅ᴺੱో࿖ᄢቇ଻ஜ▤ℂදળ⹏⼏ຬ(ᐔᚑ 20 ᐕ 12 ᦬㨪⃻࿷)8㧕 ᐔᚑ 20 ᐕᐲᣂߚߥ␠ળ⊛࠾࡯࠭ߦኻᔕߒߚቇ↢ᡰេࡊࡠࠣ࡜ࡓ࡟ࡈࠚ࡝࡯(ᐔᚑ 20 ᐕᐲ)
9㧕 ጘ㒂⋵කᏧળ♧ዩ∛ኻ╷ᆔຬળᆔຬ㐳(㨪⃻࿷)↰ਛ↢㓷㧦1㧕 ᧲ᶏ࡮ർ㒽࿾඙ࡔࡦ࠲࡞ࡋ࡞ࠬ⎇ⓥද⼏ળታⴕᆔຬળᆔຬ㐳(ᐔᚑ 18 ᐕᐲ)
2㧕 ጘ㒂⋵㓚ኂ⠪ᣉ╷ផㅴද⼏ળᆔຬ(㨪⃻࿷)3㧕 ጘ㒂⋵ኅᐸߦ߅ߌࠆ᥸ജ㒐ᱛද⼏ળ㈩஧⠪᥸ജ╬㒐ᱛኾ㐷ㇱળᆔຬ(㨪⃻࿷)4㧕 ጘ㒂㓚ኂ⠪⡯ᬺ࠮ࡦ࠲࡯ᜰዉຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
5㧕 ጘ㒂ഭ௛ዪ࠮ࠢࡂ࡜ࠞ࠙ࡦ࠮࡜࡯(ᐔᚑ 19 ᐕ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ↰ਛ↢㓷㧦ጘ㒂ᄢቇ଻ஜ▤ℂ࠮ࡦ࠲࡯ቯᦼஜᐽ⸻ᢿᤨࠕࡦࠤ࡯࠻⺞ᩏࠃࠅ㧦ో࿖ᄢቇ଻ஜ▤ℂදળ᧲ᶏ㨯ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦45(2006 ᐕ)
2㧕 ጊᧄ⋿↱⟤㧘♿ࡁቯ଻⤿㧘㋈ᧁᐽਯ㧘㜞Ⴆ⋥⢻㧦ක≮ᖱႎ▤ℂࠪࠬ࠹ࡓߣ⸻≮ࡕ࠺࡞-♧ዩ∛-㧦ක≮⚻༡ੱ᧚⢒ᚑᢎ⢒ࡊࡠࠣ࡜ࡓ㐿⊒ࡊࡠࠫࠚࠢ࠻ 㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ㧦ᐔᚑ 17 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦଥࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޠ‬ታ❣ႎ๔ᦠ㧦141㧙176(2006 ᐕ 3 ᦬)
3㧕 ጊᧄ⋿↱⟤㧦ࠠࡖࡦࡄࠬᢝ࿾ౝో㕙⑌ᾍ 2 ᐕࠍ⚻ㆊߒߡ㧙ࠠ࡯ࡢ࡯࠼ߪቇ↢ߩஜᐽ㧙㧦ో࿖ᄢቇ଻
ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ(ᐔᚑ 19 ᐕᐲ)㧦28㧙31(2007 ᐕ)㧙㧙4㧕 ጊᧄ⋿↱⟤㧦♧ዩ∛੍㒐ߦะߌߚขࠅ⚵ߺߦߟ޿ߡ㧦ጘ㒂⋵࿖᳃ஜᐽ଻㒾࿅૕ㅪวળ ࿖଻੐ᬺផㅴ
࠻࠶ࡊ࠮ࡒ࠽࡯⻠Ṷ⸥㍳㧦24㧙31(2007 ᐕ 1 ᦬)
5㧕 㜞Ⴆ⋥⢻㧘Ꮉญ㗅ᢘ㧘㜞ᯅቁᄦ㧘♿ࡁቯ଻⤿㧘ጊᧄ⌀↱⟤㧦․ቯᯏ⢻∛㒮ᶖൻེᄖ⑼ߦ߅ߌࠆ∛ᐥࡑࡀ࡯ࠫࡔࡦ࠻㧦ᐔᚑ 18 ᐕᐲ⚻ᷣ↥ᬺ⋭‫ޟ‬ක≮⚻༡ੱ᧚⢒ᚑ੐ᬺㆇ༡ߦଥࠆᢎ⢒ࡊࡠࠣ࡜ࡓ‫ޠ‬ႎ๔ᦠ㧦578㧙619(2007 ᐕ 1 ᦬)
6㧕 ᷡ᳓సᤨ㧦㗖ᬁ੝ో៰೨ᣇ࿕ቯⴚᓟߩ⣦㛽ቯ⌕ߣౝ࿕ቯ᧚ᢱߩᄌൻߦ㑐ߔࠆ⎇ⓥ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ⣄ᩇ㕤Ꮺ㛽ൻ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 19 ᐕᐲ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ㧦106㧙107(2008 ᐕ 3 ᦬)
7㧕 㐳ἑᷡ㧘㜞Ⴆ⋥⢻㧘♿ࡁቯ଻⤿㧘ጊᧄ⌀↱⟤㧦ᕆᕈᦼ∛㒮⚻༡ߦ߅ߌࠆᚻⴚㇱࡑࡀࠫࡔࡦ࠻㧙․ቯ
ᯏ⢻∛㒮ᚻⴚቶߩࠤ࡯ࠬ㧙㧦ᐔᚑ 19 ᐕᐲ⚻ᷣ↥ᬺ⋭‫↥ࠬࡆ࡯ࠨޟ‬ᬺੱ᧚⢒ᚑ੐ᬺ‫ޠ‬ႎ๔ᦠ(2008 ᐕ
3 ᦬)
8㧕 ጊᧄ⋿↱⟤㧦ᄢቇ↢ߩ⢈ḩߣ૕⾰ߩ㑐ଥ⺞ᩏ́዁᧪ߩ↢ᵴ⠌ᘠ∛ߩ⊒∝ࠍ੍㒐ߔࠆߚ߼ߦ́㧦ᐔᚑ
17 ᐕᐲ㧙ᐔᚑ 19 ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)⎇ⓥᚑᨐႎ๔ᦠ(2008 ᐕ 5 ᦬)
9㧕 ጊᧄ⋿↱⟤㧦ቇ↢ᡰេߦ߅ߌࠆ IT ൻߩ዁᧪ߦߟ޿ߡ㧦ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦49(2008 ᐕ 12 ᦬)
10㧕 ጊᧄ⋿↱⟤㧦․ቯஜ⸻ߣ․ቯ଻ஜᜰዉߦ߆߆ࠊࠆ⹤㗴ߣቇ↢ߩࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓ੍㒐㧦ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦88㧙92(2008 ᐕ 12 ᦬)
11㧕 ↰ਛ↢㓷㧦♖␹ක≮ᯏ㑐ฃ⸻ਛߩቇ↢ߩᄢቇ߳ߩㆡᔕ㧦ో࿖ᄢቇ଻ஜ▤ℂදળ ᧲ᶏ࡮ർ㒽࿾ᣇㇱળႎ๔ᦠ㧦30㧙31(2008 ᐕ 12 ᦬)
11㧚ႎ㆏1㧕 ጊᧄ⋿↱⟤㧦㜞ᐲක≮ᢎ⢒ࠦࡦ࠰࡯ࠪࠕࡓ዁᧪ߩක≮ឭଏ૕೙ߩ࿷ࠅᣇࠍ⺰⼏㧦ᣣೀ⮎ᬺ(2006 ᐕ 3
᦬ 7 ᣣ)
2㧕 ጊᧄ⋿↱⟤㧦ක≮ߩല₸ൻ⠨߃ࠆ ጘ㒂ᄢߣච౐㌁ⴕ IT ᵴ↪ߢ࠮ࡒ࠽࡯㧦ጘ㒂ᣂ⡞(2006 ᐕ 12 ᦬ 8ᣣ)3㧕 ↰ਛ↢㓷㧦଻ஜ▤ℂ࠮ࡦ࠲࡯ߣࡔࡦ࠲࡞ࡋ࡞ࠬгᄢቇ↢ߩᔃߩ㘑᥊ߣቇ↢⋧⺣ߦ᳞߼ࠄࠇࠆ߽ߩг㧦ጘ㒂⋵଻㒾කᣂ⡞㧦╙ 358 ภ(2007 ᐕ 1 ᦬)
4㧕 ᷡ᳓సᤨ㧦⥄ォゞߢᔃ߽ஜᐽߦ ࠷ࠕ࡯࡮ࠝࡉ࡮ࠫࡖࡄࡦ㐿௅⸥ᔨ㧦ጘ㒂ᣂ⡞(2007 ᐕ 3 ᦬ 2 ᣣ)
5㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ㧙ቇ↢ᡰេ GP ߦㆬቯ㧙↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧦ਛᣣᣂ⡞(2007 ᐕ 9 ᦬ 30 ᣣ)
6㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ㧙ቇ↢ᡰេ GP ߦណᛯ㧙ᄢቇߪ↢ᶦஜᐽߩࠬ࠲࡯࠻࿾ὐ㧦ᦺᣣᣂ⡞(2007 ᐕ
10 ᦬ 4 ᣣ)
7㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ㧙↢ᶦஜᐽࠍ⋡ᜰߒߚቇ↢ஜᐽᡰេࡊࡠࠣ࡜ࡓ㧙↢ᶦஜᐽᢎ⢒ߩផㅴߣஜᐽ
ᡰេߩలታ㧦ᦺᣣᣂ⡞(2007 ᐕ 10 ᦬ 31 ᣣ)
8㧕 ጊᧄ⋿↱⟤㧦ጘ㒂ᄢቇ⑂ߩ቟ోⴡ↢▤ℂߦߟ޿ߡ㧦CBC(2008 ᐕ 7 ᦬ 2 ᣣ)
9㧕 ጊᧄ⋿↱⟤㧦ቇ࿦⑂ߩⴡ↢▤ℂ㧘⋙ⷞ૕೙ᒝൻ߳㧘ጘ㒂ᄢታⴕᆔ㧙㘩ਛᲥ㒐ᱛߦ⻠⠌ળ㧙㧦ਛᣣᣂ⡞(2008 ᐕ 7 ᦬ 3 ᣣ)
10㧕 ጊᧄ⋿↱⟤㧦ቇ↢ߩஜᐽ▤ℂ㧘ጘ㒂ߢ⎇ⓥ㓸ળ 㧙᧲ᶏ࡮ർ㒽ߩㇱળ㧙㧦ਛᣣᣂ⡞(2008 ᐕ 7 ᦬ 25
ᣣ)11㧕 ᷡ᳓సᤨ㧦ࡑ࡞ࡎᢛᒻᄖ⑼࠮ࡒ࠽࡯㧦࡜ࠫࠝ NIKKEI ᧄ␠ࠬ࠲ࠫࠝ(2008 ᐕ 9 ᦬ 3 ᣣ᡼ㅍ)12㧚⥄Ꮖ⹏ଔ
⹏ଔᬺോ㕙ߢߪቇ↢ߩஜᐽࠍ቞ࠅ㧘዁᧪ߩ∔∛੍߽㒐ߔࠆஜᐽᢎ⢒ߦߟ޿ߡචಽߥᚑᨐࠍ޽ߍߡ޿ࠆ‫ޕ‬ቇ↢ᡰេ GP ߩ੍▚⊛⢛᥊߇޽ࠆߚ߼㧘࿖ౝᄖ߳ߘߩታ❣ࠍ౏⴫ߢ߈ࠆߣߎࠈ߳᧪ߡ޿ࠆ‫ޕ‬⎇ⓥ㕙ߢߪ㧘ᄢቇ↢ߩஜᐽߦὶὐࠍ޽ߡߚ㧘࡙࠾࡯ࠢߥ⎇ⓥ⺖㗴ߦขࠅߊࠎߢ޿ࠆ‫↢ޕ‬ᵴ⠌ᘠ∛㧘ญ⣧ౝஜᐽ㧘ᘟᕈ㗡∩㧘♖␹∛ℂ㧘ᔃℂಽᨆߥߤߩ஥㕙߆ࠄ㧘࠺࡯࠲߽⫾Ⓧߒ㧘ቇળ⊒⴫╬ߔߔ߼ߡ߈ߚ‫ޕ‬⃻࿷㧘⧷ᢥ⺰ᢥߩ⊒⴫ࠍḰ஻ਛߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ᧄቇቇ↢ߩஜᐽᡰេߩ࠾࡯࠭ߪᐕ‫ޘ‬Ⴧߒߡ߅ࠅ㧘ቇ↢ᡰេᬺോߣ⎇ⓥߣߩਔ┙ߦ㔍ᷦߒߡ޿ࠆ‫ޕ‬㧙㧙੹ᓟߩዷᦸ
ᄢቇතᬺ↢ߩ⛮⛯⊛ߥஜᐽ⺞ᩏࠍታᣉߔࠆ㧔almni cohort study㧕ߩߪ㧘਎⇇⊛ߦᢙࡩᚲߒ߆ߥ޿‫ᧄޕ‬ቇߢ⎇ⓥࡈࠖ࡯࡞࠼ߣߒߡ⏕┙ߐߖߚ޿‫ޕ‬㧙㧙㧔15㧕↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯㧔ࠥࡁࡓ⎇ⓥಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
ࠥࡁࡓ⎇ⓥಽ㊁ߢߪቇౝߦ߅ߌࠆࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߩ᜚ὐߣߒߡࠪ࡯ࠤࡦࠨ࡯㧘࡝ࠕ࡞࠲ࠗࡓ
PCR㧘DNA ࡑࠗࠢࡠࠕ࡟ࠗ㧘MALDI-TOF/TOF ⾰㊂ಽᨆⵝ⟎ߥߤߦട߃ߡ౒ὶὐ࡟࡯ࠩ࡯ࠬࠠࡖࡦ㗼ᓸ㏜㧘ࡃࠗࠝࠗࡦࡈࠜࡑ࠹ࠖࠢࠬ㑐ㅪᯏེࠍᢛ஻ߒ㧘ࠪ࡯ࠢࠛࡦࠬฃ⸤ࠨ࡯ࡆࠬߣߣ߽ߦቇౝ↢๮⑼ቇ⎇ⓥᡰេࠍⴕߞߡ޿ࠆ‫ ߦࠄߐޕ‬2 ߟߩ᡼኿ᕈห૏ర⚛ታ㛎ᣉ⸳߽߆߆߃ߡ߅ࠅ㧘ᢎຬߪߎࠇࠄߩ▤ℂㆇ༡ࠍⴕ޿ߥ߇ࠄ⥄ࠄ߽ᵴ↪ߒߡ㧘ࡅ࠻ઍ⻢∛㧘⣺ౝ⚦⩶㧘ᬀ‛∛ේ⩶㧘ᓸ↢‛േᘒߦࠃࠆⅣႺࡕ࠾࠲࡝ࡦࠣߥ
ߤࠍ࠹࡯ࡑߦࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆࠍਛᔃߣߔࠆ⎇ⓥࠍⴕߞߡ޿ࠆ‫ޕ‬1㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩࠥࡁࡒࠢࠬ࡮ࡊࡠ࠹ࠝࡒࠢࠬ࡮ࡔ࠲ࡏࡠࡒࠢࠬߦࠃࠆ⸻ᢿ㧘∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒࿖ౝ໑৻ߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛⸻ᢿ⎇ⓥ࠮ࡦ࠲࡯ߣߒߡో࿖ࠃࠅㅍࠄࠇߡ߈ߚࠨࡦࡊ࡞ߩ⢽⢌㉄ಽᨆ㧘࠲ࡦࡄࠢ࡮ㆮવሶ⸃ᨆߦࠃࠆ⸻ᢿࠪࠬ࠹ࡓߦട߃ߡ㧘ᖚ⠪⚦⢩ࠍ↪޿ߡㆮવሶዉ౉߿ siRNA㧘ࡑࠗࠢࡠࠕ࡟ࠗ⸃ᨆ╬ࠍ㚟૶ߒߡ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ࠍⴕߞߡ޿ࠆ‫ోߦࠄߐޕ‬࿖ߩᬌᩏᯏ㑐ߣ߽දജߒߡ࿖ౝ
ోߡߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᖚ⠪ࠍ✂⟜ߒߡ㧘࠺࡯࠲ࡌ࡯ࠬߦ⊓㍳ߒߡ⸻ᢿ㧘ࡈࠜࡠ࡯ࠕ࠶ࡊߩࡀ࠶࠻ࡢ࡯
ࠢࠍᒻᚑߒ㧘ᖚ⠪ QOL ߩะ਄ࠍ⋡ᜰߒߡ޿ࠆ‫ߚ߹ޕ‬⢽⢌⚵❱߿␹⚻⚵❱ߦ߅ߌࠆࡍ࡞ࠝࠠࠪ࠰࡯ࡓߩ↢ℂ⊛ᯏ⢻ࠍ⸃ᨆߒ㧘ࡔ࠲ࡏ࡝࠶ࠢࠪࡦ࠼ࡠ࡯ࡓߥߤߩ↢ᵴ⠌ᘠ∛߿␹⚻ᄌᕈ∔ᖚߦኻߒߡࡍ࡞ࠝࠠࠪ࠰࡯
ࡓࠍਛᔃߣߒߚࡔ࠲ࡏࡠ࡯ࡓ⸃ᨆߩ౒ห⎇ⓥࠍㅴ߼ߡ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ߦขࠅ⚵ߺ㧘ࡍ࡞ࠝࠠࠪ࠰
࡯ࡓ߇↢૕ߦ߅޿ߡᭂ߼ߡࡔࠫࡖ࡯ߥࠝ࡞ࠟࡀ࡜ߢ޽ࠆߎߣࠍጘ㒂ᄢቇ߆ࠄ⊒ାߒߡ޿ࠆ‫ޕ‬
2㧕⣺ౝ⚦⩶ߩࠥࡁࡓ⸃⺒ࡊࡠࠫࠚࠢ࠻ —⣺ౝ఺∉ࠪࠬ࠹ࡓߩ⸃᣿ߣක⮎ຠ㧘ஜᐽ㘩ຠߩ㐿⊒ࡅ࠻ߩ⣺▤ߪ 100 ళߣ޿ࠊࠇࠆ߶ߤߩ⚦⩶߇↢ᕷߒߡᏂᄢߥ↢ᘒ♽ࠍ૞ࠅ㧘ᗵᨴ㧘ࠕ࡟࡞ࠡ࡯ߥߤߩ
఺∉♽ߦ㑐ਈߒߡ߅ࠅ㧘ߘߩࡔ࠲ࠥࡁࡓ⸃ᨆߦࠃࠆක⮎ຠ߿⎇ⓥ㘩ຠߩ㐿⊒ၮ⋚ߩ⏕┙ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
3㧕ᬀ‛∛ේ⩶ߩࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߦࠃࠆ↢ᘒ⸃᣿ —㘩ߩ቟ోᕈߩ⏕┙࿯ფ∛ኂࠍ⿠ߎߔᬀ‛∛ේᕈ Fusarium ⩶ߩࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆߦࠃࠆ∛ේᕈߩ⸃᣿ߦࠃࠅ㧘㘩ߩ቟ో㧘቟ቯߒߚ㘩♳↢↥㧘ߐࠄߦߪᣣ๺⷗ᗵᨴߩ⿠࿃⩶ኻ╷ߣߒߡක≮ߩಽ㊁߳ߩ⽸₂߽⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ਅỈિⴕ
ᢎ᝼㧦
ಎᢎ᝼㧦 㗇⾐᥍ਭ㐳ἑ᦮ሶഥᢎ㧦Nobuyuki Shimozawa
Haruhisa Suga
Tomoko Nagase3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਅỈિⴕ㧚Zellweger ∝୥⟲㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✬㧚ዊఽ⑼ቇ ╙ 3
㧙484㧚㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦481⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛㧘ዊఽ⑼⸻≮ 2006 ᐕ㧧69 Ꮞ㧦1646㧙1652㧚
2㧕 㗇⾐᥍ਭ㧚ࡓࠡ㘃⿒߆߮∛⩶ߦ߅ߌࠆㄭᐕߩ⎇ⓥേะ㧘ᣣᧄᬀ‛∛ℂቇળႎ 2006 ᐕ㧧72 Ꮞ㧦121㧙134㧚
3㧕 ਅỈિⴕ㧘㋈ᧁᐽਯ㧚ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᒻᚑ⇣Ᏹ∝гZellweger ∝୥⟲ࠍਛᔃߦ㧘ዊఽౝ⑼ 2007 ᐕ㧧Ⴧೀ 39 ภ㧦536㧙538㧚
✚⺑㧔᰷ᢥ㧕
1㧕 Suga H. Genetic diversity in Fusarium spp. causing Fusarium head blight of wheat and barley and its
paradoxes. Soil Microorganisms. 2006;60:99-103.
2㧕 Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inherit Metab Dis.
2007;30:193-197.
ේ⪺㧔๺ᢥ㧕
ߥߒේ⪺㧔᰷ᢥ㧕
1㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal㧙㧙beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
2㧕 Shiozawa K, Goda N, Shimizu T, Mizuguchi K, Kondo N, Shimozawa N, Shirakawa M, Hiroaki H. The
common phospholipid binding activity of the N-terminal domains of PEX1, VCP/p97. FEBS J.
2006;273:4959-4971.
3㧕 Sawada T, Hashimoto T, Nakano H, Suzuki T, Ishida H, Kiso M. Why does avian influenza A virus
hemagglutinin bind to avian receptor stronger than to human receptor? Ab initio fragment molecularorbital studies. Biochem Biophys Res Commun. 2006;351:40-43.
4㧕 Magesh S, Suzuki T, Miyagi T, Ishida H, Kiso M. Homology modeling of human sialidase enzymes
NEU1, NEU3 and NEU4 based on the crystal structure of NEU2: Hints for the design of selective
NEU3 inhibitors. J Mol Graph Model. 2006;25:196-207.
5㧕 Villa NO, Kageyama K, Asano T, Suga H. Phylogenetic relationships of Pythium and Phytophthora
species based on ITS rDNA, cytochrome oxidase II and b-tubulin gene sequences. Mycologia.
2006;98:410-422.
6㧕 Takahashi N, Morita M, Maeda T, Harayama Y, Shimozawa N, Suzuki Y, Furuya H, Sato R,
Kashiwayama Y, Imanaka T. Adrenoleukodystrophy: subcellular localization and degradation ofadrenoleukodystrophy protein (ALDP/ ABCD1) with naturally occurring missense mutations. J
Neurochem. 2007;101:1632-1643.
7㧕 Starkey DE, Ward TJ, Aoki T, Gale LR, Kistler HC, Geiser DM, Suga H, Toth B, Varga J, O’Donnell K.
Global molecular surveillance reveals novel Fusarium head blight species and trichothecene toxin
diversity. Fungal Genet Biol. 2007;44:1191-1204.
8㧕 Moriyasu Y, Maruyama-Funatsuki W, Kikuchi A, Ichimi K, Zhong B, Yan J, Zhu Y, Suga H, Watanabe
Y, Ichiki-Uehara T, Shimizu T, Hagiwara K, Kamiunten H, Akutsu K, Omura T. Molecular analysis of
the genome segments S1, S4, S6, S7 and S12 of a Rice gall dwarf virus isolate fromThailand;completion of the genomic sequence. Arch Virol. 2007;152:1315-1322.
9㧕 Kageyama K, Senda M, Asano T, Suga H, Ishiguro K. Intra-isolate hetelogeneity of the ITS region of
rDNA in Pythium helicoids. Mycol Res. 2007;111:416-423.
10㧕 Sawada T, Hashimoto H. Nakano T, Suzuki Y, Kawaoka H, Ishida H, Kiso M. Influenza viralhemagglutinin complicated shape is advantageous to its binding affinity for sialosaccharide receptor.
Biochem Biophys Res Commun. 2007;355:6-9.
11㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of Childhood X-linked
Adrenoleukodystrophy : High Risk for Depression and Neurosis. Brain Dev. 2008;30:477-482.
12㧕 Morita M, Kanai M, Mizuno S, Iwashima M, Hayashi T, Shimozawa N, Suzuki Y, Imanaka T. Bicalein
5,6,7- trimethyl ether activates peroxisomal but not mitochondrial fatty acid beta-oxidation. J Inherit
Metab Dis. 2008;31:442-449.
13㧕 Al-Dirbashi OY, Santa T, Rashed MS, Al-Hassnan Z, Shimozawa N, Chedrawi A, Jacob M,
Al-Mokhadab M. Rapid UPLC-MS/MS method for routine analysis of plasma pristanic, phytanic andvery-long chain fatty acid markers of peroxisomal disorders. J Lipid Res. 2008;49:1855-1862.
14㧕 Saito M, Yamashita S, Shimozawa N, Mizuguchi M, Iwamori M. Changes in the amounts of myelin
lipids and molecular species of plasmalogen PE in the brain of an autopsy case with d-bifunctional
protein deficiency. Neurosci Lett. 2008;442:4-9.
15㧕 Suga H, Karugia GW, Ward T, Gale LR, Tomimura K, Nakajima T, Miyasaka A, Koizumi S, Kageyama
K, Hyakumachi M. Molecular characterization of the Fusarium graminearum species complex in
Japan. Phytopathology. 2008;98:159-166.

IF 1.464

IF 3.396

IF 2.796

IF 1.932

IF 1.808

IF 4.451

IF 3.425

IF 1.839
IF 1.861

IF 2.796
IF 1.464

IF 1.668

IF 4.336

IF 2.085

IF 2.3774㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ਅỈિⴕ㧧⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦ࡕ࠺࡞േ‛ࠍ↪޿ߚࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢㓚ኂߦၮߠߊ⊒↢⇣Ᏹߣ↢ᵴ⠌ᘠ∛ߩ∛ᘒ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧1,200 ජ౞2㧕 ⎇ⓥઍ⴫⠪㧦㋈ᧁ ᔀ㧧⑼ቇ⎇ⓥ⾌․ቯ㗔ၞ㧦࠹࡯࡜࡯ࡔ࡯࠼ࡊࡠࡃࠗࠝ࠹ࠖࠢࠬࠍ⋡ᜰߒߚࡆࡈ
ࠖ࠭ࠬ⩶ዻߩୄ⍑⊛ࠥࡁࡓ⸃㧧ᐔᚑ 18㧙19 ᐕᐲ㧧8,100 ජ౞(4,000㧦4,100 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦㗇⾐᥍ਭ㧧⑼ቇ⎇ⓥ⾌⧯ᚻ⎇ⓥ(B)㧦ࡓࠡ㘃ࡑࠗࠦ࠻ࠠࠪࡦᳪᨴ㒐ᱛߩߚ߼ߩ DNA ࡑ࡯ࠞ࡯ࠍ૶ߞߚ∛ේ⩶ߩേᘒ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧700 ජ౞4㧕 ⎇ⓥಽᜂ⠪㧦㗇⾐᥍ਭ㧧⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)㧦࿯ფ♻⁁⩶ߦࠃࠆⅣႺࡕ࠾࠲࡝ࡦࠣࠪࠬ࠹ࡓߩ㐿⊒㧧ᐔᚑ 18 ᐕᐲ㧧3,520 ජ౞5㧕 ⎇ⓥಽᜂ⠪㧦㗇⾐᥍ਭ㧧⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(B)㧦᦭↪ᓸ↢‛㑆ߩ⋧੕૞↪ߣᬀ‛ߦ߅ߌࠆ↢૕㒐ᓮᯏ᭴ߩ⸃᣿㧧ᐔᚑ 18 ᐕᐲ㧧3,700 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦ਅỈિⴕ㧧⑼ቇ⎇ⓥ⾌⪚⧘⎇ⓥ㧦ઍ⻢ࡀ࠶࠻ࡢ࡯ࠢߦၮߠ޿ߚࠪࠬ࠹ࡓࡃࠗࠝࡠࠫ࡯
ߦࠃࠆㆮવ∛⊒∝ⷙቯ࿃ሶߩត⚝㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,200 ජ౞(2,200㧦1,000 ජ౞)㧙㧙2㧕ฃ⸤⎇ⓥ
1㧕 ਅỈિⴕ㧦వᄤઍ⻢⇣Ᏹ∝ߩ⸻ᢿࡀ࠶࠻ࡢ࡯ࠢࠍ੺ߒߚ㐳ᦼ੍ᓟㅊ〔ࠪࠬ࠹ࡓߩ᭴▽㧧ᐔᚑ 18㧙20
ᐕᐲ㧧3,000 ජ౞(1,000㧦1,000㧦1,000 ජ౞)㧦ᚑ⢒ක≮⎇ⓥᆔ⸤੐ᬺ⎇ⓥ
2㧕 ㋈ᧁ ᔀ㧦ቇㇱࠍ⿥߃ߚᓸ↢‛ቇᢎ⢒ߩㅪ៤ቇㇱࠍ⿥߃ߚᓸ↢‛ቇᢎ⢒ߩㅪ៤㧦ᐔᚑ 18 ᐕᐲ㧧500ජ౞㧦ጘ㒂ᄢቇᢎ⢒⎇ⓥᵴᕈൻ⚻⾌
3㧕 ㋈ᧁ ᔀ㧦࠙ࡠࡦ㉄ൻࠠࠪࡠࠝ࡝ࠧ♧ߩ㜞⚐ᐲ⵾ㅧᴺ㧧ᐔᚑ 18 ᐕᐲ㧧3,000 ජ౞㧦⑼ቇᛛⴚᝄ⥝ᯏ
᭴⵬ഥ㊄࠺࡯࠲⵬ቢ
4㧕 㗇⾐᥍ਭ㧦቟ోߢା㗬ᕈ㧘ᯏ⢻ᕈ߇㜞޿㘩ຠ࡮ㄘ↥‛ଏ⛎ߩߚ߼ߩ⹏ଔ࡮▤ℂᛛⴚߩ㐿⊒㧘⮎೷(࠴ࠝࡈࠔࡀ࡯࠻ࡔ࠴࡞)⠴ᕈࠍᜬߟ⿒߆߮∛⩶ߩㆮવሶ⸻ᢿᛛⴚߩ㐿⊒㧧ᐔᚑ 18㧙19 ᐕᐲ㧧4,500 ජ౞(2,000㧦2,500 ජ౞)㧦ㄘᬺ࡮㘩ຠ↥ᬺᛛⴚ✚ว⎇ⓥᯏ᭴
5㧕 ㋈ᧁ ᔀ㧦⣺ౝ⚦⩶ߩࠗ࠰ࡈ࡜ࡏࡁࠗ࠼ઍ⻢ㆮવሶ⸃ᨆ㧧ᐔᚑ 19 ᐕᐲ㧧600 ජ౞㧦ጘ㒂⋵↢‛Ꮏቇ⎇ⓥᚲ
6㧕 ਅỈિⴕ㧦࡜ࠗ࠰࠱࡯ࡓ∛(ࡈࠔࡉ࡝∛฽߻)ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,000 ජ౞(1,500㧦1,500 ජ౞)㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄(㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ)7㧕 ਅỈિⴕ㧦Dravet ∝୥⟲ߩ Na ࠴ࡖࡀ࡞ㆮવሶ⇣Ᏹߩ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧1,000 ජ౞㧦࿖┙∛㒮ᯏ᭴㕒ጟߡࠎ߆ࠎ࡮␹⚻ක≮࠮ࡦ࠲࡯8㧕 㗇⾐᥍ਭ㧦↢↥࡮ᵹㅢ࡮ടᎿᎿ⒟ߦ߅ߌࠆ૕♽⊛ߥෂኂⷐ࿃ߩ․ᕈ⸃᣿ߣ࡝ࠬࠢૐᷫᛛⴚߩ㐿⊒㧘⮎೷⠴ᕈࠍᜬߟ㤈㘃⿒߆߮∛⩶ߩㆮવሶ⸻ᢿߣવ᠞ᛥ೙ᛛⴚߩ㐿⊒㧧ᐔᚑ 20 ᐕᐲ㧧4,000 ජ౞㧦ㄘᬺ࡮㘩ຠ↥ᬺᛛⴚ✚ว⎇ⓥᯏ᭴
3㧕౒ห⎇ⓥ1㧕 ਅỈિⴕ㧦ࠨ࠙ࠫࠕ࡜ࡆࠕߦ߅ߌࠆࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩ⸻ᢿߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 20 ᐕᐲ㧧ࠨ࠙ࠫࠕ࡜ࡆࠕ࡮ࠠࡦࠣࡈࠔࠗࠨ࡞ኾ㐷∛㒮࡮⎇ⓥ࠮ࡦ࠲࡯5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬਅỈિⴕ㧦
1㧕 ᣣᧄዊఽ␹⚻ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽㆮવቇળᐙ੐(㨪⃻࿷)4㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(㨪⃻࿷)㗇⾐᥍ਭ㧦1㧕 ᬀ‛∛ኂ↢ᘒ⎇ⓥળᐙ੐(㨪⃻࿷)2㧕 ᬀ‛∛ේ⩶㘃⺣⹤ળᐙ੐(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ਅỈિⴕ㧦
1㧕 10th. International Congress of Inborn Errors of Metabolism (2006.09, Chiba, Plenary lecture:
Molecular and clinical aspects of peroxisomal disease; Speaker)
2㧕 ╙ 48 ࿁ᣣᧄዊఽ␹⚻ቇળ(ᐔᚑ 18 ᐕ 6 ᦬㧘ᶆ቟㧘ࡢ࡯࡚ࠢࠪ࠶ࡊ‫ޟ‬ㆮવᕈ␹⚻╭∔ᖚߩ⸻ᢿ࡮ᴦ≮ᚢ⇛‫ޠ‬㧚‫⸻ߩ∛ࡓ࡯࠰ࠪࠠࠝ࡞ࡍޟ‬ᢿߣᴦ≮‫ޠ‬Ṷ⠪)
3㧕 ╙ 49 ࿁ᣣᧄవᄤઍ⻢⇣Ᏹቇળ㧘╙ 6 ࿁ࠕࠫࠕవᄤઍ⻢⇣Ᏹቇળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ጊᒻ㧘ࡢ࡯ࠢࠪ㧙㧙࡚࠶ࡊ‫ޟ‬వᄤઍ⻢⇣Ᏹ∝ߦ߅ߌࠆᴦ≮ߩㅴᱠ‫ޠ‬㧚‫ޟ‬೽⣢⊕⾰ࠫࠬ࠻ࡠࡈࠖ࡯ߩㅧⴊᐙ⚦⢩⒖ᬀ≮ᴺߩ⃻⁁ߣ໧㗴ὐ‫ޠ‬Ṷ⠪)㗇⾐᥍ਭ㧦
1㧕 ╙ 14 ࿁ᣣᧄᓸ↢‛⾗Ḯቇળ(ᐔᚑ 19 ᐕ 6 ᦬㧘ᧅᏻ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ㆮવ⊛ᄙ᭽ᕈߩ⸃ᨆߢ၂㑆⷗߃ߡ߈ߚࡓࠡ㘃⿒߆߮∛⩶ߩㅴൻ࡮↢ᘒ‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേਅỈિⴕ㧦
1㧕 ጘ㒂⋵ఽ┬⑔␩ክ⼏ળఽ┬ಣㆄኾ㐷ㇱળᆔຬ(㨪⃻࿷)2㧕 ⁛┙ⴕ᡽ᴺੱක⮎ၮ⋚⎇ⓥᚲၮ␆⊛⎇ⓥ⹏ଔᆔຬળኾ㐷ᆔຬ(㨪⃻࿷)㗇⾐᥍ਭ㧦1㧕 ࠨࠗࠛࡦࠬࡄ࡯࠻࠽࡯ࠪ࠶ࡊࡊࡠࠣ࡜ࡓ੐ᬺ‫ߩ⾰ࠢࡄࡦ࠲ޟ‬ቯᕈታ㛎ߣ⸃⺑‫(ޠ‬ᐔᚑ 20 ᐕ 10 ᦬ 14
ᣣ)2㧕 వ┵⑼ቇᛛⴚ૕㛎⻠ᐳ‫ޟ‬ㆮવሶ⚵឵߃ߢᄢ⣺⩶߇శࠆ‫(ޠ‬ᐔᚑ 20 ᐕ 12 ᦬ 4 ᣣ)
3㧕 ࠨࠗࠛࡦࠬࡄ࡯࠻࠽࡯ࠪ࠶ࡊࡊࡠࠣ࡜ࡓ੐ᬺ‫ޟ‬ㆮવሶ߇⺆ࠆ↢๮⃻⽎‫(ޠ‬ᐔᚑ 20 ᐕ 12 ᦬ 13 ᣣ)ࠥࡁࡓ⎇ⓥಽ㊁㧦
1㧕 㜞ᩞ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ߡߞࡓࡁࠥޟ‬૗㧫‫(ޠ‬ᐔᚑ 18 ᐕ 8 ᦬ 7 ᣣ㧘8 ᣣ)
2㧕 ਛቇ↢ߩߚ߼ߩ⥄ὼ᡼኿✢ታ㛎⻠ᐳ(ᐔᚑ 18 ᐕ 8 ᦬ 11 ᣣ)3㧕 ℂ⑼♽ᢎᏧߩߚ߼ߩ⚵឵߃ DNA ታ㛎ᢎ⢒⎇ୃળ(ᐔᚑ 18 ᐕ 8 ᦬ 22 ᣣ㧘23 ᣣ)
4㧕 ᐔᚑ 18 ᐕᐲጘ㒂ᄢቇ౏㐿⻠ᐳ‫↢ࠆ߆ࠊߊࠃޟ‬๮⑼ቇ㨪⎇ⓥߩᚑᨐ߇ߤߩࠃ߁ߦ↢߆ߐࠇߡ޿ࠆ߆㨪‫ޠ‬(ᐔᚑ 18 ᐕ 10 ᦬ 1 ᣣ)
5㧕 㜞ᩞ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ߡߞࡓࡁࠥޟ‬૗㧫‫(ޠ‬ᐔᚑ 19 ᐕ 8 ᦬ 8 ᣣ㧘9 ᣣ)
6㧕 ਛቇ↢ߩߚ߼ߩ⥄ὼ᡼኿✢ታ㛎⻠ᐳ(ᐔᚑ 19 ᐕ 8 ᦬ 10 ᣣ)7㧕 ℂ⑼♽ᢎᏧߩߚ߼ߩ⚵឵߃ DNA ታ㛎ᢎ⢒⎇ୃળ(ᐔᚑ 19 ᐕ 8 ᦬ 23 ᣣ㧘24 ᣣ)
8㧕 ᐔᚑ 19 ᐕᐲጘ㒂ᄢቇ౏㐿⻠ᐳ‫↢ࠆ߆ࠊߊࠃޟ‬๮⑼ቇ㨪⎇ⓥߩᚑᨐ߇ߤߩࠃ߁ߦ↢߆ߐࠇߡ޿ࠆ߆‫ޠ‬(ᐔᚑ 19 ᐕ 9 ᦬ 30 ᣣ)
9㧕 㜞ᩞ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ߡߞࡓࡁࠥޟ‬૗㧫‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬ 5 ᣣ㧘6 ᣣ)
10㧕 ਛቇ↢ߩߚ߼ߩ↢๮⑼ቇ૕㛎ࡊࡠࠣ࡜ࡓ‫ޟ‬ำߦ߽ߢ߈ࠆ DNA 㐓ቯ‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬ 20 ᣣ)
11㧕 ਛቇ↢ߩߚ߼ߩ⥄ὼ᡼኿✢ታ㛎⻠ᐳ(ᐔᚑ 20 ᐕ 8 ᦬ 22 ᣣ)
10㧚ႎ๔ᦠ
1㧕 ਅỈિⴕ㧦ࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢⇣Ᏹ∝ߦ߅ߌࠆ⊒∝ᯏᐨߩ⸃᣿ߣᴦ≮ᴺߩ㐿⊒㧦਄ේ⸥ᔨ↢๮⑼ቇ⽷࿅⎇ⓥႎ๔㓸㧦144㧙147(ᐔᚑ 18 ᐕ)
2㧕 ਅỈિⴕ㧦ࡕ࠺࡞േ‛ࠍ↪޿ߚࡍ࡞ࠝࠠࠪ࠰࡯ࡓઍ⻢㓚ኂߦၮߠߊ⊒↢⇣Ᏹߣ↢ᵴ⠌ᘠ∛ߩ∛ᘒ⸃᣿㧦ᐔᚑ 17㧙18 ᐕᐲ⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦1㧙71(ᐔᚑ 19 ᐕ 3 ᦬)
3㧕 ਅỈિⴕ㧦ㆮવᕈࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᐥ଀ߩ㐳ᦼ੍ᓟㅊ〔ߩߚ߼ߩ࠺࡯࠲ࡌ࡯ࠬ૞ᚑ㧦ᐔᚑ 17㧙19ᐕᐲෘ↢ഭ௛⋭ᚑ⢒ක≮⎇ⓥᆔ⸤੐ᬺ⎇ⓥႎ๔ᦠ(᧻ේ⃰)㧦254㧙255(ᐔᚑ 19 ᐕ 4 ᦬)
11㧚ႎ㆏1㧕 ᝼ᬺߢ DNA ታ㛎㧦ਛᣣᣂ⡞(2006 ᐕ 2 ᦬ 1 ᣣ)
2㧕 㜞ᩞ↢߇ㆮવሶቇ߱㧦ਛᣣᣂ⡞(2006 ᐕ 8 ᦬ 10 ᣣ)
3㧕 㜞ᩞ↢㧘ࠥࡁࡓࠍቇ⠌㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 10 ᣣ)
4㧕 ㆮવሶ߆ࠄ∛ᘒ⸃᣿⋡ᜰߔ㧦ጘ㒂ᣂ⡞(2006 ᐕ 8 ᦬ 15 ᣣ)
5㧕 ⥄ὼ᡼኿✢ࠍⷰኤ㧦ਛᣣᣂ⡞(2006 ᐕ 8 ᦬ 16 ᣣ)6㧕 ⎇ⓥᚑᨐࠍ੤߃‫↢ޟ‬๮⑼ቇ‫੺⚫ޠ‬㧦ਛᣣᣂ⡞(2006 ᐕ 10 ᦬ 2 ᣣ)
7㧕 ኾ㐷⊛ߦࠥࡁࡓ૕ᗵ㧦ਛᣣᣂ⡞(2007 ᐕ 8 ᦬ 8 ᣣ)
8㧕 ጘᄢߣࠨ࠙ࠫ㔍∛స᦯ㅪ៤ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ᴦ≮⎇ⓥ㧦ਛᣣᣂ⡞(2008 ᐕ 11 ᦬ 18 ᣣ)㧙㧙12㧚⥄Ꮖ⹏ଔ
⹏ଔోቇ⊛ߥᢎ⢒⎇ⓥᡰេᬺോߣߒߡߪ↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯ߣᡷ⒓ߒߡࠃࠅ⎇ⓥᡰេߩ┙႐ࠍ᣿⏕ߦߒ㧘ጘ㒂ᄢቇߦ߅ߌࠆᢎ⢒⎇ⓥߩၮ⋚⊛⸳஻ߩᢛ஻ࠍⴕ߁ߣߣ߽ߦ㧘↢๮⑼ቇߦ㑐ߔࠆၮ␆⎇ⓥߩ⥃ᐥᔕ↪߳ߩዷ㐿ࠍㅴ߼ߡ޿ࠆ‫⎇ޕ‬ⓥ㕙ߢߪో࿖໑৻ߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛⸻ᢿ⎇ⓥ࠮ࡦ࠲࡯ߣߒߡ
⸻ᢿࠪࠬ࠹ࡓ㧘ᖚ⠪㐳ᦼࡈࠜࡠ࡯ࠕ࠶ࡊࠪࠬ࠹ࡓࠍ⏕┙ߒ㧘࿖ౝᄖߩ⎇ⓥᯏ㑐ߣ౒หߢ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ߦ❬߇ࠆ⎇ⓥࠍⴕߞߚ‫ޕ‬1㧕ጘ㒂ᄢቇߩࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⎇ⓥᡰេ㧦ࠥࡁࡓ࡮ࡊࡠ࠹ࠝ࡯ࡓ⸃ᨆᯏེߦ౒ὶὐ࡟࡯ࠩ࡯㗼ᓸ㏜㧘
ࡃࠗࠝࠗࡦࡈࠜࡑ࠹ࠖࠢࠬ㑐ㅪ⸳஻╬ࠍᢛ஻ߒߡోቇ߆ࠄߩ೑↪ߦኻᔕߔࠆߣߣ߽ߦ㧘ฃ⸤ࠪ࡯ࠢࠛ
ࡦࠬࠨ࡯ࡆࠬߢߪቇౝ LAN ࠍ↪޿ߡㄦㅦߦ⚿ᨐࠍ㈩ାߒߡ⎇ⓥᡰេࠍⴕߞߡ޿ࠆ‫ޕ‬
2㧕ࠥࡁࡓ⎇ⓥಽ㊁ RI කቇᣉ⸳ߩ㐿⸳ߦࠃࠅ㧘ቇౝߦ㓸⚂ߒߚ 2 ᣉ⸳ߢోቇ⊛ߦ቟ో߆ߟりㄭߥ RI ታ㛎߇น⢻ߥᢎ⢒⎇ⓥⅣႺࠍᢛ஻ߒߚ‫ޕ‬
3㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ߩ࿖ౝ⸻ᢿࠪࠬ࠹ࡓࠍ⏕┙ߒ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓᰳ៊∝ߢߪ࿖ౝో∝଀ߩ࠲ࡦࡄ
ࠢ࡮ㆮવሶ࡟ࡌ࡞ߢߩ⸻ᢿ㧘ᣂⷙ∛࿃ㆮવሶߩ⸃᣿㧘ጘ㒂ᄢቇߩಽ㘃ࠍ⊒⴫ߔࠆߣߣ߽ߦ㧘ࡍ࡞ࠝࠠࠪ࠰࡯ࡓߣ␹⚻⊒↢ߩ㑐ࠊࠅ߿ᴦ≮ᴺߩ㐿⊒ߦߟ޿ߡ౒ห⎇ⓥࠍዷ㐿ߒߡႎ๔ߒߚ‫ޕ‬
4㧕⎇ⓥᚑᨐߩ␠ળ߳ߩㆶరߥࠄ߮ߦ␠ળ⽸₂ߣߒߡࠨ࠙ࠫࠕ࡜ࡆࠕߩࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛⸻ᢿᡰេࠪ
ࠬ࠹ࡓࠍࠨ࠙ࠫࠕ࡜ࡆࠕ࿖┙∛㒮ߣ౒หߢ⏕┙ߒߚ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷1㧕↢๮⑼ቇᛛⴚߩㅴᱠߣߣ߽ߦࠪࠬ࠹ࡓࡃࠗࠝࡠࠫ࡯㑐ㅪ⸃ᨆᯏེߩㅴᱠ߽⋡ⷡ߹ߒߊ㧘ቇౝߦ߅ߌࠆ
↢๮⑼ቇߩᢎ⢒⎇ⓥ᳓Ḱࠍ㜞ᐲߦ⛽ᜬߔࠆߚ߼ߦߪ㧘㓸⚂ൻߒߚᣉ⸳ߦ⸳஻߿ᄢဳᯏེࠍ⸳⟎ߒߡᦝᣂߒߡ೑↪ࠍᐢߍ㧘ቇౝߦ߅ߌࠆ࠰ࡈ࠻߿ࡂ࡯࠼㕙ߢߩ⎇ⓥᖱႎࠪࠬ࠹ࡓࠍᢛ஻ߒߡㇱዪߩ၂ᩮࠍ⿧
߃ߚోቇ⊛ߥᢎ⢒⎇ⓥߩផㅴ߇ᦸ߹ࠇࠆ‫ޕ‬
2㧕RI ታ㛎ᣉ⸳ߦ㑐ߒߡߪ 2 ᣉ⸳ߩ቟ቯߒߚㆇ༡ߣ RI ߦ♖ㅢߒߚኾછᢎቭߩ㈩ዻ߇ਇนᰳߢ޽ࠆ‫ޕ‬
3㧕⎇ⓥᡰេ࠮ࡦ࠲࡯ߩㆇ༡ߦᓥ੐ߒߥ߇ࠄ⎇ⓥ⠪ߣߒߡߩࡕ࠴ࡌ࡯࡚ࠪࡦࠍ଻ߟߚ߼ߦߪ㧘⥄ࠄ߇₸వߒߡ⎇ⓥ࠹࡯ࡑࠍ⸳ቯߒߡ౒ห⎇ⓥࠍዷ㐿ߒ㧘ᄢቇ㒮߽฽߼ߚ⎇ⓥ⠪ߩᢎ⢒࡮⢒ᚑߦ㑐ࠊࠆᆫ൓߇ᔅ
ⷐߣᕁࠊࠇࠆ‫ޕ‬੹ᓟߩዷᦸ
1㧕ጘ㒂⮎⑼ᄢቇߩ⒖ォ߽㐓ߺ㧘‫ޟ‬࿾ၞߩ⍮ߩ᜚ὐ‫ߡߒߣޠ‬ㇱዪ㧘ᄢቇߩᨒࠍ⿧߃ߚጘ㒂ᄢቇ࿾඙ߩ↢๮⑼ቇ⎇ⓥߩ᜚ὐߣߒߡᣉ⸳㧘⸳஻㧘⚵❱ࠍᢛ஻ߒߡ౒ห⎇ⓥࠍᡰេߒ㧘ၮ␆ߣ⥃ᐥߩ᨞ߌᯅࠍ⋡ᜰߔ‫ޕ‬
2㧕ࡍ࡞ࠝࠠࠪ࠰࡯ࡓ∛ࠍߪߓ߼ߣߔࠆㆮવᕈઍ⻢∛ߩ⸻ᢿ⎇ⓥߩ᜚ὐߣߒߡන৻ㆮવሶ∛߆ࠄ↢ᵴ⠌ᘠ∛߹ߢ∛ᘒ⸃᣿㧘ᴦ≮ᴺߩ㐿⊒ࠍⴕ޿㧘ጘ㒂ᄢቇࠃࠅ‫⊒ࠍޠࡓ࡯࠰ࠪࠠࠝ࡞ࡍޟ‬ାߒߡ޿ߊ‫ޕ‬㧙㧙㧔16㧕↢๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯㧔ህ᳇ᕈ⩶⎇ⓥಽ㊁㧕1㧚⎇ⓥߩ᭎ⷐ
ᒰಽ㊁ߢߪ㧘⥃ᐥᓸ↢‛ቇߩ┙႐߆ࠄ㧘ህ᳇ᕈ⩶࡮ህ᳇ᕈ⩶ᗵᨴ∝ߦ㑐ߔࠆၮ␆⊛࡮⥃ᐥ⊛⎇ⓥࠍㅴ߼ߡ޿ࠆ‫ౕޕ‬૕⊛ߦߪ⎕்㘑㧘ࠟࠬუ∓㧘ࡏ࠷࡝࠿ࠬ∝ߥߤᲥ⚛↥↢ᕈߩህ᳇ᕈ⩶ߦࠃࠆᄖ࿃ᕈߩᗵᨴ∝㧘߅߽ߦⴚᓟߦ⷗ࠄࠇࠆህ᳇ᕈ⩶ߣㅢᕈ⩶߇⋧ਸ਼⊛ߦ∛ේᕈࠍ⊒ើߔࠆౝ࿃ᕈߩⶄᢙ⩶ᗵᨴ∝㧘⧘⢩ࠍ߽ߟ
ህ᳇ᕈ⩶ߦࠃࠆ㒮ౝᗵᨴ∝ߥߤߩህ᳇ᕈ⩶߇㑐ଥߔࠆᄙ⒳ᄙ᭽ߩᗵᨴ∝ߩ⸻ᢿ㧘ᴦ≮㧘ߘߒߡ੍㒐ߦᓎߛߟࠃ߁ߥ⎇ⓥࠍ⚦⩶ቇ⊛ߥ┙႐߆ࠄⴕߞߡ޿ࠆ‫ޕ‬ህ᳇ᕈ⩶ߩಽ㔌ၭ㙃หቯᴺߩᡷ⦟㧘ህ᳇ᕈ⩶ߩ∛ේ࿃ሶ㧘
ህ᳇ᕈ⩶ߩ᛫⩶⮎ᗵฃᕈߩ᷹ቯߣߘߩ᷹ቯᴺߩᡷ⦟㧘᛫ህ᳇ᕈ⩶૞↪ࠍ᦭ߔࠆ‛⾰ߩត⚝ߣߘࠇࠄߩ᛫⩶ജߩ⹏ଔ㧘ህ᳇ᕈ⩶ߩ᛫⩶⮎ߦኻߔࠆ⠴ᕈ⃻⽎ߩ⸃᣿㧘ߘߒߡ㧘ህ᳇ᕈ⩶߇ఝ൓ߥࡅ࠻࿕᦭⚦⩶ฌߩ⇣Ᏹൻ߇ේ࿃ߣߥߞߡ߅ߎࠆ⒳‫ޟߩޘ‬21 ਎♿∛‫⎇ߩߡ޿ߟߦޠ‬ⓥߥߤࠍዷ㐿ߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᷰㆺ㇌෹
ᢎ᝼㧦
ಎᢎ᝼㧦 ↰ਛ㚅߅㉿
ᓟ⮮㓉ᰴ
ഥᢎ㧦

Kunitomo Watanabe
Kaori Tanaka
Takatsugu Goto3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ਃ㡞ᑝ❥㧚Q27 ᄖ⑼㗔ၞߢᵈᗧߔߴ߈⌀⩶∝ߣ࡝ࠬࠢߪ㧫㧦὇ጊཅિ㧘㐷↰቞ੱ㧘〔⷗⵨✬㧚ᷓ࿷ᕈ⌀⩶∝ Q&A㧘ᄢ㒋㧦ක⮎ࠫࡖ࡯࠽࡞␠㧧2006 ᐕ㧦84㧙86㧚
2㧕 ਃ㡞ᑝ❥㧚╙Υ┨ Ꮢਛᗵᨴ∝ߦኻߔࠆᚻⴚᤨߩ᛫⩶⮎ߩ૶޿ᣇ D㧚↥ᇚੱ⑼∔ᖚ㧦὇ጊཅિ✬㧚๟ⴚᦼᗵᨴኻ╷ࡑ࠾ࡘࠕ࡞ ᛫⩶⮎૶↪ᴺ߆ࠄ๟ⴚᦼ▤ℂ߹ߢ㧘᧲੩㧦ධᳯၴ㧧2006 ᐕ㧦62㧙67㧚
3㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚╙ 1 ┨ ∝⁁࡮∝୥߆ࠄߤࠎߥᬌ૕ࠍណขߒߤߩࠃ߁ߦ⸻ᢿࠍㅴ߼ࠆ
߆ 7 ↥ᇚੱ⑼㗔ၞߩᗵᨴ∝߇⇼ࠊࠇߚߣ߈㧦ᴡ㊁⨃㧘ᐔẟᵗ৻✬㧚ࡌ࠶࠼ࠨࠗ࠼ߢᓎ┙ߟᓸ↢‛ᬌᩏࠟࠗ࠼ ૗ߩᬌᩏࠍߔࠆ߆࡮⚿ᨐࠍߤ߁⹏ଔߔࠆ߆㧘᧲੩㧦ᢥశၴ㧧2006 ᐕ㧦50㧙57㧚
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ࡏ࠷࡝࠿ࠬਛᲥߩ․ᓽߣኻᔕ㧦ᷰㄝᴦ㓶✬㧚㘩ਛᲥᬌᩏ࡮⸻≮ߩࠦ࠷ߣ⪭ߣߒⓣ㧘᧲੩㧦ਛጊᦠᐫ㧧2006 ᐕ㧦20㧙21.
5㧕 ᷰㆺ㇌෹㧚4 ᗵᨴ∝߅ࠃ߮ነ↢⯻∔ᖚ 4㧙5 ৻⥸⚦⩶ᗵᨴ∝ 1)ࠣ࡜ࡓ㓁ᕈ⃿⩶ᗵᨴ∝(4)⎕்㘑⩶㧘(5)ࠟ
ࠬუ∓⩶⟲㧘(6)࠺ࡈࠖࠪ࡞⩶㧘4)ࠣ࡜ࡓ㒶ᕈ⚦⩶ᗵᨴ∝ 20)ࡃࠢ࠹ࡠࠗ࠺ࠬ╬ߩή⧘⢩ህ᳇ᕈ⩶߇㑐ਈߔ
ࠆⶄᢙ⩶ᗵᨴ∝㧦᧖ᧄᕡ᣿㧘⍫ፒ⟵㓶✬㧚ౝ⑼ቇ╙ 9 㧘᧲੩㧦ᦺୖᦠᐫ㧧2007 ᐕ㧦303㧙305㧘324㧙325㧚
6㧕 ᷰㆺ㇌෹㧚ᗵᨴ∝ᬌᩏ ᗵᨴ∝ㆮવሶᬌᩏ ࠢࡠࠬ࠻࡝ࠫ࠙ࡓ࡮࠺ࠖࡈࠖࠪ࡟ㆮવሶᬌᩏ ᓸ↢‛↥↢‛࡮ઍ⻢↥‛ ࡏ࠷࡝࠿ࠬᲥ⚛㧘CD ࠻ࠠࠪࡦ㧘࠹࠲ࡁࠬࡄࠬࡒࡦ㧦㜞ਭਭ㤚⋙ୃ㧚⥃ᐥᬌᩏ࠺࡯࠲ࡉ࠶ࠢ 2007
㧙2008㧘᧲੩㧦කቇᦠ㒮㧧2007 ᐕ㧦491㧙492㧘524㧙528㧚
7㧕 ᷰㆺ㇌෹㧚3.ᗵᨴ∝ ή⧘⢩ህ᳇ᕈ⩶ᗵᨴ∝㧦ጊญᔀ㧘ർේశᄦ㧘⑔੗ᰴ⍫✚✬㓸㧚੹ᣣߩᴦ≮ᜰ㊎㧘᧲੩㧦කቇᦠ㒮㧦2007 ᐕ㧦166㧙167㧚
8㧕 ᷰㆺ㇌෹㧚╙ 3 ┨ 1 ᦨᣂߩህ᳇ᕈ⩶ߩಽ㘃࡮๮ฬ㧘╙ 3 ┨ 2 Ᏹ࿷⚦⩶ฌࠍ᭴ᚑߔࠆህ᳇ᕈ⩶㧦ᣣᧄൻቇ≮ᴺቇળ㧘ᣣᧄህ᳇ᕈ⩶ᗵᨴ∝⎇ⓥળ✬㧚ህ᳇ᕈ⩶ᗵᨴ∝⸻ᢿ࡮ᴦ≮ࠟࠗ࠼࡜ࠗࡦ 2007㧘᧲੩㧦౒๺ડ↹㧧
2007 ᐕ㧦192㧙209㧚
9㧕 ↰ਛ㚅߅㉿㧚╙ 1 ┨ 3 ⮎೷ᗵฃᕈ⹜㛎㧘╙ 3 ┨ 3 ⠴ᕈህ᳇ᕈ⩶㧦ᣣᧄൻቇ≮ᴺቇળ㧘ᣣᧄህ᳇ᕈ⩶ᗵᨴ∝⎇ⓥળ✬㧚ህ᳇ᕈ⩶ᗵᨴ∝⸻ᢿ࡮ᴦ≮ࠟࠗ࠼࡜ࠗࡦ 2007㧘᧲੩㧦౒๺ડ↹㧧2007 ᐕ㧦30㧙37㧘210㧙213㧚
10㧕 ᷰㆺ㇌෹㧚3㧚ህ᳇ᕈ⩶ᗵᨴ∝㧦੗᧛⵨ᄦ✬㓸ਥᐙ㧚ࠊ߆ࠅ߿ߔ޿ౝ⑼ቇ ╙ਃᗵᨴ∝ ᧲੩ ಽశၴ2008 ᐕ㧦485㧙487㧚
11㧕 ᷰㆺ㇌෹㧚3㧚ህ᳇ᕈ⩶ᗵᨴ∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✚✬㓸㧚ዊఽ⑼ቇ ᧲੩ කቇᦠ㒮 2008 ᐕ㧦809
㧙811㧚
⪺ᦠ㧔᰷ᢥ㧕
ߥߒ✚⺑㧔๺ᢥ㧕
1㧕 ↰ਛ㚅߅㉿㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧚ࡃࠢ࠹ࡠࠗ࠺ࠬዻ㧘ᗵᨴߣ᛫⩶⮎ 2006 ᐕ㧧9 Ꮞ㧦2㧙4.
2㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᓸ↢‛ቇ⷗࿾߆ࠄߺߚ᛫⩶⮎ߩㆡᱜ૶↪ᴺߣ⮎೷⠴ᕈ⩶೙ᓮߩߚ߼ߩ
ᚢ⇛㧘࡝࠙ࡑ࠴⑼ 2006 ᐕ㧧35 Ꮞ㧦63㧙68㧚
3㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚MRSA ᗵᨴ∝ߦ߅ߌࠆ࡝ࡀ࠱࡝࠼ߩ᦭ലᕈ㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦
83㧙84㧚
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ᵈᗧߔߴ߈ᗵᨴ∝ߣኻ╷ 5㧚↥ᇚੱ⑼㗔ၞߩᗵᨴ∝ߣኻ╷㧘ᢇᕆකቇ
2006 ᐕ㧧30 Ꮞ㧦216㧙220㧚
5㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚ህ᳇ᕈ⩶ߦࠃࠆ࠮ࡊࠪࠬߪሽ࿷ߔࠆ߆㧘ᴦ≮ቇ 2006 ᐕ㧧40 Ꮞ㧦521
㧙524㧚

㧙㧙

6㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚๟↥ᦼߦ߅ߌࠆ B ⟲ㅪ㎮⃿⩶ᗵᨴ∝ߩ੍㒐ߦ㑐ߔࠆ CDC ߩᡷ⸓ࠟࠗ
࠼࡜ࠗࡦ ᣂߒߊ⊒⴫޽ࠆ޿ߪᡷ⸓ߐࠇߚᗵᨴ∝ߦ㑐ߔࠆࠟࠗ࠼࡜ࠗࡦ㧘ൻ≮ߩ㗔ၞ 2006 ᐕ㧧22 Ꮞ
Suppl. 1㧦134㧙137㧚
7㧕 ਃ㡞ᑝ❥㧚↥ᇚੱ⑼㗔ၞߦ߅ߌࠆ๟ⴚᦼߩᗵᨴ೙ᓮ㧘PHYSICIAN’S THERAPY MANUAL 2006 ᐕ㧧5Ꮞ㧦1㧙2㧚
8㧕 ਃ㡞ᑝ❥㧚ࠃߊㆣㆄߔࠆᗵᨴ∝‫߇޿ߒ⃟ޔ‬⍮ߞߡ߅߈ߚ޿ᗵᨴ∝ ᇚੱ⑼㧘INFECTION FRONT 2006
ᐕ㧧7 Ꮞ㧦12㧙13㧚
9㧕 ਃ㡞ᑝ❥㧚․ᱶ∛ᘒߦ߅ߌࠆ᛫⩶ൻቇ≮ᴺ ᅧᇚ㧘ᣣᧄౝ⑼ቇળ㔀⹹ 2006 ᐕ㧧95 Ꮞ㧦2208㧙2213㧚
10㧕 ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧚⣪Ᏹ࿷⩶ 㨪ߘߩሽ࿷ᗧ⟵ߣᓎഀ㨪㧚ᣣᧄ⣺ౝ⥃ᐥᓸ↢‛ቇળળ⹹ 2006 ᐕ㧧8 Ꮞ㧦
31㧙34.
11㧕 ᷰㆺ㇌෹㧘ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧚ẩ≌ᕈᄢ⣺Ἳߩᚑ࿃߅ࠃ߮Ⴧᖡߦ㑐ࠊࠆ⚦⩶࿃ሶߩ৻ߟߣߒߡߩ⎫㉄ㆶర⚦⩶ ᣣᧄ⥃ᐥ 2007 ᐕ㧧65 Ꮞ㧦1337㧙1346.
12㧕 ᷰㆺ㇌෹㧚ญ⣧ౝ⚦⩶ฌ᭴ᚑህ᳇ᕈ⩶ߣህ᳇ᕈ⩶ᗵᨴ∝㧘ᣣᧄญ⣧ᗵᨴ∝ቇળ㔀⹹ 2007 ᐕ㧧14 Ꮞ㧦3㧙
8.
13㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹.᛫⩶⮎ࠍㆬᛯߔࠆ਄ߢ⍮ߞߡ߅߈ߚ޿ህ᳇ᕈ⩶ᗵᨴ∝ߣህ᳇ᕈ⩶ߩ⠴ᕈൻ ࠕࠬ࠹࡜ࠬ⵾⮎‫ޟ‬ᗵᨴ∝‫ ޠ‬2007 ᐕ㧧37 Ꮞ㧦41㧙48.
14㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚․㓸 ᛫⩶⮎ߩ․ᕈࠍ↢߆ߒߡ਄ᚻߦ૶߁ߎߟ ᛫⩶⮎ߩ PK/PD ࠍᵴ߆ߔᴦ≮⁁ᴫߣߪ㧚ᗵᨴߣ᛫⩶⮎ 2007 ᐕ㧧10 Ꮞ㧦102㧙110.
15㧕 ᷰㆺ㇌෹. ஍ᕈህ᳇ᕈ⩶ᗵᨴ∝ߩၮ␆ߣ⥃ᐥ஍ᕈህ᳇ᕈ⩶ߩಽ㘃 ⥃ᐥߣᓸ↢‛ 2008 ᐕ㧧35 Ꮞ㧦21
㧙28.
✚⺑㧔᰷ᢥ㧕
1㧕 Nagayama A, Yamaguchi K, Watanabe K, Tanaka M, Kobayashi I, Nagasawa Z. Final report fromthecommittee on Antimicrobial Susceptibility Testing, Japanese Society of Chemotherapy, on the agar
dilution method (2007). J Infect Chemother. 2008;14:383-392.
ේ⪺㧔๺ᢥ㧕
1㧕 ਃ㡞ᑝ❥㧘₹⥢ノᒾ㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧦ࠢ࡜ࡒࠫࠕຜ㗡ᗵᨴߩ⃻⁁ߣᴦ≮ᣇᴺߦ㑐ߔࠆᬌ⸛㧘Jpn J
Antibiotics㧚2006 ᐕ㧧59 Ꮞ㧦35㧙40㧚
2㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚⠴ᕈൻ㒐ᱛߩߚ߼ߩ᛫⩶⮎૶↪ ᛫⩶⮎ࠨࠗࠢ࡝ࡦࠣ≮ᴺ㧘᦬ೀ⮎੐
2006 ᐕ㧧48 Ꮞ㧦1521㧙1527㧚
3㧕 ਃ㡞ᑝ❥㧚PK/PD ߦၮߠ޿ߚ᛫⩶⮎ߩㆡᱜߥᛩਈ⸳⸘㧘PHYSICIAN’S THERAPY MANUAL (PTM)
2006 ᐕ㧧5 Ꮞ㧦9㧚
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘ጊጟ৻ᷡ㧘ਃベ߹ࠁߺ㧘Ỉ᧛ᴦ᮸㧘᧻Ꮉᵗሶ㧘૒ષᶈ๺㧘ᵻ㊁⵨ሶ㧘⍹ㇹầ⟤㧘ᧃ᧻ኡਯ㧘᧻ේ⨃ⷙ㧘ᯅᷰᒾౖ㧘ኹ࿾⌀ᑿ㧘ች㉿ᱜ༹㧘ᏒᎹᖝม㧚ጘ㒂⋵ਅߦ߅޿ߡಽ㔌ߐࠇߚ✛⤥⩶ߦ㑐ߔࠆ∉ቇ⊛ᬌ⸛ 㨪2004 ᐕ㨪㧘Jpn J Antibiot㧚2006 ᐕ㧧59 Ꮞ㧦355㧙363㧚
5㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧘₹⥢ノᒾ㧘๺ᴰቁᴦ㧚PK/PD ℂ⺰ߦၮߠ޿ߚࠟ࠴ࡈࡠࠠࠨࠪࡦߩᛩਈ
ᣇᴺߦ㑐ߔࠆ⥃ᐥ⊛ᬌ⸛㧘Jpn J Antibiot㧚2006 ᐕ㧧59 Ꮞ㧦364㧙372㧚
6㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧦⢖Ἳ⃿⩶߅ࠃ߮ࠗࡦࡈ࡞ࠛࡦࠩ⩶ߦኻߔࠆ⚻ญࠠࡁࡠࡦ⮎ߩ Monte
Carlo Simulation ࠍ↪޿ߚ᦭ലᕈ⹏ଔ㧘Jpn J Antibiot㧚2006 ᐕ㧧59 Ꮞ㧦468㧙473㧚
7㧕 ↰ਛ㚅߅㉿㧘ખየ⾫৻㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧦ࡑࠗࠢࡠ࡝ࡦࠣ AN ࠍ↪޿ߚህ᳇ᕈή⧘⢩ࠣ࡜ࡓ㓁ᕈ᪝⩶⟲ߩ࡟ࡌ࡞ 1 ◲ᤃหቯߩឭ᩺㧘Rinsho Biseibutshu Jinsoku Shindan Kenkyukai Shi㧚2006 ᐕ㧧17 Ꮞ㧦
115㧙124.
8㧕 ੗਄ᣇ᥍㧘⩵ᳰ⨊↭㧘ዊ᫪⼱෹⛗㧘๺ᴰ೰㧘ᷰㆺ㇌෹㧘␹㊁⧷Პ㧚Clostridium perfringens ǩᲥ⚛↥↢ㆮવሶߩࠢࡠ࡯࠾ࡦࠣߣᄢ⣺⩶ߦ߅ߌࠆ⚵ߺ឵߃࠲ࡦࡄࠢ⾰ߩ⊒⃻ߣಽᴲ㧘⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ⹹
2007 ᐕ㧧18 Ꮞ㧦127㧙135.
9㧕 ຠᎹ㐳ᄦ㧘↰ਛ㚅߅㉿㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧘┻ጊᑝశ㧘ᮮጊ㓉㧘ᱞᧃ⧐↢㧘⼱ญᱜື㧦⓫ሹᕈ⣻⤑Ἳ߆ࠄߩಽ㔌⩶ߣߘߩ⮎೷ᗵฃᕈ㧘The Japanese Journal of Antibiotics 2007 ᐕ㧧60 Ꮞ㧦206㧙220.
10㧕 ਃ㡞ᑝ❥㧘₹⥢ノᒾ㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧦 ∝଀ႎ๔ ሶችౝㆱᅧౕེࠍⵝ⌕ਛߦሶች㗪ㇱߦ⊒∝ߒߚ
Actinomyces israelii ߦࠃࠆ᡼✢⩶∝ߩ 1 ଀㧚ᣣᧄᄖ⑼ᗵᨴ∝ቇ㔀⹹ 2007 ᐕ㧧4 Ꮞ㧦139㧙141.
11㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚⢖Ἳ⃿⩶߅ࠃ߮ࠗࡦࡈ࡞ࠛࡦࠩ⩶ߦࠃࠆᗵᨴ∝ߦኻߔࠆฦ⒳ࠞ࡞ࡃࡍ
ࡀࡓ⮎ߩࡕࡦ࠹ࠞ࡞ࡠ࡮ࠪࡒࡘ࡟࡯࡚ࠪࡦߦࠃࠆ᦭ലᕈ⹏ଔ㧘The Japanese Journal of Antibiotics 2007
ᐕ㧧60 Ꮞ㧦47㧙57.
12㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧘ᷰㆺ㇌෹㧚Monte Carlo Simulation ᴺࠍ↪޿ߚህ᳇ᕈ⩶ᗵᨴ∝ߦኻߔࠆࡈ࡞ࠝࡠ
ࠠࡁࡠࡦ♽⮎ߩ᦭↪ᕈ੍᷹㧘The Japanese Journal of Antibiotics 2007 ᐕ㧧60 Ꮞ㧦335㧙343.
13㧕 ᴡ↰ᐘ㆏㧘⍹ේື㧘᧻੗㓉㧘ᵤᎹ᣽਽㧘᧻ᧄືᦶ㧘ᷰㆺ㇌෹㧘ਛፉశᅢ㧚ⶄ㔀ᕈዩ〝ᗵᨴ∝ࠍኻ⽎ߣߒߚ
Sitafloxacin ߣ Levofloxacin ߩੑ㊀⋤ᬌᲧセ⹜㛎㧘ᣣᧄൻቇ≮ᴺቇળ㔀⹹ 2008 ᐕ㧧56 Ꮞ(Ⴧೀ 1 ภ)㧦
S81㧙91.
ේ⪺㧔᰷ᢥ㧕
1㧕 Tanaka K, Mikamo H, Nakao K, WatanabeK. In vitro antianaerobic activity of DX-619, a new
des-fluoro(6) quinolone. Antimicrob Agents and Chemother. 2006;50:3908-3913.
IF 4.3902㧕 Matsubara K, Mikamo H, Numa M, Yamamoto G, Kusano H, Takamine Y. Three fatal cases of invasive㧙㧙serotype VI group B streptococcal infection. J Infect. 2006;53:139-142.
3㧕 Ishida Y, Hayashi T, Goto T, Kimura A, Akimoto S, Mukaida N, Kondo T. Essential involvement of
CX3CR1-mediated signals in the bactericidal host defense during septic peritonitis. J Immunol.
2008;181:4208-4218.
4㧕 Sakai A, Watanabe K, Koketsu M, Akuzawa K, Yamada R, Li Z, Sadanari H, Matsubara K,
MurayamaT. Anti-human cytomegalovirus activity of constituents from Sasa albo-marginata{Kumazasa in Japan}. Anti Chem Chemother. 2008;19:125-132.
5㧕 Takumi S, Komatsu M, Aoyama K, Watanabe K, Takeuchi T. Oxygen induces mutation in a strict
anaerobe, Prevotella melaninogenica. Free Rad Biol Medi. 2008;44:1857-1862.
6㧕 Yasui K, Kano Y, Tanaka K, Watanabe K, Shimizu-Kadota M, Yoshikawa H, Suzuki T. Improvement ofBacterial transformation efficiency using plasmid artificial modification. Nuc Acids Res. 2008,1-7.

IF 2.849

IF 6.068

IF 4.813
IF 6.954

4㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦౎ᧁື਽(࿖┙㐳ኼක≮࠮ࡦ࠲࡯∛㒮)㧘⎇ⓥಽᜂ⠪㧦↰ਛ㚅߅㉿㧧㐳ኼක≮⎇ⓥᆔ⸤⾌㧦㔍ᴦᕈߩ㜞㦂⠪⢖Ἳߦኻߔࠆ቟ోߢ᦭ലߥᴦ≮ᴺߦ㑐ߔࠆ⎇ⓥ(ಽᜂ⎇ⓥ⺖㗴ฬ ⺋ྚᕈ⢖Ἳߩ⿠Ἳ⩶ߩ⚦⩶ቇ⊛ᬌ⸛ߣߘߩ∛ᘒ߳ߩ㑐ਈߩᬌ⸛)㧧ᐔᚑ 19 ᐕᐲ㧧1,500 ජ౞
2㧕ฃ⸤⎇ⓥ1㧕 ᷰㆺ㇌෹㧦㔍ᴦᕈߩ㜞㦂⠪⢖Ἳߦኻߔࠆ቟ోߢ᦭ലߥᴦ≮ᴺߦ㑐ߔࠆ⎇ⓥ(ಽᜂ⎇ⓥ⺖㗴ฬ ⺋ྚᕈ⢖Ἳߩ⿠Ἳ⩶ߩ⚦⩶ቇ⊛ᬌ⸛ߣߘߩ∛ᘒ߳ߩ㑐ਈߩᬌ⸛)㧧ᐔᚑ 18 ᐕᐲ㧧1,100 ජ౞㧦࿖┙㐳ኼක≮࠮ࡦ࠲࡯
2㧕 ਃ㡞ᑝ❥㧦ࡈ࡞ࠝࡠࠠࡁࡠࡦ⮎߇ Clostridium difficile ߩ⚦⢩Ქ⚛↥↢ߦ෸߷ߔᓇ㗀ߦߟ޿ߡ㧧ᐔᚑ18 ᐕᐲ㧧4,538.625 ජ౞㧦╙৻⵾⮎ᩣᑼળ␠ ⎇ⓥ㐿⊒ᧄㇱ ഃ⮎╙৻⎇ⓥᚲ
3㧕 ᷰㆺ㇌෹㧘ਃ㡞ᑝ❥㧦CS-023 ߩ⚦⩶ቇ⊛⹏ଔߦ㑐ߔࠆฃ⸤⎇ⓥ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧4,000 ජ౞(2,000㧦2,000 ජ౞)㧦ਃ౒ᩣᑼળ␠ ╙ੑ↢‛⎇ⓥᚲ
4㧕 ਃ㡞ᑝ❥㧘↰ਛ㚅߅㉿㧦ᣂⷙࠞ࡞ࡃࡍࡀࡓൻว‛ SMP-601 ߩฦ⒳ህ᳇ᕈ⩶ߦኻߔࠆ᦭ലᕈߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19㧙20 ᐕ㧦1,000 ජ౞㧦ᄢᣣᧄ૑෹⵾⮎ᩣᑼળ␠ ⎇ⓥᧄㇱ3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷰㆺ㇌෹㧦
1㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ࡮ਛᣣᧄ࿾ᣇળℂ੐(㨪⃻࿷)2㧕 ⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળᐙ੐(㨪⃻࿷)3㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⥃ᐥ⣺ౝᓸ↢‛ቇળℂ੐(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)
5㧕 ᣣᧄ⚦⩶ቇળ⹏⼏ຬ(ᐔᚑ 18 ᐕ㨪⃻࿷)
6㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)7㧕 ᣣᧄൻቇ≮ᴺቇળࡉ࡟ࠗࠢࡐࠗࡦ࠻ᬌ⸛ᆔຬળᆔຬ(㨪ᐔᚑ 20 ᐕ 5 ᦬)
8㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
9㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᡷ⸓ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)ਃ㡞ᑝ❥㧦
1㧕 ᣣᧄᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ࡮᛫⌀⩶⮎⥃ᐥ⹏ଔᆔຬળᆔຬ(㨪⃻࿷)3㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄᕈᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)5㧕 ᣣᧄⅣႺᗵᨴቇળ⹏⼏ຬ(㨪⃻࿷)6㧕 ᣣᧄ⥃ᐥ⣺ౝᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)㧙㧙7㧕 ᣣᧄᄖ⑼ᗵᨴ∝ቇળ⹏⼏ຬ(㨪⃻࿷)↰ਛ㚅߅㉿㧦
1㧕 ᣣᧄൻቇ≮ᴺቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᆔຬળᆔຬ(ᐔᚑ 18 ᐕ 7 ᦬㨪ᐔᚑ 20 ᐕ 5 ᦬)
3㧕 ᣣᧄൻቇ≮ᴺቇળህ᳇ᕈ⩶ᗵᨴᴦ≮ߩࠟࠗ࠼࡜ࠗࡦᡷ⸓ᆔຬળᆔຬ(ᐔᚑ 20 ᐕ 9 ᦬㨪⃻࿷)
4㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹ᷰㆺ㇌෹㧦
1㧕 ⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ⹹(JARMAM)㧧✬㓸ᆔຬ(㨪⃻࿷)ਃ㡞ᑝ❥㧦1㧕 ᣣᧄൻቇ≮ᴺቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)2㧕 ᣣᧄᄖ⑼ᗵᨴ∝ቇળ㧧✬㓸ᆔຬ(㨪⃻࿷)↰ਛ㚅߅㉿㧦
1㧕 ᣣᧄ⥃ᐥᓸ↢‛ቇળ㧧✬㓸ᆔຬ(㨪ᐔᚑ 20 ᐕ 3 ᦬)
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷰㆺ㇌෹㧦
1㧕 ╙ 51 ࿁ᣣᧄญ⣧ᄖ⑼ቇળ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ർ਻ᎺᏒ㧘᜗ᓙ⻠Ṷ‫ޟ‬ᾢ╣ߩ㜞࿶ടᾲಣℂᶧߩᜬ
ߟ᛫⩶૞↪ߣක≮߳ߩᔕ↪‫ޠ‬Ṷ⠪)
2㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂Ꮢ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛ᗵᨴ߇ේ࿃࡮
Ⴧᖡ࿃ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴‫ޠ‬ᐳ㐳)
3㧕 ╙ 15 ࿁ᣣᧄญ⣧ᗵᨴ∝ቇળ✚ળ(ᐔᚑ 18 ᐕ 11 ᦬㧘ᄢ㒋Ꮢ㧘᜗ᓙ⻠Ṷ‫ޟ‬ญ⣧ౝ⚦⩶ฌ᭴ᚑ⩶ߣህ᳇
ᕈ⩶ᗵᨴ∝ߦ㑐ߔࠆ⹤㗴㨪ህ᳇ᕈ⩶ಽ㘃๮ฬߩᄌൻߣ⃻࿷ߩ᛫⩶ൻቇ≮ᴺߦኻᔕߒߡ㨪‫ޠ‬Ṷ⠪)
4㧕 ╙ 37 ࿁ᣣᧄህ᳇ᕈ⩶ᗵᨴ∝⎇ⓥળ(ᐔᚑ 19 ᐕ 3 ᦬㧘ᄹ⦟Ꮢ㧘ᢎ⢒⻠Ṷ‫࠻ࡅޟ‬૕ౝᏱ࿷ህ᳇ᕈ⩶⎇ⓥ
ߩᣂዷ㐿‫ޠ‬ᐳ㐳)
5㧕 ╙ 10 ࿁⥃ᐥ⣺ౝᓸ↢‛ቇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 9 ᦬㧘㐳ፒᏒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬⣺ౝ⚦⩶೙ᓮߣ∔ᖚ੍㒐࡮ᴦ≮‫ޠ‬ᐳ㐳)
6㧕 ╙ 20 ࿁⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ✚ળ(ᐔᚑ 19 ᐕ 7 ᦬㧘੩ㇺᏒ㧘ࠪࡦࡐࠫ࠙ࡓ‫ߩࠄ߆ࠇߎޟ‬ᓸ↢‛ㄦㅦ⸻ᢿߩᣇะ‫ޠ‬ᐳ㐳)7㧕 ᣣᧄㄘ⧓ൻቇቇળਛㇱᡰㇱ╙ 153 ࿁଀ળ(ᐔᚑ 19 ᐕ 11 ᦬㧘ฬฎደ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ή㉄⚛ߢ௛ߊᓸ↢‛̆ህ᳇ᕈ⩶ߩ਎⇇㨪ⅣႺߣஜᐽߩⷞὐ߆ࠄ㨪‫ޠ‬Ṷ⠪)8㧕 ╙ 51 ࿁ᣣᧄᗵᨴ∝ቇળਛᣣᧄ࿾ᣇળቇⴚ㓸ળ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᄢ㒋㧘․೎⻠Ṷ‫⮎ޟ‬೷⠴ᕈᯏ᭴̆ၮ␆⎇ⓥߢࠊ߆ߞߡ߈ߚߎߣ‫ޠ‬ᐳ㐳)ਃ㡞ᑝ❥㧦
1㧕 ╙ 21 ࿁ᣣᧄⅣႺᗵᨴቇળቇⴚ㓸ળ(ᐔᚑ 18 ᐕ 2 ᦬㧘᧲੩㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬੐଀߆ࠄቇ߱㒮ౝᗵᨴኻ╷ Bacillus cereus group ߦࠃࠆࠕ࠙࠻ࡉ࡟ࠗࠢ߇⇼ࠊࠇߚ߇ࠕ࠙࠻ࡉ࡟ࠗࠢߣᢿቯߢ߈ߥ߆
ߞߚ੐଀‫ޠ‬Ṷ⠪)
2㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ✚ળ(ᐔᚑ 18 ᐕ 5 ᦬㧘੩ㇺ㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ህ᳇ᕈ⩶ᗵᨴ∝ᴦ≮ߩࠟࠗ࠼࡜ࠗࡦ‫ޠ‬มળ࡮Ṷ⠪)3㧕 ╙ 19 ࿁⥃ᐥᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ(ᐔᚑ 18 ᐕ 6 ᦬㧘᧻ጊ㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ᧄߡߞࠇߘޟ‬ᒰߦᧄᒰ㧫ㄦㅦ⸻ᢿ㧍㧍 ↥ᇚੱ⑼㗔ၞ‫ޠ‬Ṷ⠪)
4㧕 ╙ 43 ࿁ᣣᧄ⚦⩶ቇળਛㇱᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 10 ᦬㧘ጘ㒂㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᓸ↢‛ᗵᨴ߇ේ࿃࡮
Ⴧᖡ࿃ሶߣߥࠆ∔ᖚߦߟ޿ߡߩᦨㄭߩ⹤㗴 ẩ≌ᕈᄢ⣺Ἳᚻⴚᓟߦ⿠ߎࠆ࿁⣺ྙἻߦ߅ߌࠆ⎫ൻ᳓⚛ㆶర⚦⩶ߩ㑐ਈ‫ޠ‬Ṷ⠪)
5㧕 ╙ 54 ࿁ᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱ✚ળ(ᐔᚑ 18 ᐕ 12 ᦬㧘⑔ጟ㧘᜗ᓙࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ᗵᨴ೙ᓮቇ

㧙㧙߆ࠄߺߚൻቇ≮ᴺߩ޽ࠅᣇ ᛫⩶⮎㑐ㅪਅ∯∝/⣺Ἳߩ⃻⁁ߣ⺖㗴‫ޠ‬Ṷ⠪)↰ਛ㚅߅㉿㧦
1㧕 ╙ 46 ࿁ਛㇱකቇᬌᩏቇળ(ᐔᚑ 19 ᐕ 9 ᦬㧘ᄢ၂Ꮢ㧘ࠪࡦࡐࠫ࠙ࡓ‫ޟ‬ህ᳇ᕈ⩶ࠍ⍮ߞߡ㧘ᢛℂᢛ㗐ࡐࠗࡦ࠻ࠍߟ߆߽߁‫ޠ‬Ṷ⠪)
2㧕 ╙ 50 ળᣣᧄᗵᨴ∝ቇળਛᣣᧄ࿾ᣇળቇⴚ㓸ળ࡮╙ 55 ળᣣᧄൻቇ≮ᴺቇળ⷏ᣣᧄᡰㇱ✚ળ(ᐔᚑ 19
ᐕ 10 ᦬㧘␹ᚭᏒ㧘࡟ࠢ࠴ࡖ࡯࠮࠶࡚ࠪࡦ 2‫⩶⚦ޟ‬ᬌᩏ-⮎೷ᗵฃᕈߣህ᳇ᕈ⩶ߦߟ޿ߡߩၮ␆⍮⼂‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ↰ਛ㚅߅㉿㧘ખየ⾫৻㧘ਃ㡞ᑝ❥㧘ᷰㆺ㇌෹㧦╙ 17 ࿁ JARMAM(ㄦㅦᓸ↢‛ㄦㅦ⸻ᢿ⎇ⓥળ)⾨(2007ᐕᐲ)
9㧚␠ળᵴേᷰㆺ㇌෹㧦
1㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷ද⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ)ਃ㡞ᑝ❥㧦1㧕 ᐔᚑ 18 ᐕᐲጘ㒂⋵ᢎ⢒ᆔຬળ ቇᩞ࡮࿾ၞ଻ஜផㅴ੐ᬺ⻠Ꮷ(ᐔᚑ 18 ᐕᐲ)
2㧕 ጘ㒂⋵කᏧળ STD(ᕈᗵᨴ∝)ታᘒ⺞ᩏᬌ⸛ᆔຬળ೽ᆔຬ㐳(ᐔᚑ 18 ᐕᐲ)
3㧕 ጘ㒂⋵㒮ౝᗵᨴኻ╷ද⼏ળᆔຬ(ᐔᚑ 18 ᐕᐲ)
4㧕 ጘ㒂⋵ࠬࡐ࡯࠷⑼ቇ࠻࡟࡯࠾ࡦࠣ࠮ࡦ࠲࡯ ࠬࡐ࡯࠷࠼ࠢ࠲࡯(ᐔᚑ 18 ᐕᐲ)
5㧕 ␠࿅ᴺੱᣣᧄᗵᨴ∝ቇળኾ㐷ක໧㗴૞ᚑᆔຬ(ᐔᚑ 18 ᐕᐲ)
10㧚ႎ๔ᦠ
1㧕 ㋈ᧁᔀ㧘ᷰㆺ㇌෹㧘↰ਛ㚅߅㉿㧦࠹࡯࡜࡯ࡔ࡯࠼ࡊࡠࡃࠗࠝ࠹ࠖࠢࠬࠍ⋡ᜰߒߚࡆࡈࠖ࠭ࠬ⩶ዻߩୄ⍑⊛ࠥࡁࡓ⸃ᨆ㧦2006 ᐕᢥㇱ⑼ቇ⋭⎇ⓥ⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ㨬ࠥࡁࡓ㨭4 㗔ၞᐲႎ๔ᦠ㧦295 (2007ᐕ 3 ᦬)11㧚ႎ㆏ߥߒ12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥ࡮ᢎ⢒࡮⸻≮ᡰេߪචಽߦߘߩ⽿ോࠍᨐߚߒߡ޿ࠆߣ⠨߃ࠆ߇㧘ᢎຬߩ⎇ⓥ㕙ߦ߅޿ߡߪ㆐ᚑ₸߇ૐ޿ߎߣࠍ⹺߼ߑࠆࠍᓧߥ޿‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷⃻⁁ߢߪ㧘ಽ㊁ߩኾછᛛⴚ⡯ຬ߇ሽ࿷ߒߥ޿ߚ߼㧘ಽ㊁ߩᢎຬߩߺߢ㧘ߔߴߡߩ᩺ઙߦኻᔕߒߥߌࠇ
߫ߥࠄߥ޿‫↢ޕ‬๮⑼ቇ✚ว⎇ⓥᡰេ࠮ࡦ࠲࡯ߣߒߡߩ⽿ോߢ޽ࠆᡰេᬺോࠍᨐߚߔߎߣߦ߶ߣࠎߤߩᤨ
㑆߇ഀ߆ࠇ㧘චಽߥ⎇ⓥ૕೙߇ߣࠇߡ޿ߥ޿ߎߣ߇ᦨᄢߩ⺖㗴ߢ޽ࠆ‫ޕ‬੹ᓟߩዷᦸ೨ㅀߒߚ໧㗴ὐࠍ⸃᳿ߔࠆߚ߼ߦ㧘ኾછߩᛛⴚ⡯ຬࠍ 2 ฬ㈩⟎ߒߡ޿ߚߛߌࠆࠃ߁௛߈߆ߌߡ޿ࠆ‫ޕ‬ቇౝᡰេ࠮ࡦ࠲࡯ߣߒߡߩ⽿ോએᄖߦ㧘ዋߒߢ߽ߘࠇߙࠇߩᢎຬ⁛⥄ߩ⎇ⓥࠍㅴ߼ࠆߚ߼ߩ૕೙૞ࠅࠍ
⠨߃ߡ޿ࠆ‫ޕ‬㧙㧙㧔17㧕ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯㧔ࡊ࡝ࠝࡦ⎇ⓥㇱ㐷㧕1㧚⎇ⓥߩ᭎ⷐ
Ԙᣂⷙ᛫ࡊ࡝ࠝࡦൻว‛ࠍ⚂ 200 ⒳㘃᦭ᯏวᚑߒߚ‫ޕ‬ԙᒰೋߩ࡝࡯࠼ൻว‛ߢ޽ࠆ GN8 ࠃࠅ߽ᵴᕈߩ㜞޿ᣂⷙൻว‛ࠍ⚂ 20 ⒳㘃⷗಴ߒߚ‫ޕ‬Ԛ᛫ࡊ࡝ࠝࡦൻว‛ࠍᦨㆡൻߔࠆߎߣߦࠃࠅ㧘࡝࡯࠼ࠃࠅ߽ᵴᕈ߇৻ᩴ㜞޿ൻว‛ߩഃ⵾ߦᚑഞߒߡ߅ࠅ㧘⎇ⓥߩㅴዷߦᔕߓߡᵴᕈ߇ะ਄ߒߡ޿ࠆ⁁ᴫߦ޽ࠆ‫ޕ‬ԛࡊ࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߣฦ⒳᛫ࡊ࡝ࠝࡦൻว‛ߣߩ⚿วㇱ૏ࠍหቯߒ㧘ᦨㆡൻߩᣇะࠍ᣿ࠄ߆ߦߒߚ‫ޕ‬Ԝ࡝࡯࠼ൻว‛ߣߪ㛽ᩰߩ⇣ߥࠆ᛫ࡊ࡝ࠝࡦൻว‛ࠍ 4 ⒳㘃⷗಴ߒߚ‫ޕ‬ԝࡊ࡝ࠝࡦߩㇱಽࡍࡊ࠴࠼ߩ✢⛽ᒻᚑࠍ⸃ᨆߔࠆߎߣߦࠃࠅ㧘ࡊ࡝ࠝࡦߩ⇣Ᏹൻߦ㑐ਈߔࠆߣ⠨߃ࠄࠇࠆㇱ૏ࠍหቯߒߚ‫ޕ‬Ԟ࠲ࡦࡄࠢ⾰ߣൻว‛ߣߩ⋧੕૞↪ࠍㇱ૏ߏߣߦ㧘෩ኒߦ⹏ଔߔࠆߚ߼ߩࡈ࡜ࠣࡔࡦ࠻ MO ᴺࡊࡠࠣ࡜ࡓ㧔PAICS㧕ࠍᣂⷙߦ㐿⊒ߒ㧘࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߣ᛫ࡊ࡝ࠝࡦ‛⾰ߣߩ⋧੕૞↪ߦㆡ↪ߒߚ‫ޕ‬ԟൻቇ‛⾰ߩⰮ⊕⾰ߦኻߔࠆࠁࠄ߉ᛥ೙૞↪ࠍ⹏ଔߔࠆߚ߼ߩ☻ⷞൻࡊࡠࠣ࡜ࡓࠍᣂⷙߦ㐿⊒ߒ㧘᛫ࡊ࡝ࠝࡦ‛⾰ߩࡊ࡝ࠝࡦⰮ⊕⾰ߩࠁࠄ߉ߦኻߔࠆലᨐࠍ⺞ߴߚ‫ޕ‬Ԡಽሶ゠㆏ᴺߦࠃࠅ㧘␹⚻ᄌᕈࠍᒁ߈⿠ߎߔૐಽሶ‛⾰㧘ࠢࡊ࡝࠱ࡦߣ㌃ࠗࠝࡦߣߩ⋧੕૞↪ࠍ⸃ᨆߒ㧘㌃ࠗࠝࡦߩ⩄㔚⁁ᘒߦ⇣Ᏹ߇޽ࠆߎߣࠍ⓭߈ᱛ߼ߚ‫ޕ‬ԡ᛫ࡊ࡝ࠝࡦ‛⾰ߣࡊ࡝ࠝࡦⰮ⊕⾰ߣߩ⋧੕૞↪ࠍಽሶേജቇᴺߦࠃࠅ⸃ᨆߒ㧘᛫ࡊ࡝ࠝࡦᵴᕈ߇㜞ߊߥࠆේ࿃ࠍ⸃᣿ߒߚ‫ޕ‬Ԣ⺰ℂ⊛ഃ⮎ᴺߩㆡ↪ߦࠃࠅ㧘᛫ࠗࡦࡈ࡞ࠛࡦࠩ࠙ࠗ࡞ࠬ૞↪ࠍ᦭ߔࠆ‛⾰ࠍⶄᢙ⊒⷗ߒߚ‫ޕ‬ԣ⺰ℂ⊛ഃ⮎ᴺߩㆡ↪ߦࠃࠅ㧘᛫ AIDS ૞↪ࠍ᦭ߔࠆ‛⾰ࠍⶄᢙ⊒⷗ߒߚ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦
ഥᢎ㧦

᪀↰৻ᄦ
㎨⿷㓶ม
ᱞ⮮ᷕੑ
ᧁ᧛ ജ
ጊᧄౖผ
ਛ᧛ኡೣ
⍹Ꮉጪᔒ

Kazuo Kuwata
Yuji Kamatari
Junji Muto
Tsutomu Kimura
Norifumi Yamamoto
Hironori Nakamura
Takeshi Ishikawa

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ㧦ᴡ㊁ ⨃✬㧚࠙ࠗ࡞ࠬࡂࡦ࠼ࡉ࠶ࠢ No.16 ਛᨔ␹⚻♽࠙ࠗ࡞ࠬ㧘᧲੩㧦ᩣᑼળ␠ᣣ
ᧄකቇ㙚㧧2008 ᐕ㧦44㧙45㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kuwata K. Semi-classical quantization of protein dynamics: Novel NMR relaxation formalism and its
application to prion. In: Kitamoto T, ed. PRIONS- Food and drug safety, Tokyo: Springer;
2006:155-170.
✚⺑㧔๺ᢥ㧕
1㧕 ᪀↰৻ᄦ㧚Ǫ-࡜ࠢ࠻ࠣࡠࡉ࡝ࡦಽሶߩ┙૕᭴ㅧᒻᚑ෻ᔕ ᐔᚑ 19 ᐕᐲᣣᧄ㈼ㄘ⑼ቇࠪࡦࡐࠫ࠙ࡓ‫੃‐ޟ‬㧘Milk Science 2007 ᐕ㧧56 Ꮞ㧦61
ǩ-࡜ࠢ࠻ࠕ࡞ࡉࡒࡦߣǪ-࡜ࠢ࠻ࠣࡠࡉ࡝ࡦߩ᭴ㅧߣᯏ⢻ߩᣂዷ㐿‫ޠ‬㧙64㧚
2㧕 ᧻ᧄ෹ᴦ㧘㎨⿷㓶ม㧘ᱞ⮮ᷕੑ(⚦Ꮉ)㧘ਛ᧛ኡೣ㧘᪀↰৻ᄦ㧚᭴ㅧ࠳ࠗ࠽ࡒࠢࠬ߆ࠄ↢߹ࠇߚ᛫ࡊ࡝ࠝࡦ
ൻว‛㧙⺰ℂ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆഃ⮎⎇ⓥ㧘ൻቇ 2008 ᐕ㧧63 Ꮞ㧦40㧙44㧚
3㧕 ᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ∛ᴦ≮⮎ߩ⺰ℂ⊛㐿⊒ࠍ߼ߑߒߡ㧙Ⱞ⊕⾰ߩ࠳ࠗ࠽ࡒࠢࠬ⸃ᨆ߆ࠄ᭴ㅧᄌ឵೙ᓮ‛⾰ߩត⚝߳ Rational drug discovery for prion diseases㧙㧘Ⱞ⊕⾰ ᩭ㉄ ㉂⚛ 2008 ᐕ㧧53 Ꮞ㧦727㧙732㧚
4㧕 ᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ㧘Ⱞ⊕⾰࡮ᩭ㉄࡮㉂⚛ 6 ᦬ภჇೀ‫࠼࡯ࡢ࡯ࠠޟ‬㧦Ⱞ⊕⾰ߩ৻↢‫ ޠ‬2008 ᐕ㧧53 Ꮞ㧦
991㧚
5㧕 ᪀↰৻ᄦ㧚࠳ࠗ࠽ࡒࠢࠬߣ቟ቯᕈ߇੤෷ߔࠆ㗔ၞߩᾲജቇ㧙㊂ሶᥧภᾲജቇߣࡊ࡝ࠝࡦ㧙㧘ᾲ᷹ቯ 2008
ᐕ㧧35 Ꮞ㧦140㧙147㧚
✚⺑㧔᰷ᢥ㧕ߥߒ㧙㧙ේ⪺㧔๺ᢥ㧕1㧕 ᪀↰৻ᄦ㧚ㅪタ ⹤㗴ߩ࠙ࠗ࡞ࠬ No.12 ࡊ࡝ࠝࡦ㧘Drug Delivery System (DDS) 2006 ᐕ㧧21 Ꮞ㧦156
㧙157㧚
2㧕 ᪀↰৻ᄦ㧚ࡃࠗࠝࠗࡦࡈࠜ࡯ࡑ࠹ࠖࠢࠬߦࠃࠆࡊ࡝ࠝࡦ∛ᴦ≮⮎ߩ㐿⊒㧘ൻቇ≮ᴺߩ㗔ၞ 2006 ᐕ㧧22
Ꮞ㧦87㧙93㧚
3㧕 ጊญ࿻৻㧘᧻ᧄ෹ᴦ㧘ఽ₹⠹ᄥ㧘ጯ ⋥ੱ㧘᪀↰৻ᄦ㧚ࡊ࡝ࠝࡦ∛ߩ⊒∝ߣવ᠞ᯏ᭴㧙․㓸 ࠕࡒࡠࠗ࠼ߩ
⻘ߪ⸃ߌࠆ߆㧫㧦ࡊ࡝ࠝࡦ∛࡮ࠕ࡞࠷ࡂࠗࡑ࡯∛࡮ㅘᨆࠕࡒࡠࠗ࠼࡯ࠪࠬߥߤߩ∛ᘒࠍ⚌⸃ߊ㧙㧘⚦⢩Ꮏ
ቇ 2007 ᐕ㧧26 Ꮞ㧦151㧙155㧚
4㧕 ᓟ⮮␭ఽ㧘᪀↰৻ᄦ㧘㑐ፉ⦟᮸㧘↰ਛర㓷㧘ౝᧁብᑧ㧘᳗੗⟵㓉㧘᧻ፒൎᏈ㧘ᮘญ੩৻㧚ࠕࡒࡠࠗ࠼࡯ࠪ
ࠬ⊒∝ߩಽሶᯏ᭴⸃᣿ࠍ⋡ᜰߒߡ㧦⃻⁁ߣዷᦸ㧘ᄞ㧙․㓸 ࠕࡒࡠࠗ࠼ߩ⻘ߪ⸃ߌࠆ߆㧫㧦ࡊ࡝ࠝࡦ∛࡮ࠕ࡞࠷ࡂࠗࡑ࡯∛࡮ㅘᨆࠕࡒࡠࠗ࠼࡯ࠪࠬߥߤߩ∛ᘒࠍ⚌⸃ߊ㧙㧘 ⚦⢩Ꮏቇ 2007 ᐕ㧧26 Ꮞ㧦181㧙185㧚
5㧕 ᱞ⮮ᷕੑ㧔⚦Ꮉ㧕㧘㎨⿷㓶ม㧘᧻ᧄ෹ᴦ㧘ਛ᧛ኡೣ㧘᪀↰৻ᄦ㧦ᱜᏱဳࡊ࡝ࠝࡦⰮ⊕⾰᭴ㅧ቟ቯൻ߳ߩ᜸ᚢ
㧙․㓸 ⇣Ᏹဳࡊ࡝ࠝࡦⰮ⊕⾰߳ߩ᜸ᚢ㧔ᓟ✬㧕㧙㧘⥃ᐥ₞ක 2007 ᐕ㧧25 Ꮞ㧦10㧙14㧘41㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Kimura K, Nagaki M, Nishihira J, Kuwata K, Moriwaki H. Role of macrophage migration inhibitory
factor for CTL-induced liver injury in hepatitis B transgenic mice. Clin Vaccine Immunol.
2006;13:415-419.
2㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40 caused necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
3㧕 Kodama K, Shoji Y, Nakashima H, Katayama Y. The features and shortcomings for gene delivery of
current non-viral carriers. Curr Med Chem. 2006;13:2155-2161.
4㧕 Oishi J, Kawamura K, Kang HJ, Kodama K, Sonoda T, Murata M, Niidome T, Katayama Y. An
intracellular kinase signal-responsible gene carrier for disordered cell-specific gene therapy. J Control
Release. 2006;110:431-436.
5㧕 Sukegawa KH, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effect ofHunter disease (mucopoly saccharidosis typeII) mutations on molecular phenotypes of
iduronate-2-sulfatase : Enzymatic activity, protein processing and structural analysis. J Inherit MetabDis. 2006;29:755-761.
6㧕 Kimura K, Moriwaki H, Nagaki M, Saio M, Nakamoto Y, Naito M, Kuwata K, Chisari FV. Pathogenicrole of B cells in anti-CD40-induced necroinflammatory liver disease. Am J Pathol. 2006;168:786-795.
7㧕 Kremer W, Kachel N, Kuwata K, Akasaka K, Kalbitzer HR. Species specific differences in theintermediate states of human and hamster prion protein detected by high pressure NMR spectroscopy.
J Biol Chem. 2007;282:22689-22698.
8㧕 Kuwata K, Nishida N, Matsumoto T, Kamatari YO, Hosokawa-Muto J, Kodama K, Nakamura HK,
Kimura K, Kawasaki M, Takakura Y, Shirabe S, Takata J, Kataoka Y, Katamine S. Hot spots in prion
protein for pathogenic conversion. Proc Natl Acad Sci USA. 2007;104:11921-11926.
9㧕 Nakamura HK, Takano M, Kuwata K. Modeling of a propagation mechanism of infectious prion protein;a hexamer as the minimum infectious unit. Biochem Biophys Res Commun. 2007;361:789-793.
10㧕 Kamatari YO, Nakamura HK, Kuwata K. Strange kinetic phase in the extremely early folding processof Ǫ-lactoglobulin. FEBS Lett. 2007;581:4463-4467.
11㧕 Kimura K, Nagaki M, Kakimi K, Saio M, Saeki T, Okuda Y, Kuwata K, Moriwaki H. Critical role ofCD44 in hepatotoxin-mediated liver injury. J Hepatol. 2008;48:952-961.
12㧕 Kato Z, Stern JN, Nakamura HK, Kuwata K, Kondo N, Strominger JL. Positioning of autoimmune
TCR-Ob.2F3 and TCR-Ob.3D1 on the MBP85-99/HLA-DR2 complex. Proc Natl Acad Sci USA.
2008;105:15523-15528.
13㧕 Yamaguchi K, Matsumoto T, Kuwata K. Critical region for amyloid fibril formation of mouse prion
protein: unusual amyloidogenic properties of helix 2 peptide. Biochemistry. 2008;47:13242-13251.

IF 1.995
IF 5.487
IF 4.944

IF 4.756

IF 1.668
IF 5.487

IF 5.581

IF 9.598
IF 2.749
IF 3.263
IF 6.642

IF 9.598
IF 3.3684㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦᪀↰৻ᄦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧧ᐔᚑ 18㧙19 ᐕᐲ㧧11,300 ජ౞(5,500㧦5,800 ජ౞)2㧕 ⎇ⓥઍ⴫⠪㧦᳓Ỉ⧷ᵗ(᧲੩ක⑼ᱤ⑼ᄢቇᄢቇ㒮⣖␹⚻∛ᘒቇ(␹⚻ౝ⑼))㧘⎇ⓥಽᜂ⠪㧦᪀↰৻ᄦ㧧ෘ↢ഭ௛⋭㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ㧦ࡊ࡝ࠝࡦ∛෸߮ㆃ⊒ᕈ࠙ࠗ࡞ࠬᗵᨴ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧔H16㔍ᴦ-013㧕㧧ᐔᚑ 18㧙20 ᐕᐲ㧧6,000 ජ౞(2,000㧦2,000㧦2,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦᪀↰৻ᄦ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄․ቯ㗔ၞ⎇ⓥ㧧⚦⢩ౝࡊ࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߩ┙૕᭴ㅧ㧘࠳ࠗ࠽ࡒࠢࠬ㧘෸߮┙૕᭴ㅧᄌ឵෻ᔕߩ⸃᣿㧧ᐔᚑ 20㧙21 ᐕᐲ㧧5,800 ජ౞(2,900㧦2,900
ජ౞)

㧙㧙

4㧕 ⎇ⓥઍ⴫⠪㧦ᱞ⮮ᷕੑ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⪚⧘⎇ⓥ㧦ࡊ࡝ࠝࡦⰮ⊕⾰ߩ࠺ࡘࠕ࡞ࡇࡦࡐ
ࠗࡦ࠻Ⱟశᮡ⼂ᴺߩ⏕┙ߣߘߩᔕ↪ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,600 ජ౞(1,800㧦1,800 ජ౞)5㧕 ⎇ⓥઍ⴫⠪㧦ጊᧄౖผ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡊ࡝ࠝࡦ∛⊒∝ࡔࠞ࠾࠭ࡓߩ⸃᣿㧦ࡊ࡝ࠝࡦⰮ⊕⾰࡮⢵ࠗࠝࡦⶄว૕ߩ᭴ㅧߣᕈ⾰㧧ᐔᚑ 20 ᐕᐲ㧧2.860 ජ౞6㧕 ⎇ⓥઍ⴫⠪㧦⍹Ꮉጪᔒ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(ࠬ࠲࡯࠻ࠕ࠶ࡊ)㧦ࡊࡠࠣ࡜ࡓ㐿⊒ߣࡊ࡝ࠝࡦ࠲ࡦࡄࠢ⾰ߩ⋧੕૞↪⸃ᨆ߳ߩᔕ↪㧧ᐔᚑ 20 ᐕᐲ㧧1,140 ජ౞7㧕 ⎇ⓥઍ⴫⠪㧦ጊญ࿻৻㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄⧯ᚻ⎇ⓥ(B)㧦ࡊ࡝ࠝࡦߩࠕࡒࡠࠗ࠼✢⛽ߦㆬᛯ⊛ߦ⚿วߔࠆૐಽሶൻว‛ߩត⚝ߣߘߩ૞↪ᯏ᭴ߩ⸃᣿㧧ᐔᚑ 19㧙20 ᐕᐲ㧧3,300 ජ౞(2,100㧦
1,200 ජ౞)2㧕ฃ⸤⎇ⓥ1㧕 ᪀↰৻ᄦ㧦⺰ℂ⊛ഃ⮎ߦࠃࠆⰮ⊕⾰┙૕᭴ㅧ೙ᓮᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛ᴦ≮⮎㐿⊒߳ߩᔕ↪㧧ᐔᚑ
18㧙22 ᐕᐲ㧧361,000 ජ౞(80,000㧦80,000㧦67,000㧦67,000㧦67,000 ජ౞)㧦⁛┙ⴕ᡽ᴺੱක⮎ၮ⋚⎇ⓥᚲ
2㧕 ⎇ⓥઍ⴫⠪㧦ർየᓆᦶ(᧲੩ᄢቇಽሶ⚦⢩↢‛ቇ⎇ⓥᚲ⚦⢩ᯏ⢻ᖱႎ⎇ⓥ࠮ࡦ࠲࡯ഃ↢⎇ⓥಽ㊁)㧘⎇ⓥಽᜂ⠪㧦᪀↰৻ᄦ㧧ᐔᚑ 19 ᐕᐲᚢ⇛⊛ഃㅧ⎇ⓥផㅴ੐ᬺ㧔CREST ࠲ࠗࡊ㧕⎇ⓥ㗔ၞ‫ࠬ࠴࡞ࡑޟ‬ࠤ࡯࡞࡮ࡑ࡞࠴ࡈࠖࠫ࠶ࠢࠬ⃻⽎ߩ⛔วࠪࡒࡘ࡟࡯࡚ࠪࡦ‫⎇ޠ‬ⓥ⺖㗴‫ࠝࠗࡃޟ‬ಽሶ㑆⋧੕૞↪ᒻᘒߩ㓏ጀ⊛ࡕ࠺࡝ࡦࠣ‫ޠ‬㧧ᐔᚑ 19㧙23 ᐕᐲ㧧27,000 ජ౞(3,000㧦6,000㧦6,000㧦6,000㧦6,000 ජ౞)
3㧕 ⎇ⓥઍ⴫⠪㧦⪤ේᱜᢅ(᧲੩ක⑼ᱤ⑼ᄢቇ࡮ᄢቇ㒮∔ᖚ↢๮⑼ቇ⎇ⓥㇱ/㔍ᴦ∔ᖚ⎇ⓥᚲ)㧘⎇ⓥಽᜂ⠪㧦᪀↰৻ᄦ㧧ᐔᚑ 19 ᐕᐲ⑼ቇᛛⴚ⹜㛎⎇ⓥᆔ⸤੐ᬺ‫ޟ‬㔍ᴦᗵᨴ∝ߦኻߔࠆᣂⷙᴦ≮⮎㐿⊒ߩߚ߼ߩࠗࡔ࡯ࠫࡦࠣ⎇ⓥ‫ޠ‬㧧ᐔᚑ 19㧙23 ᐕᐲ㧧19,500 ජ౞(6,500㧦6,500㧦6,500 ජ౞)
4㧕 ਛ᧛ኡೣ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄᡽╷ഃ⮎✚ว⎇ⓥ੐ᬺ‫⺰ޟ‬ℂ⊛ഃ⮎ᚻᴺߦࠃࠆ
HIV-1 ࡊࡠ࠹ࠕ࡯࠯ੑ㊂૕ൻࠍ㒖ኂߔࠆૐಽሶൻว‛ߩត⚝‫ޠ‬㧧ᐔᚑ 18㧙20 ᐕᐲ㧧12,000 ජ౞(4,000㧦4,000㧦4,000 ජ౞)
3㧕౒ห⎇ⓥ1㧕 ᪀↰৻ᄦ㧦⺰ℂ⊛ഃ⮎ߦࠃࠆⰮ⊕⾰┙૕᭴ㅧ೙ᓮᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛ᴦ≮⮎㐿⊒߳ߩᔕ↪㧧ᐔᚑ
18㧙22 ᐕᐲ㧧361,000 ජ౞(80,000㧦80,000㧦67,000㧦67,000㧦67,000 ජ౞)㧦㐳ፒᄢቇ2㧕 ᪀↰৻ᄦ㧘ጊญ࿻৻㧦ࠕࡒࡠࠗ࠼ߩ᭴ㅧ↢‛ቇ⎇ⓥ㧧ᐔᚑ 18㧙20 ᐕᐲ㧧6,000 ජ౞(2,000㧦2,000㧦
2,000 ජ౞)㧦ᄢ㒋ᄢቇⰮ⊕⾰⎇ⓥᚲ
3㧕 ᪀↰৻ᄦ㧦ࡑ࡞࠴ࠬࠤ࡯࡞࡮ࡑ࡞࠴ࡈࠖࠫ࠶ࠢࠬ⃻⽎ߩ⛔วࠪࡒࡘ࡟࡯࡚ࠪࡦ㧧ᐔᚑ 19㧙23 ᐕᐲ㧧
27,000 ජ౞(3,000㧦6,000㧦6,000㧦6,000㧦6,000 ජ౞)㧦᧲੩ᄢቇ4㧕 ᪀↰৻ᄦ㧘ਛ᧛ኡೣ㧦ᣂⷙ᛫ࠗࡦࡈ࡞ࠛࡦࠩ⮎ߩ㐿⊒㧧ᐔᚑ 19㧙23 ᐕᐲ㧧19,500 ජ౞(6,500㧦6,500㧦
6,500 ජ౞)㧦ℂൻቇ⎇ⓥᚲ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫ
1㧕 ਛ᧛ኡೣ㧦ࡅ࠻఺∉ਇో࠙ࠗ࡞ࠬߩჇᱺ㒖ኂ೷(․⸵)㧧ᐔᚑ 20 ᐕ(․㗿 2008-226642)
6㧚ቇળᵴേ
1㧕ቇળᓎຬ᪀↰৻ᄦ㧦
1㧕 ᣣᧄ↢ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄ⏛᳇౒㡆කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ⥃ᐥࠬ࠻࡟ࠬᔕ╵ቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅
ߥߒ
3㧕ቇⴚ㔀⹹ߥߒ㧙㧙

7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳᪀↰৻ᄦ㧦
1㧕 ᣣᧄ↢‛‛ℂቇળ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫ ╙ޠ‬3 ࿁౏㐿ࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጟፒ㧘᜗ᓙ⻠Ṷ‫ޟ‬Dynamics of Prion in Water‫ޠ‬Ṷ⠪)
2㧕 ␠࿅ᴺੱ ᣣᧄ⡊㥦ຜ༄⑼ቇળ ╙ 56 ࿁ਛㇱ࿾ᣇㇱળㅪวળ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘᜗ᓙ⻠Ṷ‫⺰ޟ‬ℂ⊛ഃ⮎ᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛߳ߩᔕ↪‫ޠ‬Ṷ⠪)
3㧕 ᣣᧄࡅ࠻ࡊࡠ࠹ࠝ࡯ࡓᯏ᭴╙ 6 ࿁ᄢળ‫ޟ‬ഃ⮎㧘ࡃࠗࠝࡑ࡯ࠞ࡯ត⚝ߦะߌߡ‫(ޠ‬ᐔᚑ 20 ᐕ 7 ᦬㧘็↰㧘᜗ᓙ⻠Ṷ‫⺰ߣ∛ࡦࠝ࡝ࡊޟ‬ℂ⊛ഃ⮎㧙Application of Dynamics Based Drug Discovery (DBDD)
to Prion Diseases㧙‫ޠ‬Ṷ⠪)4㧕 ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍⍮ᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ࠕࡒࡠࠗ࠼࡯ࠪࠬߦ㑐ߔࠆ⺞ᩏ⎇ⓥ⃰‫ ࠬࠪ࡯࠼ࠗࡠࡒࠕޟ‬ᄐߩࡢ࡯࡚ࠢࠪ࠶ࡊ 2008‫(ޠ‬ᐔᚑ 20 ᐕ 8 ᦬㧘㊄ᴛ㧘᜗ᓙ⻠Ṷ‫┙ߩࠢࡄࡦ࠲ޟ‬૕᭴ㅧࠍ೙ᓮߔࠆൻว‛ࠍ࠺ࠩࠗࡦߔࠆ‫ޠ‬Ṷ⠪)
5㧕 ℂ⺰ഃ⮎࠮ࡒ࠽࡯㧔౏㐿⻠ᐳ㧕(ᐔᚑ 20 ᐕ 11 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ޟ‬ℂ⺰⊛ߦ࠺ࠩࠗࡦߐࠇߚૐಽሶ
ൻว‛ߦࠃࠆ࠲ࡦࡄࠢ⾰ߩࠦࡦࡈࠜ࡯ࡔ࡚ࠗࠪࡦ೙ᓮ 㧙21 ਎♿කቇߩᣂᚢ⇛㧙‫ޠ‬Ṷ⠪)6㧕 ┙๮㙚ᄢቇℂᎿቇ⎇ⓥᚲࠪࡦࡐࠫ࠙ࡓ ‫ ⾰ࠢࡄࡦ࠲ޟ‬NMR ⎇ⓥߩᦨ೨✢‫(ޠ‬ᐔᚑ 20 ᐕ 11 ᦬㧘⨲ᵤ㧘᜗ᓙ⻠Ṷ‫ޟ‬ૐಽሶൻว‛ߦࠃࠅ㧘࠲ࡦࡄࠢ⾰ߩࠦࡦࡈࠜ࡯ࡔ࡚ࠗࠪࡦࠍ೙ᓮߔࠆ‫ޠ‬Ṷ⠪)7㧕 ᖱႎ⸘▚ൻቇ↢‛ቇળ㧔CBI ቇળ㧕╙ 292 ࿁ CBI ⎇ୃ⻠Ṷળ‫⚻␹ޟ‬ᄌᕈ∔ᖚߩᮡ⊛ߣഃ⮎㧙Σ‫(ޠ‬ᐔ
ᚑ 20 ᐕ 12 ᦬㧘᧲੩㧘᜗ᓙ⻠Ṷ‫ޟ‬᭴ㅧ↢‛ቇ⊛ࠕࡊࡠ࡯࠴ߦࠃࠆ᛫ࡊ࡝ࠝࡦൻว‛ߩ㐿⊒‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫ1㧕 ᪀↰৻ᄦ㧦╙౐࿁᧖↰₵⊕⾨ ᅑബ⾨(ᐔᚑ 19 ᐕᐲ)
2㧕 ᪀↰৻ᄦ㧦magic bullet ⾨(ᐔᚑ 20 ᐕᐲ)
9㧚␠ળᵴേ᪀↰৻ᄦ㧦
1㧕 ᧲੩㜞╬ⵙ್ᚲ㧘᧲੩࿾ᣇⵙ್ᚲ෸߮ᄢ㒋࿾ᣇⵙ್ᚲᚲዻኾ㐷ᆔຬ(ᐔᚑ 19 ᐕᐲ㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ᪀↰৻ᄦ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧦ᐔᚑ 19
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫⎇ޠ‬ⓥ⁁ᴫႎ๔ᦠ㧦
92㧙93(2007 ᐕ 3 ᦬)
2㧕 ᪀↰৻ᄦ㧦ࡊ࡝ࠝࡦㇱಽࡍࡊ࠴࠼߇૞ࠆࠝ࡝ࠧࡑ࡯ߩ┙૕᭴ㅧ᳿ቯ㧦ᐔᚑ 14 ᐕᐲ㧙ᐔᚑ 18 ᐕᐲᢥ
ㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫⎇ޠ↢৻ߩ⾰ࠢࡄࡦ࠲ޟ‬ⓥᚑᨐႎ๔ᦠ㧦112(2007 ᐕ 5 ᦬)
3㧕 ᪀↰৻ᄦ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧦ᐔᚑ 19
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫⎇ޠ‬ⓥᚑᨐႎ๔ᦠ㧦
32(2008 ᐕ 3 ᦬)
4㧕 ᪀↰৻ᄦ㧦ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ‫∛ࡦࠝ࡝ࡊޟ‬෸߮ㆃ⊒ᕈ࠙ࠗ࡞ࠬ
ᗵᨴ∝ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ‫ޠ‬ᐔᚑ 17 ᐕᐲ㧙ᐔᚑ 19 ᐕᐲಽᜂ⎇ⓥႎ๔ᦠ㧦47㧙50(2008 ᐕ 3 ᦬)
5㧕 ᪀↰৻ᄦ㧘᧻ᧄ෹ᴦ㧘ጊญ࿻৻㧘㎨⿷㓶ม㧘ਛ᧛ኡೣ㧘ጊᧄౖผ㧘⍹ୖቁ৻㧘ᧁ᧛ജ㧘ᱞ⮮ᷕੑ㧦
⁛┙ⴕ᡽ᴺੱ ක⮎ၮ⋚⎇ⓥᚲ ଻ஜක≮ಽ㊁ߦ߅ߌࠆၮ␆⎇ⓥផㅴ੐ᬺ‫⺰ޟ‬ℂ⊛ഃ⮎ߦࠃࠆⰮ⊕⾰┙૕᭴ㅧ೙ᓮᴺߩ⏕┙ߣࡊ࡝ࠝࡦ∛ᴦ≮⮎㐿⊒߳ߩᔕ↪‫ޠ‬ᐔᚑ 19 ᐕᐲႎ๔ᦠ㧦1㧙42㧘65㧙
115(2008 ᐕ 4 ᦬)
6㧕 ᪀↰৻ᄦ㧦ේሶಽ⸃⢻߆ߟ࠽ࡁ⑽ᤨ㑆ಽ⸃⢻ߢߩࡊ࡝ࠝࡦ࡮ࡈࠜ࡯࡞࠺ࠖࡦࠣ෻ᔕߩ᷹ⷰ㧦ᐔᚑ 20
ᐕᐲ⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ․ቯ㗔ၞ⎇ⓥ‫ޟ‬᳓ߣ↢૕ಽሶ߇❱ࠅᚑߔ↢๮⃻⽎ߩൻቇ‫⎇ޠ‬ⓥᚑᨐ╬ߩႎ๔ᦠ㧦56(2008 ᐕ 7 ᦬)
7㧕 ጘ㒂ᄢቇ ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ ╙ 1 ࿁ᄖㇱ⹏ଔႎ๔ᦠ(2007 ᐕ 11 ᦬)
11㧚ႎ㆏1㧕 ᪀↰৻ᄦ㧦ࡗࠦࡉ∛ ᴦ≮⮎߳೨ㅴ㧦ᣣᧄ⚻ᷣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
2㧕 ᪀↰৻ᄦ㧦⇣Ᏹࡊ࡝ࠝࡦᛥ೙‛⾰㧦ਛᣣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
3㧕 ᪀↰৻ᄦ㧦ࡊ࡝ࠝࡦ⇣Ᏹ߆㒐ߋ‛⾰⊒⷗㧦ᦺᣣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
4㧕 ᪀↰৻ᄦ㧦ᗵᨴᕈࡊ࡝ࠝࡦ߳ߩᄌൻ㒐ᱛ BSE ᴦ≮ߦᦼᓙ㧦Ფᣣᣂ⡞(2007 ᐕ 7 ᦬ 3 ᣣ)
5㧕 ᪀↰৻ᄦ㧦ࡊ࡝ࠝࡦ⇣Ᏹൻᛥ೙ ࡗࠦࡉ∛‫ޔ‬BSE ᴦ≮ߦ㆏㧦ጘ㒂ᣂ⡞(2007 ᐕ 7 ᦬ 4 ᣣ)㧙㧙

6㧕 ᪀↰৻ᄦ㧦ᗵᨴᕈࡊ࡝ࠝࡦ߳ߩᄌൻ㒐ߋ‛⾰㧦Ფᣣᣂ⡞(2007 ᐕ 7 ᦬ 4 ᣣ)
7㧕 ᪀↰৻ᄦ㧦᛫ࡊ࡝ࠝࡦ‛⾰ࠍ㐿⊒ ࿖㓙ቇળ⾨ࠍฃ⾨㧦ጘ㒂ᣂ⡞(2008 ᐕ 10 ᦬ 17 ᣣ)
8㧕 ᪀↰৻ᄦ㧦࿖㓙ቇળߢฃ⾨㧦Ფᣣᣂ⡞(2008 ᐕ 10 ᦬ 16 ᣣ)
9㧕 ᪀↰৻ᄦ㧦࿖㓙ቇળߩ‫ޠ⾨࠻࠶࡟ࡃࠢ࠶ࠫ࠶ࡑޟ‬ฃ⾨ BSE ․ല⮎㐿⊒ࠍ⎇ⓥ㧦ਛᣣᣂ⡞(2008 ᐕ
10 ᦬ 25 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ߩ⋡⊛࡮⸘↹߇㧘㗅⺞ߦ㆐ᚑߐࠇߡ޿ࠆ㧘ߣ⹏ଔߔࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ੱ₞ᗵᨴ㒐ᓮ⎇ⓥ࠮ࡦ࠲࡯ߦߪ㧘NMR3 บ㧔500, 600, 800㧔੍ቯ㧕MHz㧕㧘X ✢࿁᛬ⵝ⟎‫ࠗ࡜ࠢޔ‬ࠝ㔚㗼㧔200kV㧕㧘ࡆࠕࠦࠕ╬㧘කቇ⎇ⓥߦ᦭↪ߥᦨవ┵ߩታ㛎ⵝ⟎߇ᄙᢙ޽ࠅ㧘౒ห೑↪߇น⢻ߣߥߞߡ޿ࠆ‫੹ޕ‬ᓟ㧘කቇ⎇ⓥ⑼ࠍ฽߻ቇౝᄖߩ⎇ⓥᯏ㑐╬ߣߩ౒ห೑↪࡮౒ห⎇ⓥࠍផㅴߒߚ޿‫ޕ‬੹ᓟߩዷᦸ∔ᖚ㑐ㅪ࠲ࡦࡄࠢ⾰ࠍᮡ⊛ߣߔࠆ⺰ℂ⊛ഃ⮎ࠍ㧘࿖ౝᄖߩ⎇ⓥᯏ㑐ߣߩ౒ห⎇ⓥࠍㅢߓߡផㅴߔࠆ‫ޕ‬㧙㧙㧔18㧕ᄢቇ㒮ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼㧔ක≮ᖱႎቇኾ᡹㧕1㧚⎇ⓥߩ᭎ⷐ
ᧄ⎇ⓥ⑼ߪ㧘ࡐࠬ࠻ࠥࡁࡓᤨઍߩഃ⮎⑼ቇ㧘ක≮⑼ቇ෸߮↢‛࡮↢๮⑼ቇߩಽ㊁ࠍᎿቇ㧘⮎ቇ㧘කቇߥߤߩቇ໧㗔ၞ߆ࠄ‫ޟ‬ഃ⮎‫ߡߒߣࡑ࡯࠹ࠍޠ‬㧘↢૕࠺࡯࠲߿ઍ⻢ᖱႎ㧘ᖚ⠪ᖱႎߥߤߩ‫ޟ‬ක≮ᖱႎ‫ࠅࠃߦޠ‬⸃ᨆߔࠆ㜞ᐲߥᢎ⢒⎇ⓥࠍⴕ߁‫ࠅࠃߦߣߎߩߎޕ‬㧘⥄ࠄ߇⸃᣿㧘ഃㅧ㧔㐿⊒㧕㧘ᬌ⸽㧘ᔕ↪ߦዷ㐿ߢ߈ࠆੱ᧚ߣߥࠅ㧘ੱ㘃ߩஜᐽჇㅴߣ↢๮࡮ஜᐽ⑼ቇ㗔ၞߩ⊒ዷߦነਈߢ߈ࠆ୶ℂⷰߦንࠎߛ㜞ᐲኾ㐷⡯ᬺੱ෸߮⎇ⓥ⠪ࠍ㙃ᚑߔࠆߎߣࠍ⋡ᮡߣߒߡ޿ࠆ‫ޕ‬એਅ㧘ᄢቇ㒮ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ක≮ᖱႎቇኾ᡹ߩ߁ߜ
කቇㇱᚲዻᢎຬߦߟ޿ߡ⸥ߔ‫ޕ‬1㧕ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝㧔⢽⢌㉄ઍ⻢⇣Ᏹ∝ࠍ฽߻㧕ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩಽ㊁ߢߪ਎⇇⊛ߦ߽ጘ㒂ᄢቇߣ޿ࠊࠇߡ߅ࠅ㧘ࠨࠢࠪ࠾࡞-CoA:3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯㧔SCOT㧕߅ࠃ߮Ǫࠤ࠻࠴ࠝ࡜࡯࠯ᰳ៊∝ߦߟ޿ߡߪ਎⇇ฦ࿾ࠃࠅ⥃ᐥ࠺࡯࠲࡯෸߮⚦⢩߇㓸߹ࠅ㧘phenotype/genotype ߩ㑐ㅪߥߤߩ⎇ⓥࠍ਎⇇ߦవ㚟ߌㅴ߼ߡ޿ࠆ‫࡯࡞ࠣߩ࠼ࡦ࡜ࡦࠖࡈޕ‬ࡊߣߩ౒ห⎇ⓥߢ㧘ࡅ࠻࠴ࠝ࡜࡯࠯ߩ 3 ᰴ᭴ㅧ᳿ቯ㧘ᄌ⇣Ⱞ⊕ߩ᭴ㅧ⊛⸃ᨆࠍ߅ߎߥߞߡ߅ࠅ㧘߹ߚፉᩮᄢቇߣߩ౒ห⎇ⓥߢ㧘⢽⢌㉄Ǫ㉄ൻ♽⇣Ᏹ∝ߩⰮ⊕ㆮવሶ⸃ᨆ߽ⴕߞߡᚑᨐ߇಴ߡ޿ࠆ‫ޕ‬
2㧕ࠕ࡟࡞ࠡ࡯
ዊఽ∛ᘒቇᢎቶߢ㧘ࠕ࡟࡞ࠡ࡯ኾ㐷කߣߒߡࠕ࡟࡞ࠡ࡯ߩ⥃ᐥߦ៤ࠊࠅߥ߇ࠄ㧘ࠕ࡟࡞ࠡ࡯ߣ㑐ㅪߔࠆㆮવሶᄙဳߩ⎇ⓥߦෳടߒ㧘޿ߊߟ߆ߩ୥⵬ㆮવሶᄙဳࠍႎ๔ߒߡ߈ߚ‫ޕ‬2004 ᐕ߆ࠄߪ㧘ࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝ߩ੍⍮੍㒐ߦ㑐ߔࠆ಴↢ࠦࡎ࡯࠻⎇ⓥࠍ㐿ᆎߒ㧘ᧄᐕߢ 3 ᐕ߹ߢߩࡈࠜࡠ࡯߇⚳ੌߒ㧘⃻࿷⚿ᨐࠍ߹ߣ߼ߡ޿ࠆߣߎࠈߢ޽ࠆ‫ߦ࡯ࡇ࠻ࠕޕ‬㑐ㅪߔࠆㆮવሶᄙဳߩ⸃ᨆ㧘⤯Ꮺⴊ㧘↢ᓟ 6 ࡩ᦬㧘1 ᱦ 2 ࡩ᦬ߩណⴊ⚿ᨐ߿ 1 ᱦ 2 ࡩ᦬ߩኢౕਛߩ၎ਛߩ᛫ේ㊂ߩ᷹ቯ㧘∔ᖚ⊒∝ߥߤߩ㑐ㅪߢ⥝๧ᷓ޿⚿ᨐ߇಴ߡ߈ߡ
޿ࠆ‫ޕ‬3㧕వᄤᕈ఺∉ਇో∝
IgG ࠨ ࡉ ࠢ ࡜ ࠬ ᰳ ៊ ∝ ߩ ∛ ࿃ ߣ ߥ ࠆ ㆮ વ ሶ ⇣ Ᏹ ࠍ ਎ ⇇ ߦ వ 㚟 ߌ ᣿ ࠄ ߆ ߦ ߒ 㧔 J Clin Invest 㧕
Ataxia-telangiectasia ߩ∛࿃ㆮવሶ ATM ߦߟ޿ߡߩ⸃ᨆߢ߽޿ߊߟ߆ߩᚑᨐࠍ಴ߒߡ߈ߚ㧔Blood,
Oncogene, Gene Chromosome Cancer ߥߤ㧕‫ޕ‬4㧕ዊఽ␹⚻∔ᖚ⣄㜑ᕈ╭⪜❗∝ߩේ࿃Ⱞ⊕ SMN ߩᯏ⢻ߦߟ޿ߡߩ⸃ᨆࠍࠬ࠲࡯࠻ߒߡ޿ࠆ‫ޕ‬
5㧕␹⚻⚦⢩㓚ኂߩ⊒⃻ᯏᐨ⸃᣿㧘ਗ߮ߦߘߩ㒐ᓮߦ㑐ߔࠆ⎇ⓥ
Ԙㆃ⊒ᕈ␹⚻⚦⢩ᱫ㧦৻ㆊᕈ೨⣖⯯ⴊᓟᶏ㚍 CA1 ⚦⢩ߦ․⇣⊛ߦ⊒⃻ߔࠆㆃ⊒ᕈ␹⚻⚦⢩ᱫߪታ㛎⊛⣖⯯ⴊࡕ࠺࡞ߣߒߡ᳢↪ߐࠇߡ޿ࠆ߇ߘߩ⊒⃻ᯏᐨߪ⸃᣿ߐࠇߡ޿ߥ޿‫ޕ‬ᚒ‫ߩߘߪޘ‬ᯏᐨࠍ᣿ࠄ߆ߦߔࠆߣߣ߽ߦ㧘ഃ⮎ߩⷰὐ߆ࠄ㧘ߘߩ⊒⃻੍㒐࡮ᴦ≮ࠍ⹜ߺߡ޿ࠆ‫ޕ‬ԙ✂⤑␹⚻⚦⢩ᱫ㧦⯯ⴊౣẑᵹߦߣ߽ߥ߁✂⤑⚦⢩ᱫࡕ࠺࡞ߩ㐿⊒ࠍᚻ߇ߌ㧘ᦨㄭߢߪൻቇ‛⾰ࠍ↪޿ߚⷞ⚦⢩ㆬᛯ⊛⚦⢩ᱫࡕ࠺࡞ഃ⵾߽㐿⊒ߒߚ‫޿↪ࠍ࡞࠺ࡕߩࠄࠇߎޕ‬㧘✂⤑␹⚻⚦⢩ᱫߩࡔࠞ࠾࠭ࡓࠍ᣿ࠄ߆ߦߔࠆߣߣ߽ߦ㧘੍㒐࡮ᴦ≮⮎ߩ㐿⊒ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬
6㧕ES ⚦⢩ߦࠃࠆ␹⚻㓚ኂౣ↢ߦ㑐ߔࠆ⎇ⓥౣ↢ක≮ߩၮ␆⊛⎇ⓥߩ৻Ⅳߣߒߡ㧘✂⤑␹⚻⚦⢩㓚ኂࡕ࠺࡞ߦࡑ࠙ࠬ↱᧪ ES ⚦⢩߿ࡅ࠻↱᧪ ES ⚦⢩ࠍ⒖ᬀߒ㧘ߘߩ↢⌕₸ߩ੣ㅴ㧘ࠟࡦൻߩᛥ೙㧘␹⚻߳ߩಽൻߩଦㅴࠍ߼ߑߒߚ⎇ⓥࠍⴕߞߡ޿ࠆ‫੹ޕ‬ᓟ㧘ࡅ࠻↱᧪ੱᎿᄙ⢻ᕈᐙ⚦⢩㧔iPS ⚦⢩㧕ߢߩᬌ⸛߽ⴕ߁‫ޕ‬7㧕ᅢਛ⃿ߩᵴᕈൻߥࠄ߮ߦࠕࡐ࠻࡯ࠪࠬ⊒⃻ᯏᐨߩ⸃᣿
ᅢਛ⃿ߪᵴᕈ㉄⚛⒳ࠍ↥↢ߒ㧘↢૕㒐ᓮ⢻ࠍ᦭ߔߣߣ߽ߦ⚵❱㓚ኂᕈࠍ૬ߖᜬߟ‫ޕ‬ᅢਛ⃿ߩᵴᕈൻᯏ
᭴࡮ࠕࡐ࠻࡯ࠪࠬᒻᚑ⢻ࠍ⸃᣿ߒ∛ᘒߣߩ㑐ㅪ㧘ഃ⮎߳ߩᔕ↪ߦขࠅ⚵ࠎߢ޿ࠆ‫ޕ‬8㧕ක≮♽ᄢቇ↢࡮ᄢቇ㒮↢ߩᣂߚߥࠆᢎ⢒ᴺߩ⎇ⓥ࡮㐿⊒࡮ታ〣ጘ㒂ᄢቇකቇㇱ߇వ㚟⊛ߦขࠅ⚵ࠎߢ߈ߚ㧘໧㗴⸃᳿ဳቇ⠌ߢ޽ࠆ PBL ࠹ࡘ࠻࡯࡝ࠕ࡞ߩ㐳ᚲࠍ↢߆ߒ㧘ᰳὐࠍ⵬߁ᣂߚߥࠆᢎ⢒ᴺߩ㐿⊒ࠍᚻ߇ߌߡ޿ࠆ‫ޕ‬ᣢߦࠗࡦ࠲࡯ࡀ࠶࠻ࠍᵴ↪ߒߚ෺ᣇะဳቇ⠌ᴺ‫ޟ‬ᭉ૏⟎ᭉ The Tutorial‫ࠍޠ‬㐿⊒࡮ታ〣ߒߡ߈ߚ߇㧘ߎߩᄢቇ㒮ᢎ⢒ߢߩᔕ↪ࠍ⋡ᜰߒߡ޿ࠆ‫ޕ‬
2㧚ฬ★
ᢎ᝼㧦
ᢎ᝼㧦

ᷓየ ᢅᐘ
ਤ⠀ 㓷ਯ

Toshiyuki Fukao
Masayuki Niwa

㧙㧙

3㧚⎇ⓥᚑᨐߩ⊒⴫⪺ᦠ㧔๺ᢥ㧕
1㧕 ᷓየᢅᐘ㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧦ᄢ㑐ᱞᒾ㧘ฎᎹ ẋ㧘ᮮ↰ବ৻㇢✬㧚੹ᣣߩዊఽᴦ≮ᜰ㊎ ╙ 14 㧘᧲੩㧦කቇᦠ㒮㧧2006 ᐕ㧦168㧙169㧚
2㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̈05 ⑺㧚╙ 18 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦112㧚
3㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ౻࡮╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦110㧚
4㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ᤐ࡮╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2006 ᐕ㧦185㧚
5㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ᄐ࡮╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦237㧚
6㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉06 ⑺࡮╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦89㧚
7㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ౻࡮╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦120㧚
8㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ᤐ࡮╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦152㧚
9㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ᄐ࡮╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2007 ᐕ㧦121㧚
10㧕 ਤ⠀㓷ਯ㧚ਛᨔ␹⚻૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ
⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦73㧙101㧚
11㧕 ਤ⠀㓷ਯ㧚ᶖൻེ૞↪⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦143㧙153㧚
12㧕 ਤ⠀㓷ਯ㧚᛫ᖡᕈ⣲≌⮎(᛫≸⮎)㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩ
ଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦191㧙203㧚
13㧕 ਤ⠀㓷ਯ㧚᛫Ἳ∝⮎࡮⸃ᾲ㎾∩⮎࡮᛫ࠕ࡟࡞ࠡ࡯⮎࡮఺∉ᛥ೙⮎㧦ᬀ᧻ବᒾ㧘㊄ਣశ㓉✬㧚ᣂ૕♽⋴⼔ቇ
ోᦠ 5 ∔∛ߩᚑࠅ┙ߜߣ࿁ᓳߩଦㅴԚ⮎ℂቇ㧘᧲੩㧦ࡔ࠵ࠞ࡞ࡈ࡟ࡦ࠼␠㧧2007 ᐕ㧦205㧙224㧚
14㧕 ᷓየᢅᐘ㧚DNA㧘ㆮવሶ㧘ࠥࡁࡓ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦181㧙184㧚
15㧕 ᷓየᢅᐘ㧚ㆮવᕈ∔ᖚߩಽ㘃ߣ㗫ᐲ㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦185㧙187㧚
16㧕 ᷓየᢅᐘ㧚න৻ㆮવሶ∛㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦188㧙190㧚
17㧕 ᷓየᢅᐘ㧚ዩ⚛ࠨࠗࠢ࡞⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦221㧙222㧚
18㧕 ᷓየᢅᐘ㧚♧ઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦223㧙226㧚
19㧕 ᷓየᢅᐘ㧚ࡆ࡝࡞ࡆࡦઍ⻢⇣Ᏹ∝ߣࡐ࡞ࡈࠖ࡝ࡦઍ⻢⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦237㧙239㧚
20㧕 ᷓየᢅᐘ㧚Ძ⚦ⴊ▤᜛ᒛᕈᄬ⺞∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦355㧙356㧚
21㧕 ᷓየᢅᐘ㧚ߘߩઁߩ఺∉⇣Ᏹ∝㧦૒ᴦീ㧘᦭ဈᴦ㧘ᄢỈ⌀ᧁሶ㧘ㄭ⮮⋥ታ㧘┻᧛ม✬㧚⻠⟵㍳ዊఽ⑼ቇ㧘᧲੩㧦ࡔࠫࠞ࡞ࡆࡘ࡯␠㧧2008 ᐕ㧦359㧙360㧚
22㧕 ᷓየᢅᐘ㧚ᭂ㐳㎮ࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘㐳㎮ 3-ࡅ࠼ࡠࠠࠪࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘⍴㎮3-ࡅ࠼ࡠࠠࠪࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝ਛ㎮ࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘⍴㎮ࠕࠪ࡞-CoA ⣕᳓⚛㉂⚛ᰳ៊∝㧘2㧘4 ࠫࠛࡁࠗ࡞-CoA ㆶర㉂⚛ᰳ៊∝㧦ᄢ㑐ᱞᒾ㧘ㄭ⮮⋥ታ✚✬㓸㧚ዊఽ⑼ቇ ╙ 3 㧘᧲੩㧦කቇᦠ㒮㧧2008 ᐕ㧦475㧙479㧚
23㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉07 ⑺࡮╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦100㧚
24㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉08 ౻࡮╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦130㧚
25㧕 ㋈ᧁᐽਯ㧘⮮ፒ๺ᒾ㧘ਤ⠀㓷ਯ✬㧚ᣂߒ޿කቇᢎ⢒ߩᵹࠇ̉08 ᤐ࡮╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯ࠢࠪ
࡚࠶ࡊߩ⸥㍳㧘ฬฎደ㧦ਃᕺ␠㧧2008 ᐕ㧦152㧚
26㧕 ਤ⠀㓷ਯ㧚⸃ᾲ㎾∩⮎࡮᛫Ἳ∝⮎㧦㊁᧛㓉⧷࡮⍹Ꮉ⋥ਭ✬㧚ࠪࡦࡊ࡞⮎ℂቇ ᡷ⸓╙ 4 㧘᧲੩㧦ධᳯၴ㧧
2008 ᐕ㧦229㧙245㧚⪺ᦠ㧔᰷ᢥ㧕
1㧕 Kondo N, Kato Z, Kaneko H, Fukao T, Matsui E, Aoki M. Molecular mechanisms of hygiene hypothesis.
In: (Holgate S, Matone G, Ring J eds. Cellular and Melecular Targets in Allergy and Clinical
Immunology. Cambridge: Hogrefe & Huber Publishers; 2007:36-37.
2㧕 Hara A, Niwa M, Aoki H, Taguchi A, Yamada Y, Mori H. New research on neuronal networks. In:㧙㧙Neuronal Network Research Horizons, ed Weiss ML, Nova Science Publish; 2007:99-118.
3㧕 Suzuki Y, Niwa M, Shibata T, Chirasak K, Ramesh JC, Evans P, Takahashi Y. Internet PBL:
International Collaborative Learning Experiences, Title of the book: Problem-Based Learning ineLearning Breakthroughs, ed. Tan O-S, Singapore: Publisher: Thomson Learning; 2007:131-146.
4㧕 Hara A, Oka N, Aoki H, Taguchi A, Yamada Y, Niwa M, Mori H. OCT-3/4 Expressing Cells as Cancer
Stem Cells in Human Immature Teratoma: Cancer Differentiation Potential. In: Saitama H (ed); New
Cell Differentiation Research Topics. New York: Nova Science Publisher ; 2008:1-6.
✚⺑㧔๺ᢥ㧕
1㧕 ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚ᵈ⋡ߔߴ߈ࠕ࡟࡞ࠥࡦߣߘߩ∛ᘒ ࠗ࠿㧘ࡀࠦ㘺⢒ߣࠕ࡟࡞ࠡ࡯ߩ⊒∝㧘⥃ᐥ఺∉࡮ࠕ࡟࡞ࠡ࡯⑼ 2006 ᐕ㧧46 Ꮞ㧦604㧙612㧚
2㧕 ᛬ዬᕡᴦ㧘ᷓየᢅᐘ㧚ߌ޿ࠇࠎ㧘ᗧ⼂㓚ኂࠍ⿠ߎߔ∔ᖚߩᴦ≮࡮▤ℂߩࡐࠗࡦ࠻㧚᦭ᯏ㉄ઍ⻢⇣Ᏹ∝㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ㧦452㧙454㧚
3㧕 ᷓየᢅᐘ㧚ዊఽ∔ᖚߩ⸻ᢿᴦ≮ၮḰ ataxia telangiectasia㧘ዊఽౝ⑼ 2006 ᐕ㧧38 Ꮞ㧔⥃ᤨჇೀภ㧕㧦
232㧙233㧚
4㧕 ኹᧄ⾆⧷㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚RS ࠙ࠗ࡞ࠬᗵ
ᨴߣ༎ᕷ⊒∝̅ᗵᨴߦࠃࠆ༎ᕷߩ⊒∝㧘Ⴧᖡߩᯏᐨ㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2006 ᐕ㧧13 Ꮞ㧦1031㧙1037㧚
5㧕 ੹੗৾㊀㧘⑔ን⌀ᥓሶ㧘᭑ᧄ߭ߣߺ㧘ᐔᨋ⹞ሶ㧘ጤ⿧ᶈሶ㧘ᧁ᧛ ⽕㧘ዊỈ ੫㧘ᰞ੗㉿⟤㧘ᷓየᢅᐘ㧘⑔ንᖈ㧘᛬ዬᔘᄦ㧚∛ఽ଻⢒࿦ߢߩ଻⢒ਛߩ∝⁁ߩᄌൻߦߟ޿ߡߩᬌ⸛㧘଻⢒ߣ଻ஜ 2006 ᐕ㧧12 Ꮞ㧦
31㧙33㧚
6㧕 ⑔ን ᖈ㧘ฬ↰ආ೑㧘㕍ᧁ㓶੺㧘㋈ᧁ໪ሶ㧘ᣂ੗㓉ᐢ㧘ᷓየᢅᐘ㧘ㄭ᧻↱⟤ሶ㧘ጤ⿧ᶈሶ㧚㤗㤛ḡߩࠗࡦࡈ࡞ࠛࡦࠩߩว૬∝⁁ߦኻߔࠆലᨐߩᬌ⸛㧘ṽᣇߣ఺∉࡮ࠕ࡟࡞ࠡ࡯ 2006 ᐕ㧧20 Ꮞ㧦44㧙53㧚
7㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘᪀ේᗲ⟤㧘Ꮉᧄౖ↢㧘㕍ᧁ⟤ᄹሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧚᳇▤ᡰ༎ᕷߩ⊒∝੍㒐㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦23㧙27㧚
8㧕 ㄭ⮮⋥ታ㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧘ᣂ੗㓉ᐢ㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᪀ේᗲ⟤㧚ⅣႺ߇↢૕ߦ෸߷ߔᓇ㗀㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2007 ᐕ㧧21 Ꮞ㧦92㧙95㧚
9㧕 ᷓየᢅᐘ㧚ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ ․ߦࠕ࠮࠻ࡦⴊᕈཌྷฯ∝ߣ㐓೎ߔߴ߈ࠨࠢࠪ࠾࡞-CoA㧦3-ࠤ࠻㉄ CoA ࠻࡜ࡦࠬࡈࠚ࡜࡯࠯ᰳ៊∝ࠍਛᔃߦ㧘ᣣᧄዊఽ⑼ቇળ㔀⹹ 2007 ᐕ㧧111 Ꮞ㧦727㧙739㧚
10㧕 ᷓየᢅᐘ㧚ࡍ࠶࠻㘺⢒ⅣႺߣዊఽࠕ࡟࡞ࠡ࡯㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧356 Ꮞ㧦129㧙135㧚
11㧕 Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧘㊄ሶ⧷㓶㧘ㄭ⮮⋥ታ㧚⤯Ꮺⴊࠍ↪޿ߚ಴↢ࠦࡎ࡯࠻⎇ⓥߦ
ࠃࠆዊఽࠕ࡟࡞ࠡ࡯∔ᖚߩ⹏ଔ㧘ࠕ࡟࡞ࠡ࡯ߩ⥃ᐥ 2007 ᐕ㧧27 Ꮞ㧦77㧙82㧚
12㧕 ᧻੗᳗ሶ㧘Ꮉᧄౖ↢㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚੃ᐜఽᦼߩ఺∉ᔕ╵ᕈߩᄌㆫߣࠕ࡟࡞ࠡ࡯∔ᖚ⊒∝㧘ࠕ࡟࡞ࠡ࡯࡮఺∉ 2008 ᐕ㧧15 Ꮞ㧦170㧙174㧚
13㧕 ᷓየᢅᐘ㧚⾰⇼ᔕ╵ ዊఽߩࠤ࠻࡯ࠪࠬ㧘ᣣᧄක੐ᣂႎ 2008 ᐕ㧧4329 Ꮞ㧦89㧙90㧚✚⺑㧔᰷ᢥ㧕
1㧕 Matsui E, Kaneko H, Fukao T, Teramoto T, Kondo N. Tailor-made Medicine and GenePolymorphisms
in Bronchial Asthma. International Review of Asthma. 2006;8:64-72.
ේ⪺㧔๺ᢥ㧕
1㧕 ㄭ⮮⋥ታ㧘ᐔጊ⠹৻㇢㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘㊄ሶ⧷㓶㧘ᷓየᢅᐘ㧘᛬ዬᑪᴦ㧘Ꮉᧄ⟤ᄹሶ㧘⥵ᚭ㆏ᓼ㧘
ᄢ⷏⑲ౖ㧘Ꮉᧄౖ↢㧘᫪↰⑲ⴕ㧘ᧁ᧛⽕㧘ฬ↰ආ೑㧘ᓼ⷗ືม㧘ၳ෹ඳ㧘ᷰㆻ୶ሶ㧚ዊఽ᳇▤ᡰ༎ᕷᖚఽ
ߣⷫ෶ߪ଻⼔⠪ߩ QOL ⺞ᩏ␿◲ᤃᡷ⸓ 2008(GIFU)㧘ࠕ࡟࡞ࠡ࡯ 2008 ᐕ㧧57 Ꮞ㧦1022㧙1033㧚
2㧕 ᐔᨋ⹞ሶ㧘᎑੗⌀ᄹ⟤㧘⨹Ꮉౖሶ㧘⑔ን⌀ᥓሶ㧘ጤ⿧ᶈሶ㧘ᷓየᢅᐘ㧘቟⮮ᕺ⟤ሶ㧘ኹỈᄢ␭㧘ዊ㑐㆏ᄦ㧘⑔ንᖈ㧚∛ఽ଻⢒ߦ߅ߌࠆ∝⁁ߦวࠊߖߚㆆ߮ߩᬌ⸛㧘଻⢒ߣ଻ஜ 2008 ᐕ㧧14 Ꮞ㧦46㧙49㧚
3㧕 ᫪↰⑲ⴕ㧘㊄ሶ⧷㓶㧘ᄢ⷏⑲ౖ㧘ㄭ⮮ᙥ㧘᧻੗᳗ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧚఺∉ኡኈ⺃ዉߩߚ߼ߩ㘩‛ࠕ࡟࡞ࠡ࡯ਥⷐ᛫ේ࠲ࡦࡄࠢߩၮ␆⊛ᬌ⸛㧘ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ⹹ 2008 ᐕ㧧22 Ꮞ㧦233㧙238㧚ේ⪺㧔᰷ᢥ㧕
1㧕 Gueven N, Fukao T, Luff J, Paterson C, Kay G, Kondo N, Lavin MF. Regulation of the Atm promoter invivo. Genes Chromosomes Cancer. 2006;45:61-71.
2㧕 Funato M, Shimozawa N, Nagase T, Takemoto Y, Suzuki Y, Imamura Y, Matsumoto T, Tsukamoto T,
Kojidani T, Osumi T, Fukao T, Kondo N. Aberrant peroxisome morphology in peroxisomal
beta-oxidation enzyme deficiencies. Brain Dev. 2006;28:287-292.
3㧕 Teramoto T, Fukao T, Tomita Y, Terauchi Y, Hosoi K, Matsui E, Aoki M, Kondo N, Mikawa H.
Pharmacokinetics of beclomethasone dipropionate in an hydrofluoroalkane-134a propellant system injapanese children with bronchial asthma. Allergol Int. 2006;55:317-320.
4㧕 Zhang G, Fukao T, Sakurai S, Yamada K, Michael Gibson K, Kondo N. Identification of Alu-mediated,large deletion-spanning exons 2-4 in a patient with mitochondrial acetoacetyl-CoA thiolase deficiency.
Mol Genet Metab. 2006;89:222-226.
5㧕 Kawamoto N, Kaneko H, Takemura M, Seishima M, Sakurai S, Fukao T, Kasahara K, Iwasa S, Kondo
N. Age-related changes in intracellular cytokine profiles and Th2 dominance in allergic children.
Pediatr Allergy Immunol. 2006;17:125-133.

㧙㧙

IF 4.532

IF 1.464

IF 2.550

IF 2.454

6㧕 Fukao T, Sakurai S, Rolland MO, Zabot MT, Schulze A, Yamada K, Kondo N. A 6-bp deletion at the
splice donor site of the first intron resulted in aberrant splicing using a cryptic splice site within exon 1
in a patient with succinyl-CoA: 3-ketoacid CoA transferase (SCOT) deficiency. Mol Genet Metab.
2006;89:280-282.
7㧕 Sukegawa-Hayasaka K, Kato Z, Nakamura H, Tomatsu S, Fukao T, Kuwata K, Orii T, Kondo N. Effectof Hunter disease (mucopolysaccharidosis type II) mutations on molecular phenotypes of
iduronate-2-sulfatase: enzymatic activity, protein processing and structural analysis. J Inherit MetabDis. 2006;29:755-761.
8㧕 Hara A, Niwa M, Kumada M, Aoki H, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H.
Intraocular injection of folate antagonist methotrexate induces neuronal differentiation of embryonicstem cells transplanted in the adult mouse retina. Brain Res. 2006;1085:33-42.
9㧕 Hara A, Niwa M, Aoki H, Kumada M, Kunisada T, Oyama T, Yamamoto T, Kozawa O, Mori H. A newmodel of retinal photoreceptor cell degeneration induced by a chemical hypoxia-mimicking agent,cobalt chloride. Brain Res. 2006;1109:192-200.
10㧕 Niwa M, Hotta K, Hara A, Hirade K, Ito H, Kato K, Kozawa O. TNF-alpha decreases hsp 27 in humanblood mononuclear cells: involvement of protein kinase C. Life Sci. 2006;80:181-186.
11㧕 Sakurai S, Fukao T, Haapalainen AM, Zhang G, Yamada S, Lilliu F, Yano S, Robinson P, Gibson MK,
Wanders RJA, Mitchell GA, Wierenga RK, Kondo N. Kinetic and Expression Analyses of Seven Novel
Mutations in Mitochondrial Acetoacetyl-CoA Thiolase (T2): Identification of a Km Mutant and an
Analysis of the Mutational Sites in the Structure. Mol Genet Metab. 2007;90:370-378.
12㧕 Kondo M, Fukao T, Shinoda S, Kawamoto N, Kaneko H, Kato Z, Matsui E, Teramoto T, Nakano T,
Kondo N. Lymphocyte responses to chymotrypsin- or trypsin V-digested Ǫ-lactoglobulin in patientswith cow’s milk allergy. Allergy Asthma Clin Immunol. 2007;3:1-9.
13㧕 Yamada K, Fukao T, Zhang G, Sakurai S, Ruiter JPN, Wanders RJA, Kondo N. Single-basesubstitution at the last nucleotide of exon 6 (c.671G >A), resulting in the skipping of exon 6, and exons
6 and 7 in human Succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet Metab.
2007;90:291-297.
14㧕 Haapalainen A, Merilinen G, Piril P, Kondo N, Fukao T, Wierenga R. Crystallographic and kinetic
studies of human mitochondrial acetoacetyl-CoA thiolase (T2): the importance of potassium andchloride ions for its structure and function. Biochemistry. 2007;46:4305-4321.
15㧕 Yamada K, Fukao T, Suzuki H, Inoue R, Kondo T, Kondo N. Vitamin K-Deficient Intracranial
Hemorrhage as the First Symptom of Cytomegalovirus Hepatitis with Cholestasis. Tohoku J Exp Med.
2007;212:335-339.
16㧕 Funato M, Kaneko H, Matsui E, Teramoto T, Kato Z, Fukao T, Okusu K, Kondo N. Refractoryosteomyelitis caused by bacille Calmette-Guerin vaccination: a case report. Diagn Microbiol Infect Dis.
2007;59:89-91.
17㧕 Aoki M, Fukao T, Kaneko H, Mizunaga S, Mitsuyama J, Sawamura H, Seishima M, Kondo N. Clinicaland bacteriological evaluation of the efficacy of piperacillin in children with pneumonia. J InfectChemother. 2007;13:224-229.
18㧕 Fukao T, Zhang G, Aoki Y, Arai T, Teramoto T, Kaneko H, Sugie H, Kondo N. Identification of
Alu-mediated, large deletion-spanning introns 19-26 in PHKA2 in a patient with X-linked liver
glycogenosis (hepatic phosphorylase kinase deficiency). Mol Genet Metab. 2007;92:179-182.
19㧕 Ozeki M, Funato M, Kanda K, Ito M, Teramoto T, Kaneko H, Fukao T, Kondo N. Clinical improvementof diffuse lymphangiomatosis with pegylated interferon alfa-2b therapy: Case report and review of theliterature. Pediatr Hematol Oncol. 2007;24:513-524.
20㧕 Funato M, Kaneko H, Ozeki M, Suzuki H, Orii K, Teramoto T, Fukao T, Kondo N.A positive
Donath-Landsteiner test in paroxysmal cold haemoglobinuria. Eur J Haematol. 2007;79:462.
21㧕 Fukao T, Kursula P, Owen EP, Kondo N. Identification and characterization of a temperature-sensitive
R268H mutation in the human succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene. Mol Genet
Metab. 2007;92:216-221.
22㧕 Fukao T, Zhang G, Rolland M-O, Zabot M-T, Guffon N, Aoki Y, Kondo N. Identification of an
Alu-mediated tandem duplication of exons 8 and 9 in a patient with mitochondrial acetoacetyl-CoA
thiolase (T2) deficiency. Mol Genet Metab. 2007;92:375-378.
23㧕 Gobin-Limballe S, Djouadi F, Aubey F, Olpin S, Andresen BS, Yamaguchi S, Mandel H, Fukao T,
Ruiter JP, Wanders RJ, McAndrew R, Kim JJ, Bastin J.Genetic basis for correction of very-long-chain
acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a
genotype-based therapy. Am J Hum Genet. 2007;81:1133-1143.
24㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. An in vitro mouse model for retinal
ganglion cell replacement therapy using eye-like structures differentiated from ES cells. Exp Eye Res.
2007;84:868-875.
25㧕 Hara A, Taguchi A, Niwa M, Aoki H, Yamada Y, Ito H, Nagata K, Kunisada T, Mori H. Localization of
septin 8 in murine retina, and spatiotemporal expression of septin 8 in a murine model ofphotoreceptor cell degeneration. Neurosci Lett. 2007;423:205-210.

㧙㧙

IF 2.550

IF 1.688

IF 2.218

IF 2.218
IF 2.257

IF 2.550

IF 2.550

IF 3.368

IF 1.133

IF 2.553

IF 2.550

IF 0.720
IF 2.163

IF 2.550

IF 2.550

IF 11.092

IF 2.651

IF 2.08526㧕 Kondo M, Fukao T, Omoya K, Kawamoto N, Aoki M, Teramoto T, Kaneko H, Kondo N. Protein-losing
enteropathy associated with egg allergy in a 5-month-old boy. J Investig Allergol Clin Immunol.
2008;18:63-66.
27㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N: Anaphylactoid transfusion reactions
associated with a positively charged white-cell reduction filter: a case report. Transfus Apher Sci.
2008;38:199-201.
28㧕 Jin R, Kaneko H, Suzuki H, Arai T, Teramoto T, Fukao T, Kondo N. Age-related changes in BAFF andAPRIL profiles and upregulation of BAFF and APRIL expression in patients with primary antibody
deficiency. Int J Mol Med. 2008;21:233-238.
29㧕 Bai CY, Matsui E, Ohnishi H, Kimata K, Kasahara K, Kaneko H, Kato Z, Fukao T, Kondo N. A Novel
Polymorphism in the 5-lipoxygenase Gene Associated with Bronchial Asthma in Japanese Children.
Int J Mol Med. 2008;21:139-144.
30㧕 Kondo M, Kaneko H, Fukao T, Suzuki K, Sakaguchi H, Shinoda S, Kato Z , Matsui E, Teramoto T,
Nakano T, Kondo N. The response of bovine beta-lactoglobulin-specific T-cell clones to single aminoacid substitutions of T-cell core epitope. Pediatr Allergy Immunol. 2008;19:592-598.
31㧕 Yamada K, Yamamoto Y, Uchiyama A, Ito R, Aoki Y, Uchida Y Nagasawa H, Kimura H, Ichiyama T,
Fukao T, Kohno Y. A successfully treated case of neonatal herpes simplex type 1 infection complicatedby hemophagocytic lymphohistiocytosis and acute hepatic failure. Tohoku J Exp Med. 2008;214:1-5.
32㧕 Funato M, Kaneko H, Ozeki M, Kanda K, Fukao T, Kondo N. Pediatric synovial sarcoma of the rightmasseter muscle: A case report and review of the literature. Int J Pediatr Otorhi Extra.
2008;3:105-108.
33㧕 Suzuki H, Kaneko H, Rong J, Kawamoto N, Asano T, Matsui E, Kasahara K, Fukao T, Kondo N.
Induction of 1 and 2 gene expression in selective IgA deficiency. Molecular Medicine Report.
2008;1:395-399.
34㧕 Yotsumoto Y, Hasegawa Y, Fukuda S, Kobayashi H, Endo M, Fukao T, Yamaguchi S. Clinical andmolecular investigations of Japanese cases of glutaric acidemia type 2. Mol Genet Metab.
2008;94:61-67.
35㧕 Fukao T, Boneh A, Aoki Y, Kondo N. A Novel Single-Base Substitution (c.1124A>G) that Activates a
5-Base Upstream Cryptic Splice Donor Site within Exon 11 in the Human Mitochondrial
Acetoacetyl-CoA Thiolase Gene. Mol Genet Metab. 2008;94:417-421.
36㧕 Kuratsubo I, Suzuki Y, Shimozawa N, Kondo N. Parents of childhood X-linked adrenoleukodystrophy:
High risk for depression and neurosis. Brain Dev. 2008;30:477-482.
37㧕 Orii KE, Fukao T, Song X-Q, Mitchell GA, Kondo N. Liver-Specific Silencing of the Human Gene
Encoding Succinyl-CoA: 3-Ketoacid CoA Transferase. Tohoku J Exp Med. 2008;215:227-236.
38㧕 Ozeki M, Funato M, Kanda K, Ito M, Teramoto T, Kaneko H, Fukao T, Kondo N. Clinical Improvementof Diffuse Lymphangiomatosis with Pegylated Interferon ALFA-2B Therapy. Pediatr Hemat Oncol.
2008;24:513-524.
39㧕 Purevsuren J, Fukao, T, Hasegawa Y; Fukuda S, Kobayashi H, Yamaguchi S. Study of deep intronic
sequence exonization in a Japanese neonate with a mitochondrial trifunctional protein deficiency. Mol
Genet Metab. 2008;95:46-51.
40㧕 Kawamoto M, Matsui E, Kaneko H, Fukao T, Teramoto T, Kasahara K, Kondo N. IL-10 plays animportant role as an immune-modulator in the pathogenesis of atopic diseases. Molecular Medicine
Reports. 2008;1:837-842.
41㧕 Arai T, Kaneko H, Ohnishi H, Matsui E, Fukao T, Kawamoto N, Kasahara K, Kondo N. Hypothermia
Augments NF-kappa B Activity and the Production of IL-12 and IFN-gamma. Allergol Int.
2008;57:331-338.
42㧕 Teramoto T, Fukao T, Hirayama K, Asano T, Aoki Y, Kondo N. Escherichia coli O-157-induced
hemolytic uremic syndrome: Usefulness of SCWP score for the prediction of neurological complication.
Pediatrics International. 2008;50:1-3.
43㧕 Aoki H, Hara A, Niwa M, Motohashi T, Suzuki T, Kunisada T. Transplantation of cells from eye-likestructures differentiated from embryonic stem cells in vitro and in vivo regeneration of retinal
ganglion-like cells. Graefes Arch Clin Exp Ophthalmol. 2008;246:255-265.
44㧕 Hara A, Aoki H, Taguchi A, Niwa M, Yamada Y, Kunisada T, Mori H. Neuron-like differentiation andselective ablation of undifferentiated embryonic stem cells containing suicide gene with Oct-4
promoter. Stem Cells Dev. 2008;17:619-627.
45㧕 Taguchi A, Hara A, Saito K, Hoshi M, Niwa M, Seishima M, Mori H. Localization and spatiotemporal
expression of IDO following transient forebrain ischemia in gerbils. Brain Res. 2008;1217:78-85.

IF 1.254

IF 0.970

IF 1.847

IF 1.847

IF 2.454

IF 1.133

IF 0.851

IF 2.550

IF 2.550
IF 1.464
IF 1.133

IF 0.720

IF 2.550

IF 0.737

IF 1.590

IF 3.224
IF 2.2184㧚⎇ⓥ⾌₪ᓧ⁁ᴫ
1㧕┹੎⊛⾗㊄1㧕 ⎇ⓥઍ⴫⠪㧦ᷓየᢅᐘ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ၮ⋚⎇ⓥ(C)(2)㧦ࠤ࠻ࡦ૕ઍ⻢⇣Ᏹ∝ߩಽሶ∛ᘒ㧙Ⱞ⊕ 3 ᰴᯏㅧᄌൻߣࠬࡊ࡜ࠗࠪࡦࠣ⇣Ᏹࠍਛᔃߦ㧙㧧ᐔᚑ 18㧙19 ᐕᐲ㧧3,500 ජ౞(1,900㧦1,600

㧙㧙

ජ౞)
2㧕 ⎇ⓥઍ⴫⠪㧦ጊญᷡᰴ㧘⎇ⓥදജ⠪㧦ᷓየᢅᐘ㧧ෘ↢ഭ௛⋭⑼ቇ⎇ⓥ⾌⵬ഥ㊄ሶߤ߽ኅᐸ✚ว⎇ⓥ੐ᬺ㧦࠲ࡦ࠺ࡓࡑࠬ╬ߩᣂᛛⴚࠍዉ౉ߒߚᣂߒ޿ᣂ↢ఽࡑࠬࠬࠢ࡝࡯࠾ࡦࠣ૕೙ߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ㧧ᐔᚑ 19㧙20 ᐕᐲ㧧700 ජ౞(400㧦300 ජ౞)
3㧕 ᢥㇱ⑼ቇ⋭․⦡޽ࠆᄢቇᢎ⢒ᡰេࡊࡠࠣ࡜ࡓ(․⦡ GP)㧦⢻േ࡮ᕁ⠨ଦㅴဳࠍᩇߣߔࠆోੱ⊛කቇᢎ⢒㧦ᐔᚑ 15㧙18 ᐕᐲ㧧60,000 ජ౞(15,000㧦15,000㧦15,000㧦15,000 ජ౞)
4㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ጘ㒂ᄢቇᵴᕈൻ⚻⾌㧦CoCl2 ߩㆬᛯ⊛ⷞ␹⚻㓚ኂࡕ࠺࡞ߩ⏕┙㧧ᐔᚑ 18 ᐕᐲ㧧900 ජ౞5㧕 ⎇ⓥઍ⴫⠪㧦ਤ⠀㓷ਯ㧧ᢥㇱ⑼ቇ⋭⑼ቇ⎇ⓥ⾌ၮ⋚⎇ⓥ(C)(2)㧦ࠦࡃ࡞࠻ࠢࡠ࡜ࠗ࠼⺃⊒ⷞ⚦⢩ㆬᛯ⊛㓚ኂࡕ࠺࡞ߩ⊒⃻ᯏᐨ⸃᣿ߥࠄ߮ߦߘߩ㒐ᓮ࡮ᴦ≮㧧ᐔᚑ 19̆20 ᐕᐲ㧧3,500 ජ౞(2,700㧦800
ජ౞)6㧕 ⎇ⓥઍ⴫⠪㧦㜞ᯅఝਃ㧘⎇ⓥදജ⠪㧦ਤ⠀㓷ਯ㧧⍮⊛ࠢ࡜ࠬ࠲࡯ഃᚑ੐ᬺ‫ࡑ࡯࠹ޟ‬Σ㧦ૐଚⷅᓸ⚦ᚻⴚᡰេ࡮ᢎ⢒⸠✵ࠪࠬ࠹ࡓߩ㐿⊒㧦ක≮ᢎ⢒⸠✵ࡠࡏ࠶࠻‫ޠ‬㧧ᐔᚑ 19㧙20 ᐕᐲ㧧46,432 ජ౞(23,200㧦23,232 ජ౞)
7㧕 ᐔᚑ 19 ᐕᐲ ⃻ઍ⊛ᢎ⢒࠾࡯࠭ข⚵ᡰេࡊࡠࠣ࡜ࡓ(⃻ઍ GP)ណᛯ‫⥃ޟ‬ᐥකቇᢎ⢒ࠍᒝൻะ਄ߐߖࠆ
ICT㧦e-Learning ߢၭ߁කߩᔃߣᛛ‫ޠ‬㧧ᐔᚑ 19㧙21 ᐕᐲ㧧69,973 ජ౞(23,993㧦21,980㧦24,000 ජ౞(੍ቯ))
2㧕ฃ⸤⎇ⓥߥߒ
3㧕౒ห⎇ⓥߥߒ
5㧚⊒᣿࡮․⸵಴㗿⁁ᴫߥߒ
6㧚ቇળᵴേ
1㧕ቇળᓎຬᷓየᢅᐘ㧦
1㧕 ᣣᧄవᄤઍ⻢⇣Ᏹቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄੱ㘃ㆮવቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄዊఽ⑼ቇળ᧲ᶏ࿾ᣇળᐙ੐(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
4㧕 ᣣᧄੱ㘃ㆮવቇળᜰዉක(ᐔᚑ 18 ᐕ 4 ᦬㨪⃻࿷)
5㧕 ᣣᧄዊఽ⑼ቇળઍ⼏ຬ(ᐔᚑ 20 ᐕ 4 ᦬㨪⃻࿷)ਤ⠀㓷ਯ㧦
1㧕 ᣣᧄ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕 ᣣᧄἻ∝࡮ౣ↢කቇળ⹏⼏ຬ(㨪⃻࿷)3㧕 ᣣᧄකቇᢎ⢒ቇળ⹏⼏ຬ(㨪⃻࿷)4㧕 ᣣᧄ⥃ᐥ⮎ℂቇળ⹏⼏ຬ(㨪⃻࿷)2㧕ቇળ㐿௅ਤ⠀㓷ਯ㧦
1㧕 ╙ 19 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 1 ᦬㧘ጘ㒂)2㧕 ╙ 20 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 4 ᦬㧘ߟߊ߫)3㧕 ╙ 21 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 8 ᦬㧘ጘ㒂)
4㧕 ╙ 22 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 18 ᐕ 10 ᦬㧘ᮮᵿ)
5㧕 ╙ 23 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 1 ᦬㧘ጘ㒂)
6㧕 ╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 4 ᦬㧘᧲੩)7㧕 ╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧛╙ 7 ࿁ᣣᧄዊఽකቇᢎ⢒⎇ⓥળ(ᐔᚑ 19 ᐕ 7 ᦬㧘ጘ㒂)8㧕 ╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 19 ᐕ 10 ᦬㧘ᓼፉ)9㧕 ╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 1 ᦬㧘ฬฎደ)㧙㧙

10㧕 ╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 5 ᦬㧘ᄢ㒋)11㧕 ╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 8 ᦬㧘ጘ㒂)12㧕 ╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ(ᐔᚑ 20 ᐕ 10 ᦬㧘᧲੩)
3㧕ቇⴚ㔀⹹
ߥߒ
7㧚ቇળ᜗ᓙ⻠Ṷ㧘᜗ᓙࠪࡦࡐࠫࠬ࠻㧘ᐳ㐳ᷓየᢅᐘ㧦
1㧕 10th International congress of inborn errors of metabolism(2006.09, Chiba,‫ޟ‬Mutation update ofhuman mitochondrial acetoacetyl-CoA thiolase (T2) deficiency‫ޠ‬Ṷ⠪)2㧕 10th International congress of inborn errors of metabolism(2006.09, Chiba,‫ޟ‬Mutation update of
succinyl-CoA:3-ketoacid CoA transferase deficiency‫ޠ‬Ṷ⠪)3㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism (2008.08,‫ޟ‬CpG
islands around exon 1 in succinyl-CoA:3-ketoacid CoA transferase (SCOT) gene were
hypomethylated even in human and mouse hepatic tissues where SCOT gene expression wascompletely suppressed‫ޠ‬speaker)
4㧕 2008 Annual symposium of Society for the Study of Inborn Errors of Metabolism(2008.08,‫ޟ‬A
novel single-base substitution(c.1124A>G)that activates 5-base upstream cryptic splice donorsite within exon 11 in the human mitochondrial acetoacetyl-CoA thiolase gene‫ޠ‬speaker)
5㧕 ╙ 11 ࿁ᐢፉవᄤઍ⻢⇣Ᏹ⎇ⓥળ(ᐔᚑ 20 ᐕ 2 ᦬㧘ᐢፉ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ
⠪)
6㧕 ╙ 7 ࿁᧲ർઍ⻢⇣Ᏹ∝ᴦ≮⎇ⓥળ(ᐔᚑ 20 ᐕ 7 ᦬㧘઄บ㧘․೎⻠Ṷ‫ࡦ࠻ࠤޟ‬૕ઍ⻢ߣߘߩ⇣Ᏹ∝‫ޠ‬Ṷ⠪)7㧕 ╙ 10 ࿁ጘ㒂ࡊ࡜ࠗࡑ࡝࡯ࠤࠕࠞࡦࡈࠔ࡜ࡦࠬ(ᐔᚑ 20 ᐕ 7 ᦬㧘ጘ㒂㧘․೎⻠Ṷ‫ޟ‬ૐⴊ♧㧘㜞ࠕࡦࡕ࠾ࠕⴊ∝㧘ઍ⻢ᕈࠕࠪ࠼࡯ࠪࠬ‫ޠ‬Ṷ⠪)8㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫ޟ‬ㆮવሶߣ∛᳇‫ޠ‬Ṷ⠪)9㧕 ╙ 45 ࿁ᣣᧄዊఽࠕ࡟࡞ࠡ࡯ቇળ(ᐔᚑ 20 ᐕ 12 ᦬㧘ᮮᵿ㧘ࠪࡦࡐࠫ࠙ࡓ 10‫ߩࡦࠥ࡞࡟ࠕޟ‬ᗧ⟵ߣߘߩᄙ᭽ߥᯏ⢻‫ޠ‬Ṷ⠪)ਤ⠀㓷ਯ㧦
1㧕 6th Asia-Pacific Conference on Problem-Based Learning(2006.01, Tokyo, Symposium 2 “E-PBL”:‫ޟ‬Web-based Internet PBL-tutorial/Rakuichi The Tutorial‫ޠ‬Symposist)2㧕 ╙ 45 ࿁ᣣᧄ⮎ቇળਛ࿖྾࿖ᡰㇱ଀ળ(2006 ᐕ 6 ᦬㧘⑔ጊ㧘ቇળ᜗ᓙ⻠Ṷ‫ޟ‬ᣂߒ޿ක≮♽ᢎ⢒ߩᵹࠇߣ PBL/࠹ࡘ࠻࡯࡝ࠕ࡞‫ޠ‬Ṷ⠪)3㧕 వ┵ഃ⮎ක≮ࠪࡦࡐࠫ࠙ࡓ(ᐔᚑ 20 ᐕ 10 ᦬㧘ጘ㒂㧘⻠Ṷ‫⚦ޟ‬⢩ᱫߣ∛᳇㧘ߘߩౣ↢‫ޠ‬Ṷ⠪)8㧚ቇⴚ⾨╬ߩฃ⾨⁁ᴫߥߒ9㧚␠ળᵴേᷓየᢅᐘ㧦
1㧕 ጘ㒂⋵ዊఽ଻ஜදળᏱછℂ੐(㨪⃻࿷)2㧕 ጘ㒂⋵੍㒐ធ⒳ஜᐽⵍኂ⺞ᩏኾ㐷කᏧ㓸࿅ኾ㐷කᏧ(㨪⃻࿷)3㧕 ጘ㒂Ꮢ଻⢒ᚲఽ┬ߩஜᐽࠍ⠨߃ࠆળᆔຬ ᆔຬ㐳(㨪⃻࿷)4㧕 ጘ㒂⋵ዊఽᢇᕆක≮ද⼏ળᆔຬ(㨪⃻࿷)5㧕 ጘ㒂Ꮢ଻ஜක≮ክ⼏ળᆔຬ(㨪⃻࿷)10㧚ႎ๔ᦠ
1㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ㧘◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛╬ߦࠃࠆࠕ࠽ࡈࠖ࡜ࠠࠪ࡯෻ᔕߩේ࿃‛⾰(ࠕ࡟࡞ࠥࡦ)ߩ⏕ቯ㧘੍㒐࡮੍⍮ᴺߩ⏕┙ߦ㑐ߔࠆ⎇ⓥ 㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄⎇ⓥႎ๔ᦠ╙ 1 ಽౠ(ᶏ⠧Ỉ⃰)㧦90㧙92(2006 ᐕ 3 ᦬)㧙㧙

2㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ, ◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦22㧙24(2006 ᐕ 3 ᦬)
3㧕 ㄭ⮮⋥ታ㧘㊄ሶ⧷㓶㧘ㄭ⮮ᙥ㧘ᷓየᢅᐘ, ◉↰⚩ม㧘ട⮮ༀ৻㇢㧘㕍ᧁ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦㘩‛ࠕ࡟࡞ࠥࡦߩ఺∉ᔕ╵߅ࠃ߮㕖හᤨဳ෻ᔕߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 15 ᐕᐲ㧙17 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ✚ว⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦22㧙24(2006 ᐕ 3 ᦬)
4㧕 ᛬ዬᑪᴦ㧘ᷓየᢅᐘ, ㊄ሶ⧷㓶, ㄭ⮮⋥ታ㧦Ataxia telangiectasia(Ძ⚦ⴊ▤᜛ᒛᕈㆇേᄬ⺞∝)ߩ∛ᘒߦ㑐ߔಽሶ↢‛ቇ⊛⸃ᨆ㧦ᐔᚑ 17 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽ
ᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦49㧙51(2006 ᐕ 3 ᦬)
5㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘㊄ ᩕ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ㧦ෘ↢ഭ௛⋭ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ ᐔᚑ 18 ᐕᐲ╙ 1 ࿁⃰ળ⼏✚ળࡊࡠࠣ࡜ࡓ(ች⣁⃰)㧦6(2007 ᐕ 1 ᦬)
6㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦125(2007 ᐕ 2 ᦬)
7㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦143(2007 ᐕ 2 ᦬)
8㧕 ㊄ሶ⧷㓶㧘㋈ᧁ໪ሶ㧘ᷓየᢅᐘ㧘ㄭ⮮⋥ታ㧦IgA ᰳ៊∝ߩ∛ᘒߣ∛࿃ㆮવሶߩ⸃ᨆ ේ⊒ᕈ఺∉ਇో∝୥⟲ߦ㑐ߔࠆ⺞ᩏ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢⑼ቇ⎇ⓥ⾌⵬ഥ㊄ 㔍ᴦᕈ∔ᖚస᦯⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ች⣁⃰)㧦41㧙43(2007 ᐕ 3 ᦬)
9㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᶏ⠧Ỉ⃰)㧦9㧙11(2007 ᐕ 3 ᦬)
10㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘ጤ⍾⋿৻㧘⊕ᧁ ⺈㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘ㄭ⮮ ᙥ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᶏ⠧Ỉ⃰)㧦161㧙163(2007 ᐕ 3 ᦬)
11㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ᦠ ෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ੐ോዪ ⊒ⴕ ╙ 3 ಽౠ(ᴡ㊁⃰)㧦210㧙212(2007 ᐕ 3 ᦬)
12㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘㊄ሶ⧷㓶㧘㕍ᧁ⟤ᄹሶ㧘᧻੗᳗ሶ㧘ኹᧄ⾆⧷㧘ᷓየᢅᐘ㧦఺∉ᯏ⢻ૐਅࠍ᦭ߔࠆዊఽߦኻߔࠆ੍㒐ធ⒳ߩᬌ⸛(╙ 3 ႎ)఺∉⛽ᜬߦ㑐ߔࠆᬌ⸛㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌
⵬ഥ㊄ ක⮎ຠ࡮ක≮ᯏེ╬࡟ࠡࡘ࡜࡯ࠨࠗࠛࡦࠬ✚ว⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ਅ↰⃰)㧦
85㧙87(2007 ᐕ 4 ᦬)
13㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘㕍ᧁ⟤ᄹሶ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 18 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ✚᜝࡮ಽᜂ⎇ⓥႎ๔ᦠ(ᴡ㊁⃰)㧦20㧙22(2007 ᐕ 4 ᦬)
14㧕 ㄭ⮮⋥ታ㧘ᷓየᢅᐘ㧘᧻੗᳗ሶ㧘㊄ሶ⧷㓶㧘Ꮉᧄ⟤ᄹሶ㧘Ꮉᧄౖ↢㧦ࠕ࡟࡞ࠡ࡯ᕈ∔ᖚߩ⊒∝࡮㊀∝ൻߩ੍⍮ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᶏ⠧Ỉ⃰)㧦98(2008 ᐕ 2 ᦬)
15㧕 ㄭ⮮⋥ታ㧘◉↰⚩ม㧘᧻੗᳗ሶ㧘Ꮉᧄ⟤ᄹሶ㧦ዊఽ༎ᕷ QOL ⎇ⓥߩ✚᜝ ࠟࠗ࠼࡜ࠗࡦ᥉෸ߩߚ߼
ߩኻ╷ߣߘࠇߦ઻߁ QOL ߩะ਄ߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(㗇↲⃰)㧦73(2008 ᐕ 2 ᦬)
16㧕 ㄭ⮮⋥ታ㧘Ꮉᧄ⟤ᄹሶ㧘ᷓየᢅᐘ㧘㊄ሶ⧷㓶㧘᧻੗᳗ሶ㧘ᄢ⷏⑲ౖ㧦ࠕ࠻ࡇ࡯ᕈ⊹⤏Ἳ⊒∝ߣᲣ੃ߩ㑐ㅪ㧘․ߦᲣ੃ᚑಽߩ⸃ᨆߦ㑐ߔࠆ⎇ⓥ㧦ᐔᚑ 19 ᐕᐲෘ↢ഭ௛⑼ቇ⎇ⓥ⾌⵬ഥ㊄ ఺∉ࠕ࡟࡞ࠡ࡯∔ᖚ੍㒐࡮ᴦ≮⎇ⓥ੐ᬺ ⎇ⓥႎ๔ળᛞ㍳㓸(ᴡ㊁⃰)㧦8(2008 ᐕ 2 ᦬)
17㧕 ਤ⠀㓷ਯ㧦╙ 24 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 121(2007ᐕ 1 ᦬)
18㧕 ਤ⠀㓷ਯ㧦╙ 25 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38 Ꮞ 334(2007 ᐕ 10
᦬)19㧕 ਤ⠀㓷ਯ㧦╙ 26 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 354(2007㧙㧙ᐕ 10 ᦬)20㧕 ਤ⠀㓷ਯ㧦╙ 27 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 410(2007ᐕ 12 ᦬)21㧕 ਤ⠀㓷ਯ㧦╙ 28 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 38 Ꮞ 86(2008ᐕ 4 ᦬)
22㧕 ਤ⠀㓷ਯ㧦╙ 29 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘࠾ࡘ࡯࠭㧦කቇᢎ⢒ 38 Ꮞ 359(2008 ᐕ 10
᦬)23㧕 ਤ⠀㓷ਯ㧦╙ 30 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39 Ꮞ 346(2008ᐕ 10 ᦬)24㧕 ਤ⠀㓷ਯ㧦╙ 31 ࿁කቇᢎ⢒࠮ࡒ࠽࡯ߣࡢ࡯࡚ࠢࠪ࠶ࡊ㧘ࠕ࠽࠙ࡦࠬࡔࡦ࠻㧦කቇᢎ⢒ 39 Ꮞ 469(2008ᐕ 12 ᦬)11㧚ႎ㆏
1㧕 ᷓየᢅᐘ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㧦ጘ㒂ᣂ⡞(2006 ᐕ 4 ᦬ 4 ᣣ)
2㧕 ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼㧙⎇ⓥቶ⚫੺㧦ᣣ⚻ᣂ⡞㧘ᦺᣣᣂ⡞(2007 ᐕ 6 ᦬ 27 ᣣ)
3㧕 ਤ⠀㓷ਯ㧦‫⎇ޟ‬ⓥቶ߆ࠄ ᄢቇߪ޿߹‫ޠ‬㧦ጘ㒂ᣂ⡞(2007 ᐕ 11 ᦬ 13 ᣣ)
12㧚⥄Ꮖ⹏ଔ
⹏ଔ⎇ⓥᚑᨐߪ㊂⊛ߦ޽ࠆ⒟ᐲߩ⚿ᨐࠍ␜ߖߚߣᕁ߁߇㧘⾰⊛ߦߪᦝߥࠆദജ߇ᔅⷐߢ޽ࠆ‫ޕ‬⃻⁁ߩ໧㗴ὐ෸߮ߘߩኻᔕ╷ㅪวഃ⮎ක≮ᖱႎ⎇ⓥ⑼ߪ 2007 ᐕ 4 ᦬ 1 ᣣߦ⊒⿷ߒߚ߫߆ࠅߢቇᐕㅴⴕਛߩ⎇ⓥ⑼ߢ޽ࠆ‫⎇ޕ‬ⓥᵴ
േߩ᜚ὐߣ߽ߥࠆᣉ⸳߽⃻࿷઒૑߹޿ߢ޽ࠅ㧘ᧄᩰ⊛ߥᵴേߪ᧪ᐕᐲකቇㇱࠠࡖࡦࡄࠬౝߦቢᚑ੍ቯߩጘ㒂⮎⑼ᄢቇ߳ߩ⒖ォᓟߣߥࠄߑࠆࠍᓧߥ޿‫⎇ߚ߹ޕ‬ⓥ⑼ࠬ࠲࠶ࡈ㑆ߢߩ౒ห⎇ⓥ߿ߘߩᣇะᕈ߇߹ߛ
ਇචಽߢ޽ࠅ㧘⃻⁁ߢߪᲣ૕ಽ㊁ߩ⎇ⓥ߇ਥߣߥߞߡ޿ࠆ‫ޕ‬⒖ォᓟߪᲣ૕ಽ㊁ߩ․ᕈࠍߐࠄߦ㜞߼ࠆߣߣ߽ߦ㧘⎇ⓥ⑼ߣߒߡᣂߚߥࡊࡠࠫࠚࠢ࠻ߩ┙ߜ਄ߍ╬ࠍㅢߓ㧘㗔ၞ࡮ኾ᡹ࠍ⿥߃ߚᢎຬ㑆ߩㅪ៤ࠍ㜞߼ࠆᔅⷐ߇޽ࠆ‫ޕ‬੹ᓟߩዷᦸ੹ᓟߐࠄߦකቇ࡮Ꮏቇ࡮⮎ቇߣߩㅪ៤ߩᒝߺࠍ↢߆ߒߚ⎇ⓥࠍㅴ߼㧘ഃ⮎߳ߩ⿷߇߆ࠅࠍ࿕߼ߚ޿‫ޕ‬㧙㧙